purpos
concern
within
medic
profess
antimicrobi
agent
use
livestock
product
contribut
increas
antibiot
resist
observ
zoonot
bacteri
pathogen
minimis
risk
evidencebas
control
strategi
need
implement
investig
effect
chlortetracyclin
treatment
tetracyclin
resist
popul
salmonella
typhimurium
commens
escherichia
coli
popul
pig
result
result
show
pig
treat
chlortetracyclin
consist
shed
higher
number
resist
typhimurium
untreat
pig
week
posttreat
also
identifi
increas
e
coli
chlortetracyclin
mic
mgl
increas
e
coli
mic
mgl
effect
persist
week
posttreat
tetracyclin
resist
gene
characteris
gene
probe
pcr
level
chlortetracyclin
pig
faec
measur
hplc
fell
detect
limit
day
treatment
conclus
studi
provid
direct
evid
oral
administr
chlortetracyclin
pig
significantli
increas
proport
resist
enter
bacteria
shift
resist
outlast
residu
chlortetracyclin
pig
faec
background
helicobact
pylori
resist
antimicrobi
agent
import
factor
compromis
efficaci
therapi
sinc
initi
treatment
h
pylori
infect
often
empir
therefor
import
monitor
local
resist
pattern
object
aim
studi
determin
preval
h
pylori
resist
clarithromycin
metronidazol
amoxycillin
children
prior
erad
therapi
detect
mutat
respons
clarithromycin
resist
materi
method
h
pylori
strain
isol
gastric
biopsi
suscept
antimicrobi
determin
e
test
mutat
rrna
gene
associ
clarithromycin
resist
analys
pcrrflp
direct
sequenc
result
overal
strain
resist
metronidazol
strain
resist
clarithromycin
strain
simultan
resist
drug
cultur
isol
sensit
amoxicillin
primari
resist
clarithromycin
mainli
associ
mutat
rrna
gene
h
pylori
howev
isol
contain
mutat
higher
mic
clarithromycin
conclus
result
show
high
preval
h
pylori
resist
clarithromycin
polish
children
impli
need
pretreat
suscept
test
rrna
genotyp
helicobact
pylori
strain
resist
clarithromycin
children
object
studi
primari
resist
clarithromycin
cla
children
analys
point
mutat
associ
cla
resist
compar
data
resist
obtain
adult
method
thirtysix
resist
strain
children
adult
obtain
gastric
biopsi
vitro
suscept
cla
determin
agar
dilut
method
dna
isol
extract
ge
taylor
method
mutat
determin
pcrrflp
versalov
kpb
rrna
gene
amplifi
digest
bsa
mbo
ii
x
contribut
rdxa
frxa
mutat
metronidazol
resist
helicobact
pylori
examin
multipleisol
patient
set
chisholm
sa
owen
rj
central
public
health
laboratori
laboratori
enter
pathogen
london
uk
purpos
mutat
rdxa
frxa
gene
encod
nadph
nitroreductas
nadph
flavin
oxidoreductas
respect
reportedli
lead
metronidazol
mtz
resist
helicobact
pylori
singl
mutat
type
identifi
directli
correl
resist
acquisit
examin
rdxa
frxa
pair
mtz
sensit
resist
r
isol
mix
mtzsr
strain
popul
isol
nine
dyspept
patient
differ
mtz
suscept
r
therapi
mix
mtzsr
subpopul
separ
test
rdxa
frxa
isol
popul
sequenc
result
sever
differ
mutat
identifi
rdxa
rare
frxa
mtzr
strain
posttreat
absent
match
mtz
strain
pretreat
contrast
sequenc
pretreat
mtzr
subpopul
ident
mtz
strain
case
rdxa
case
frxa
conclus
data
suggest
mutat
rdxa
alway
essenti
acquisit
mtz
resist
observ
mutat
posttreat
mtzr
isol
may
therefor
coincident
contribut
mtzr
phenotyp
strain
frxa
mutat
factor
mtz
resist
isol
mechan
therefor
may
contribut
mtz
resist
h
pylori
accuraci
ribosom
rna
gene
mutat
analysi
predict
high
level
clarithromycin
resist
helicobact
pylori
unit
kingdom
elviss
nc
owen
rj
central
public
health
labortori
laboratori
enter
pathogen
london
uk
pretreat
resist
helicobact
pylori
clarithromycin
cla
metronidazol
mtz
key
factor
erad
therapi
failur
adenin
guanin
g
cytosin
c
mutat
nucleotid
g
rdna
confer
vitro
cla
resist
aim
determin
mutat
type
high
level
cla
resist
link
test
crossassoci
high
level
mtz
resist
one
thousand
one
hundr
fiftyon
uk
isol
routin
endoscopi
test
suscept
cla
mtz
use
e
test
pcrrflp
identifi
rdna
mutat
cla
resist
isol
use
mbo
ii
bsa
respect
mutat
pcr
assay
mutat
mutat
frequenc
addit
heterozyg
mutat
detect
resist
strain
confirm
sequenc
high
level
cla
resist
mic
mgml
occur
strain
repres
mutat
fiftysix
isol
cla
mtz
resist
strain
high
level
cla
resist
high
level
mtz
resist
singl
mutat
predomin
dual
resist
strain
find
indic
mutat
predict
likelihood
high
level
cla
resist
mutat
assay
provid
specif
basi
obtain
cla
resist
data
treatment
surveil
realtim
pcr
detect
rdna
mutat
confer
clarithromycin
resist
helicobact
pylori
use
roch
lightcycl
lawson
aj
elviss
nc
owen
rj
central
public
health
laboratori
laboratori
enter
pathogen
london
uk
helicobact
pylori
colon
gastric
mucosa
world
human
popul
signific
subgroup
infect
host
h
pylori
associ
aetiolog
number
gastric
diseas
notabl
gastric
duoden
ulcer
macrolid
antibiot
clarithromycin
key
compon
mani
combin
therapi
use
erad
h
pylori
infect
howev
resist
clarithromycin
import
caus
treatment
failur
clarithromycin
resist
associ
mutat
rrna
nucleotid
inhibit
bind
drug
ribosom
rapid
realtim
pcr
assay
detect
rdna
mutat
confer
clarithromycin
resist
develop
use
roch
lightcycl
assay
util
pair
biprob
one
specif
mutat
one
wild
type
sequenc
mutat
detect
characterist
reduct
biprob
tm
pcr
assay
appli
dna
extract
select
h
pylori
isol
uk
patient
identifi
rdna
wild
type
heterozyg
result
correl
obtain
disk
diffus
sensit
test
pcrrflp
base
methodolog
lightcycl
assay
success
appli
dna
extract
gastric
biopsi
sampl
thu
offer
potenti
inform
patient
manag
without
necess
cultur
efficaci
toler
differ
tripl
macrolidecontain
antihelicobact
pylori
treatment
regimen
children
f
spain
introduct
preval
erythromycin
resist
err
group
streptococci
ga
increas
spain
sinc
earli
current
rate
exceed
region
studi
determin
emm
type
associ
erythromycin
resist
spain
materi
method
isol
belong
sauc
surveil
collect
rapid
sequenc
analysi
specif
pcr
product
use
deduc
emm
type
correspond
major
known
ga
serotyp
pcr
primer
use
sequenc
done
big
dye
termin
mix
autosequen
appli
biosystem
dna
sequenc
subject
homolog
search
bacteri
dna
databas
result
overal
ga
isol
err
analys
three
mtype
account
err
isol
wherea
repres
eri
err
isol
strongest
associ
seen
ci
second
last
tempor
period
studi
homogen
distribut
err
mtype
centr
seen
conclus
mtype
lead
respons
err
spain
remain
err
type
show
tempor
geograph
homogen
distribut
sauc
acronym
stand
sensibilidad
lo
antimicrobiano
utilizado
en
la
comunidad
en
espana
suscept
antimicrobi
commonli
use
commun
spain
spanish
word
willow
tree
signific
increas
preval
erythromycinresist
clindamycin
miocamycinsuscept
mphenotyp
streptococcu
pyogen
spain
purpos
varieti
method
use
molecular
type
enterococcu
spp
relat
gramposit
bacteria
includ
dnabas
method
macrorestrict
analysi
use
pulsedfield
gel
electrophoresi
pfge
ribotyp
amplificationbas
method
rapid
amplif
polymorph
dna
rapd
amplifi
fragment
length
polymorph
aflp
use
homogen
strain
collect
transconjug
result
filterm
differ
antibioticresist
e
faecium
recipi
isol
lab
influenc
transfer
antibioticresist
determin
outcom
differ
type
method
investig
result
fragment
pattern
result
pfge
indic
minor
differ
transconjug
recipi
respect
differ
primer
use
rapd
none
singl
fragment
shift
detect
result
fragment
pattern
aflp
cluster
transconjug
group
major
related
result
strongli
depend
mathemat
method
use
cluster
analysi
fragment
pattern
digest
plasmid
show
possess
differ
wide
relat
plasmid
transconjug
conclus
result
studi
clearli
show
certain
situat
type
method
commonli
use
enterococci
relat
gramposit
bacteria
come
limit
sasss
network
aim
set
nation
surveil
studi
obtain
standard
inform
antimicrobi
suscept
variou
bacteri
pathogen
current
hospit
particip
project
differ
geograph
region
saudi
arabia
year
sasss
focus
set
network
overal
high
frequenc
resist
antibiot
differ
bacteri
pathogen
saudi
arabia
seen
geograph
variat
resist
notic
could
relat
differ
prescrib
practic
approxim
escherichia
coli
k
pneumonia
respect
extend
spectrum
ebl
produc
resist
enterobacteriaca
group
carbapenem
pipracillintazobactam
low
resist
pseudomona
aeurginosa
variou
antipseudomon
antibiot
includ
carbapenem
high
alarm
methicillin
resist
staphylococcu
aureu
mrsa
compris
aureu
isol
vancomycin
intermedi
aureu
visa
detect
high
level
resist
gentamicin
enterococcu
seen
isol
enterococcu
facieum
glycopeptid
resist
resist
streptococcu
pneumonia
penicillin
rang
almost
surveil
antibiot
resist
nation
level
necessarili
give
guidanc
practic
physician
best
agent
use
worldwid
problem
betalactam
resist
r
streptococcu
pneumonia
sp
complic
increas
r
macrolid
older
fluoroquinolon
fq
ciprofloxacin
cip
aim
studi
evalu
rate
acquisit
resist
differ
fq
cip
sparfloxacin
spx
levofloxacin
lev
sp
strain
differ
level
suscept
penicillin
p
fifteen
strain
serial
daili
passag
subinhibitori
concentr
four
antibiot
gradient
plate
method
acquisit
resist
clinic
strain
isol
children
daycar
center
use
five
strain
suscept
penicillin
p
one
refer
strain
four
clinic
isol
p
mgl
five
intermedi
p
one
refer
strain
p
mic
mgl
four
clinic
strain
p
mic
mgl
five
resist
r
p
p
mic
mgl
mean
number
passag
n
necessari
reach
r
level
fq
select
agent
follow
tabl
spx
lev
induc
resist
slowli
cip
result
show
rate
acquisit
resist
fq
strongli
relat
alter
suscept
p
probabl
modif
cell
wall
result
concord
clinic
result
clinic
relev
phase
variat
pneumococc
opac
nasopharyng
np
colon
children
day
care
center
dcc
carsenti
h
mancini
g
bensoussan
dunai
b
pradier
ch
dellamonica
p
archet
hospit
infecti
diseas
nice
franc
streptococcu
pneumonia
sp
adher
nasopharyng
np
epithelium
prerequisit
induct
otiti
transpar
sp
shown
colon
np
infant
rat
better
opaqu
sp
opaqu
sp
proven
virul
form
system
infect
mous
model
aim
studi
evalu
phase
variat
nasopharynx
children
sp
strain
isol
winter
epidemiolog
studi
np
sampl
children
famili
dcc
mic
determin
perform
e
test
penicillin
p
amoxicillin
amx
ceftriaxon
cro
serotyp
perform
use
quellung
reaction
upon
oil
immers
microscop
examin
short
chain
six
eight
cocci
note
absenc
chain
field
respect
phase
variat
detect
catalas
trypticas
soja
plate
amx
cro
mic
bactericid
activ
determin
pair
variant
differ
serotyp
suscept
penicillin
seventi
strain
sp
screen
phase
variat
nine
chain
length
variant
strain
chain
length
show
variant
proport
variant
predomin
chain
length
increas
serotyp
preval
bactericid
activ
variant
show
fourto
eightfold
increas
mbc
variant
may
present
np
children
predomin
form
colon
virul
variant
lower
level
autolysi
show
less
suscept
kill
antibiot
may
persist
np
explain
absenc
erad
activ
molecul
antimicrobi
resist
among
clinic
strain
pneumonia
isol
patient
communityacquir
respiratori
tract
infect
carti
russia
kozlov
rs
bogdanovitch
tm
sivaya
ov
agapova
ed
b
ahmetova
li
b
furletova
b
gudkova
lv
b
gugutsidg
b
ilyina
vn
b
marusina
b
multich
ig
b
ortenberg
ea
b
schetinin
ev
b
shturmina
purpos
determin
antimicrobi
resist
pneumococci
caus
carti
differ
russian
citi
method
total
nondupl
strain
isol
russian
citi
studi
antimicrobi
test
includ
penicillin
pen
amoxicillin
amo
erythromycin
eri
azithromycin
azi
clarithromycin
cla
midecamycin
mid
spiramycin
spi
clindamycin
cli
levofloxacin
lev
vancomycin
van
rifampicin
rif
tetracyclin
tet
cotrimoxazol
sxt
suscept
test
perform
broth
microdilut
interpret
result
accord
nccl
guidelin
map
bacteri
resist
hungarian
region
farka
juhasz
b
orosi
p
miszti
c
c
balogh
kenezi
teach
hospit
hygieni
debrecen
hungari
b
kenezi
teach
hospit
laboratori
debrecen
hungari
c
univers
debrecen
microbiolog
lab
debrecen
hungari
region
hospit
laboratori
debrecen
hungari
background
region
trend
microbiolog
resist
pattern
constitut
basic
data
qualifi
criteria
effect
infect
control
purpos
aim
studi
establish
intern
compat
region
databas
hungarian
counti
bihar
method
model
nation
nosocomi
infect
societi
public
format
us
publish
contain
data
regard
variou
icu
type
ambulatori
patient
hospitalis
patient
format
use
antibiot
utilis
data
devic
relat
infect
rate
well
collect
clean
data
year
microbiolog
laboratori
counti
result
ciprofloxacin
p
e
coli
suscept
significantli
differ
us
data
follow
mr
cn
streptococcu
pneumonia
penicillin
gener
cephalosporin
pseudomona
aeruginosa
piperacillin
enterobact
spp
escherichia
coli
ceftriaxon
conclus
databas
prove
use
tool
choos
primari
ward
activ
surveil
includ
place
infecti
diseas
physician
visit
icu
rehabilit
unit
addit
analysi
need
individu
institut
level
heavili
use
useabl
antibiot
bacteria
well
aminoglycosid
betalactam
lactamas
inhibitor
combin
gener
cephalosporin
corynebacteria
compar
epidemiolog
clinic
immunolog
featur
add
haart
introduct
patient
p
diagnos
p
detect
sinc
casecontrol
studi
though
mean
number
newli
diagnos
aid
p
sharp
drop
haart
era
pyear
pyear
sinc
p
distribut
add
underli
immunodefici
show
limit
chang
exclud
greater
frequenc
tuberculosi
tb
p
wast
syndrom
p
add
show
differ
frequenc
tendenc
toward
higher
mean
count
aid
diseas
notic
vs
cellsml
p
signific
differ
candida
esophag
toxoplasmosi
kaposi
sarcoma
tb
p
limit
variat
clinic
immunolog
present
attribut
poor
impact
haart
aid
recognit
p
detect
sinc
receiv
haart
insuffici
complianc
antiretrovir
p
aid
present
haart
era
increas
mean
age
sexual
transmiss
found
p
notwithstand
effect
haart
natur
histori
hiv
diseas
consequ
add
distribut
relat
immunodefici
neglig
sinc
p
could
benefit
haart
aid
onset
high
clinic
suspicion
add
maintain
face
p
miss
undertr
hiv
diseas
radata
commun
internet
platform
manag
resist
analysi
guid
haart
switch
implement
clinic
practic
hivinfect
individu
paech
v
lorenzen
stoehr
plettenberg
ifi
interdisciplinari
infectiolog
immunolog
hamburg
germani
purpos
hivresist
analys
indic
prepar
switch
haart
hivinfect
individu
failur
ongo
haart
regimen
specialist
sever
respons
site
often
feel
lack
complementari
inform
interpret
resist
analys
done
independ
clinic
benefit
resist
analysi
assay
sigfnificantli
higher
physician
access
extern
advic
hivexpert
possibl
treatment
option
databas
concept
radata
wwwradatad
develop
germani
gener
expert
advic
implement
haart
switch
result
fifteen
hivtreat
centr
seven
laboratori
high
rank
author
hivmedicin
contribut
radata
databas
sinc
start
januari
germani
hivinfect
subject
elig
particip
project
present
failur
haart
viral
load
cml
expert
advic
gener
data
evalu
base
recommend
extern
hivexpert
observ
therapi
switch
schedul
period
month
conclus
radata
novel
databas
concept
featur
evalu
data
avail
complementari
inform
particip
site
project
design
provid
profici
patient
centr
germani
foreign
countri
inform
provid
number
enclos
subject
enlarg
vitro
effect
hiv
infect
abc
transport
express
antiretrovir
drug
efficaci
therefor
evalu
primari
cultur
human
monocytederiv
macrophag
mdm
lymphocyt
effect
retrovir
infect
haart
express
activ
pgp
mrp
specif
inhibitor
host
protein
antiretrovir
activ
nrti
nonnrti
ip
result
one
hand
evidenc
transitori
increas
pgp
mrna
express
lymphocyt
mdm
respons
vitro
hiv
infect
correl
increas
pgp
cell
surfac
express
activ
increas
tnfalpha
product
mrna
contrast
signific
modul
mrp
observ
hand
probenecid
potenti
vitro
antihiv
activ
azt
indinavir
effect
accentu
probenecid
combin
conclus
result
show
hiv
infect
increas
abc
transport
express
could
favoris
efflux
antiretrovir
drug
decreas
pharmacolog
effect
specif
inhibitor
transport
could
revers
deleteri
effect
effect
interferon
alpha
plu
ribavirin
therapi
frequenc
hcv
hiv
cmv
specif
respons
peripher
blood
hivhcv
coinfect
patient
month
treatment
method
two
group
patient
chronic
hcv
infect
studi
hiv
coinfect
progressor
antiretrovir
therapi
hivneg
control
twelv
hcvhiv
hcv
patient
alreadi
reach
month
ifnalpharibavirin
therapi
virusspecif
peripher
blood
analyz
ifngammaelispotassay
use
one
cmv
three
hcv
core
antigen
result
baselin
hcvspecif
frequenc
significantli
lower
hivand
cmvspecif
one
frequenc
hcv
well
cmv
similar
two
group
hcvhiv
hcv
specif
frequenc
chang
baselin
month
antihcv
treatment
decreas
three
increas
one
case
hivand
cmvspecif
frequenc
decreas
seven
patient
similar
result
observ
hivneg
group
conclus
hcvspecif
immun
respons
might
prone
tissu
compartment
hivspecif
one
immun
defect
induc
hiv
infect
might
respons
low
level
hcvspecif
respons
observ
hivprogressor
ifnalpharibavirin
therapi
influenc
hcvand
hivspecif
frequenc
month
treatment
discuss
frequenc
specif
cell
elispot
correl
plasma
viral
load
cohort
ltnp
slow
progressor
martinez
v
alatrakchi
n
costagliola
b
bonduel
agut
h
c
autran
b
alt
studi
group
hopit
laboratoir
dimmunologi
cellulair
pari
franc
b
de
medecin
saintantoin
inserm
pari
franc
c
hopit
laboratoir
de
virologi
pari
franc
background
cell
respons
associ
longtermnonprogress
ltnp
hiv
infect
correl
frequenc
cell
viral
load
yet
studi
prospect
quantifi
frequenc
use
ifngamma
elispot
assay
cohort
ltnp
method
cohort
ltnp
slow
progressor
infect
year
count
analys
cell
analyz
use
prolifer
ifngamma
elispot
assay
ifngamma
product
cell
supernat
result
wide
rang
observ
frequenc
cell
assess
elispot
pbmc
median
pbmc
frequenc
neg
correl
viral
load
p
count
associ
low
level
cell
activ
assess
cell
p
similar
result
obtain
cell
prolifer
ifngamma
product
conclus
interestingli
number
cell
correl
plasma
viral
load
independ
count
indic
defect
cell
reflect
global
deplet
respons
strongli
correl
control
viru
replic
impact
drug
interact
therapeut
manag
activ
tuberculosi
hiv
infect
patient
martinez
v
truffot
c
b
caum
e
c
katlama
c
c
jarlier
v
b
bricair
f
c
jouan
depart
infecti
tropic
diseas
hospit
institut
pasteur
de
pari
franc
b
depart
bacteriolog
hospit
pari
franc
c
depart
infecti
tropic
diseas
hospit
pari
franc
institut
pasteur
de
pari
franc
sinc
use
haart
manag
hiv
patient
activ
tuberculosi
rais
question
drug
interact
therapeut
manag
infect
retrospect
cohort
studi
followup
hiv
patient
activ
tuberculosi
diagnos
studi
data
includ
evolut
tuberculosi
hiv
cell
count
plasma
hiv
viral
load
antituberculosi
antiretrovir
regimen
ninetyfour
percent
patient
treat
quadrupl
combin
antituberculosi
drug
rifabutin
five
patient
fourteen
patient
treat
doubl
antiretrovir
therapi
nucleosid
revers
transcriptas
inhibitor
nrti
tripl
drug
nrti
andor
nonnucleosid
revers
transcriptas
inhibitor
nnrti
andor
proteas
inhibitor
pi
median
followup
month
differ
cell
count
viral
load
two
group
patient
treat
nnrti
pi
diagnosi
tuberculosi
time
antituberculosi
drug
discontinu
concern
cure
rate
tuberculosi
hand
plasma
hiv
viral
load
significantli
better
control
patient
nnrti
pi
p
hiv
patient
activ
tuberculosi
receiv
haart
antiretrovir
combin
includ
nnrti
allow
better
control
viral
replic
regimen
includ
pi
without
impact
use
rifampin
rifabutin
adher
essenti
effect
antiretrovir
therapi
pharmaci
visit
would
improv
patient
advis
survey
carri
period
month
umit
selfreport
distribut
patient
nineti
evalu
inform
given
clinician
suffici
treatment
advic
card
use
howev
would
like
attend
pharmaci
visit
topic
would
prefer
tackl
drug
interact
side
effect
effect
forget
treatment
well
accept
toler
respect
patient
viral
load
count
well
known
respect
howev
inaccur
pattern
treatment
frequent
bad
adher
observ
treatment
forgotten
occasion
regularli
inadequ
attitud
treatment
forgotten
number
pill
dose
frequenc
length
treatment
would
risk
factor
nonadher
major
patient
pharmaci
visit
necessari
benefici
first
result
show
better
understand
treatment
improv
adher
enhanc
plasma
concentr
antiretrovir
drug
vivo
activ
glycopeptid
aureu
infect
rabbit
endocard
model
mic
predict
vivo
efficaci
asseray
n
caillon
j
lemabecqu
v
jacquelin
c
batard
e
potel
g
bugnon
laboratoir
antibiologi
facult
de
medecin
nant
franc
studi
vivo
efficaci
vancomycin
v
teicoplanin
five
staphylococcu
aureu
sa
strain
two
methicillinsuscept
mssa
two
methicillinresist
mrsa
one
glycopeptideintermedi
gisa
strain
rabbit
endocard
model
mic
v
vt
mssa
mssa
mrsa
mrsa
gisa
respect
anim
randomli
infect
one
strain
treat
day
v
continu
infus
v
simul
h
human
dose
use
infus
continu
infus
allow
simul
mgkg
human
dose
follow
initi
bolu
regimen
achiev
clinic
relev
serum
steadyst
concentr
glycopeptid
mg
l
result
follow
express
log
cfug
veget
follow
parenthesi
number
rabbit
use
purpos
determin
preval
decreas
glycopeptid
suscept
among
clinic
isol
staphylococcu
aureu
collect
patient
hospit
strasbourg
univers
hospit
suscept
glycopeptid
aureu
isol
collect
hospit
environ
approxim
period
also
investig
method
suscept
glycopeptid
studi
among
mrsa
isol
use
detect
decreas
suscept
glycopeptid
use
agar
plate
contain
mgl
teicoplanin
detect
heterovisa
strain
use
agar
plate
contain
mg
l
vancomycin
determin
mic
vancomycin
teicoplanin
use
agar
dilut
e
test
strip
method
result
thirtynin
percent
aureu
clinic
isol
strain
mrsa
visa
heterovisa
strain
detect
six
percent
mrsa
isol
teicoplanin
intermedi
aureu
strain
environ
aureu
isol
methicillinresist
five
five
strain
suscept
glycopeptid
conclus
result
regard
vancomycin
reassur
howev
high
rate
mrsa
presenc
teicoplanin
intermedi
aureu
isol
prove
prevent
control
measur
need
improv
compar
investig
polymeras
chain
reaction
convent
method
detect
methicilin
resist
staphylococcu
amont
clinic
isol
kantardjiev
tv
vachevadobrevski
rs
b
panajotov
sv
bachvarova
velinov
ti
levterova
vs
nation
center
infecti
parasit
diseas
microbiolog
sofia
bulgaria
b
militari
medic
academi
clinic
microbiolog
sofia
bulgaria
purpos
identif
methicillin
resist
staphylococci
great
clinic
implic
signific
impact
antibiot
therapi
aim
studi
compar
discdiffus
test
ddt
oxacillin
agar
screen
test
oast
pcr
detect
mec
gene
fifti
select
clinic
isol
staphylococcu
aureu
nine
epidermidi
determin
methicillin
resist
ddt
enrol
studi
ddt
perform
oxacillin
disk
mkgml
muellerhinton
agar
mha
without
nacl
nccl
oast
perform
mha
nacl
oxacillin
mkg
ml
strain
genotyp
character
mec
gene
presenc
pcr
method
use
mec
aaa
atc
cat
ggt
aaa
ggt
tgg
mec
agt
tct
gca
gta
ccg
gat
ttg
primer
gibco
brl
result
group
mr
isol
detect
pcr
posit
result
follow
aureu
six
epidermidi
six
aureu
isol
ddt
oast
posit
pcrneg
two
aureu
two
epidermidi
isol
pcr
posit
phenotyp
methodsneg
conclus
accur
rapid
detect
mr
constant
challeng
laboratori
pcr
assay
first
time
countri
appear
reliabl
routin
suscept
test
rapid
diagnosi
mrsa
infect
hospit
particularli
due
heterogen
resist
mani
strain
v
distribut
antibiot
suscept
bacteria
isol
suspect
urinari
tract
infect
inpati
hungari
rozgonyi
f
z
kamotsay
k
e
berek
z
c
institut
medic
microbiolog
semmelwei
univers
budapest
hungari
l
januari
decemb
total
urin
sampl
cultur
nativ
urin
nu
uricultplu
orion
diagnostica
finland
cultiv
neg
nu
specimen
contamin
reveal
nu
clinic
bacteriolog
evalu
posit
nu
cultur
distribut
gramneg
similar
predomin
escherichia
coli
follow
enterobact
spp
distribut
gramposit
differ
significantli
accord
type
specimen
nu
result
groupd
groupb
streptococcu
respect
third
gener
cephalosporin
fluoroquinolon
equal
effect
e
coli
strain
ampicillin
inhibit
growth
carbapenem
cefepim
fluoroquinolon
activ
enterobact
strain
interestingli
trimethoprim
sulfarmetoxazol
combin
could
inhibit
enterobacteriacea
strain
piperacillintazobactam
imipenem
ciprofloxacin
could
drog
choic
pseudomona
aeruginosa
enterococcu
strain
highli
sensit
glycopeptid
nitrofurantoin
imipenem
amoxicillinclavulan
acid
antimicrobi
suscept
level
escherichia
coli
isol
cultur
urin
tertiari
care
teach
hospit
tempor
trend
comparison
communityacquir
nosocomi
urinari
tract
infect
nanetti
manfredi
r
valentini
r
calza
l
chiodo
f
uni
versiti
bologna
infecti
diseas
bologna
itali
order
assess
local
tempor
trend
antibiot
sensit
common
urinari
tract
bacteri
pathogen
urinecultur
escherichia
coli
isol
review
suscept
profil
specimen
sourc
communityversu
hospitalacquir
infect
evalu
sensit
level
communityacquir
pathogen
signific
resist
rise
limit
cotrimoxazol
p
nalidix
acid
p
tendenc
toward
increas
resist
regard
norfloxacin
p
fig
communityacquir
e
coli
isol
compar
nosocomi
strain
test
year
greater
suscept
communityacquir
e
coli
isol
limit
cotrimoxazol
versu
compound
year
p
extend
amoxicillin
cephalotin
nitrofurantoin
piperacillin
year
p
fig
whole
e
coli
show
elev
sensit
rate
test
strain
nitrofurantoin
gentamicin
amikacin
cephalosporin
amoxicillin
piperacillin
mean
resist
rate
regardless
commun
nosocomi
origin
perman
surveil
sensit
level
common
pathogen
respons
infecti
diseas
enabl
identifi
local
antimicrobi
activ
tempor
variat
play
key
role
start
empir
therapi
pend
bacteri
identif
vitro
assay
conclus
uti
antimicrobi
agent
cg
combin
aminoglycosid
recommend
initi
treatment
well
cephalosporin
gener
monotherapi
addit
fluoroquinolon
aminoglycosid
effect
uti
preval
resist
mutat
antirretrovir
relat
virolog
failur
garcia
f
suarez
alvarez
martinez
nm
valera
b
b
pasquau
j
b
hernandez
quero
j
maroto
mc
hospit
san
cecilio
microbiolog
granada
spain
b
hospit
virgen
niev
microbiolog
granada
spain
purpos
investig
preval
resist
mutat
revers
transcriptas
rt
proteas
p
gene
hiv
relat
type
virolog
failur
vf
studi
patient
pregnant
women
first
vf
second
vf
two
vf
resist
mutat
investig
use
trugen
genotyp
kit
visibl
genet
result
global
preval
resist
mutat
rt
inhibitor
rti
p
inhibitor
pi
preval
resist
mutat
patient
studi
low
rti
pi
patient
first
vf
rti
well
pi
patient
second
vf
studi
rti
pi
preval
final
patient
two
vf
studi
follow
resist
mutat
rti
pi
conclus
preval
primari
resist
popul
studi
low
preval
mutat
revers
transcriptas
proteas
gene
increas
parallel
type
virolog
failur
genotyp
resist
rna
patient
plasma
compar
rapid
viru
isol
phenotyp
resist
patient
pbmc
stuermer
groeschel
b
cinatl
j
doerr
hw
institut
medic
virolog
univers
clinic
frankfurt
frankfurt
germani
object
compar
viru
isol
presenc
antiretrovir
drug
plasma
genotyp
materi
method
genotyp
perform
use
viroseqtm
ver
appli
biosystem
interpret
genotyp
done
accord
intern
standard
purifi
patient
plasma
cultiv
microtit
plate
coat
antibodi
presenc
differ
concentr
antiretrovir
drug
viru
product
measur
use
antigen
assay
phenotyp
activ
express
reduct
concentr
result
seventeen
sampl
analyz
sampl
result
obtain
method
two
sampl
could
analys
phenotyp
four
sampl
genotyp
sampl
show
total
sampl
partial
concord
sampl
show
discord
two
assay
discord
sampl
genotyp
gave
definit
interpret
conclus
viru
isol
phenotyp
pbmc
may
overcom
problem
current
use
resist
assay
analys
revers
transcriptas
proteas
gene
possibl
mutat
region
may
influenc
viral
fit
therefor
contribut
growth
viru
popul
present
lack
concord
two
assay
relat
differ
blood
compart
use
clinic
valu
resist
test
use
pbmc
investig
cooper
new
type
ifn
ifntau
inhibit
earli
step
hivi
biolog
cycl
rogez
c
clayett
p
martin
dereuddrebosquet
n
martal
j
b
dormont
c
cea
drm
fontenayauxros
franc
b
inra
physiologi
animal
jouyenjosa
franc
c
cea
crssa
eph
drm
fontenayauxros
franc
background
type
interferon
ifn
exhibit
effici
antivir
activ
notabl
hiv
sever
side
effect
restrict
clinic
use
ifntau
ovin
bovin
noncytotox
type
ifn
display
higher
inhibitori
effect
toward
hiv
replic
ifnalpha
particularli
human
monocytederiv
macrophag
mdm
antiretrovir
activ
ifntau
seem
involv
antivir
immunomodulatori
mechan
synthesi
increas
dosedepend
manner
mdm
treat
ifntau
specif
inhibit
biolog
activ
decreas
antiretrovir
effici
result
infect
signific
decreas
intracellular
hiv
rna
amount
found
mdm
treat
ifntau
parallel
addit
inhibit
observ
ifntau
elong
provir
dna
result
suggest
either
inhibit
hiv
nucleocapsid
uptak
immedi
hiv
rna
degrad
express
oa
mxa
protein
pkr
measur
ifntau
induc
express
three
host
cell
factor
role
differ
step
evalu
show
cooper
ifntau
earli
step
hiv
biolog
cycl
conclus
altogeth
result
evid
ifntau
use
antiretrovir
pathway
other
type
ifn
mdm
take
part
inhibit
earli
step
hiv
biolog
cycl
actinomycind
modul
resist
due
cellwal
activ
agent
like
bacitracin
bc
lysozym
lz
chakrabarti
dastidar
sg
b
calcutta
univers
medic
microbiolog
calcutta
india
b
jadavpur
univers
pharmaceut
technolog
calcutta
india
observ
develop
lzr
lzr
mutant
took
place
three
differ
level
accompani
unselect
distinct
elev
level
bcr
similarli
bcr
bcrmutant
also
detect
three
differ
level
although
level
bcr
mgml
bcr
mutant
could
rais
persist
effort
increas
level
lzr
crossresist
mutant
could
easili
achiev
correl
actinomycind
resist
lzr
bcr
mutant
bacteria
effect
lipas
treatment
show
rise
actinomycind
resist
lzr
bcr
mutant
gramposit
bacteria
compar
correspond
wildtyp
find
suggest
lzr
bcr
control
sever
gene
account
reduc
cellwal
cellmembran
permeabl
indirectli
phenotyp
alter
lipid
content
cellwal
thu
alter
cellwal
membran
phenotyp
extra
lipid
layer
work
conjunct
efflux
pump
mechan
final
determin
level
drugresist
experiment
develop
drug
resist
nonantibiot
role
alter
membran
fluiditi
efflux
system
dastidar
sg
mazumdar
k
asok
kumar
k
chakrabarti
b
jadavpur
univers
pharmaceut
technolog
calcutta
india
b
depart
medic
microbiolog
calcutta
univers
calcutta
india
drug
resist
among
clinic
strain
studi
select
mutant
resist
promazin
pr
methdilazin
md
result
show
success
stepup
mutant
pr
md
develop
crossresist
sever
unrel
drug
subsequ
step
broader
resist
spectra
higher
level
resist
experi
membran
fluiditi
permeabl
bacteri
cell
use
diphenyl
hexatrin
dph
fluoresc
probe
mdmutant
show
three
mark
reduct
membran
fluiditi
permeabl
sever
analogu
basic
phenothiazin
structur
eg
methylpyrrolidin
cmp
mmpc
hydroxymethyln
methylpyrrolidin
hmp
md
final
substitut
test
antibacteri
function
differ
strain
highest
activ
observ
respect
md
anaerob
bacteria
resist
depend
efflux
pump
show
higher
level
resist
even
md
found
nonantibiot
agent
triflupromazin
trimeprazin
diclofenac
sodium
high
degre
activ
vibrio
staphylococci
pseudomonad
explan
phenomenon
term
possibl
efflux
pump
discuss
csf
plasma
urin
pcr
lyme
neuroborreliosi
l
v
e
b
charl
univers
medic
school
clinic
infecti
diseas
pragu
czech
republ
b
depart
cellular
molecular
biolog
charl
univers
medic
school
clinic
infecti
diseas
pragu
czech
republ
main
reason
high
diagnost
valu
pcr
neuroborreliosi
nb
direct
way
spirochet
detect
two
set
primer
nest
pcr
use
one
plasmid
gene
encod
ospc
protein
second
chromosom
gene
rdna
far
patient
clinic
manifest
involv
nb
enrol
prospect
design
studi
continu
main
includ
criterion
posit
prove
intrathec
specif
antibodi
secret
patient
pcr
posit
csf
patient
repeatedli
examin
neurologist
sampl
csf
plasma
urin
taken
treatment
treatment
month
treatment
patient
pcr
posit
csf
six
plasma
urin
five
parallel
posit
csf
plasma
four
three
bodi
fluid
urin
treatment
posit
seven
case
complet
neg
month
pcr
rel
high
sensit
rich
sensit
antibodi
index
support
grant
mzcr
consumpt
imipenem
correl
blactam
resist
pseudomona
aeruginosa
lepper
pm
gel
j
b
trautmann
grusa
e
c
depart
medic
microbiolog
hygien
univers
ulm
ulm
germani
b
depart
biostatist
univers
ulm
ulm
germani
c
hospit
memmingen
central
pharmaci
memmingen
germani
purpos
present
studi
investig
monthli
consum
three
antipseudomonasact
antibiot
name
imipenem
piperacillintazobactam
pt
ceftazidim
period
year
use
antibiot
correl
rate
resist
pseudomona
aeruginosa
result
inspect
time
seri
use
imipenem
ceftazidim
pt
correspond
time
seri
resist
avail
juli
juli
indic
remark
coincid
use
imipenem
resist
three
antibiot
mention
pearson
coeffici
correl
use
imipenem
resist
imipenem
p
imipenem
use
pt
resist
p
imipenem
use
ceftazidim
resist
p
found
posit
regress
coeffici
quantifi
associ
imipenem
use
month
p
use
preced
month
p
true
check
depend
ceftadizim
resist
p
pt
resist
p
imipenem
use
observ
month
neither
use
ceftadizim
pt
could
identifi
factor
creat
resist
one
three
antibiot
consider
within
reason
period
time
conclus
might
strong
pressur
toward
resist
creat
carbapenem
could
limit
use
carbapenem
initi
empir
therapi
treat
hard
fast
short
cours
antibiot
treatment
relat
patient
complianc
effect
perezgorricho
bpg
ripol
b
pecher
jc
c
jesu
hospit
infecti
diseas
madrid
spain
b
insalud
outpati
consult
madrid
spain
c
univers
genev
microbiolog
genev
switzerland
treat
hard
fast
short
cours
antibiot
treatment
relat
patient
complianc
effect
find
import
implic
way
physician
manag
patient
mild
respiratori
tract
infect
relat
manag
percept
antibiot
effect
complianc
antibiot
regimen
main
purpos
research
paneuropean
market
research
studi
patient
design
determin
behaviour
antibiot
manag
mildmoder
respiratori
tract
infect
patient
expect
antibiot
therapi
identifi
particularli
aspect
relat
efficaci
complianc
studi
identifi
three
key
driver
patient
perceiv
antibiot
efficaci
length
antibiot
cours
time
onset
symptom
relief
time
complet
resolut
symptom
result
demonstr
daili
treatment
short
period
perceiv
patient
significantli
effect
longer
antibiot
cours
thu
better
meet
patient
expect
therapi
studi
macrolid
azithromycin
select
drug
therapi
shortest
cours
antibiot
shortest
dosag
schedul
common
outpati
infect
percept
efficaci
short
cours
therapi
also
correl
overal
satisfact
manag
physician
patient
complianc
antibiot
therapi
purpos
studi
group
b
streptococci
gb
remain
major
caus
neonat
infect
consensu
guidelin
recommend
intrapartum
antibioprophylaxi
amoxicillin
reduc
incid
earlyonset
neonat
gb
infect
howev
increas
incid
betalactamresist
gramneg
neonat
sepsi
report
aim
studi
analys
consequ
antibioprophylaxi
intestin
microbi
colon
newborn
studi
fecal
flora
carri
stool
sampl
daysold
newborn
divid
group
group
intrapartum
treat
mother
n
group
b
untreat
mother
group
match
regard
known
factor
affect
intestin
microbi
colon
gestat
age
type
deliveri
feed
result
colon
enterobacteria
enterococci
significantli
differ
occurr
amoxicillinresist
enterobacteria
similar
group
b
respect
howev
colon
clostridia
modifi
number
newborn
colon
significantli
less
import
group
group
b
group
group
b
p
conclus
studi
intrapartum
antibioprophylaxi
affect
intestin
colon
aerob
reduc
significantli
colon
clostridia
potenti
anaerob
pathogen
impact
antibiot
polici
restrict
use
blactam
macrolid
incid
clostridium
difficil
associ
diarrhoea
gener
medic
renal
elderli
patient
boswel
tc
pacey
b
broomfield
c
westmoreland
c
yate
c
c
nottingham
citi
hospit
microbiolog
nottingham
uk
b
nottingham
citi
hospit
pharmaci
nottingham
uk
c
nottingham
citi
hospit
infect
control
nottingham
uk
purpos
studi
investig
shortterm
impact
new
antibiot
polici
treatment
urinari
respiratori
infect
incid
clostridium
difficil
associ
diarrhoea
cdad
hospitalis
medic
elderli
care
renal
patient
result
obtain
polici
restrict
use
blactam
except
parenter
penicillin
promot
altern
antibiot
includ
levofloxacin
pneumonia
doxycyclin
nonpneumon
respiratori
infect
launch
juli
result
signific
sustain
reduct
use
aminopenicillin
cefuroxim
macrolid
correspond
increas
doxycyclin
levofloxacin
incid
cdad
determin
month
new
polici
compar
last
month
old
polici
incid
cdad
fell
per
patient
per
inpati
day
p
contrast
chang
incid
cdad
specialti
surgeri
oncolog
etc
introduc
new
polici
chang
incid
nosocomi
bacteraemia
quinoloneresist
coliform
mrsa
despit
increas
use
levofloxacin
conclus
hospitalwid
reduct
blactam
macrolid
use
medic
patient
result
signific
immedi
reduct
cdad
longer
followup
determin
effect
sustain
use
imipenemcilastatin
iv
tienam
iv
treatment
low
respiratori
tract
infect
intens
care
unit
izzo
l
orsetti
r
b
boschetto
binda
b
della
casa
u
caramanico
l
la
mazza
depart
surgeri
degli
studi
di
roma
la
sapienza
p
valdoni
rome
itali
b
camilloforlanini
intens
care
unit
rome
itali
ventil
associ
pneumonia
vap
consid
frequent
infect
intens
care
unit
icu
occur
patient
intub
longer
h
besid
nosocomi
pneumonia
common
complic
critic
ill
surgic
trauma
patient
inadequ
treatment
lead
complic
acut
respiratori
distress
syndrom
ard
empyema
lung
abscess
import
aetiolog
agent
vap
pneumonia
aris
complic
surgic
trauma
patient
bacteria
whit
mark
predomin
staphylococcu
aureu
pseudomona
aeruginosa
author
present
experi
case
employ
imipenemcilastatin
iv
tienam
v
initi
empir
monotherapi
dose
mg
g
day
treatment
seriou
lower
respiratori
tract
infect
icu
tienam
well
toler
broad
spectrum
antibacteri
agent
effect
major
gramposit
gram
neg
aerob
anaerob
bacteria
includ
pseudomona
speci
except
one
patient
deceas
caus
relat
poor
gener
condit
three
case
necessari
addit
aminoglycosid
patient
imipenem
cilastatin
tienam
monotherapi
shown
satisfactori
clinic
bacteriolog
respons
clinic
audit
impact
recommend
antibiot
treatment
kinoo
j
davidouaknin
f
hacquard
b
echard
decaz
jm
b
centr
hospitali
lagni
marn
la
lagni
sur
marn
franc
b
hospit
saint
loui
pari
franc
aim
studi
assess
impact
cur
antibiot
recommend
suitabl
prescript
lagnymarn
la
hospit
gener
hospit
bed
two
prospect
exhaust
audit
made
complet
hospit
exclud
psychiatri
februari
detail
cur
antibiot
prescript
distribut
intern
recommend
methodolog
design
multidisciplinari
team
use
period
antibiot
avail
pharmaci
prescript
assess
infecti
diseas
specialist
pharmacist
use
preestablish
criteria
literatur
recommend
audit
intern
recommend
audit
six
hundr
fiftysix
prescript
patient
collect
analys
patient
exhaust
recov
prescript
patient
characterist
infect
site
microbiolog
find
similar
group
suitabl
prescript
significantli
increas
p
unsuit
prescript
econom
reason
short
long
cours
incorrect
administr
underdosag
significantli
reduc
prescript
incorrect
indic
unchang
necessari
combin
treatment
prescrib
increas
local
recommend
improv
prescript
effort
done
order
go
improv
practic
behaviour
costeffect
analysi
antibiot
therapi
hospit
patient
copd
exacerb
aecopd
beghi
g
aiolfi
maghini
l
patruno
v
aiolfi
e
marta
hospit
pulmonari
rehabilit
unit
ao
rivolta
dadda
itali
antibiot
cost
repres
high
burden
total
drug
cost
hospit
administr
scientif
approach
consid
also
econom
aspect
therapeut
decis
may
gain
optim
treatment
object
ponder
cost
studi
retrospect
evalu
clinic
effect
cost
antibiot
therapi
patient
aecopd
retrospect
studi
result
support
previou
pharmacoeconom
consider
accord
choos
antibiot
regimen
aecopd
must
take
consider
expect
clinic
microbiolog
result
without
forget
consid
econom
burden
decis
signific
increas
fungaemia
due
nonalbican
candida
speci
shah
pm
klinikum
der
jw
goeth
universitaet
schwerpunkt
infektiologi
frankfurt
main
germani
predomin
candida
speci
blood
cultur
candida
albican
account
candida
speci
cultur
blood
sinc
observ
gradual
increas
number
nonalbican
candida
speci
onward
nonalbican
candida
speci
outnumb
c
albican
observ
especi
import
nonalbican
candida
speci
gener
nonsuscept
azol
deriv
empir
use
azol
suspect
candidaemia
recommend
amphotericin
b
uniform
activ
almost
candida
speci
echinocandin
may
altern
see
figur
search
newer
antifung
chemotherapeut
chakrabarti
dastidar
sg
b
saha
b
b
basu
l
b
calcutta
univers
medic
microbiolog
calcutta
india
b
jadavpur
univers
pharmaceut
technolog
calcutta
india
fungal
infect
due
mucorrhizopu
mz
group
present
formid
problem
due
lack
appropri
effect
drug
seen
increas
number
clinic
situat
death
due
mycoromycosi
nearli
inevit
analys
biolog
weakspot
mucorrhizopu
group
attempt
devis
suitabl
drug
use
weakspot
note
like
mani
freeliv
fungi
mz
fungi
facult
chemoautotroph
grow
simpl
sourc
carbon
nitrogen
solut
miner
salt
like
human
pathogen
chemoautotroph
nocardioform
bacteria
devis
minim
medium
base
davi
mingioli
supplement
simpl
chemic
compound
sole
sourc
carbon
nitrogen
key
chemic
diphenylamin
trypan
blue
dpa
similar
sourc
c
n
found
media
free
chemic
control
allow
good
growth
differ
strain
mz
fungi
mixtur
dpa
complet
prevent
growth
wide
concentr
rang
experi
immunocompromis
mice
show
drug
concentr
use
well
toler
mice
experiment
infect
sever
clinic
isol
mz
fungi
receiv
chemic
show
fungi
could
grow
vivo
vitro
activ
newer
fluoroquinolon
multidrug
resist
salmonella
typhimurium
nolon
resist
also
report
studi
vitro
activ
blactam
fluoroquinolon
multidrug
resist
typhimurium
human
sourc
materi
method
fifti
multidrug
resist
typhimurium
test
cefazolin
cefuroxim
cefotaxim
cefepim
ofloxacin
levofloxacin
moxifloxacin
agar
dilut
method
accord
nccl
guidelin
result
conclus
strain
resist
four
follow
antibiot
ampicillin
tetracyclin
chloramphenicol
streptomycin
sulphonamid
nalidix
acid
high
proport
strain
intermedi
resist
amoxicillinclavulan
found
resist
cephalosporin
nevertheless
intermedi
first
andor
second
gen
cephalosporin
cefotaxim
cefepim
activ
cephalosporin
mgl
though
increas
fluoroquinolon
resist
describ
among
kind
strain
resist
fluoroquinolon
found
levofloxacin
activ
fluoroquinolon
mgl
follow
ofloxacin
mgl
moxifloxacin
mgl
high
rate
resist
antibiot
salmonella
diarrhoeic
children
zlitenlibya
ghenghesh
ks
ben
ali
b
abuhelfaia
b
dufani
faculti
medicin
alfateh
univers
medic
microbiolog
tripoli
libyan
arab
jamahiriya
b
faculti
art
scienc
elghom
univers
biolog
elghom
libyan
arab
jamahiriya
salmonella
major
bacteri
caus
diarrhoea
libya
particularli
children
includ
present
studi
salmonella
speci
isol
children
diarrhoea
zliten
citylibya
children
age
day
year
organ
test
suscept
antibacteri
agent
use
disc
diffus
method
isol
examin
resist
ampicillin
amoxicillin
acid
combin
cefoxitin
chloramphenicol
doxycyclin
gentamicin
nalidix
acid
trimethoprim
none
resist
norfloxacin
strong
relationship
observ
avail
antibiot
pharmaci
citi
resist
isol
salmonella
drug
misus
antibiot
commun
may
import
factor
among
other
emerg
high
rate
resist
salmonella
examin
effect
ceftriaxon
along
probiot
administr
intestin
ecosystem
betalactamas
activ
bertazzoni
minelli
e
benini
zoppi
g
b
depart
medicin
public
healthpharmacolog
section
univers
verona
verona
itali
b
depart
paediatr
univers
verona
verona
itali
oral
bacteriotherapi
antibiot
treatment
much
debat
topic
aim
studi
whether
differ
probiot
prevent
imbal
intestin
ecosystem
dysbiosi
children
therapi
ceftriaxon
cx
method
fiftyon
children
mean
age
year
febril
respiratori
tract
infect
treat
cx
mgkgday
iv
alon
therapi
along
follow
prepar
saccharomyc
boulardii
enterococcu
spp
lactulos
l
casei
gg
l
rhamnosu
l
bifidu
l
acidophilu
b
bifidum
l
acidophilu
mixtur
variou
lactobacilli
bifidobacteria
high
concentr
faecal
sampl
collect
treatment
analys
microflora
composit
cx
concentr
betalactamas
bl
activ
result
cx
caus
intestin
dysbiosi
c
difficil
found
faecal
bl
increas
therapi
treat
group
cx
alon
increas
bl
activ
children
activ
treatment
higher
incid
found
group
therapi
bl
activ
found
children
cx
detect
faecal
sampl
conclus
probiot
administr
seem
protect
dysbiosi
caus
cx
contain
increas
faecal
bl
activ
effect
differ
accord
probiot
administ
peculiar
certain
bacteri
speci
preliminari
data
need
studi
compar
studi
initi
acquir
drug
resist
pulmonari
tuberculosi
iran
mansoori
arami
mirabolhasani
z
nritld
infecti
diseas
tehran
islam
republ
iran
purpos
resist
antituberculosi
agent
particularli
multipl
drug
resist
mdr
major
obstacl
treatment
tuberculosi
world
septemb
march
smear
cultur
posit
pulmonari
tuberculosi
patient
old
pretreat
suscept
test
isol
bacilli
inh
rif
emb
stm
perform
standard
proport
method
result
attribut
three
group
newli
diagnos
without
histori
treatment
ii
patient
histori
treatment
one
cours
iii
patient
histori
treatment
two
cours
suppos
mdr
case
result
collect
drug
individu
differ
combin
two
three
four
medic
result
resist
one
two
three
four
drug
significantli
increas
group
iii
compar
group
ii
also
group
ii
compar
group
observ
high
rate
primari
resist
inh
stm
group
ii
high
rate
mdr
inh
rif
resist
group
ii
iii
conclus
durat
bacilli
exposur
antituberculosi
agent
past
major
factor
develop
resist
contrast
guidelin
due
high
rate
primari
resist
especi
stm
area
recommend
addit
stm
treatment
patient
whose
initi
fourdrug
regimen
fail
group
ii
donor
understand
host
interact
bacteria
develop
new
method
diagnosi
defin
new
vaccin
candid
nineteen
tb
patient
seven
healthi
donor
enrol
french
hospit
cellular
immun
respons
evalu
lymphoprolifer
exvivo
quantif
specif
cell
elispotifngamma
assay
four
recombin
protein
tuberculosi
test
erp
tb
compar
tuberculin
confirm
studi
give
higher
respons
tb
patient
compar
donor
accord
result
prolifer
assay
p
addit
frequenc
specif
cell
tuberculin
statist
differ
two
group
respect
patient
test
respond
elispotassay
versu
prolifer
assay
new
antigen
erp
tb
differ
observ
two
group
conclus
recognis
larg
number
patient
seem
promis
antigen
develop
new
method
diagnosi
develop
new
vaccin
erp
tb
preferenti
recognis
tb
patient
export
antigen
test
incid
tuberculosi
tb
increas
worldwid
recent
year
geograph
differ
incid
tb
former
yugoslavia
observ
import
rise
tb
case
regist
border
region
bosnia
like
poorer
live
condit
influenc
war
emot
stress
may
promot
rise
incid
tb
renal
tuberculosi
diagnos
patient
femal
male
district
brcko
bosnia
period
year
time
none
patient
activ
pulmonari
tb
lesion
fibrou
lesion
notic
patient
diagnos
sign
previou
pulmonari
tb
seven
patient
seven
patient
develop
relaps
renal
tb
year
previou
treatment
guid
clinic
paramet
precis
done
renal
echosonographi
enabl
earli
suspicion
search
renal
tb
radiolog
method
bacteriolog
diagnosi
perform
detect
mycobacterium
tuberculosi
loewenstein
medium
patient
pcr
simpl
fast
highli
sensit
method
enabl
diagnosi
incipi
stadium
diseas
antitubercul
therapi
could
institut
month
earlier
prompt
diagnosi
renal
tuberculosi
use
pcr
besid
standard
method
necessari
otherwis
delay
diagnosi
may
danger
studi
resist
first
gener
antituberculosi
drug
mycobacterium
kansasii
mirsaeidi
sm
farnia
p
mohammadi
f
mansoori
sd
jabbari
r
taghizadeh
r
masjedi
mr
velayati
aa
nation
research
inistitut
tuberculosi
lung
diseas
infecti
diseas
immunolog
nritld
tehran
islam
republ
iran
purpos
research
perform
determin
antibiot
resist
atyp
mycobacteria
especi
mycobacterium
kansasi
result
twentythre
pigment
coloni
indic
atyp
agent
nritld
mycobacterium
culturebank
select
underw
type
identif
antibiogram
inh
rif
etb
stm
nine
sampl
kansasi
nonmtb
gordonei
xenopi
mac
bovi
tererra
asiatioum
marinum
mean
age
kansasi
case
year
nonkansasi
case
year
whole
societi
ntm
frequenc
resist
kansasi
group
inh
rif
etb
stm
preval
mdr
nonkansasi
group
frequenc
resist
inh
rif
etm
stm
mdr
conclus
signific
differ
seen
age
group
patient
affect
kansasi
nonkansasi
p
b
also
frequenc
resist
first
gener
antitb
drug
kansasi
detect
common
atyp
mycobacterium
agent
pulmonari
infect
attent
antibiogram
recommend
treatment
buruli
ulcer
caus
mycobacterium
ulceran
third
common
mycobacteri
tuberculosi
leprosi
west
africa
nowaday
effect
treatment
surgeri
consist
larg
excis
lesion
often
follow
skin
transplant
studi
effect
rifampin
amikacin
combin
estim
treatment
mice
infect
experiment
ulceran
week
treatment
rifampin
amikacin
combin
viabl
bacilli
found
infect
tissu
anim
kept
month
among
mice
treat
rifampin
alon
two
mice
relaps
minim
inhibitori
concentr
isol
strain
went
mgml
dna
sequenc
obtain
rpob
gene
strain
show
missens
mutat
affect
replac
phenylalanin
modif
gene
lead
import
inefficaci
treatment
rifampin
use
alon
studi
show
rifampin
amikacin
bactericid
action
ulceran
combin
antibiot
necessari
avoid
select
resist
mutant
histopatholog
electron
microscopi
studi
sever
isol
hiv
enteropathi
detect
aid
present
favor
respons
haart
introduct
manfredi
r
calza
l
chiodo
f
univers
bologna
infecti
diseas
bologna
itali
advanc
hiv
infect
detect
heterosexu
femal
histori
chronic
diarrhoea
sever
wast
express
bodi
weight
kg
count
cellsml
plasma
viraemia
million
copiesml
malabsorpt
syndrom
confirm
dxylos
test
repeat
pathogen
search
test
neg
stool
examin
light
microscopi
scan
electron
microscopi
em
transmiss
em
studi
enter
mucosa
em
assay
detect
ultrastructur
modif
duoden
mucosa
never
report
date
extens
thin
enterocyt
microvilli
disappear
glycocalix
larg
vacuol
enterocyt
cytoplasm
two
week
start
indinavirbas
haart
diarrhoea
disappear
patient
significantli
gain
bodi
weight
kg
kg
kg
year
parallel
increas
cellsml
undetect
hiv
viraemia
subsequ
followup
confirm
absenc
gut
disturb
stabl
bodi
weight
count
cellsml
hiv
viraemia
persist
copiesml
repeat
endoscopi
relat
histopatholog
em
assay
document
notabl
improv
mucos
damag
complet
cure
reach
year
haart
direct
intestin
local
hiv
may
respons
sever
diarrhoea
malabsorpt
wast
though
morpholog
featur
hiv
enteropathi
still
unclear
haart
act
favour
also
isol
hivrel
enteropathi
kaposi
sarcoma
nonhiv
immunocompet
adult
relaps
due
develop
squamu
cell
carcinoma
sioula
e
magira
ee
georgopoul
c
rontogiani
b
gounari
evagelismo
intern
medicin
infecti
diseas
athen
greec
b
evagelismo
patholog
athen
greec
heterosexu
hiv
neg
girl
diagnos
cutan
kaposi
sarcoma
diseas
start
year
earlier
appear
lesion
left
feet
right
knee
absolut
number
cellsdl
respect
decreas
lymphocyt
prolifer
human
herpesviru
type
detect
biopsi
specimen
place
recombin
interferon
follow
month
later
lesion
decreas
size
two
year
onset
diseas
patient
readmit
mass
left
paratrach
region
along
mediastin
bodi
temperatur
increas
patient
underw
thorac
ct
scan
demonstr
mediastin
well
defin
soft
tissu
infiltr
associ
mediastin
welldefin
mass
left
paratrach
region
mass
biopsi
reveal
squamou
cell
carcinoma
sever
violaceu
lesion
observ
arm
hand
face
sever
bilater
lymphedema
leg
reddish
papul
nodul
tumor
cm
diamet
sole
toe
calv
present
case
illustr
signific
relaps
cutan
kaposi
sarcoma
soon
appear
carcinoma
mediastin
male
patient
insulindepend
diabet
underw
cardiac
surgeri
aortocoronari
bypass
year
ago
two
week
surgeri
develop
mediastin
sternal
osteomyel
caus
methicillinresist
staphylococcu
aureu
mrsa
twice
revis
plastic
surgeri
sternal
osteomyel
perform
patient
receiv
initi
treatment
vancomycin
patient
receiv
intraven
outpati
treatment
teicoplanin
week
follow
treatment
fusid
acid
trimethoprimsulfametrol
fistula
close
four
month
later
present
substern
pain
purul
discharg
cultur
reveal
growth
staphylococci
first
mistaken
coagulaseneg
staphylococci
closer
investig
staphylococci
identifi
small
variant
mrsa
comput
tomographi
ct
reveal
multipl
mediastin
abscess
patient
treat
intraven
linezolid
mg
bid
day
switch
oral
linezolid
mg
bid
oral
therapi
pursu
week
close
surveil
patient
improv
substanti
purul
discharg
disappear
mediastin
abscess
detect
longer
ct
end
treatment
treatment
linezolid
well
toler
platelet
decreas
initi
rose
normal
valu
without
treatment
modif
nosocomi
pneumonia
due
stenotrophomona
maltophilia
profound
granulocytopen
patient
hospit
communityacquir
staphylococcu
aureu
sever
sepsi
radulescu
sasca
n
b
lups
c
tatulescu
c
univers
medicin
pharmac
epidemiolog
clujnapoca
romania
b
teach
hospit
infecti
diseas
laboratori
clujnapoca
romania
c
univers
medicin
pharmaci
infecti
diseas
clujnapoca
romania
object
present
divers
opportunist
infect
immunocompromis
patient
treatment
difficulti
find
women
admit
teach
hospit
infecti
diseas
cluj
histori
fever
myalgia
lumbar
pain
hemorrhag
syndrom
sever
sepsi
diagnos
condit
evolv
paronychia
patient
chronic
leukemia
prolong
profound
granulocytopenia
due
aggress
treatment
ifn
condit
admiss
critic
due
trombocytopenia
plateletsml
hemorrhag
syndrom
evolut
favor
antimicrobi
treatment
imipenem
blood
platelet
transfus
intraven
immunoglobulin
granulocyt
colonystimul
factor
antifung
prophylaxi
support
care
blood
pu
cultur
reveal
mssa
day
hospit
develop
bronchopneumonia
respiratori
failur
sputum
cultur
posit
stenotrophomona
maltophilia
suscept
ceftazidim
fluoroquinolon
treatment
unsatisfactori
introduc
ticarcillin
ciprofloxacin
unev
recoveri
despit
remain
granulocytotrombocytopen
conclus
treatment
infect
emerg
agent
immunocompromis
patient
difficult
guidanc
result
suscept
test
mislead
poor
correl
test
treatment
outcom
earli
dissemin
listeriosi
liver
transplant
recipi
ltr
rare
case
due
vitro
multiresist
strain
manfredi
r
de
ruvo
n
vivarelli
bellusci
r
montalti
r
la
barba
g
abtu
aden
cucchetti
attard
l
calza
l
cavallari
univers
bologna
infecti
diseas
bologna
itali
ltr
receiv
cyclosporin
azathioprin
steroid
develop
extraordinari
episod
sepsi
pleural
effus
due
multiresist
listeria
monocytogen
lm
isol
lm
strain
serov
show
extens
resist
pattern
penicillin
cephalosporin
isol
multipl
blood
cultur
pleural
fluid
week
surgeri
stool
exam
neg
p
spent
life
countrysid
bred
anim
deni
consumpt
uncontrol
food
iv
cotrimoxazol
administr
achiev
complet
clinic
microbiolog
cure
day
underli
immunodefici
may
prompt
unusualsever
lm
infect
usual
communityacquir
origin
lm
diseas
remain
infrequ
hospit
p
seven
anecdot
report
lm
infect
describ
ltr
occur
month
surgeri
earli
respiratori
system
infect
caus
communityacquir
lm
strain
prove
resist
firstchoic
antibiot
favor
respons
cotrimoxazol
use
ltr
lm
sepsi
character
episod
epidemiolog
survey
retriev
possibl
sourc
usual
communityacquir
infect
lm
regard
emerg
opportunist
pathogen
ltr
specif
risk
factor
seek
immunodefici
concern
unpredict
sensit
lm
prompt
vitro
assay
adjust
antimicrobi
therapi
problem
discuss
hbv
liver
carcinogenesi
viral
influenc
end
pappa
ga
univers
hospit
intern
medicin
ioannina
greec
hepatocellular
carcinoma
hcc
major
clinic
problem
worldwid
usual
evolv
longstand
liver
patholog
latter
stage
form
cirrhosi
hbv
hcv
chronic
infect
common
etiolog
cirrhosi
henc
hcc
number
studi
attempt
clarifi
role
virus
progress
toward
hcc
end
stage
cirrhosi
progress
toward
hcc
independ
etiolog
cirrhosi
sinc
alcohol
cirrhosi
also
proce
hcc
trial
interferon
alfa
patient
hbv
hcv
cirrhosi
exhibit
favor
result
due
antivir
properti
interferon
interferon
exhibit
antioncogen
potenti
hcc
cytokin
hormon
sensit
view
ongo
trial
somatostatin
analogu
versu
hcc
henc
treat
alcohol
cirrhosi
patient
interferon
could
favor
respons
patient
hbv
hcv
cirrhosi
elig
interferon
treatment
interferon
treatment
potenti
hazard
thrombocytopenia
ethic
conduct
randomis
trial
one
leg
cirrhot
patient
left
without
antivir
therapi
basi
classif
system
two
leg
trial
separ
moreov
viral
protein
oncogen
potenti
exist
controversi
recent
discov
hbv
protein
still
unresolv
major
topic
await
major
debat
assess
role
hivassoci
campylobacteriosi
c
accord
haart
avail
patient
posit
cultur
identifi
sinc
compar
hivinfect
p
follow
last
decad
epidemiolog
differ
shown
save
greater
sexual
exposur
hiv
p
introduct
haart
caus
drop
frequenc
c
episod
per
pyear
p
modifi
clinic
featur
disappear
dissemin
mortal
report
patient
p
hivrel
immunodefici
diseas
stage
significantli
relat
c
featur
haart
avail
p
neutrophil
count
p
aid
diagnosi
case
communityacquir
alimentari
environment
risk
factor
never
found
ten
patient
receiv
cotrimoxazol
prophylaxi
nine
p
b
relationship
occur
steroid
antibiot
use
caus
case
sensit
found
quinolon
follow
cephalosporin
gentamicin
macrolid
cotrimoxazol
antimicrobi
therapi
cure
p
relaps
caus
similar
strain
occur
patient
within
week
prehaart
era
p
c
still
occur
haart
era
probabl
due
vari
mode
transmiss
frequenc
c
greater
hivinfect
patient
less
frequent
viscer
recurr
mortal
character
haart
era
object
determin
incid
risk
factor
nosocomi
viral
respiratori
infect
nrvi
involv
human
coronavirus
hcov
neonat
pediatr
intens
care
unit
method
prospect
observ
studi
nasal
sampl
obtain
cytolog
brush
admiss
weekli
thereaft
hospit
infant
nasal
sampl
taken
monthli
staff
virolog
studi
perform
use
immunofluoresc
respiratori
synciti
viru
rsv
influenza
virus
paramyxovirus
adenovirus
immunofluoresc
rtpcr
use
hcov
detect
result
hcov
relat
nrvi
detect
nn
six
children
three
hcovrel
outbreak
observ
februari
august
decemb
associ
high
preval
infect
staff
august
outbreak
hcovinfect
nrvi
detect
hospit
infant
seventyf
hospit
preterm
nn
gestat
age
week
staff
member
infect
risk
factor
nrvi
nn
birth
weight
gestat
age
ventil
oxygen
hospit
length
ninetytwo
percent
infect
preterm
nn
symptomat
mainli
bradycardia
respiratori
worsen
conclus
data
provid
addit
evid
signific
role
hcov
nrvi
occur
hospit
preterm
nn
strain
type
screen
dna
target
assess
echinococcu
sp
transmiss
new
old
geograph
endem
foci
bart
jm
piarroux
r
dia
l
b
benchikhelfegoun
mc
c
vuitton
da
bardonnet
k
serf
parasitolog
besancon
franc
b
nation
centr
veterinari
studi
parasitolog
nouakchott
mauritania
c
univers
mentouri
parasitolog
constantin
algeria
purpos
cystic
echinococcosi
due
echinococcu
granulosu
parasit
cycl
depend
main
intermedi
host
speci
involv
differ
foci
describ
promot
mix
infect
definit
host
strain
type
tool
identifi
main
intermedi
host
involv
via
dog
human
infect
rout
focu
control
measur
mani
dna
target
use
compar
sampl
access
parasit
cycl
differ
countri
studi
compar
valu
target
eight
target
test
mauritania
echinococcosi
emerg
diseas
algeria
strain
type
never
done
thirtyf
cyst
sampl
human
ovin
camel
bovin
test
six
nuclear
two
mitochondri
target
result
two
mitochondri
target
four
six
nuclear
target
allow
discrimin
differ
foci
two
strain
found
infecti
human
sheep
strain
algeria
camel
strain
mauritania
conclus
although
overlap
geograph
sometim
rais
question
respect
genet
evolut
differ
strain
involv
human
infect
alveolar
echinococcosi
franc
updat
bardonnet
k
bressonhadni
bartholomot
b
watelet
j
beytout
j
saurin
jc
piarroux
r
vuitton
da
centr
collabor
prevent
treatment
human
echinococcosi
univers
franc
introduct
highest
preval
rate
alveolar
echinococcosi
ae
europ
found
franc
french
observatori
human
ae
done
order
get
data
could
use
evalu
present
evolut
manag
ae
materialmethod
french
case
collect
period
registr
everi
case
perform
subject
agreement
questionnair
fill
refer
patient
medic
file
practition
patient
complet
collect
case
ensur
multipli
sourc
inform
result
two
hundr
sixti
nine
french
patient
regist
sex
ratio
averag
mean
age
diagnost
year
diagnosi
perform
echinococcosi
free
french
area
symptom
alway
specif
liver
symptom
present
diagnosi
case
liver
main
locat
lesion
case
wide
spectrum
manag
patient
observ
account
region
differ
conclus
french
observatori
human
ea
facilit
better
manag
diseas
nation
level
show
new
epidemiolog
trend
especi
extens
endem
area
coin
paper
currenc
transmit
bacillu
anthraci
ghenghesh
ks
faculti
medicin
alfateh
univers
medic
microbiolog
tripoli
libyan
arab
jamahiriya
anthrax
often
fatal
bacteri
infect
caus
bacillu
anthraci
recent
event
began
septemb
us
gain
organ
worldwid
attent
heighten
awar
concern
anthrax
mani
case
anthrax
number
death
report
result
contact
envelop
sent
postal
mail
contain
b
anthraci
endospor
number
studi
shown
currenc
colon
bacteri
organ
includ
enteropathogen
eg
shigella
sp
enter
flora
eg
escherichia
coli
potenti
pathogen
eg
staphylcoccu
sp
pseudomona
sp
bacillu
sp
furthermor
methicillinresist
aureu
mrsa
isol
produc
enterotoxin
seb
toxic
shock
syndrom
also
report
studi
agre
currenc
may
consid
method
spread
potenti
pathogen
pathogen
bacteria
commun
therefor
currenc
could
also
vehicl
spread
highli
pathogen
organ
includ
b
anthraci
addit
introduct
euro
could
also
allow
bacteria
greater
freedom
travel
across
euro
zone
threat
use
currenc
particularli
paper
note
spread
lethal
organ
investig
proper
measur
prevent
use
method
terrorist
implement
salvag
temporari
femor
cathet
haemodialysi
use
antibiot
ambulatori
patient
gerasimovska
v
oncevski
dejanov
p
depart
nephrolog
clinic
centr
skopj
former
yugoslav
republ
macedonia
stay
femor
cathet
fc
haemodialysi
typic
shortterm
sever
day
use
fc
temporari
vascular
access
va
longer
period
time
outpati
go
regular
ambulatori
haemodialysi
problem
perman
access
analys
patient
discharg
hosptal
fc
durat
time
fc
day
averag
day
cummul
total
day
incid
bacteriaemia
cathet
day
six
patient
sign
infect
accord
protocol
took
blood
cultur
peripher
vein
cathet
time
start
antibiot
therapi
ab
system
local
ab
lock
cathet
differ
durat
time
domin
microorgan
staphylococcu
coagulasa
neg
much
less
staphylococcu
aureu
enterococcusab
frequent
use
cefotaxim
vancomycin
ciprofloxacin
one
six
patient
remov
cathet
without
tri
save
cathet
cathet
tip
sent
microbiolog
analysi
criteria
catheterrel
bacteriemia
crb
found
one
patient
possibl
crb
five
patient
remov
cathet
absenc
clinic
sign
infect
ab
treatment
provid
posit
tip
cultur
alon
posit
blood
cultur
cathet
neg
blood
cultur
peripher
vein
advanc
mening
educ
holt
de
tait
mi
b
cavanna
al
b
worganbrown
hart
b
mening
trust
stroud
uk
b
computeraid
learn
unit
school
health
scienc
univers
wale
swansea
uk
background
mening
remain
import
caus
death
worldwid
despit
improv
diagnosi
treatment
prevent
clinic
lay
awar
diseas
reli
educ
howev
educ
deliveri
chang
introduct
materi
suitabl
comput
internet
applic
necessari
develop
educ
materi
cdrom
internet
applic
tertiari
univers
secondari
school
level
applic
computeraid
learn
program
cdrom
cover
aspect
mening
produc
suitabl
undergradu
teach
healthcar
profession
student
nurs
doctor
pharmacist
order
reach
school
children
form
accept
pupil
teacher
develop
curriculumlink
websit
applic
simpl
use
incorpor
exist
cours
studi
issu
rais
discuss
tutor
group
peer
comment
introduct
new
method
teach
learn
mean
compat
educ
materi
must
produc
believ
applic
focus
mening
first
kind
offer
tutor
opportun
progress
teach
diseas
methodolog
content
brivudin
compar
famciclovir
improv
therapi
herp
zoster
effect
acut
diseas
postherpet
neuralgia
potenti
treatmentrel
advers
event
occur
brivudin
recipi
famciclovir
recipi
p
conclus
zoster
patient
year
brivudin
mg
famciclovir
mg
show
equival
effect
preval
durat
phn
brivudin
effect
famciclovir
stop
viral
replic
acut
herp
zoster
brivudin
offer
advantag
daili
dosag
regimen
well
toler
famciclovir
activ
complex
pt
ii
pd
ii
thiosemicarbazon
hfotsc
acta
virol
select
index
si
time
higher
acyclovir
acv
order
evalu
viru
specif
respons
structur
relationship
continu
investig
three
pt
ii
three
pd
ii
complex
activ
evalu
sensit
acv
hsv
strain
bja
resist
strain
hsv
pu
hsv
compar
obtain
strain
victoria
hsv
infect
si
indic
activ
viru
specif
respons
demonstr
fact
virus
sensit
acv
also
sensit
pt
hfotsc
cl
acv
resist
virus
sensit
ptcl
fotsc
structur
relationship
prove
fact
less
activ
hsv
infect
pd
fotsc
influenza
diagnosi
treatment
impact
new
antivir
current
treatment
behaviour
influenza
outbreak
schaetz
l
sessa
b
hoffmanla
roch
f
basel
switzerland
b
italian
colleg
gener
practition
itali
introduct
annual
influenza
epidem
sever
affect
individu
famili
health
care
system
societi
avail
new
specif
antivir
provid
opportun
better
manag
influenza
method
influenza
season
physician
public
usa
europ
interview
determin
percept
influenza
behaviour
treatment
result
patient
recognis
influenza
ill
sever
identifi
symptom
fever
muscl
achespain
cough
physician
use
symptom
diagnos
influenza
clinic
fever
muscl
achespain
cough
main
treatment
object
reduc
complic
antibiot
influenza
treatment
broadli
recommendedprescrib
european
physician
wherea
current
avail
antivir
recommend
recommend
antivir
us
physician
increas
season
markedli
decreas
antibiot
use
experi
two
influenza
season
show
influenza
antivir
use
viru
circul
volum
use
proport
size
outbreak
conclus
experi
usa
show
prompt
outbreak
inform
antivir
use
appropri
time
influenza
activ
influenza
treatment
oseltamivir
cost
benefit
individu
well
societi
object
evalu
effect
treatment
influenza
antivir
oseltamivir
health
outcom
cost
patient
societi
method
base
clinic
trial
data
data
literatur
simul
model
develop
underli
clinic
pathway
cover
morbid
mortal
due
influenza
specifi
complic
health
outcom
data
cost
attach
event
model
model
compar
variou
scenario
defin
treatment
scheme
within
defin
popul
paramet
applic
model
shown
use
uk
unit
cost
data
simul
otherwis
healthi
adult
popul
compar
oseltamivir
usual
care
result
earli
treatment
result
reduc
morbid
translat
faster
recoveri
return
normal
activ
day
lower
morbid
mortal
make
costeffect
intervent
societ
perspect
analysi
cover
differ
scenario
increment
cost
effect
ratio
discuss
conclus
antivir
treatment
appear
effect
term
health
outcom
cost
otherwis
healthi
adult
perspect
individu
patient
societi
howev
effect
sensit
time
treatment
start
accuraci
diagnosi
influenza
oseltamivir
well
toler
patient
group
thakar
b
dutkowski
r
b
froelich
e
c
gilbrid
j
ward
p
roch
global
develop
welwyn
uk
b
f
hoffmanla
roch
nutley
usa
c
f
hoffmanla
roch
basel
switzerland
introduct
oral
oseltamivir
ethyl
ester
prodrug
potent
inhibitor
influenza
viru
neuraminidas
licens
treatment
prophylaxi
influenza
usa
patient
method
safeti
data
advers
event
laboratori
safeti
evalu
deriv
clinic
trial
involv
subject
includ
children
highrisk
adult
healthi
volunt
larg
studi
investig
ecg
paramet
spontan
event
report
medwatch
yellowcard
report
follow
use
individu
worldwid
observ
casecontrol
studi
subject
influenzalik
ill
treat
oseltamivir
result
oseltamivir
well
toler
clinic
trial
drugrel
sideeffect
limit
transient
gi
effect
occur
expos
individu
resolv
spontan
caus
drop
treat
subject
effect
ecg
paramet
note
dose
sixfold
licens
regimen
oseltamivir
advers
effect
pulmonari
function
addit
effect
identifi
among
highrisk
adult
children
follow
prolong
dose
prophylaxi
occasion
report
liver
dysfunct
document
postmarket
causal
associ
establish
conclus
oral
oseltamivir
effect
safe
antivir
suitabl
influenza
manag
patient
group
decis
stop
vaccin
smallpox
loss
specif
immun
high
proport
popul
made
apocalypt
perspect
natur
provok
reemerg
smallpox
therefor
import
improv
current
capac
prevent
treat
orthopoxviru
infect
uracil
dna
glycosylas
udg
one
viral
enzym
indispens
replic
poxvirus
udg
copenhagen
strain
vaccinia
viru
vv
character
aim
defin
specif
inhibitor
suscept
use
new
class
activ
antivir
substanc
virus
orthopoxviru
genu
activ
enzym
analys
real
time
origin
method
pcr
quantit
instrument
digest
amplifi
dna
reveal
fluoresc
interc
molecul
techniqu
use
screen
select
sever
activ
antivir
substanc
udg
moreov
antivir
activ
estim
cytopath
effect
vv
infect
vero
cell
cytotox
determin
inhibit
trypan
blue
exclus
specif
action
test
compound
estim
select
index
cytotox
effect
dose
two
antivir
compound
select
inhibitori
effect
udg
activ
vv
replic
vero
cell
cultur
deoxyuridin
compound
candid
chemotherapi
poxviru
infect
object
studi
efficaci
toler
russian
antivir
drug
produc
dna
limit
resourc
context
result
drug
derinat
produc
salmon
milt
mm
dna
kda
hyperchrom
effect
protein
content
conjug
dna
result
new
drug
name
ferrovir
influenc
dna
rna
synthesi
earli
stage
replic
block
viru
action
cell
metabol
reduc
cytomegaloviru
titr
fibroblast
cell
ig
protect
effect
ferrovir
fatal
herp
enceph
mice
found
drug
toxic
mgml
ferrovir
mgml
limit
clinic
trial
patient
receiv
mg
drug
twice
daili
day
administr
well
toler
side
effect
observ
derinat
case
herpesviru
infect
patient
improv
heal
shorten
durat
ill
hivinfect
patient
treat
ferrovir
show
sustain
elev
count
signific
reduct
viral
load
median
ig
appar
remiss
found
patient
concomit
hiv
herp
viru
infect
conclus
antivir
show
good
antivir
potenc
rnaand
dnavirus
well
toler
patient
use
case
mix
infect
low
price
make
access
popul
low
financi
resourc
ortho
total
hcv
core
antigen
assay
aid
earli
predict
respons
patient
treat
interferonribavirin
lunel
f
veillon
p
b
payan
c
b
ahu
anger
laboratoir
de
bacteriovirologi
anger
franc
b
chu
anger
laboratoir
de
bacteriovirologi
anger
franc
aim
evalu
predict
valu
total
hcv
core
antigen
assay
viral
kinet
patient
chronic
hcv
method
one
hundr
twenti
two
patient
infect
genotyp
pretreat
viral
load
bdna
chiron
meqml
previou
treatment
receiv
mu
interferon
ifn
month
ribavirin
given
ifn
month
therapi
month
patient
detect
rna
viral
load
express
log
uiml
hcv
ag
log
pgml
result
pretreat
ag
valu
correl
viral
load
r
observ
rapid
decreas
ag
log
pgml
viral
load
log
uiml
sustain
respond
sr
patient
relaps
rr
ifn
alon
fall
less
import
log
pgml
log
uiml
sr
rr
combin
therapi
decreas
ag
viral
load
respect
ag
log
pgml
rna
log
uiml
observ
signific
variat
ag
viral
load
nonrespond
neg
predict
valu
hcv
rna
ag
treatment
posit
predict
valu
month
ifn
alon
hcv
ag
decreas
highli
predict
sr
correl
rna
negativ
earli
reduct
hcv
rna
log
conclus
earli
measur
total
hcv
core
antigen
use
predict
longterm
respons
treatment
lamivudin
treatment
acut
hepat
b
vincenti
meini
luchi
de
gennaro
ricciardi
l
moneta
scasso
infecti
diseas
depart
infecti
diseas
lucca
itali
acut
hepat
b
selflimit
infect
case
cours
may
particularli
sever
report
case
woman
affect
acut
hepat
b
treat
lamivudin
admiss
hospit
alaninoaminotransferas
ul
aspartateaminotransferas
ul
bilirubin
mgdl
hbsag
hbcigm
hbeag
posit
hbv
dna
copiesml
follow
day
level
ast
alt
gradual
rose
day
prothrombin
time
bilirubin
mgdl
patient
develop
sign
encephalopathi
four
plasmapheresi
practic
without
benefit
patient
treat
lamivudin
mgday
day
therapi
lamivudin
discontinu
appear
diffus
maculopapular
rash
time
result
liver
function
test
normal
four
month
hbsag
hbv
dna
longer
detect
patient
lamivudin
prevent
acut
hepat
failur
experi
suggest
promis
role
lamivudin
treatment
acut
hepat
b
long
therapi
practic
patient
prospect
control
clinic
studi
use
lamivudin
patient
acutehepat
b
necessari
costeffect
amantadin
versu
symptomat
care
treatment
influenza
morri
carman
wf
b
barber
j
c
citi
univers
london
uk
b
west
scotland
specialist
virolog
centr
glasgow
uk
c
allianc
pharmaceut
chippenham
uk
aim
assess
costeffect
amantadin
versu
best
symptomat
care
treatment
influenza
uk
method
construct
econom
model
popul
paramet
publish
literatur
model
structur
use
econom
evalu
zanamivir
publish
nation
institut
clinic
excel
uk
conduct
costutil
analysi
increment
cost
per
qali
gain
amantadin
versu
best
symptomat
care
analys
conduct
adult
averagerisk
group
atrisk
popul
highrisk
group
base
preval
influenza
averag
season
viru
circul
perspect
nh
result
averagerisk
group
increment
cost
per
qali
gain
amantadin
rel
best
symptomat
care
averag
influenza
season
viru
circul
highrisk
individu
figur
respect
result
sensit
hospitalis
rate
conclus
threshold
costeffect
per
qali
gain
amantadin
repres
valu
money
treatment
influenza
varieti
scenario
includ
baselin
averagerisk
highrisk
group
viru
circul
background
surveil
studi
world
reveal
extraordinari
increas
preval
penicillin
resist
streptococcu
pneumonia
newer
quinolon
believ
broad
activ
pneumonia
method
total
penicillin
resist
clinic
strain
isol
patient
hacettep
children
hospit
ankara
turkey
test
vitro
suscept
variou
antibiot
commonli
use
treatment
respiratori
tract
infect
minimum
inhibitori
concentr
mic
penicillin
amoxicillinclavulan
acid
doxycyclin
azithromycin
clarithromycin
ceftriaxon
ciprofloxacin
levofloxacin
moxifloxacin
gemifloxacin
determin
use
nccl
recommend
procedur
e
test
result
rang
mic
valu
agent
test
strain
shown
tabl
gemifloxacin
moxifloxacin
highest
invitro
activ
among
quinolon
test
strain
test
suscept
mgml
gemifloxacin
mgml
moxifloxacin
mgml
levofloxacin
conclus
degre
resist
drug
except
newer
quinolon
activ
isol
studi
purpos
stenotrophomona
maltophilia
preval
grow
mainli
hospit
area
maltophilia
frequent
multidrug
resist
fluoroquinolon
fq
resist
vari
one
anoth
studi
whole
resist
moder
high
gyra
parc
qrdr
partial
code
recent
describ
studi
correl
fqresist
mutat
sequenc
maltophilia
clinic
strain
materi
method
gyra
parc
qrdr
region
six
fqresist
two
fqsuscept
maltophilia
clinic
strain
amplifi
sequenc
mic
ciprofloxacin
cfx
gatifloxacin
gfx
clinafloxacin
cnfx
determin
agar
dilut
method
accord
guidelin
defin
nccl
p
aeruginosa
result
conclus
mic
rang
cfx
gfx
cnfx
resist
strain
mgl
suscept
strain
mic
cfx
gfx
cnfx
mgl
respect
suscept
resist
strain
signific
mutat
fragment
sequenc
one
resist
strain
mic
cfx
mgl
one
suscept
strain
mic
mgl
signific
gyra
mutat
strain
thu
fq
resist
maltophilia
shall
deriv
chang
area
topoisomeras
probabl
mechan
resist
efflux
pump
purpos
corynebacterium
urealyticum
caus
encrust
cystiti
inespecif
uti
system
infect
frequent
multidrug
resist
high
rate
resist
fluoroquinolon
fq
mechan
resist
fq
describ
c
urealyticum
describ
c
urealyticum
parc
gene
qrdr
region
relationship
quinolon
resist
materi
method
activ
ciprofloxacin
cfx
levofloxacin
lfx
gatifloxacin
gfx
clinafloxacin
cnfx
moxifloxacin
mfx
c
urealyticum
clinic
strain
determin
follow
nccl
guidelin
enterococci
amplifi
sequenc
parc
qrdr
standard
method
result
conclus
five
strain
cfxsuscept
mic
mgl
mic
mgl
highlevel
cfxresist
mic
mgl
cnfx
activ
cfx
mfx
gfx
mgl
strain
includ
type
strain
show
c
chang
posit
refer
wild
type
aureu
parc
gene
lead
chang
describ
main
parc
chang
fqresist
aureu
find
suggest
mutant
sequenc
compar
parc
sequenc
gramposit
might
wildtyp
speci
might
explain
part
high
resist
rate
appar
light
develop
highlevel
resist
purpos
routin
surveil
identifi
ciprofloxacinresist
mic
mgl
pneumococc
isol
compar
clinic
detail
resist
pattern
result
isol
sputa
blood
cultur
adult
heart
lung
diseas
hospit
admiss
common
half
inpati
previou
month
nineteen
patient
receiv
quinolon
preced
month
part
reflect
local
polici
introduc
penicillin
ofloxacin
first
line
treatment
pneumonia
thirteen
patient
radiolog
sign
pneumonia
pyrexi
rais
inflammatori
marker
agar
dilut
mic
quinolon
includ
norfloxacin
without
reserpin
penicillin
erythromycin
perform
increas
norfloxacin
mic
note
period
mgl
mgl
fluoroquinolon
efflux
suggest
three
isol
resist
moxifloxacin
mic
mgl
note
onward
isol
serotyp
resist
penicillin
mic
mgl
thirtyon
resist
erythromycin
mic
mgl
conclus
polici
use
quinolon
may
contribut
develop
quinolon
resist
cluster
isol
increas
level
quinolon
resist
observ
rais
concern
futur
use
newer
quinolon
treatment
respiratori
infect
maltophilia
emerg
last
year
import
nosocomi
pathogen
inher
resist
antimicrobi
agent
new
quinolon
propos
treatment
choic
enhanc
activ
sever
paramet
atmospher
method
affect
result
mic
method
perform
mic
use
two
differ
method
agar
dilut
microdilut
differ
condit
temperatur
atmospher
co
incub
time
h
total
strain
assay
nine
quinolon
follow
standard
nccl
comparison
made
result
h
use
x
test
result
differ
found
h
result
agar
dilut
except
atb
case
mic
co
contrari
almost
atb
show
signific
differ
result
h
use
microdilut
method
condit
ta
atmospher
comparison
mic
p
valu
signific
level
incub
time
h
differ
procedur
condit
incub
time
paramet
seem
affect
significantli
result
mic
quinolon
microdilut
method
use
wherea
differ
encount
agar
dilut
method
result
breakpoint
use
propos
nccl
studi
period
pneumococci
resist
note
follow
pc
em
sxt
rank
order
activ
five
fq
multidrug
resist
pneumococci
cip
mic
mgl
ofx
mic
mgl
lvx
mic
mgl
grx
mic
mgl
tvx
mic
mgl
conclus
romania
fluoroquinolon
repres
altern
treatment
betalactam
macrolid
firstlin
empir
treatment
respiratori
tract
infect
caus
pneumococci
continu
vigil
emerg
resist
fq
indic
introduct
materialmethod
suscept
test
semiautom
broth
microdilut
method
sensititr
trek
diagnost
usa
follow
nccl
recommend
perform
six
differ
quinolon
streptococcu
pneumonia
isol
ciprofloxacincip
mic
mgl
collect
two
consecut
sauc
surveil
spain
nccl
resist
r
breakpoint
use
ofloxacinofl
levofloxacinlev
sparfloxacinspa
gatifloxacingat
moxifloxacinmox
gemifloxacingem
use
result
follow
conclus
cipr
isol
gem
mox
activ
agent
gem
agent
influenc
cip
mic
increas
regard
preval
r
resist
strain
cip
mic
mgl
sauc
acronym
stand
sensibilidad
lo
antimicrobiano
utilizado
en
la
comunidad
en
suscept
antimicrobi
commonli
use
commun
spain
spanish
word
willow
tree
vitro
activ
gatifloxacin
seven
antibiot
respiratori
urinari
tract
pathogen
commun
first
result
basic
studi
grimm
h
behalf
european
multicent
studi
group
institut
med
microbiolog
weingarten
germani
total
center
austria
belgium
franc
germani
itali
portug
spain
switzerland
involv
basic
studi
bacteri
annual
suscept
inform
collect
mic
gatifloxacin
gati
ciprofloxacin
cipro
clarithromycin
clari
benzylpenicillin
g
pen
amoxicillin
amox
amoxicillinclavulan
acid
augm
cefuroxim
cur
cefixim
cix
determin
use
microdilut
method
center
request
investig
strain
follow
speci
pneumonia
spn
pyogen
spi
aureu
sau
e
faecali
efa
catarrhali
mca
h
influenza
hin
e
coli
eco
k
pneumonia
kpn
p
mirabili
pmi
p
aeruginosa
pae
far
approxim
strain
enrol
import
percentag
resist
follow
oral
antibiot
test
gatifloxacin
highest
activ
broadest
spectrum
relev
respiratori
urinari
tract
pathogen
gatifloxacin
promis
altern
therapi
respiratori
tract
bacteri
infect
vitro
activ
gatifloxacin
bordetella
pertussi
comparison
erythromycin
ciprofloxacin
levofloxacin
bourgeoi
n
pangon
b
ghnassia
jc
doucetpopulair
f
de
versail
ch
microbiologi
le
chesnay
franc
purpos
studi
bordetella
pertussi
infect
far
common
adult
adolesc
gener
estim
howev
often
recognis
infect
colonis
adult
act
reservoir
infect
pass
children
fluoroquinolon
current
recommend
treatment
respiratori
tract
infect
adult
patient
usual
empir
gatifloxacin
novel
potent
activ
gramneg
posit
bacteria
vitro
activ
gatifloxacin
compar
erythromycin
drug
choic
treatment
prophylaxi
pertussi
ciprofloxacin
levofloxacin
clinic
isol
strain
b
pertussi
includ
erythromycin
resist
strain
result
use
agar
dilut
method
mueller
medium
supplement
hors
blood
determin
mic
antibiot
gatifloxacin
activ
ciprofloxacin
levofloxacin
sensit
erythromycin
mgl
resist
erythromycin
mgl
strain
conclus
gatifloxacin
may
effect
drug
treatment
prophylaxi
adult
suspect
confirm
pertussi
ex
vivo
serum
activ
kill
rate
gemifloxacin
mg
versu
trovafloxacin
mg
singl
dose
ciprofloxacinsuscept
andresist
streptococcu
pneumonia
calvo
mj
b
alou
l
mezlu
ml
aguilar
l
b
prieto
j
microbiolog
depart
universidad
complutens
madrid
spain
b
glaxosmithklin
medic
depart
tre
canto
madrid
spain
serum
bactericid
activ
measur
ex
vivo
singl
dose
administr
gemifloxacin
gem
mg
trovafloxacin
tro
mg
healthi
volunt
random
crossov
phase
trial
blood
sampl
collect
h
cmax
dose
serum
kill
rate
determin
serotyp
penicillin
pen
cip
suscept
strain
mic
mgl
pen
cip
gem
tro
serotyp
pen
resist
strain
mic
mgl
pen
cip
gem
tro
tube
ml
serum
sampl
ml
broth
todd
hbss
incub
h
final
inocula
cfuml
mean
coloni
count
sampl
control
k
shown
figur
gem
exhibit
higher
coloni
count
decreas
initi
inocula
versu
tro
strain
h
incub
initi
inocula
decreas
obtain
tro
cip
suscept
strain
similar
obtain
gem
resist
strain
show
lower
influenc
cip
mic
increas
ex
vivo
bactericid
activ
gem
versu
tro
urin
bactericid
activ
administr
gemifloxacin
trovafloxacin
singl
dose
phase
studi
g
parra
mj
b
pont
c
aguilar
l
b
soriano
f
medic
microbiolog
madrid
spain
b
glaxosmithklin
medic
madrid
spain
urin
bactericid
activ
od
administr
gemifloxacin
gem
mg
trovafloxacin
tro
mg
assess
six
adult
male
crossov
phase
trial
urin
kill
rate
ukr
escherichia
coli
atcc
mic
mgl
gem
tro
saprophyticu
atcc
mic
mgl
gem
tro
perform
sampl
collect
h
ml
isosensitest
broth
ml
bacteri
logarithm
growth
ad
ml
sampl
give
final
inoculum
cfuml
coloni
count
perform
h
incub
percentag
initi
inocula
reduct
iir
calcul
mean
urin
concentr
measur
bioassay
mgl
gem
tro
e
coli
iir
obtain
h
incub
sampl
except
tro
h
saprophyticu
iir
obtain
h
incub
sampl
except
tro
h
bacteri
regrowth
found
mainten
h
gem
urin
antibacteri
activ
suggest
efficaci
treatment
uncompl
cystiti
influenc
decreas
suscept
ciprofloxacin
gemifloxacin
versu
levofloxacin
efficaci
experiment
pneumococc
pneumonia
guinea
pig
garciaolmo
parra
gimenez
mj
b
garciacalvo
g
pont
c
aguilar
l
b
soriano
f
fundacion
jimenez
diaz
medic
microbiolog
madrid
spain
b
glaxosmithklin
medic
madrid
spain
efficaci
ciprofloxacin
cip
levofloxacin
lev
gemifloxacin
gem
treatment
pneumococc
pneumonia
assess
guinea
pig
model
use
three
strain
mic
mgl
cip
lev
gem
respect
intraperiton
treatment
start
h
pneumonia
intratrach
inocul
continu
tid
four
dose
ten
anim
includ
group
dose
mgkg
use
cip
lev
gem
respect
order
mimic
h
cmax
obtain
human
standard
dose
anim
surviv
h
inocul
sacrif
coloni
count
perform
lung
purpos
studi
levofloxacin
lfx
fluoroquinolon
whose
activ
gramneg
bacilli
gramposit
cocci
enabl
use
monotherapi
treatment
nosocomi
pneumonia
aim
studi
pharmacokinet
appropri
lfx
iv
bid
treatment
six
inpati
ventilatorassoci
pneumonia
vap
year
kg
blood
urin
sampl
collect
steadyst
condit
appropri
interv
lfx
concentr
analys
hplc
aetiolog
agent
identifi
case
vitro
sensit
lfx
alway
assess
result
obtain
mean
valu
major
pharmacokinet
paramet
cmax
mgml
vdss
lkg
h
cl
mlminkg
mgml
h
cumul
urinari
excret
confirm
lfx
clearanc
mainli
renal
clinic
cure
microbiolog
erad
obtain
patient
day
therapi
suprainfect
due
acinetobact
anitratu
insensit
lfx
occur
case
major
pharmacodynam
paramet
fluoroquinolon
efficaci
significantli
higher
propos
threshold
cmaxmic
aucmic
case
conclus
reach
find
suggest
lfx
mg
bid
iv
may
consid
effect
treatment
vap
caus
sensit
bacteria
compar
pharmacokinet
levofloxacin
patient
lower
respiratori
tract
infect
lrti
treat
sequenti
therapi
pea
f
brollo
l
lugatti
e
b
di
qual
e
dolcet
f
b
talmasson
g
b
furlanut
institut
clinic
pharmacolog
toxicolog
dpmsc
univers
udin
udin
itali
b
divis
pneumolog
sm
misericordia
hospit
udin
itali
purpos
studi
levofloxacin
lfx
fluoroquinolon
whose
activ
gramneg
bacilli
gramposit
cocci
enabl
use
monotherapi
treatment
lrti
aim
studi
pharmacokinet
appropri
standard
switch
lfx
ivo
regimen
mg
iv
od
day
follow
mg
os
od
day
treatment
seven
inpati
lrti
year
kg
blood
sampl
collect
steadyst
condit
appropri
interv
lfx
plasma
concentr
analys
hplc
aetiolog
agent
identifi
case
vitro
sensit
lfx
assess
result
obtain
absolut
oral
bioavail
cmax
vs
mgml
iv
oral
administr
respect
signific
differ
main
pharmacokinet
paramet
observ
two
rout
major
pharmacodynam
paramet
fluoroquinolon
efficaci
significantli
higher
propos
threshold
cmaxmic
aucmic
two
assess
case
patient
clinic
cure
day
therapi
conclus
reach
ad
interim
find
show
lfx
mg
od
may
guarante
per
os
exposur
similar
achiev
iv
administr
suggest
sequenti
therapi
may
consid
effect
treatment
lrti
levofloxacin
exacerb
copd
due
pseudomona
ae
micheletto
c
tognella
pomari
c
dal
negro
r
ospedal
orlandi
divpneumologia
bussolengo
itali
develop
antibiot
resist
bacteria
problem
great
concern
gramneg
bacteria
includ
multidrugresist
mdr
pseudomona
aeruginosa
ps
respons
signific
proport
episod
copd
exacerb
particularli
elderli
aim
check
suscept
common
antimicrobi
treatment
ps
strain
isol
bronchial
secret
patient
sever
exacerb
copd
method
microbi
investig
conduct
specimen
spontan
purul
sputum
tracheobronchi
aspir
collect
protect
specimen
brush
result
fiftyseven
ps
pathogen
strain
cfu
identifi
test
period
ps
aeruginosa
ps
putida
ps
fluorescen
burkholderia
cepacia
assess
suscept
common
antibiot
levofloxacin
ciprofloxacin
ipenem
cil
ceftazidim
amikacin
piperacillintazobactam
much
lower
suscept
found
ticarcillin
acid
gentamicin
netilmicin
present
levofloxacin
prove
effect
antimicrob
option
treat
copd
exacerb
due
ps
infect
much
effici
polici
antibiot
prescrib
promot
order
prevent
select
resist
strain
case
result
confirm
excel
vitro
activ
levofloxacin
nosocomi
gramneg
pathogen
includ
esbl
produc
strain
escherichia
coli
e
cloaca
k
pneumonia
inhibit
mgl
levofloxacin
rapid
ciprofloxacin
determin
bactericid
effect
particularli
maltophilia
moreov
consid
favour
pkpd
profil
levofloxacin
repres
valid
therapeut
option
treatment
sever
gramneg
nosocomi
infect
moretti
f
quirosroldan
e
casari
chiodera
vial
p
carosi
g
univers
brescia
institut
infecti
tropic
diseas
brescia
itali
man
ivdu
hiv
posit
attend
aur
hospit
fever
torac
pain
xchest
radiographi
reveal
round
lesion
cm
near
lingula
central
hyperdiaphan
area
lymphocyt
count
cellsmm
viral
load
cp
ml
hospit
stay
rhodococcu
equi
found
cultur
peripher
blood
faecal
sputum
specimen
antibiot
treatment
oral
rifampin
mgqd
intraven
imipenem
mg
tid
start
due
persist
fever
immodif
radiographi
neg
p
carinii
mycobacteria
bacteria
bal
coltur
imipenem
substitut
parenter
vancomycin
mg
bid
day
persist
fever
increas
diamet
lung
lesion
cm
vancomycin
sustitut
oral
levofloxacyn
mg
bid
continu
rifampin
day
cours
levofloxacyn
therapi
fever
remit
patient
discharg
levofloxacyn
mg
bid
rifampin
month
followup
radiolog
control
pointedout
remark
resolut
lung
lesion
may
suppos
levofloxacyn
effect
treatment
r
equi
infect
even
studi
particularli
control
studi
necessari
liberti
izzo
b
loiacono
l
b
calabria
g
patarino
izzo
e
ii
depart
napl
cotugno
hospit
itali
b
iii
depart
napl
cotugno
hospit
itali
increas
preval
salmonella
typhi
strain
reduc
suscept
chloramphenicol
prompt
search
antibiot
efficacyquinolon
class
antibiot
activ
vitro
vivo
enteropathogen
inwestig
use
levoxacin
two
regimen
treatment
typhoid
paratyphoid
infect
patient
method
thirtytwo
adult
patient
inclut
studi
septemb
april
patient
posit
cultur
typhi
six
posit
cultur
paratyphi
isol
fulli
suscept
levoxacin
compar
treatment
levoxacin
day
mgr
bid
group
patient
treatment
day
mgr
bid
group
patient
clinic
cure
defin
defervescenz
fever
day
treatment
absenc
complic
clinic
relaps
followup
result
conclus
clinic
cure
rate
patient
group
patient
group
differ
rate
statist
signific
blood
cultur
patient
steril
day
treatment
remain
month
followup
subject
clinic
microbiolog
relaps
stool
cultur
remain
neg
also
two
regimen
treatment
good
toller
advers
event
regist
conclud
levoxacin
treatment
day
enter
fever
necessari
mulidrugresist
typhi
led
use
quinolon
firstlin
drug
treatment
enter
fever
pefloxacin
treatment
patient
acut
infecti
diarrhoea
troseljvukia
tvb
strahinja
v
b
poljak
stojanovia
c
nikolia
n
depart
infecti
diseas
univers
hospit
center
rijeka
croatia
b
glaxosmithklin
market
rijeka
croatia
c
dept
rijeka
institut
public
health
rijeka
croatia
dept
rijeka
maritim
academi
rijeka
croatia
purpos
studi
investig
clinic
bacteriolog
effici
day
pefloxacin
treatment
compar
symptomat
therapi
result
obtain
patient
treat
pefloxacin
therapi
clinic
effect
alreadi
third
day
control
group
happend
day
bacteriolog
erad
note
patient
first
patient
second
group
day
treatment
neg
cultur
week
pefloxacin
protocol
complet
patient
control
group
neg
stool
cultur
day
treatment
week
end
statist
signific
differ
clinic
p
bacteriolog
p
effici
day
pefloxacin
treatment
protocol
protocol
significantli
differ
clinic
p
bacteriolog
erad
control
group
conclus
reach
effici
pefloxacin
quinolon
treatment
acut
infectiuo
diarrhoea
justifi
use
sever
form
diseas
dalhoff
ullmann
u
b
schubert
b
bayer
ag
wuppert
germani
b
univers
kiel
institut
med
microbiolog
kiel
germani
background
antibacteri
activ
moxifloxacin
mxf
compar
levofloxacin
lev
amoxicillin
amx
clarithromycin
cla
erythromycin
eri
vitro
model
method
pharmacokinet
bronchial
mucosa
bm
serum
follow
singl
oral
dose
mg
mxf
cla
mg
lev
amx
eri
simul
use
one
compart
model
bacteria
test
staphylococcu
aureu
no
streptococcu
pneumonia
no
aliquot
taken
h
plate
brain
heart
infus
agar
enumer
result
pneumonia
elimin
agent
studi
signific
differ
appar
pneumonia
aureu
strain
object
compar
safeti
efficaci
oncedaili
moxifloxacin
oncedaili
ceftriaxon
treatment
cap
hivinfect
patient
pt
method
result
retrospect
survey
oral
moxifloxacin
mg
daili
day
compar
standard
regimen
iv
ceftriaxon
g
daili
day
treatment
cap
hiv
pt
adult
pt
clinic
sign
symptom
cap
consist
chest
xray
find
includ
pt
median
age
year
rang
male
demograph
characterist
similar
treatment
group
pt
receiv
mxifloxacin
pt
ceftriaxon
clinic
success
rate
moxifloxacin
ceftriaxon
poststudi
evalu
approxim
week
later
moxifloxacintr
pt
ceftriaxonetr
pt
relaps
advers
event
report
compar
treatment
group
fourrel
advers
event
gi
headach
moxifloxacintr
skin
ceftriaxonetr
pt
conclus
result
studi
show
moxifloxacin
oral
therapi
effect
well
toler
iv
ceftriaxon
treatment
hiv
pt
cap
therapi
moxifloxacin
associ
signific
clinic
laboratori
abnorm
data
suggest
oncedaili
oral
administr
moxifloxacin
potenti
conveni
costeffect
altern
therapi
cap
pt
hiv
infect
moxifloxacin
treatment
acut
maxillari
sinus
firstlin
therapi
failur
acut
sinus
high
risk
complic
gehanno
p
berch
p
b
perrin
b
arvi
p
c
ent
depart
bichat
claud
bernard
hospit
pari
franc
b
microbiolog
depart
necker
enfant
malad
hospit
pari
franc
c
bayer
pharma
medic
affair
depart
pari
franc
efficaci
safeti
moxifloxacin
mxf
mg
daili
day
evalu
treatment
acut
maxillari
sinus
firstlin
therapi
failur
acut
sinus
high
risk
complic
prospect
multicent
studi
total
patient
acut
bacteri
sinus
confirm
sinu
xray
valid
efficaci
analysi
one
hundr
seventi
five
patient
acut
maxillari
sinus
fail
respond
previou
antibiot
therapi
given
mean
durat
day
acut
sinus
high
risk
complic
frontal
pansinus
sphenoid
nineti
two
patient
microbiolog
valid
clinic
cure
continu
clinic
cure
rate
day
posttherapi
respect
clinic
cure
rate
day
posttherapi
sinus
firstlin
therapi
failur
sinus
high
risk
complic
respect
bacteriolog
erad
rate
therapi
day
day
posttherapi
bacteriolog
success
rate
patient
fail
respond
previou
antibiot
patient
sinus
high
risk
complic
patient
experienc
drugrel
advers
event
abdomin
pain
nausea
frequent
report
event
mxf
rapidli
effect
welltoler
treatment
kind
infect
neisseria
gonorrhoea
decreas
suscept
penicillin
ciprofloxacin
novel
mutat
pattern
gyr
par
c
gene
ciprofloxacin
resist
isol
plasmid
profil
penicillin
resist
isol
n
gonorrhoea
india
delhi
chaudhri
u
saluja
dr
b
r
ambedkar
center
biomed
research
univers
delhi
delhi
india
commerci
sex
worker
csw
serv
import
reservoir
gonorrhoea
period
monitor
antimicrobi
suscept
profil
neisseria
gonorrhoea
highrisk
popul
provid
essenti
clue
regard
rapidli
chang
pattern
antimicrobi
suscept
india
surveil
vitro
antimicrobi
suscept
n
gonorrhoea
establish
signific
increas
trend
penicillin
ciprofloxacin
resist
high
mic
mgml
respect
found
year
molecular
basi
ciprofloxacin
resist
ie
mutat
gyr
par
c
gene
isol
analyz
four
isol
mic
mgml
ciprofloxacin
harbor
tripl
mutat
phe
asn
leu
gyr
gene
third
mutat
leu
lie
downstream
quinolon
resist
determin
region
gyr
describ
gonococcu
addit
isol
tyr
substitut
par
c
hitherto
unknown
mutat
alter
par
c
gene
seen
isol
presenc
chang
gyr
gene
compris
amino
acid
chang
codon
presenc
blactamas
plasmid
among
penicillinresist
isol
determin
plasmid
profil
confirm
carri
pcr
base
protocol
find
suggest
emerg
penicillin
ciprofloxacin
resist
n
gonorrhoea
isol
major
std
center
india
indic
need
increas
awar
prudent
use
antimicrobi
vitro
activ
newer
antibiot
methicillinresist
staphylococcu
aureu
gutierrez
zufiaurr
mn
sanchez
hernandez
j
munozbellido
jl
garciarodriguez
ja
hospit
universitario
de
salamanca
salamanca
spain
purpos
mrsa
frequent
coresist
number
structur
unrel
antibiot
mrsa
resist
gentamycin
ciprofloxacin
macrolid
clindamycin
newer
antibiot
activ
multidrug
resist
gramposit
develop
test
vitro
activ
newer
antibiot
geneticallycharacter
high
level
ciprofloxacin
resist
mrsa
materi
method
thirtysix
ciprofloxacinresist
gyragrla
mutant
mrsa
clinic
strain
test
levofloxacin
lfx
ciprofloxacin
cfx
moxifloxacin
mfx
gatifloxacin
gfx
erythromycin
er
telithromycin
tl
linezolid
lin
synercid
syn
vancomycin
va
mic
determin
agar
dilut
method
accord
nccl
guidelin
result
conclus
strain
resist
cfx
lfxsuscept
gfxsuscept
nevertheless
mic
lfx
gfx
suscept
strain
highest
extrem
suscept
rang
mfx
activ
quinolon
almost
strain
highlevel
erresist
constitut
mlsb
phenotyp
tl
improv
significantli
behaviour
although
activ
er
ersuscept
strain
va
lin
syn
excel
activ
strain
show
homogen
behaviour
strain
includ
rang
mgl
lin
va
mgl
sanchez
hernandez
j
gutierrez
zufiaurr
mn
munozbellido
jl
garciarodriguez
ja
hospit
universitario
de
salamanca
salamanca
spain
purpos
corynebacterium
urealyticum
etiolog
agent
encrust
cystiti
inespecif
uti
also
involv
system
infect
c
urealyticum
frequent
multidrug
resist
glycopeptid
antibiot
tetracyclin
high
suscept
rate
fluoroquinolon
resist
rate
vari
significantli
test
vitro
activ
linezolid
telithromycin
synercid
newer
fluoroquinolon
multidrug
resist
c
urealyticum
clinic
strain
materi
method
sixtyfour
c
urealyticum
clinic
strain
test
levofloxacin
lfx
ciprofloxacin
cfx
moxifloxacin
mfx
erythromycin
er
telithromycin
tl
linezolid
lin
synercid
syn
vancomycin
va
mic
determin
agar
dilut
method
accord
guidelin
defin
nccl
enterococci
result
conclus
result
confirm
high
resist
rate
older
fluoroquinolon
macrolid
cfx
resist
erresist
lfx
activ
mgml
mfx
activ
fluoroquinolon
mgml
tl
improv
behaviour
respect
er
rang
mgml
va
lin
syn
excel
antimicrobi
activ
resist
strain
found
mgml
respect
mic
similar
strain
independ
resist
antibiot
plasma
concentr
urinari
excret
bactericid
activ
linezolid
mg
versu
ciprofloxacin
mg
healthi
volunt
singl
oral
dose
wagenlehn
fme
wydra
onda
h
kinzigschipp
b
rgel
f
b
naber
kg
hospit
st
elisabeth
urolog
clinic
straub
germani
b
institut
biomed
pharmaceut
research
ibmp
germani
purpos
studi
random
crossov
studi
volunt
receiv
singl
oral
dose
mg
linezolid
versu
mg
ciprofloxacin
assess
plasma
concentr
h
urinari
excret
hplc
urinari
bactericid
titer
ubt
h
mean
maximum
plasma
concentr
linezolid
mg
ml
ciprofloxacin
mgml
cumul
renal
excret
mean
parent
drug
linezolidciprofloxacin
ubt
determin
refer
strain
five
gramposit
clinic
uropathogen
follow
mic
mgml
linezolidciprofloxacin
aureu
atcc
aureu
mssa
aureu
mrsa
saprophyticu
msse
e
faecali
e
faecium
result
median
ubt
measur
within
first
h
linezolid
enterococc
strain
four
staphylococ
strain
median
ubt
ciprofloxacin
two
enterococc
strain
two
ciprofloxacin
suscept
two
resist
staphylococc
strain
area
ubt
show
statist
signific
differ
two
ciprofloxacin
resist
staphylococc
strain
favour
linezolid
conclus
linezolid
exhibit
bactericid
activ
ciprofloxacin
resist
suscept
strain
linezolid
test
treatment
complic
uti
due
gramposit
uropathogen
clinic
trial
whitehous
cepeda
ja
tobin
purpos
perform
pharmacokinet
within
doubleblind
randomis
trial
compar
linezolid
teicoplanin
intens
care
patient
known
suspect
gramposit
infect
receiv
either
mg
linezolid
intraven
mg
teicoplanin
first
three
dose
daili
thereaft
everi
day
renal
impair
blood
sampl
collect
creat
serum
pharmacokinet
profil
linezolid
quantit
hplc
teicoplanin
fluoresc
polar
immunoassay
result
twenti
two
patient
studi
linezolid
group
mean
age
year
rang
year
median
treatment
durat
day
rang
eighteen
patient
treat
teicoplanin
mean
age
year
rang
median
day
rang
steadi
state
peak
concentr
sd
linezolid
teicoplanin
mgl
respect
trough
concentr
day
mgl
linezolid
mgl
teicoplanin
recommend
breakpoint
staphylococcu
aureu
mgl
linezolid
mgl
teicoplanin
accumul
occur
one
linezolidtr
patient
impair
renal
function
conclus
current
recommend
dose
regimen
linezolid
teicoplanin
gener
appropri
critic
ill
though
detail
analysi
requir
stamo
g
lebessi
e
ioannid
paleolog
n
kallergi
k
foustouk
p
kyriak
children
hospit
microbiolog
athen
greec
purpos
studi
investig
suscept
methicillin
resist
staphylococcu
aureu
mrsa
isol
paediatr
hospit
quinupristindalfopristin
qd
streptogramin
combin
linezolid
lzd
oxazolidinon
materi
perform
retrospect
analysi
mrsa
strain
isol
patient
hospit
miscellan
medic
depart
neonat
unit
surgic
ward
orthopaed
ward
oncolog
unit
ward
outpati
clinic
period
sourc
isol
pu
throat
nasal
bronchial
skin
stool
ear
specimen
isol
sensit
glycopeptid
resist
gentamicin
erythromycin
method
sensit
test
perform
disk
diffus
method
bbl
sensit
disk
becton
dickinson
accord
nccl
guidelin
breakpoint
zone
diamet
lzd
q
mm
suscept
mm
resist
respect
result
isol
prove
suscept
antibiot
mean
inhibit
zone
mm
lzd
mm
qd
conclus
lzd
qd
promis
antimicrobi
agent
show
excel
activ
mrsa
clinic
isol
prudent
therapeut
use
strongli
recommend
avoid
emerg
resist
vitro
activ
streptogramin
oxazolidinon
streptococcu
pneumonia
clinic
isol
stamo
g
lebessi
e
paleolog
n
psatha
sanida
p
zaphiropoul
foustouk
p
kyriak
children
hospit
microbiolog
athen
greec
purpos
studi
evalu
vitro
activ
linezolid
lzd
member
oxazolidinon
streptogramin
combin
quinupristindalfopristin
qd
clinic
isol
streptococcu
pneumonia
tertiari
care
paediatr
hospit
materi
total
pneumococc
isol
exhibit
reduc
suscept
common
antibiot
includ
studi
strain
isol
middl
ear
fluid
eye
nasal
blood
cultur
last
year
percentag
isol
resist
penicillin
erythromycin
cotrimoxazol
clindamycin
respect
method
suscept
test
perform
standard
disk
diffus
method
bbl
sensit
disk
becton
dickinson
case
margin
result
intermedi
sensit
quinupristin
dalfopristin
mic
determin
use
e
test
method
ab
biodisk
result
isol
found
sensit
lzd
qd
activ
well
except
two
isol
exhibit
intermedi
suscept
show
crossresist
macrolid
clindamycin
well
conclus
new
antimicrobi
agent
show
excel
activ
resist
common
antimicrobi
pneumococc
isol
clinic
use
suggest
unless
therapeut
solut
avail
linezolid
new
oxazolidinon
excel
activ
gramposit
organ
includ
glycopeptideresist
strain
staphylococci
enterococci
icu
linezolid
use
treatment
sever
gramposit
infect
control
trial
suscept
pattern
gramposit
isol
icu
patient
studi
method
total
specimen
icu
patient
process
patient
enrol
antibiot
trial
methicillinresist
staphylococcu
aureu
mrsa
coagulaseneg
staphylococci
con
enterococcu
sp
methicillinsensit
staphylococcu
aureu
mssa
test
break
point
linezolid
mgl
teicoplanin
mgl
isol
test
suscept
e
test
result
linezolid
isol
mic
mgl
follow
mrsa
n
con
enterococcu
sp
mssa
teicoplanin
isol
mic
mgl
mrsa
con
n
enterococcu
sp
mssa
gramposit
isol
inhibit
concentr
linezolid
breakpoint
includ
eight
strain
staphylococci
resist
teicoplanin
conclus
linezolid
highli
activ
gramposit
isol
resist
teicoplanin
similar
report
seri
emerg
resist
linezolid
mrsa
colon
often
limit
factor
discharg
icu
clearanc
mrsa
seldom
achiev
convent
glycopeptid
treatment
oxazolidinon
linezolid
excel
soft
tissu
respiratori
tract
penetr
might
expect
erad
carriag
patient
recent
perform
doubleblind
random
trial
icu
patient
knownsuspect
gram
posit
infect
receiv
intraven
linezolid
mg
bd
patient
receiv
teicoplanin
mg
od
mrsa
clearanc
assess
end
treatment
eot
followup
result
linezolid
teicoplanin
group
known
colon
mrsa
studi
entri
respect
detect
clearanc
mrsa
colon
eot
linezolid
vs
teicoplanin
group
x
b
p
b
day
vs
x
b
p
day
vs
ns
conclus
shortterm
mrsa
clearanc
achiev
significantli
patient
treat
linezolid
howev
maintain
day
either
incomplet
initi
erad
recolon
analysi
follow
molecular
type
isol
complet
penetr
linezolid
bone
fat
muscl
hip
arthroplasti
lover
bannist
gc
zhang
j
macgowan
ap
southmead
hospit
bcare
bristol
uk
limit
data
describ
concentr
penetr
linezolid
lzd
tissu
bone
use
guid
therapi
nonvascular
infect
report
concentr
penetr
lzd
bone
fat
muscl
comparison
cefamandol
cmd
twelv
patient
receiv
mg
lzd
min
infus
mg
cmd
bolu
inject
immedi
hip
arthroplasti
bone
fat
muscl
blood
sampl
collect
time
interv
infus
assay
valid
hplc
method
bone
peak
level
agent
occur
min
administr
mean
level
lzd
mgkg
versu
cmd
mgkg
decreas
lzd
mgkg
versu
cmd
mgkg
min
correct
blood
concentr
gave
penetr
lzd
versu
cmd
min
lzd
versu
cmd
min
fat
muscl
peak
level
occur
min
infus
mean
level
lzd
mgkg
versu
cmd
mgkg
fat
lzd
mgkg
versu
cmd
mgkg
muscl
correct
blood
concentr
gave
penetr
lzd
versu
cmd
fat
lzd
versu
cmd
muscl
conclud
linezolid
exhibit
rapid
penetr
bone
associ
soft
tissu
achiev
level
excess
mic
sensit
organ
similar
distribut
penetr
profil
agent
current
use
treatment
infect
tissu
e
jc
berthaud
n
b
desmazeau
p
b
dutrucrosset
g
b
dutkamalen
b
ronan
b
b
aventi
pharma
chemistri
pari
franc
b
aventi
pharma
diseas
group
pari
franc
new
oral
streptogramin
compos
semisynthet
synergist
compon
ww
associ
pristinamycin
e
pi
pristinamycin
ii
b
pii
b
origin
synthet
rout
associ
antibacteri
activ
staphylococci
includ
methicillin
ml
b
resist
strain
rang
mgml
streptococci
mgml
pneumococci
includ
multidrug
resist
strain
mg
ml
enterococci
includ
vancomycinresist
strain
mg
ml
catarrhali
neisseria
spp
mgml
h
influenza
mgml
legionella
spp
mgml
anaerob
mic
rang
mgml
gener
bactericid
concentr
mic
aureu
pneumonia
h
influenza
demonstr
consequ
pae
h
mic
follow
exposur
h
mutant
aureu
isol
low
frequenc
mic
mutant
could
isol
mic
result
suggest
ww
promis
compound
treatment
communityacquir
infect
ex
vivo
evalu
new
oral
streptogramin
berthaud
n
diallo
n
aventi
pharma
sa
infecti
diseas
group
pari
franc
intra
cellular
activ
assess
murin
macrophag
contain
ingest
staphylococcu
aureu
three
strain
l
pneumophila
one
strain
concentr
mic
growth
aureu
strongli
inhibit
period
incub
log
cfuml
vs
control
rang
accord
strain
test
concentr
mic
growth
intracellular
l
pneumophila
inhibit
period
incub
log
cfuml
vs
control
h
respect
alon
also
inhibit
effect
bacteri
growth
log
cfuml
vs
control
h
incub
respect
bactericid
activ
also
assess
slowli
grow
aureu
experiment
condit
mimick
observ
patient
infect
indwel
devic
first
step
infect
adher
inert
support
declar
infect
biofilm
model
experiment
condit
demonstr
rapid
potent
bactericid
effect
aureu
adher
inert
support
includ
biofilm
effect
observ
three
concentr
test
mic
respect
vivo
evalu
new
oral
streptogramin
berthaud
n
huet
aventi
pharma
sa
infecti
diseas
group
pari
franc
oral
efficaci
assess
staphylococcu
pneumococc
murin
infect
mice
challeng
ip
time
ld
abscess
establish
intramuscular
inject
bacteria
right
thigh
mice
pneumonia
establish
intranas
inject
bacteria
mice
treat
twice
day
staphylococcu
aureu
septicaemia
abscess
pneunomonia
septicaemia
day
pneumonia
pneumonia
six
day
post
infect
septicaemia
abscess
result
express
ed
wherea
pneumonia
express
dose
yield
averag
surviv
time
ast
significantli
longer
untreat
infect
control
efficaci
treatment
experiment
infect
mice
caus
ml
b
sensit
constitut
resist
aureu
ed
rang
mgkgadministr
septicaemia
abscess
model
respect
also
efficaci
treatment
infect
caus
pneumonia
whatev
serotyp
resist
profil
strain
test
ed
rang
mg
kgadministr
septicaemia
ast
mgkgadministr
result
suggest
might
effect
treatment
staphylococc
pneumococc
communityacquir
infect
new
oral
streptogramin
bactericid
activ
pharmacokinet
model
streptococcu
pneumonia
mous
pneumonia
berthaud
n
huet
diallo
n
aventi
pharma
sa
infecti
diseas
group
pari
franc
bactericid
activ
streptococcu
pneumonia
new
oral
streptogramin
compos
two
semisynthet
synergist
compon
ww
associ
pristinamycin
deriv
pristinamycin
ii
deriv
assess
lung
mice
pneumonia
mice
inocul
intranas
cfu
strain
ml
bresist
eighteen
hour
later
anim
receiv
mgkg
po
administr
repeat
h
afterward
studi
influenc
vari
ratio
pi
pii
compon
administ
activ
pk
paramet
ratio
rang
also
administ
condit
oral
unitari
administr
mgkg
well
ratio
rang
demonstr
strong
quick
bactericid
activ
lung
lung
level
gener
equal
two
time
higher
blood
level
result
ratio
blood
lung
although
accord
initi
ratio
administ
synergist
h
blood
h
lung
explain
activ
observ
conclus
base
vitro
data
telithromycin
good
candid
treatment
rti
vitro
evalu
telithromycin
azithromycin
streptococcu
pneumonia
moraxella
catarrhali
haemophili
influenza
methicillinresist
staphylococcu
aureu
steelemoor
l
berg
barn
couch
k
klein
j
holloway
w
christiana
care
infecti
diseas
wilmington
us
macrolid
resist
streptococcu
pneumonia
sp
worldwid
concern
predominantli
isol
tend
multipli
drug
resist
new
agent
increas
activ
pathogen
clinic
import
ketolid
class
antimicrobi
agent
demonstr
excel
vitro
activ
sp
even
macrolid
resist
vitro
activ
ketolid
telithromycin
compar
azithromycin
az
clinic
isol
sp
moraxella
catarrhali
mcat
haemophili
influenza
hflu
mrsa
organ
test
strain
sp
includ
az
resist
hflu
mrsa
mcat
microdilut
mic
test
perform
follow
nccl
recommend
use
freshli
prepar
plate
contain
haemophili
test
medium
hflu
cation
adjust
muellerhinton
broth
camhb
lake
hors
blood
sp
camhb
mcat
mrsa
new
ketolid
superior
activ
sp
includ
az
resist
strain
mcgml
compound
excel
activ
mcat
none
demonstr
activ
mrsa
hflu
activ
compar
among
az
new
ketolid
current
approv
fda
howev
approv
europ
pez
h
vidal
gi
n
jm
scaglion
zitto
tr
centro
de
infecti
diseas
bueno
air
argentina
object
evalu
impact
initi
treatment
failur
rate
hospitalis
cost
outpati
treatment
adult
cap
argentina
compar
amoxicillin
clarithromycin
telithromycin
method
probabilist
model
implement
outpati
treatment
cap
estim
initi
treatment
amoxicillin
clarithromycin
telithromycin
assum
expect
clinic
cure
respect
patient
failur
treatment
evalu
secondlin
antibiot
amoxicillin
follow
clarithromycin
clarithromycin
follow
new
fluorquinolon
hospitalis
patient
telithromycin
failur
treatment
must
hospitalis
without
second
line
outpati
treatment
cost
cap
includ
drug
cost
day
medic
visit
chest
radiographi
analysi
hospitalis
result
estim
treatment
patient
firstlin
drug
failur
patient
amoxicillin
clarithromycin
telithromycin
respect
cost
outpati
treatment
hospitalis
secondlin
drug
secondlin
hospitalis
amoxicillin
clarithromycin
respect
hospitalis
telithromycin
conclus
telithromycin
show
lower
clinic
failur
hospitalis
cost
cap
studi
suggest
shorten
cap
telithromycin
treatment
day
help
adher
treatment
decreas
cost
even
new
macrolid
good
altern
tetracyclin
treatment
mediterranean
spot
fever
popivanova
nip
petrov
aip
boykinova
obb
kazakova
zkk
baltadjiev
agb
b
medic
univers
infecti
diseas
plovdiv
bulgaria
b
depart
anatomi
medic
univers
plovdiv
bulgaria
mediterranean
spot
fever
msf
caus
rickettsia
conorii
appear
endem
diseas
region
bulgaria
frequent
diseas
sever
cours
multipl
organ
lesion
earli
adequ
treatment
extrem
import
outcom
diseas
search
altern
antibiot
treatment
diseas
consid
macrolid
good
cell
tissu
penetr
dosedepend
bacteriostat
bactericid
effect
treat
msf
patient
doxycyclin
mgday
patient
clarithromycin
mgday
well
patient
midecamycin
mgday
midecamycin
acet
mgkgday
surrog
marker
treatment
evalu
effect
febril
syndrom
use
find
show
day
treatment
fever
normal
patient
treat
doxycyclin
clarithromycin
midecamycin
respect
period
patient
fever
decreas
respect
intox
symptom
influenc
within
period
equal
treat
patient
conclus
suggest
new
macrolid
appear
good
altern
tetracyclin
patient
msf
erythromycin
resist
gram
cocci
bulgaria
benefit
new
macrolid
treatment
respiratori
infect
popivanova
ni
yovtchev
ip
b
dobreva
md
c
argirova
ta
c
medic
univers
infecti
diseas
plovdiv
bulgaria
b
medic
univers
earnosethroat
diseas
plovdiv
bulgaria
c
medic
univers
microbiolog
plovdiv
bulgaria
recent
year
test
erythromycin
sensit
speci
gram
cocci
isol
throat
nose
secret
ear
eye
effus
sputa
cerebrospin
fluid
blood
cultur
vagin
urethr
secret
urin
fecal
sampl
patient
inflammatori
diseas
list
organ
system
staphylococcu
aureu
staphylococcu
coagulas
streptococcu
enterococcu
isol
microorgan
aureu
abund
resistogram
reveal
sensit
gram
cocci
respect
resist
respect
test
midecamycin
midecamycin
acetat
microorgan
show
sensit
resist
clinic
find
show
excel
effect
new
macrolid
includ
clarithromycin
azalid
azithromycin
conclud
resist
gram
cocci
especi
aureu
erythromycin
increas
quickli
reach
dramat
extent
new
ring
macrolid
azalid
show
high
antibacteri
activ
good
clinic
effect
pappa
ga
liberopoulo
e
tsiara
elisaf
tsiano
e
univers
hospit
intern
medicin
ioannina
greec
quinupristindalfopristin
qd
novel
inject
streptogramin
antibiot
initi
therapeut
hail
import
step
toward
treatment
vancomycinresist
enterococcu
faecium
vref
speci
initi
report
conclud
excel
respons
vref
qd
report
qdresist
strain
e
faecium
emerg
usa
europ
report
two
case
e
faecium
bacteremia
respons
isol
sensit
qd
first
patient
woman
acut
leukemia
septicemia
e
faecium
cultur
blood
sampl
speci
resist
almost
antibiot
exhibit
sensit
tetracyclin
sensit
qd
indermedi
second
patient
man
endocard
blood
cultur
isol
e
faecium
sensit
number
antibiot
includ
ciprofloxacin
vancomycin
still
sensit
qd
indermedi
qd
offici
introduc
antibiot
arsen
greek
medicin
moreov
drug
never
use
hospit
even
experiment
e
faecium
speci
isol
hospit
sensit
qd
much
hope
put
drug
seem
partli
useless
initi
increas
report
v
qresist
strain
e
faecium
europ
rais
fear
vd
stori
might
well
end
begin
varadinova
diakov
karagiozova
genova
p
pardon
p
b
baudri
c
b
quideau
b
sofia
univers
virolog
sofia
bulgaria
b
et
institut
du
pin
centr
de
recherch
en
chimi
moleculair
universit
bordeaux
bordeaux
franc
veget
tannin
poss
wide
rang
biolog
activ
aim
present
studi
evalu
cytotox
five
purifi
veget
tannin
mdbk
cell
maxim
nontox
concentr
mnc
concentr
requir
inhibit
cell
growth
cc
evalu
h
period
action
mnc
valu
h
indic
compound
stimul
cell
surveil
appli
concentr
lower
mm
cc
valu
indic
decreas
cytotox
h
cc
time
lower
observ
h
period
ii
reincreas
cytotox
period
action
prolong
h
cc
time
lower
observ
h
period
data
thu
appear
reveal
capabl
investig
natur
polyphenol
product
stimul
cell
surveil
timedepend
manner
antibacteri
effect
survey
enoxolon
periodontopathogen
capnophil
bacteria
isol
specimen
patient
periodont
salari
mh
kadkhoda
z
b
sohrabi
n
tehran
univers
medic
scienc
pathobiolog
tehran
islam
republ
iran
b
tehran
univers
medic
scienc
dentistri
tehran
islam
republ
iran
object
microorgan
associ
periodont
capnophil
anaerob
bacteria
purpos
studi
detect
antibacteri
effect
enoxolon
periodontopathogen
capnophil
bacteria
method
studi
periodontopathogen
capnophil
bacteria
isol
specimen
patient
periodont
cultur
method
antibacteri
activ
enoxolon
microorgan
investig
minimum
inhibitori
concentr
mic
minimum
bactericid
concentr
mbc
method
result
base
find
mic
mbc
lethal
enoxolon
actinobacillu
actinomycetemcomitan
eikenella
corroden
capnocytophaga
mgml
respect
conclus
result
show
enoxolon
antibacteri
effect
actinomycetemcomitan
e
corroden
capnocytophaga
spp
sakalova
stn
medic
univers
microbiolog
grodno
belaru
synthes
diamid
dicarboxyl
acid
compon
benzolsulphamid
triazol
compound
exhibit
bacteriostat
activ
toward
microorgan
studi
bacteriostat
activ
amid
diamid
dicarboxyl
acid
well
determin
structur
relationship
synthes
rang
monoamid
antibacteri
activ
synthes
compound
studi
vitro
agar
dilut
method
purpos
approxim
variou
gramposit
neg
microorgan
includ
clinic
strain
staphylococcu
aureu
bacillu
subtili
serratia
marcescen
escherichia
coli
proteu
morganii
micrococcu
lisodeicticu
staphylococcu
epidermidi
shigella
sonnei
salmonella
typhimurium
yersinia
enterocolitica
minimum
inhibitori
concentr
express
mgml
nitazol
use
comparison
substanc
analysi
new
deriv
high
antibacteri
activ
rel
toward
certain
microorgan
includ
strain
obtain
infect
depart
patient
result
shown
microbi
suscept
essenti
oil
ziziphora
clinopodiod
lam
purpos
studi
antimicrobi
activ
essenti
oil
vari
oil
oil
one
micro
organ
anoth
antimicrobi
chemic
properti
essenti
oil
ziziphora
clinopodiod
lam
studi
henc
present
studi
plan
evalu
properti
seri
micro
organ
viz
escherichia
coli
staphylococcu
aureu
pseudomona
aeroginosa
klebsiella
pneumonia
bacillu
subtili
bacillu
licheniformi
streptococcu
faecali
candida
albican
saccharomyc
cerevisia
result
z
clinopodiod
lam
essenti
oil
found
remark
antimicrobi
properti
microorgan
p
aeroginosa
oil
exhibit
best
antimicrobi
activ
within
maximum
min
seventeen
compon
identifi
ga
chromatographi
mass
spectrometri
gc
gcm
analysi
oil
pulegon
neomenthol
tran
piperiton
limonen
constitut
major
part
oil
conclus
monoterpen
seem
antimicrobi
role
seem
necessari
explor
antimicrobi
properti
new
harmless
antimicrobi
agent
natur
sourc
substitut
common
chemic
drug
methanol
extract
carpobrotu
eduli
enhanc
kill
methicillin
resist
staphylococcu
aureu
phagocytos
human
monocyt
deriv
macrophag
promot
releas
modul
cellular
immun
although
alkaloid
famili
mesembryanthemacea
anticanc
activ
speci
famili
receiv
littl
attent
alkaloid
also
exhibit
properti
normal
associ
compound
activ
level
plasma
membran
studi
crude
methanol
extract
carpabrotu
eduli
common
plant
found
along
portugues
coast
properti
normal
associ
plasma
membran
activ
compound
result
preliminari
studi
show
extract
nontox
concentr
prime
human
monocytederiv
macrophag
kill
ingest
methicillin
resist
staphylococcu
aureu
promot
releas
lymphokin
associ
cellular
immun
function
extract
also
induc
prolifer
cell
within
day
exposur
day
earlier
induc
phytohemagglutinin
similar
result
obtain
monocytederiv
macrophag
isol
human
peripher
blood
activ
compon
compon
plant
extract
may
exploit
intracellular
activ
antibacteri
well
modul
cellular
immun
enhanc
erythromycin
product
saccharopolyspora
erythraea
common
uncommon
oil
hamedi
j
malekzadeh
f
b
saghafinia
ae
b
depart
biolog
faculti
scienc
univers
tehran
tehran
islam
republ
iran
b
shafeesari
co
antibiot
product
co
teheran
iran
enhanc
effect
variou
oil
erythromycin
product
saccharopolyspora
erythraea
evalu
complex
medium
consist
soybean
flour
dextrin
main
substrat
biomass
erythromycin
dextrin
oil
concentr
ph
valu
measur
daili
basi
also
kind
frequenc
fatti
acid
oil
use
determin
satur
fatti
acid
shark
oil
higher
veget
oil
use
erythromycin
concentr
melon
cucumi
melo
var
inderu
cultivar
mashhad
seed
oil
contain
medium
time
higher
control
medium
without
oil
time
higher
rapese
oil
contain
medium
erythromycin
concentr
oil
contain
media
includ
rapese
soybean
shark
carcharhinu
dussumieri
safflow
oil
time
higher
control
medium
respect
melon
seed
oil
least
enhanc
effect
biomass
product
thu
decreas
cost
biomass
separ
varicella
elimin
univers
childhood
vaccin
epidemiolog
econom
data
germani
wutzler
p
banz
k
b
neiss
c
goertz
bisanz
h
institut
antivir
chemotherapi
univers
jena
jena
germani
b
outcom
intern
basl
switzerland
c
institut
medic
statist
epidemiolog
technic
univers
munich
germani
glaxosmithklin
pharma
munich
germani
purpos
univers
varicella
vaccin
childhood
expect
reduc
substanti
number
uncompl
case
chickenpox
decreas
number
complic
case
requir
hospit
gener
fundament
data
decis
health
author
epidemiolog
healtheconom
data
collect
two
larg
studi
use
agestructur
decis
analyt
model
benefit
cost
costeffect
varicella
immun
program
period
year
assess
result
could
shown
vast
major
varicella
case
occur
children
age
less
year
case
sever
cours
assess
overal
incid
complic
estim
routin
varicella
vaccin
program
target
healthi
children
could
prevent
varicella
case
major
complic
per
year
provid
coverag
rate
would
condit
elimin
varicella
predict
achiev
within
year
combin
measl
mump
rubella
varicella
vaccin
expect
provid
requir
coverag
conclus
routin
childhood
varicella
vaccin
appear
highli
effici
strategi
significantli
reduc
sizeabl
burden
varicella
lead
signific
save
societ
payer
perspect
bulgakova
va
balabolkin
ii
sentsova
tb
scientif
center
child
health
russian
academi
medic
scienc
scientif
research
institut
pediatr
moscow
russian
feder
object
estim
efficaci
vaccin
influvac
children
allerg
diseas
method
twenti
children
age
year
allerg
diseas
receiv
vaccin
influvac
solvay
pharma
control
group
children
allerg
patholog
receiv
vaccin
intoler
chicken
protein
children
result
vaccin
children
observ
season
month
get
influenza
gener
aborigin
reaction
vaccin
occur
control
group
observ
season
two
children
ill
influenza
four
children
acut
respiratori
viru
infect
among
vaccin
children
increas
titr
protect
level
three
strain
influenza
day
inject
vaccin
influvac
recommend
immunis
influenza
children
allerg
patholog
efficaci
absenc
side
effect
pez
h
zitto
tr
vidal
gi
mc
n
jm
scaglion
centro
de
infecti
diseas
bueno
air
argentina
object
studi
examin
possibl
econom
impact
influenza
health
work
adult
argentina
intervent
cost
save
immun
method
theoret
studi
base
mathemat
model
popul
data
publish
nation
statist
global
incid
influenza
infect
estim
estim
direct
cost
influenza
infect
outpati
visit
drug
hospit
indirect
cost
work
absente
product
loss
project
net
save
yearold
vaccin
group
vaccin
effect
estim
price
vaccin
result
conclus
influenza
vaccin
effect
diminish
case
flu
reduc
workingday
loss
safe
costeffect
vaccin
pez
h
zitto
tr
mc
centro
de
infecti
diseas
bueno
air
argentina
flu
infect
major
caus
ill
one
common
caus
work
absente
increas
institut
cost
healthcar
provid
visit
use
drug
decreas
work
product
vaccin
flu
effect
health
adult
object
evalu
impact
flulik
respiratori
tract
infect
health
institut
staff
year
compar
vaccin
notvaccin
group
method
evalu
caus
absente
along
year
base
written
note
made
profession
evalu
ill
peopl
select
flulik
respiratori
infect
caus
evalu
age
work
day
loss
relat
ill
cost
vaccin
notvaccin
group
result
one
hundr
sixti
eight
total
staff
peopl
vaccin
flulik
infect
result
work
day
lost
notvaccin
group
peopl
flu
lost
day
lost
cost
vaccin
group
notvaccin
group
conclus
observ
decreas
work
day
loss
money
wast
relat
flulik
infect
vaccin
group
safeti
effect
vaccin
flu
implement
vaccin
costeffect
institut
staff
studi
function
interferon
system
children
atop
bronchial
asthma
ba
age
year
control
group
includ
healthi
children
investig
interferon
statu
method
grigoryan
serum
concentr
ifngamma
ifng
elisa
decreas
ifnproduc
abil
leukocyt
synthesi
ifna
ifng
children
ba
serum
level
ifn
children
ba
period
ill
compar
children
without
predisposit
atopi
pgml
accordingli
significantli
decreas
product
ifna
increas
use
viferon
recombin
ifn
antioxid
decreas
abil
gammainterferonogenesi
children
affect
action
immunomodul
shown
interferon
system
dysfunct
develop
atopi
increas
predisposit
respiratori
infect
persist
atyp
infect
children
ba
harxhi
pilaca
pano
k
univers
hospit
center
tirana
infecti
diseas
tirana
albania
congocrimean
haemorrhag
fever
viral
diseas
high
rate
mortal
caus
nairoviru
bunyavirid
speci
zoonot
diseas
affect
sporad
human
geograph
distribut
even
eastern
europ
balkan
month
may
june
northeast
albania
report
eight
case
haemorrhag
fever
serolog
test
perform
laboratori
refer
thesaloniki
greec
confirm
diagnosi
congocrimean
haemorrhag
fever
mean
time
report
outbreak
southwest
kosovo
case
suspect
haemorrhag
fever
confirm
laboratori
congocrimean
haemorrhag
fever
describ
clinic
histori
one
eight
case
cchf
albania
epidemiolog
point
view
case
consid
peculiar
one
hospitali
acquir
due
graviti
haemorrhag
syndrom
admit
intens
care
unit
infecti
diseas
servic
univers
hospit
center
tirana
result
studi
includ
patient
year
age
document
hbsagcarri
month
averag
age
year
male
femal
hbv
dna
serum
test
qualit
quantit
pcr
commerci
testsystem
amplisen
hbv
hbeag
hbeab
hbsag
detect
elisa
hoffmann
la
roch
hbv
dna
qualit
pcr
detect
patient
qualit
pcr
detect
patient
concentr
copiesml
copiesml
copiesml
copiesml
fig
hbv
dna
level
distribut
among
hbsag
carrier
elev
upper
limit
normal
alt
level
determin
hbv
dna
neg
hbv
dna
posit
patient
hbeag
detect
hbv
dna
posit
patient
determin
hbv
dna
neg
patient
eleven
percent
patient
combin
biochem
serolog
virolog
criteria
typic
activ
chronic
hepat
b
hbsagcarri
month
hbv
dna
copiesml
elev
alt
conclus
smolensk
hbsagcarri
viral
replic
confirm
qualit
pcr
eleven
percent
activ
chronic
hepat
b
kandemir
polat
b
kaya
medicin
faculti
mersin
univers
clinic
microbiolog
infecti
diseas
mersin
turkey
b
medicin
faculti
mersin
univers
patholog
mersin
turkey
exact
potenti
nitric
oxid
pathogenesi
chronic
viral
hepat
known
elev
nitric
oxid
product
assum
respons
patholog
chang
mani
inflammatori
condit
mainli
via
peroxynitrit
potenti
oxid
produc
reduct
superoxyd
anion
nitric
oxid
intens
distribut
immunohistochem
stain
intrahepat
induc
nitric
oxid
synthas
studi
biopsi
specimen
obtain
patient
viral
hepat
patient
elev
transaminas
level
etiolog
hepat
induc
nitric
oxid
synthas
stain
significantli
intens
viral
hepat
group
p
induc
nitric
oxid
synthas
stain
level
correl
well
sever
viral
hepat
use
knodel
liver
histolog
activ
index
p
among
viral
hepat
group
patholog
distribut
induc
nitric
oxid
synthas
stain
favor
periport
region
wherea
less
stain
observ
bile
duct
parenchyma
region
nitric
oxid
mediat
nitrat
hepatocellular
protein
found
elev
inflam
hepat
tissu
well
correl
sever
diseas
suggest
induc
nitric
oxid
synthas
possibl
critic
role
pathogenesi
chronic
viral
hepat
patient
observ
divid
two
group
first
patient
eight
chronic
viru
hepat
three
chronic
viru
hepatitissteatosi
four
steatohepat
three
chronic
cryptogen
hepat
men
four
women
age
second
group
consist
patient
eight
chronic
viru
hepat
four
steatohepat
six
chronic
cryptogen
hepat
men
three
women
age
diagnosi
confirm
help
clinic
data
biochem
test
serolog
marker
psrdiagnost
ultrasound
examin
comput
tomographi
abdomen
first
group
patient
treatment
ursofalk
administ
dosag
mgkg
bodi
mass
month
year
improv
gener
condit
patient
heavi
pain
right
rib
nausea
skin
itch
disappear
case
improv
biochem
blood
analysi
took
place
treatment
averag
index
alt
activ
ul
ul
ast
ul
alp
ul
ggt
ul
chol
mmoll
tg
mmoll
second
group
patient
treatment
carri
variou
hepatoprotector
cours
month
averag
index
alt
activ
ul
ul
ast
ul
alp
ul
ggt
ul
chol
mmoll
tg
mmoll
treatment
patient
suffer
hepat
viral
aetiolog
ursofalk
produc
posit
effect
clinic
symptomat
biochem
indic
remiss
stabl
long
period
take
prepar
hepatoprotect
effect
ursofalk
year
sustain
whole
period
treatment
stop
acut
attack
cytolyt
syndrom
observ
hepatoprotector
get
improv
clinic
scene
diseas
biochem
indic
shavlov
nm
kletski
sk
minsk
belaru
possibl
damag
differ
organ
system
sometim
caus
damag
liver
resembl
viral
hepat
etiolog
hepat
may
confirm
result
liver
biopsi
diagnos
case
herpet
hepat
eight
children
four
adult
clinic
cours
differ
five
case
acut
begin
took
place
high
temperatur
jaundic
day
level
bilirubin
mkmol
especi
direct
cholestasi
pain
upper
right
part
abdomen
ascit
found
three
patient
acut
hepat
week
begin
diseas
seven
case
begin
gradual
temperatur
subfebril
prolong
malais
moder
pain
upper
part
abdomen
constant
complaint
jaundic
moder
bilirubin
increas
mkmol
level
alt
moder
increas
time
blood
analysi
show
moder
leukocytosi
neutrophilia
increas
sre
serolog
marker
hepat
b
c
neg
case
found
blood
diagnosi
defin
result
hystochem
investig
virus
found
liver
bioptat
confirm
result
specif
treatment
specif
damag
liver
cell
found
protein
dystrophi
specif
inclus
cell
nucleu
case
treatment
acyclovir
given
result
observ
week
temperatur
becam
normal
jaundic
decreas
bilirubin
normal
day
one
case
recid
took
place
week
later
treatment
second
cours
acyclovir
intron
gave
good
result
nesic
z
delic
b
prostran
vuckov
stojanov
r
depart
pharmacolog
school
medicin
univers
belgrad
belgrad
yugoslavia
b
clinic
center
serbia
institut
infect
tropic
diseas
belgrad
yugoslavia
larg
number
unsolv
case
acut
chronic
hepat
probabl
viral
etiolog
mid
two
independ
group
author
report
new
human
hepatotrop
viru
flaviviru
like
genom
hepat
g
viru
hgv
aim
pilot
studi
determin
preval
hepat
g
viral
infect
among
patient
high
risk
exposur
blood
blood
product
well
evalu
risk
hgv
infect
higher
among
gener
popul
immunoenzym
test
microtitr
plate
detect
antibodi
hgv
antigen
plasma
sera
r
system
minneapoli
usa
use
evidenc
antihgv
igg
antibodi
sera
antihgv
antibodi
detect
control
group
blood
donor
patient
preval
antihgv
antibodi
among
iv
drug
user
evidenc
hemophiliac
patient
acquir
multipl
blood
transfus
hemodialyz
patient
patient
transplant
organ
result
suggest
patient
expos
blood
blood
product
higher
risk
hgv
infect
gener
popul
evalu
ortho
total
hcv
core
antigen
assay
assess
followup
patient
treat
chronic
hcv
lunel
f
veillon
p
payan
c
chu
anger
laboratoir
de
anger
franc
assay
quantit
total
hvc
core
antigen
hcv
ag
serum
plasma
may
reflect
viral
load
develop
orthoclin
diagnost
method
evalu
hcv
ag
two
quantit
assay
hcv
rna
bdna
bayer
monitor
roch
studi
sampl
untreat
patient
patient
chronic
hcv
treat
ifn
ifnribavirin
result
correl
ag
quantit
assay
high
bdna
monitor
differ
level
rna
ag
among
hcv
genotyp
found
ag
valu
treatment
significantli
lower
sustain
respond
sr
group
log
versu
log
p
patient
treat
ifn
combin
therapi
found
good
correl
decreas
negativ
ag
viral
load
log
iuml
declin
interferon
significantli
correl
negativ
hcv
ag
sr
sr
rna
load
decreas
log
iuml
negativ
hcv
ag
conclus
total
hcv
core
ag
appear
new
tool
monitor
patient
hcv
infect
hepat
c
viru
rna
hcv
core
antigen
kinet
predict
effici
interferonalfa
ribavirin
therapi
naiv
patient
infect
hcv
genotyp
fiftyf
patient
infect
genotyp
treat
primari
dose
hepat
c
viru
hcv
rna
meqml
million
unit
interferon
ifn
thrice
weekli
month
ribavirin
ad
month
hcv
rna
found
posit
ifn
viral
kinet
assess
follow
serial
measur
hcv
rna
bdna
monitor
use
new
assay
orthoclin
diagnost
abl
quantifi
total
hcv
core
antigen
sustain
virolog
respons
observ
patient
month
ifn
treatment
sustain
respond
fall
hcv
rna
hcv
core
antigen
higher
nonrespond
log
uiml
versu
log
uiml
p
hcv
rna
log
pgml
versu
log
pgml
p
b
hcv
core
antigen
month
ifn
posit
neg
predict
valu
sustain
respons
respect
hcv
rna
negativ
hcv
antigenemia
negativ
result
suggest
kinet
viral
load
antigenemia
highli
predict
sustain
respons
theodor
petinelli
pontikaki
mela
c
blana
papanastasi
toliopoulo
stavrakaki
sagkana
e
microbiolog
depart
western
attika
gener
hospit
greec
egaleo
greec
greec
accept
big
number
econom
immigr
late
investig
preval
hepat
bc
well
epidemiolog
featur
might
influenc
public
health
econom
immigr
albania
eastern
europ
asiaticafrican
countri
visit
hospit
check
order
get
health
certif
obtain
green
card
test
hepat
bc
serolog
marker
determin
immunoenzymat
method
hbsag
antihcv
test
hbv
dna
hcv
rna
competit
rt
pcr
hcv
rna
genotyp
strip
hybrid
immunoassay
albanian
hbsag
hbv
dna
antihcv
hcv
rna
east
european
hbsag
hbv
dna
antihcv
hcv
rna
asiansafrican
hbsag
hbv
dna
pakistani
antihcv
hcv
rna
rest
asiansafrican
antihcv
hcv
rna
albanian
higher
preval
hbv
infect
greek
blood
donor
pakistani
hcv
infect
predomin
type
gener
greek
popul
public
health
servic
greec
europ
must
take
appropri
measur
el
zawawi
la
moham
b
ali
sm
eissa
allam
sr
faculti
medicin
parasitolog
alexandria
egypt
b
high
institut
public
health
microbiolog
alexandria
egypt
purpos
studi
investig
influenc
schistosom
suppress
antibodi
respons
hepatitisb
vaccin
hbv
studi
vaccin
protect
effect
experiment
infect
result
obtain
reveal
infect
reduc
serum
antibodi
level
hbv
parasitolog
histopatholog
find
show
signific
protect
infect
conclus
reach
order
reduc
incid
virusb
infect
especi
schistosomiasi
endem
area
public
health
offici
evalu
polici
regul
hbv
booster
vaccin
enhanc
popul
immun
hepatitisb
infect
cooper
e
fisher
shingadia
newham
gener
hospit
famili
clinic
london
uk
sustain
antiretrovir
combin
chemotherapi
requir
excel
adher
regimen
suppress
viral
replic
suffici
delay
emerg
resist
chemotherapi
taken
scale
eg
africa
errat
adher
might
soon
lead
multiresist
circul
viru
review
experi
well
establish
london
famili
clinic
team
includ
commun
nurs
review
record
african
immigr
children
age
treat
antiretrovir
exclus
centr
throughout
wherea
undetect
hiv
rna
within
year
four
undetect
rna
throughout
year
four
fail
therapi
proven
resist
mutat
nine
consid
circumstanti
evid
rise
viral
load
primarili
poor
adher
three
known
stop
take
drug
extend
period
three
boy
year
unreli
adher
one
girl
agegroup
fulli
adher
preliminari
assess
children
famili
despit
team
approach
home
visit
nonadher
haart
may
twice
common
select
domin
viral
mutant
primari
caus
failur
sustain
viral
suppress
quirosroldan
e
moretti
f
castelli
f
elhamad
carosi
g
preval
hiv
relat
lipodystrophysyndrom
depend
definit
sever
lipodystrophi
rang
retrospect
review
medic
record
african
patient
follow
characterist
shown
african
triglycerid
mgml
cholesterol
mgml
none
metabol
alter
glycemia
mgml
observ
patient
interest
highlight
african
morpholog
chang
note
show
weight
stabl
although
low
preval
metabol
alter
may
attribut
differ
ethnic
alimentari
behavior
selfbodi
percept
african
accur
caucasian
estim
bodi
chang
investig
alabaz
alhan
e
yaman
b
evliyaoglu
n
kocaba
e
aksaray
n
divis
pediatr
infecti
diseas
cukurova
univers
adana
turkey
b
depart
microbiolog
cukurova
univers
adana
turkey
hepat
viru
hav
infect
usual
asymptomat
children
howev
may
occasion
caus
sever
diseas
high
morbid
mortal
loss
school
busi
day
previou
studi
shown
everi
one
two
three
school
children
upper
social
class
live
adana
carri
high
risk
hav
infect
well
known
matern
transmit
antihav
antibodi
interfer
hav
vaccin
effort
determin
optim
age
hav
vaccin
babi
girl
boy
born
hospit
prospect
follow
least
month
presenc
matern
antibodi
hepat
antihav
igg
antihav
igg
titer
measur
blood
specimen
obtain
birth
mother
offspr
month
preval
posit
antihav
birth
similar
hav
seropreval
studi
carri
adult
area
disappear
antibodi
occur
month
life
preval
antihav
igg
among
children
age
month
respect
light
find
suggest
hepat
vaccin
given
month
age
earlier
vaccin
may
ineffect
due
interfer
matern
transmit
antihav
antibodi
ghaderi
b
alaghebandan
r
rastegar
lari
depart
microbiolog
iran
univers
tehran
islam
republ
iran
diarrhoea
major
public
health
problem
develop
countri
amoebiasi
one
common
caus
diarrhoea
iran
endem
area
amoebiasi
littl
howev
known
extent
condit
societi
aim
studi
determin
sociodemograph
clinic
characterist
patient
intestin
amoebiasi
juli
august
collect
patient
diarrhoea
among
patient
visit
referr
hospit
shahriar
area
countrysid
tehran
iran
thirti
patient
intestin
amoebiasi
follow
prospect
resolut
ill
nineteen
patient
male
remain
femal
patient
age
mean
year
patient
year
age
peak
occurr
age
year
wateri
diarrhoea
abdomin
cramp
main
clinic
featur
seventi
percent
patient
resid
urban
area
remain
rural
area
averag
famili
incom
low
patient
low
socioeconom
level
water
suppli
system
patient
pipelin
water
low
socioeconom
level
associ
poor
person
hygien
import
factor
highli
preval
problem
societi
also
seem
food
play
import
role
transmiss
protozoa
water
new
strategi
allel
identif
gene
code
pertactin
pertussi
toxin
subunit
bordetella
pertussi
bordetella
pertussi
strain
demonstr
signific
polymorph
toxin
subunit
pertactin
major
protect
antigen
organ
monitor
chang
preval
particular
allel
gene
code
protein
local
b
pertussi
popul
essenti
issu
case
observ
decreas
vaccin
effect
develop
new
method
allel
identif
gene
elimin
necess
dna
sequenc
approach
base
identif
number
repeat
presenc
specif
nucleotid
polymorph
region
residu
respect
gene
utilis
product
full
partial
pcr
amplif
nucleotid
heterogen
polymorph
site
analys
either
differenti
digest
amplicon
arm
amplificationrefractori
mutat
system
methodolog
number
repeat
particular
region
gene
reveal
size
analysi
adequ
pcr
product
restrict
fragment
case
presenc
size
pattern
dna
molecul
obtain
visualis
agaros
gel
electrophoresi
preliminari
analysi
recent
archiv
b
pertussi
strain
identifi
poland
perform
use
describ
approach
present
strategi
provid
much
easier
faster
costeffect
dna
sequenc
mean
studi
polymorph
major
b
pertussi
antigen
vaccin
coverag
histori
vaccin
prevent
infecti
diseas
among
student
second
year
medicin
pharmaci
tour
univers
borderon
jc
hame
b
ragot
b
centr
hospitali
universitair
tour
franc
b
universitair
tour
franc
purpos
studi
determin
level
infecti
risk
student
expos
patient
inform
obtain
questionnair
student
check
medic
record
immun
coverag
vaccin
prevent
infecti
diseas
answer
could
specifi
student
femal
f
male
number
nonimmun
student
diphtheria
two
tetanu
three
pertussi
four
poliomyel
two
hepat
b
six
hepat
respect
among
student
nonvaccin
measl
nine
f
five
histori
diseas
among
f
nonvaccin
rubella
f
seven
histori
diseas
uncertain
seven
other
six
f
one
date
vaccin
often
late
regard
recommend
fifteen
student
histori
varicella
one
student
receiv
bcg
vaccin
fiftyeight
student
receiv
two
three
bcg
vaccin
postbcg
tuberculin
skin
test
miss
first
bcg
second
third
bcg
date
first
tuberculin
test
often
one
sever
year
bcg
vaccin
advers
effect
vaccin
rare
report
two
case
fever
dt
polio
measl
three
case
local
reaction
dt
polio
dtp
polio
one
case
contraind
influenza
vaccin
egg
allergi
survey
show
failur
immun
coverag
actual
recommend
health
care
student
object
present
morbid
rabi
evalu
effici
prophylaxi
scheme
lasi
counti
materi
method
made
retrospect
studi
rabi
case
patient
admit
unit
period
analys
clinic
epidemiolog
biolog
aspect
result
period
case
rabi
admit
clinic
infecti
diseas
hospit
lasi
highest
incid
eight
case
highest
yearli
case
three
case
patient
male
came
suburban
area
patient
eight
case
occur
may
wild
anim
involv
half
case
fox
wolf
patient
prophylaxi
perform
incomplet
cours
four
case
period
time
appear
first
symptom
day
prophylaxi
scheme
led
good
protect
conclus
lasi
counti
rabi
problem
preval
year
trend
use
antimicrobi
riyadh
analyz
data
obtain
survey
randomli
select
famili
school
children
age
year
period
one
hundr
ninetynin
student
antibiot
month
preced
studi
receiv
antibiot
diagnosi
pharyng
student
antibiot
prescrib
physician
durat
antibiot
less
week
studi
show
major
problem
antibiot
prescript
commun
also
need
establish
effect
antibiot
polici
gener
practic
limit
potenti
emerg
drug
resist
bacteria
commun
mir
cura
erdogan
h
guler
sengul
gn
koyu
ozinel
b
depart
pediatr
ege
univers
medic
faculti
izmir
turkey
b
depart
microbiolog
ege
univers
medic
faculti
izmir
turkey
antibiot
suscept
spectrum
childhood
urinari
tract
infect
agent
geograph
variat
current
antibiot
regimen
select
antibiot
prophylaxi
reevalu
period
object
studi
determin
local
resist
rate
antibiot
give
direct
select
antibiot
uti
treatment
evalu
urinari
cultur
assay
retrospect
sent
pediatr
pediatr
surgeri
inpati
outpati
clinic
hospit
last
month
investig
isol
pathogen
resist
rate
antibiot
addit
data
obtain
compar
year
ago
respect
resist
rate
antibiot
uti
pathogen
resist
rate
e
coli
carbapenem
aminoglycosid
third
gener
cephalosporin
respect
rate
ampicillin
increas
tmpsmx
increas
conclud
resist
profil
antibiot
review
everi
year
least
thu
select
proper
antibiot
would
lessen
morbid
well
medic
expens
chanturidz
tk
tsiklauri
r
ministri
labor
health
social
affair
public
health
tbilisi
georgia
purpos
sinc
infecti
diseas
id
increas
georgia
studi
aim
reveal
econom
barrier
effect
id
control
assess
financi
contribut
id
public
privat
sourc
household
total
spend
health
capac
pay
sourc
nation
household
expenditur
revenu
survey
fair
financi
contribut
methodolog
metaanalysi
result
popul
leav
poverti
level
total
household
expenditur
averag
gel
us
spent
food
nonsubsist
incom
cover
expenditur
good
servic
includ
health
popul
refus
health
servic
inabl
pay
public
spend
health
compris
total
health
expenditur
public
spend
id
control
gel
per
capita
almost
privat
spend
goe
id
treatment
equal
gel
per
patient
conclus
insuffici
public
spend
id
control
transfer
burden
popul
extrem
low
capac
cover
health
expens
refus
util
health
servic
incomplet
treatment
increas
threat
id
spread
drug
resist
govern
increas
alloc
id
public
sourc
effect
id
control
georgia
antimicrobi
consumpt
trend
children
univers
hospit
ratchina
averchenkova
l
b
jarkova
l
local
surveil
antimicrobi
consumpt
essenti
promot
ration
use
group
drug
purpos
studi
analyz
trend
use
children
univers
hospit
data
usag
obtain
hospit
drugstor
request
multiward
children
univers
hospit
consumpt
express
number
ddd
per
bedday
b
total
consumpt
figur
similar
b
respect
notabl
differ
prescrib
pattern
penicillin
consumpt
increas
b
mostli
due
amoxicillin
overal
aminoglycosid
usag
remain
compar
vs
b
though
amikacin
consider
replac
gentamicin
sevenfold
increas
ciprofloxacin
vs
b
along
evid
decreas
tetracyclin
cotrimoxazol
consumpt
found
vs
ddd
b
vs
b
respect
tendenc
prescrib
effect
respect
local
resist
data
andor
safe
detect
compar
explain
introduct
local
guidelin
infecti
diseas
manag
clarithromycin
treatment
chronic
prostat
caus
chlamydia
trachomati
pilot
studi
aim
pilot
studi
determin
efficaci
toler
clarithromycin
treatment
chronic
prostat
caus
chlamydia
trachomati
ct
fiftytwo
patient
older
year
age
diagnos
chronic
chlamydi
prostat
enrol
presenc
ct
express
prostat
secret
urin
specimen
void
immedi
prostat
massag
confirm
isol
mccoy
cell
lugol
stain
major
patient
suffer
suprapub
pain
pain
groin
twelv
patient
clinic
symptom
accord
rectal
palpat
prostat
gland
normal
patient
tender
soft
firm
five
patient
clarithromycin
administ
oral
mg
twice
daili
day
simultan
patient
partner
receiv
mg
oral
twice
daili
day
clinic
efficaci
toler
administ
clarithromycin
evalu
day
week
end
treatment
bactericid
efficaci
administ
drug
evalu
week
end
treatment
erad
ct
achiev
patient
patient
clinic
cure
two
patient
nausea
elev
serum
transaminas
asymptomat
patient
erad
ct
achiev
patient
report
side
effect
pilot
studi
shown
excel
efficaci
toler
clarithromycin
treatment
patient
chronic
chlamydi
prostat
women
diagnosi
urinari
tract
infect
uti
often
demonstr
vagin
colonis
alphahaemolyt
escherichia
coli
strain
present
studi
decid
evalu
distribut
virul
gene
encod
cytotox
necrot
factor
type
pfimbria
aerobactin
aer
afa
gene
alphahaemolyt
e
coli
strain
isol
gynaecolog
materi
region
compar
detect
sequenc
clinic
isol
diagnost
group
alphahaemolyt
e
coli
strain
isol
urin
gynaecolog
specimen
faecal
strain
e
coli
strain
test
product
haemolyt
phenotyp
blood
agar
plate
amplif
virul
factor
perform
pcr
accord
previous
describ
protocol
le
bouguenec
et
al
blanco
et
al
yamamoto
et
al
found
gynaecolog
alphahaemolyt
strain
posit
p
compar
urin
strain
p
compar
faecal
strain
similarli
sfafoc
specif
dna
sequenc
found
gynaecolog
isol
compar
urin
strain
p
compar
faecal
strain
point
view
femal
genit
tract
seem
potenti
reservoir
uropathogen
e
coli
strain
azithromycin
treatment
pelvic
inflammatori
diseas
caus
chlamydia
trachomati
administ
hospit
patient
chlamydi
pid
diagnosi
made
prior
hospit
microbiolog
analysi
urin
blood
swab
specimen
collect
endocervix
vagina
urethra
confirm
c
trachomati
singl
suspect
caus
pathogen
pid
presenc
c
trachomati
swab
specimen
endocervix
examin
dnkrnk
hybrid
azithromycin
administ
day
sampl
microbiolog
analysi
collect
dose
mg
iv
day
clinic
efficaci
toler
therapi
assess
day
end
therapi
clinic
microbiolog
analysi
week
complet
therapi
erad
c
trachomati
normal
gynecolog
find
achiev
disappear
subject
symptom
patient
side
effect
deviat
normal
valu
hematolog
biochem
blood
paramet
record
studi
show
high
bactericid
efficaci
rapid
clinic
effect
good
toler
oncedaili
administr
mg
azithromycin
day
treatment
patient
pid
caus
c
trachomati
altindi
cevrioglu
b
aktep
oc
cetinkaya
kocatep
univers
school
medicin
microbiolog
afyon
turkey
b
kocatep
univers
school
medicin
obstetr
gynecolog
afyon
turkey
diagnosi
caus
organ
vagin
usual
base
clinic
criteria
standard
laboratori
base
rapid
diagnost
test
identif
organ
desir
determin
laboratori
method
best
predict
caus
organ
calcul
sensit
specif
predict
valu
posit
neg
test
clinic
criteria
oligonucleotid
probe
test
affirm
vpiiibd
usa
compar
combin
posit
vagin
cultur
gramstain
vagin
smear
evalu
consecut
women
age
year
attend
vagin
discharg
vagin
swab
specimen
use
cultur
gardnerella
vaginali
trichomona
vaginali
candida
sp
prepar
vagin
smear
gramstain
interpret
wet
mount
evalu
affirm
test
affirm
detect
g
vaginali
candida
sp
three
women
trichomoniasi
case
found
method
sensit
neg
predict
valu
affirm
test
clinic
sign
identifi
bacteri
vaginosi
howev
affirm
test
specif
vs
also
higher
posit
predict
valu
vs
clinic
sign
evalu
result
patient
candidiasi
less
number
accord
result
affirmmicrobi
identif
test
object
specif
rapid
diagnosi
bacteri
vaginosi
comparison
efficaci
singl
dose
tinidazol
standard
dose
metronidazol
giardia
lamblia
infect
preliminari
report
fallah
moshtaghi
aa
b
univers
medic
scienc
parasitolog
hamadan
islam
republ
iran
b
univers
medic
scienc
pediatr
hamadan
islam
republ
iran
object
giardia
lamblia
common
intestin
protozoa
develop
countri
treatment
infect
metronidazol
drug
choic
requir
long
cours
therapi
produc
side
effect
object
studi
determin
efficaci
side
effect
tinidazol
g
lamblia
infect
preliminari
report
ongo
trial
method
random
control
clinic
trial
carri
subject
g
lamblia
infect
treat
tinidazol
metronidazol
tinidazol
mgkg
singl
dose
metronidazol
mgkg
three
time
day
day
given
oral
children
respect
parasitolog
cure
document
consecut
neg
stool
examin
week
therapi
result
twentyon
individu
treat
tinidazol
children
treat
metronidazol
parasitolog
cure
cure
rate
two
group
signific
statist
major
side
effect
observ
except
one
case
metronidazol
group
mild
headach
abdomin
pain
day
conclus
conclud
tinidazol
dose
efficaci
equal
metronidazol
treatment
g
lamblia
infect
singl
dose
prescript
short
cours
therapi
good
complianc
patient
prepar
prefer
metronidazol
giardial
infect
ebeid
fa
seif
eldin
sh
theodor
bilharz
research
institut
pharmacolog
cairo
egypt
bcarotein
given
differ
dose
start
mgkg
bodi
weight
bw
differ
group
albino
mice
day
infect
mansoni
infect
anim
done
bodi
immers
use
egyptian
strain
mansoni
cercariaemous
fortynin
day
infect
anim
sacrif
hepat
mesenter
worm
extract
determin
ova
count
liver
intestin
tissu
total
number
wormsanim
also
determin
experiment
group
compar
infect
control
anim
result
indic
mark
decreas
number
worm
ova
count
liver
intestin
compar
control
one
reduct
increas
significantli
increas
dose
conclud
bcarotein
could
use
prophylact
agent
mansoni
infect
baris
z
babicerceg
borzic
e
zoran
v
carev
kaliterna
v
depart
microbiolog
public
health
institut
split
croatia
aim
studi
determin
frequenc
pseudomona
aeruginosa
urinari
tract
infect
uti
outpati
popul
south
croatia
suggest
optim
antimicrobi
treatment
patient
month
long
observ
period
total
number
examin
urin
specimen
signific
bacteriuria
found
specimen
p
aeruginosa
sixth
common
isol
isol
specimen
specimen
taken
differ
patient
suscept
test
perform
disk
diffus
method
follow
result
obtain
resist
cefibuten
occur
patient
norfoxacin
ciprofloxacin
gentamicin
netilmicin
amikacin
ceftazidim
imipenem
patient
p
aeruginosa
strain
show
better
suscept
test
parenter
antibiot
antibiot
oral
use
complic
treatment
outpati
best
suscept
shown
imipenem
drug
inappropri
use
outpati
set
best
choic
treatment
p
aeruginosa
uti
outpati
treatment
ceftazidim
second
choic
aminoglycosid
drug
amikacin
netilmicin
silan
l
breza
j
b
krcmeri
v
jr
c
depart
intern
medicin
derer
univers
hospit
bratislava
slovakia
b
depart
urolog
comeniu
univers
school
bratislava
slovakia
c
depart
pharmacolog
st
elisabeth
cancer
institut
bratislava
slovakia
studi
clinic
efficaci
oral
treatment
ciprofloxacin
cpf
alon
combin
clarithromycin
patient
complic
urinari
tract
infectioncuti
without
indwel
cather
patient
randomli
alloc
mg
cpfcpf
group
mg
cpf
plu
mg
camcombin
group
day
evalu
done
day
accord
criteria
advoc
japanes
urinari
tract
infect
committe
patient
urinari
cather
combin
achiev
higher
complet
bacteri
elimin
rate
clinic
efficaci
rate
cpf
alon
respect
signific
differ
found
bacteri
elimin
rate
two
group
clinic
effect
combin
superior
cpf
alon
patient
indwel
cather
better
clinic
efficaci
combin
may
partli
attribut
antibiofilm
effect
cam
clinic
set
result
also
indic
difficulti
still
remain
treatment
cuti
patient
indwel
cather
conclus
clinic
studi
suggest
cam
might
inhibitori
action
biofilm
format
clinic
set
combin
cam
appropri
antimicrobi
agent
may
favor
effect
treatment
cuti
vesicoureter
reflux
urinari
tract
infect
manag
primari
vesicoeureter
reflux
children
children
studi
present
primari
vesicoureter
reflux
derer
universitz
hospit
bratislava
seven
hundr
sixti
patient
boy
girl
suffer
primari
vesicoureter
reflux
age
month
year
test
systemat
analyz
outcom
data
seven
treatment
altern
key
outcom
identifi
probabl
reflux
resolut
likelihood
develop
pyelonephr
scar
possibl
complic
medic
surgic
treatment
avail
outcom
data
variou
treatment
altern
summar
rel
probabl
possibl
outcom
compar
altern
conclus
increas
urinari
tract
infect
vesicoureter
reflux
nephropathi
includ
earli
diagnosi
appropri
evalu
effect
atb
therapi
surgeri
indic
main
determin
renal
damag
bstruction
age
sex
predisposit
renal
scar
reflux
grade
later
therapeut
delay
individu
suscept
bacteri
virul
immunogenet
statu
one
absolut
indic
surgic
manag
failur
medic
therapi
prevent
chronic
recurr
pyelonephr
renal
injuri
reflux
complic
elimin
reflux
condit
minim
likelihood
genet
condit
immunopathogen
mechan
involv
pathogenesi
chronic
recurr
pyelonephr
patient
suffer
vur
children
recommend
continu
antibiot
prophylaxi
initi
treatmentmed
therapi
base
principl
reflux
often
resolv
time
antibiot
maintain
urin
steril
prevent
infect
patient
await
spontan
resolut
vur
predispos
individu
renal
infect
immunolog
inflammatori
reaction
caus
pyelonephrit
infect
may
result
renal
injuri
scar
silan
l
breza
j
b
depart
intern
medicin
derer
univers
hospit
bratislava
slovakia
b
depart
urolog
comeniu
univers
school
medicin
bratislava
slovakia
elderli
patient
uti
believ
less
like
cure
antimicrobi
therapi
younger
patient
reason
poorer
outcom
yet
clarifi
investig
efficaci
antimicrobi
therapi
elderli
patient
complic
uti
five
hundr
patient
men
women
complic
symptomat
symptomat
year
age
treat
one
three
differ
drug
one
never
quinolon
two
oral
cephem
multivari
logist
regress
analysi
treatment
outcom
reveal
clinic
respons
significantli
relat
gener
underli
diseas
diseas
urinari
tract
age
symptomat
asymptomat
uti
infect
site
kidney
bladder
conclud
clinic
effect
antimicrobi
agent
directli
relat
age
urolog
examin
underli
diseas
control
quit
import
effect
treatment
control
complic
uti
especi
elderli
patient
studi
frequenc
antimicrobi
resist
escherichia
e
coli
urin
isol
patient
admit
maribor
teach
hospit
rebersek
gorisek
j
baklan
z
unuk
novak
b
depart
infecti
diseas
teach
hospit
maribor
maribor
slovenia
b
depart
microbiolog
region
institut
public
health
maribor
maribor
slovenia
purpos
aim
studi
determin
frequenc
antimicrobi
resist
escherichia
coli
isol
urin
sampl
patient
admit
maribor
teach
hospit
frequenc
antimicrobi
resist
compar
year
method
prospect
studi
go
urin
isol
patient
maribor
teach
hospit
collect
analys
urin
cultur
done
use
modifi
sanford
method
suscept
test
perform
disk
diffus
method
accord
nccl
result
year
urin
isol
year
urin
isol
analys
e
coli
repres
urin
isol
urin
isol
e
coli
resist
rate
amoxycillin
year
year
amoxycillinclavul
cefalotin
cefaclor
trimethoprim
sulfamethoxazol
ciprofloxacin
gentamicin
conclus
compar
frequenc
e
coli
isol
urin
sampl
similar
year
resist
amoxycillin
cefaclor
gentamicin
stabl
resist
trimethoprim
sulfamethoxazol
ciprofloxacin
increas
resist
amoxycillinclavul
cefalotin
decreas
preval
resist
metronidazol
furazolidon
nitrofurantoin
helicobact
pylori
clinic
strain
de
la
obra
sanz
p
roman
jl
loma
e
villar
h
b
lopezbrea
hospit
de
la
princesa
microbiolog
madrid
spain
b
hospit
de
san
agustin
microbiolog
avil
spain
object
studi
determin
preval
metronidazol
furazolidon
nitrofurantoin
resist
helicobact
pylori
clinic
isol
method
total
strain
h
pylori
includ
studi
test
metronidazol
furazolidon
nitrofurantoin
agar
dilut
method
resist
defin
metronidazol
mic
mgl
mic
mgl
furazolidon
nitrofurantoin
result
sixtyeight
strain
resist
metronidazol
valu
mgl
respect
three
strain
furazolidon
resist
mic
mgl
two
strain
metronidazol
resist
mgl
mic
mgl
nitrofurantoin
mgl
respect
furazolidon
one
strain
nitrofurantoin
resist
mic
mgl
strain
metronidazol
resist
mic
mgl
mgl
furazolidon
mgl
respect
nitrofurantoin
conclus
low
frequenc
furazolidon
nitrofurantoin
resist
compar
metronidazol
suggest
furazolidon
nitrofurantoin
may
good
altern
metronidazol
treatment
h
pylori
infect
antimicrobi
resist
campylobact
isol
human
origin
zhukhovitski
vg
drabkina
iv
depart
bacteriolog
botkin
hospit
moscow
russian
feder
purpos
studi
determin
antimicrobi
resist
thermophil
enteropathogen
campylobact
spp
tec
isol
human
acut
diarrhoea
moscow
among
tec
strain
c
jejuni
five
c
coli
identifi
antibiot
test
disk
diffus
test
muellerhinton
agar
sheep
blood
ampicillin
amoxycillinclavulan
ac
imipenem
meropenem
erythromycin
e
clarithromycin
cl
tetracyclin
doxycyclin
gentamicin
g
azithromycin
az
chloramphenicol
ch
lincomycin
l
ciprofloxacin
c
nalidix
acid
na
resist
rate
tec
isol
highest
na
follow
n
cl
moder
resist
rate
obtain
ch
az
ac
none
isol
demonstr
resist
g
four
isol
sensit
antibiot
test
na
estim
mgl
among
na
resist
tec
strain
identifi
c
jejuni
one
c
coli
among
c
jejuni
c
coli
na
resist
rate
respect
one
na
resist
c
coli
nine
na
resist
c
jejuni
resist
ciprofloxacin
ring
c
atanassova
v
depart
food
hygien
microbiolog
school
veterinari
medicin
hannov
germani
aim
studi
poultri
meat
known
often
contamin
salmonella
foodborn
pathogen
thu
consid
possibl
sourc
human
infect
aim
studi
monitor
resist
salmonella
isol
poultri
meat
differ
european
countri
variou
antibiot
materi
method
septemb
decemb
total
sampl
frozen
poultri
meat
franc
germani
itali
spain
netherland
portug
examin
preval
salmonella
use
classic
cultur
detect
well
rflppcr
isol
test
sensit
toward
ampicillin
kanamycin
ciprofloxacin
tetracyclin
trimethoprim
sulfamethoxazol
nalidix
acid
erythromycin
use
standard
procedur
result
examin
sampl
salmonella
spp
isol
isol
character
salmonella
hadar
typhimurium
nearli
isol
resist
erythromycin
resist
toward
four
isol
observ
sever
case
discuss
consumpt
poultri
meat
insuffici
prepar
still
consid
major
sourc
human
infect
salmonella
spp
question
aris
whether
resist
isol
variou
antibiot
clinic
import
treatment
patient
object
provid
insight
epidemiolog
situat
salmonellosi
ni
area
largest
area
serbia
inhabit
method
materi
process
institut
public
health
epidemiolog
microbiolog
divis
isol
microorgan
perform
apparatu
rapid
identif
vitekbiomerieux
appli
elisa
test
classic
microbiolog
method
result
period
salmonella
laboratori
confirm
case
report
greatest
number
diseas
year
group
frequent
isol
salmonella
enteritidi
typhimurium
hadar
agona
virchow
infanti
derbi
enteritidi
show
greatest
sensit
antibiot
infrequ
resist
ampicillin
trimethoprimsulfamethoxazol
typhimurium
show
greater
resist
wide
spectrum
antibiot
isol
resist
antibiot
test
less
common
type
salmonella
sensit
antibiot
except
trimethoprimsulfamethoxazol
ampicillin
conclus
specif
resist
antibiot
relat
serotyp
typhoid
fever
retrospect
studi
case
lebanon
tohm
abboud
j
ghayad
e
hospit
intern
medicin
beirut
lebanon
object
present
epidemiolog
clinic
featur
typhoid
fever
lebanon
method
fiftytwo
patient
seen
hoteldieu
hospit
beirut
diagnost
criteria
posit
blood
cultur
typhi
paratyphi
andor
somat
agglutinin
titer
determin
widal
test
symptom
suggest
typhoid
fever
also
present
epidemiolog
studi
case
regist
ministri
health
period
result
among
case
patient
age
year
less
year
overal
male
femal
ratio
case
seen
januari
februari
august
among
patient
young
adult
affect
averag
durat
symptom
diagnosi
day
main
present
symptom
fever
diarrhoea
abdomin
pain
headach
complic
note
case
digest
complic
preval
leucopenia
help
diagnost
marker
typhi
frequent
serotyp
identifi
resist
ampicillin
cotrimoxazol
chloramphenicol
mortal
rate
conclus
typhoid
fever
still
endem
diseas
countri
occurr
resist
strain
typhi
favor
ceftriaxon
fluoroquinolon
treatment
maaloul
hammami
b
zambaa
f
elleuch
r
hammami
b
ben
jemaa
chu
hedi
chaker
servic
de
maladi
infectieus
sfax
tunisia
b
chu
habib
bourguiba
laboratoir
de
microbiologi
sfax
tunisia
although
frequent
psoa
abscess
except
entiti
order
specifi
clinic
biolog
radiolog
evolutionari
featur
retrospect
studi
led
servic
period
year
januari
whole
case
list
men
women
age
averag
year
extrem
year
studi
find
underli
diseas
except
diabet
mellitu
three
patient
clinic
symptom
domin
fever
abdominolumbar
ach
case
psoiti
eight
case
biolog
show
inflammatori
syndrom
case
hyperleucocytosi
case
diagnosi
psoa
abscess
evok
clinic
data
confirm
imageri
data
ultrasongraphi
case
ct
scan
six
case
magnet
reson
imag
three
case
tubercular
etiolog
confirm
six
case
among
two
associ
escherichia
coli
one
case
brucella
melitensi
one
case
etiolog
agent
domin
staphylococcu
aureu
eight
case
b
melitensi
two
case
e
coli
one
case
bacteroid
fragili
one
case
streptococcu
anginosu
one
case
fusobacterium
nucleaticum
one
case
candida
glabrata
one
case
patient
receiv
antiinfecti
treatment
adapt
micro
organ
question
drainag
abscess
realiz
patient
percutan
nine
case
surgic
six
case
evolut
favour
patient
howev
two
patient
relaps
stop
treatment
conclus
diagnosi
psoa
abscess
difficult
clinic
data
base
imageri
techniqu
us
ct
rmi
percutan
drainag
guid
imageri
recommend
etiolog
therapeut
aim
associ
adapt
antibiotherapi
allow
defer
surgic
drainag
zezoski
mbz
nikolova
gavriloski
pmg
medic
center
infecti
diseas
prilep
former
yugoslav
republ
macedonia
purpos
make
list
frequent
abdomin
chang
patient
human
brucellosi
materi
method
new
patient
human
brucellosi
diagnosi
made
use
standard
clinic
biochem
serolog
investig
bab
wright
coomb
rvk
elisa
igm
igg
special
ultrasound
examin
abdomen
retro
peritoneum
result
weight
loss
frequent
chang
present
patient
follow
atyp
abdomin
pain
vomit
diarrhea
enlarg
liver
enlarg
spleen
hepat
lesion
increas
ast
alt
conclus
although
frequent
abdomin
chang
seldom
could
miss
patient
human
brucellosi
recommend
routin
ultrasound
examin
standard
biochem
test
liver
function
due
avoid
unnecessari
complic
osteoarticular
complic
common
brucellosi
common
site
involv
sacroiliac
joint
osteoarticular
complic
sacroili
spondyl
diagnos
radiolog
present
studi
aim
determin
sever
grade
sacroili
use
laboratori
paramet
esr
crp
tube
agg
test
seventytwo
male
femal
patient
brucellosi
includ
studi
osteoarticular
involv
present
patient
common
osteoarticular
find
sacroili
patient
twenti
healthi
subject
form
control
group
statist
signific
differ
patient
control
regard
esr
crp
tube
agg
test
p
respect
addit
sacroili
effect
esr
crp
posit
correl
grade
sacroili
valu
crp
r
conclus
suggest
crp
may
use
auxiliari
secondari
paramet
grade
sacroiliac
joint
involv
brucellosi
magira
ee
papandreoy
gounari
spire
tasopoulo
g
anagnostopoul
b
paniara
b
gounari
p
sioulal
e
evagelismo
intern
medicin
athen
greec
b
evagelismo
micro
greek
farmer
admit
hospit
pain
scrotal
swell
hepatosplenomegali
lumbar
pain
lowgrad
fever
accompani
profus
sweat
life
style
includ
occup
anim
exposur
ingest
raw
milk
dairi
product
laboratori
data
within
normal
rang
focal
hypoecho
right
testicular
lesion
swell
concurr
epididimi
along
increas
vascular
right
testi
seen
echo
examin
find
consist
unilater
epididimoorch
ct
scan
lumbar
spine
area
show
decreas
signal
intens
local
anterior
aspect
vertebr
bodi
diskovertebr
junction
involv
subchondri
part
vertebra
standard
tube
agglutin
test
posit
antibodi
brucella
melitensi
titer
cultur
blood
specimen
posit
b
melitensi
patient
given
combin
antibiot
doxycyclin
streptomycin
rifampin
remark
improv
clinic
condit
show
week
later
case
illustr
follow
point
area
brucellosi
endem
scrotal
abnorm
seen
possibl
genitourinari
tract
complic
brucella
consid
pappa
ga
akritidi
nk
b
mastora
b
tsiano
e
univers
hospit
intern
medicin
ioannina
greec
b
g
hatzikosta
hospit
intern
medicin
ioannina
greec
aim
scope
determin
incid
form
complic
associ
brucella
infect
patient
method
studi
recent
patient
larger
seri
approach
diagnos
suffer
brucellosi
assess
presenc
sign
symptom
arthriti
spondyl
form
bone
involv
diagnosi
brucellosi
base
serolog
isol
brucella
speci
blood
cultur
cultur
media
result
osteoarticular
complic
note
patient
present
arthriti
present
spondyl
eight
patient
present
genitourinari
complic
either
orcheoepididym
four
patient
hematuria
resolv
treatment
four
patient
mening
present
two
patient
gastrointestin
complic
vomit
diarrhea
present
three
patient
one
patient
present
ascit
respiratori
tract
complic
form
pneumonia
four
patient
bronchiti
three
patient
note
seven
patient
one
patient
pneumonia
exhibit
pleural
fluid
skin
rash
macular
type
present
three
patient
patient
present
complic
heart
hematolog
complic
frequent
form
sever
one
patient
moder
two
patient
pancytopenia
isol
thrombocytopenia
three
patient
lymphocytosi
eight
patient
akritidi
nk
pappa
ga
b
mastora
g
hatzikosta
hospit
intern
medicin
ioannina
greec
b
univers
hospit
intern
medicin
ioannina
greec
aim
scope
determin
incid
mode
bone
joint
involv
cours
brucellosi
patient
method
studi
recent
patient
larger
seri
approach
diagnos
brucellosi
assess
presenc
arthriti
spondyl
diagnosi
brucellosi
base
serolog
isol
brucella
speci
blood
cultur
result
twentythre
patient
exhibit
form
osteoarticular
involv
arthriti
present
patient
often
involv
knee
also
hip
elbow
even
smaller
joint
intephalang
joint
hand
synovi
fluid
aspir
often
characteris
intens
mononuclear
infiltr
spondyl
present
patient
often
involv
lumbar
spine
also
thorac
spine
characterist
eros
upper
anterior
crest
vertebr
bodi
visibl
plain
xray
three
patient
mri
bone
scan
help
case
discuss
osteoarticular
involv
cours
brucellosi
common
focal
present
diseas
acut
brucellosi
often
accompani
bone
joint
ach
especi
lumbar
spine
still
frank
involv
form
arthriti
spondyl
rare
arthriti
usual
present
acut
form
diseas
spondyl
tend
characterist
chronic
form
diseas
often
necessit
prolong
use
antibiot
bosilkovski
krteva
l
caparoska
grozdanovski
k
sajn
b
clinic
infecti
diseas
febril
condit
medic
faculti
skopj
former
yugoslav
republ
macedonia
one
hundr
twentysix
patient
brucellosi
studi
prospect
seventyeight
osteoarticular
involv
peripher
arthriti
patient
frequent
follow
spondil
sacroili
rare
bursiti
tendin
osteomyel
overal
male
femal
ratio
averag
age
sd
year
direct
contact
anim
reason
acquisit
ill
patient
alimentari
aerogen
rout
incrimin
rout
aqisit
unknown
averag
durat
symptom
onset
establish
diagnosi
sd
day
main
present
symptom
joint
pain
sweat
fatigu
fever
hepatomegali
present
patient
involv
system
evid
comparison
patient
osteoarticular
ill
show
patient
osteoarticular
involv
significantli
often
joint
pain
fatigu
weight
loss
prolong
durat
symptom
diagnosi
establish
doxycyclin
chloroquin
combin
therapi
chronic
q
fever
endocard
calza
l
attard
l
manfredi
r
chiodo
f
divis
infecti
diseas
univers
bologna
orsola
hospit
bologna
itali
introduct
endocard
main
clinic
manifest
chronic
q
fever
occur
report
case
diagnos
almost
exclus
patient
either
cardiovascular
abnorm
immunocompromis
condit
case
report
caucasian
male
patient
biolog
prosthet
aortic
valv
first
hospit
interstiti
pneumonia
six
month
later
patient
readmit
owe
intermitt
fever
chill
weight
loss
echocardiograph
studi
show
small
veget
mm
diamet
left
cusp
aortic
valv
serolog
coxiella
burnetii
reveal
complementfix
igg
antibodi
titer
phase
antigen
consist
chronic
q
fever
endocard
antimicrobi
therapi
iv
doxycyclin
oral
chloroquin
start
lead
clinic
echocardiograph
recoveri
therapi
continu
oral
doxycyclin
chloroquin
patient
remain
asymptomat
follow
conclus
optim
treatment
q
fever
endocard
well
establish
effect
antimicrobi
fluoroquinolon
rifampin
chloramphenicol
doxycyclin
trimethoprim
also
use
role
chloroquin
combin
doxycyclin
seem
promis
chloroquin
may
increas
lysosom
ph
enhanc
doxycyclin
bactericid
activ
akritidi
nk
pappa
ga
b
mastora
liappi
e
tsiano
e
b
g
hatzikosta
hospit
intern
medicin
ioannina
greec
b
univers
hospit
intern
medicin
ioannina
greec
aim
scope
review
incid
form
lower
respiratori
tract
infect
patient
suffer
q
fever
clinic
radiolog
characterist
patient
method
twentyseven
patient
diagnos
suffer
q
fever
assess
presenc
lower
respiratori
tract
infect
diagnosi
confirm
serolog
result
thirteen
patient
express
lower
respiratori
tract
patholog
confirm
clinic
examin
chest
xray
patient
main
caus
admiss
respiratori
tract
symptom
rang
dri
cough
hemoptysi
chest
xray
patholog
patient
patient
lobar
pneumonia
two
multipl
nodular
opac
one
bronchopneumonia
hepat
common
find
patient
treat
tetracyclin
discuss
although
coxiella
burnetii
infect
acquir
via
respiratori
tract
paradox
symptom
attribut
lung
invari
posit
q
fever
pneumonia
atyp
pneumonia
usual
follow
benign
cours
diangost
suspicion
usual
rais
epidemiolog
pattern
accompani
mild
hepat
pleural
effus
common
find
usual
radiolog
appear
q
fever
pneumonia
lobar
segment
pneumonia
one
import
aspect
q
fever
pneumonia
common
present
form
multipl
nodular
opac
often
necessit
exclus
malign
cultur
serologycultur
case
per
year
mainli
octob
histori
exposit
hare
present
marmot
skin
anim
contact
bite
wound
bait
prepar
frozen
meat
hunt
note
initi
clinic
present
ulceroglandular
glandular
pneumon
involv
node
distribut
axillari
cubitalaxillari
cubit
median
incub
period
day
rang
time
consult
day
rang
time
effect
treatment
day
rang
initi
diagnosi
tularemia
made
presumpt
effect
antibiot
regimen
use
aminoglycosid
tetracyclin
note
intraven
netilmicin
use
case
complic
rate
one
death
associ
delay
effect
treatment
day
ill
p
conclus
area
tularemia
occur
mainli
male
popul
autumn
short
incub
period
histori
hare
contact
delay
appropri
treatment
increas
complic
rate
bompolaki
doukaki
triantafillid
polimili
g
kastanaki
nikiforaki
k
vittoraki
e
kastanaki
first
medic
depart
saint
georg
gener
hospit
chania
greec
sever
frontal
andor
retroorbit
headach
repres
common
neurolog
manifest
murin
typhu
neurolog
manifest
confus
stupor
nuchal
rigid
sever
case
delirium
extrem
agit
coma
appear
less
commonli
eightyfour
patient
compat
clinic
statu
murin
typhu
high
serolog
titer
antibodi
rickettsia
typhi
studi
team
seventyfour
patient
present
headach
nine
patient
present
confus
one
patient
present
nuchal
rigid
combin
sever
headach
confus
give
us
suspicion
mening
case
lumbar
punctur
perform
emerg
cerebrospin
fluid
csf
examin
find
csf
protein
mgdl
wbc
glucos
mgdl
cultur
neg
patient
treat
specif
antirickettsi
treatment
outcom
murin
typhu
favor
patient
one
patient
present
neurolog
sequela
conjunct
usual
accompani
rickettsi
diseas
rocki
mountain
spot
fever
epidem
typhu
murin
typhu
eightythre
patient
compat
clinic
statu
murin
typhu
high
serolog
titer
antibodi
rickettsia
typhi
studi
team
period
time
januari
first
semest
clinic
examin
patient
reveal
presenc
conjunct
patient
time
patient
refer
retroocular
pain
mild
photophobia
studi
show
murin
typhu
inject
conjunctiva
rather
common
almost
quarter
patient
present
conjunct
despit
fact
ocular
manifest
less
sever
typhu
spot
fever
eightythre
patient
compat
clinic
statu
murin
typhu
high
serolog
titer
antibodi
rickettsia
typhi
studi
team
period
time
januari
first
semest
three
blood
sampl
obtain
patient
studi
hematolog
abnorm
first
sampl
obtain
admiss
second
sampl
week
first
third
sampl
month
second
admiss
patient
present
anemia
patient
present
leukopenia
patient
present
thrombocytopenia
mean
valu
hematocrit
white
blood
cell
platelet
gdl
ml
respect
two
week
later
anemia
present
patient
patient
present
leukopenia
patient
present
leucocytosi
patient
present
thrombocytopenia
mean
valu
hematocrit
white
blood
cell
platelet
gdl
ml
respect
one
month
later
patient
anemia
patient
present
thrombocytopenia
mean
valu
hematocrit
white
blood
cell
platelet
gdl
ml
respect
studi
show
earli
thrombocytopenia
anemia
frequent
murin
typhu
white
blood
cell
count
usual
normal
renal
function
murin
typhu
studi
case
doukaki
polimili
g
triantafillid
kastanaki
vittoraki
e
palla
k
kastanaki
first
medic
depart
saint
georg
gener
hospit
chania
greec
clinic
cours
murin
typhu
usual
uncompl
mortal
rate
low
advanc
age
prolong
interv
administr
specif
antirickettsi
treatment
correl
sever
diseas
renal
function
murin
typhu
usual
unalt
except
elderli
patient
prolong
hypotens
eightythre
patient
compat
clinic
statu
murin
typhu
high
serolog
titr
antibodi
rickettsia
typhi
studi
team
period
time
januari
first
semest
three
blood
sampl
obtain
patient
studi
renal
function
first
sampl
obtain
admiss
second
sampl
approxim
week
first
third
sampl
taken
half
patient
obtain
one
month
second
admiss
patient
present
acut
renal
failur
outcom
murin
typhu
favour
patient
four
patient
present
acut
renal
failur
revers
administr
antirickettsi
treatment
care
administr
fluid
murin
typhu
induct
hypovolaemia
insuffici
correct
normal
homeostat
mechan
may
lead
preren
azotaemia
case
immedi
onset
antirickettsi
treatment
correct
hypovolaemia
essenti
rapid
clinic
improv
patient
experiment
ocular
toxoplasmosi
clinic
histopatholog
immunolog
therapeut
studi
el
zawawi
lae
hammoda
na
allam
sr
ali
sm
galal
b
faculti
medicin
parasitolog
alexandria
egypt
b
faculti
medicin
ophthalmolog
alexandria
egypt
purpos
studi
investig
clinic
histopatholog
immunolog
therapeut
featur
experiment
model
ocular
toxoplasmosi
sensit
non
sensit
rabbit
assess
influenc
treatment
ocular
lesion
result
obtain
toxoplasma
retnochoroid
develop
group
rabbit
pronounc
effect
non
sensit
anim
administr
improv
ocular
lesion
group
evid
effect
sensit
rabbit
immunolog
find
consist
clinic
histopatholog
observ
conclus
reach
ocular
lesion
manifest
non
sensit
rabbit
sensit
one
reveal
signific
impact
improv
host
defens
toxoplasm
infect
eye
immunotherapi
would
open
way
new
rang
treatment
base
immunomodul
expressdiagnost
streptococcu
antigen
adequ
antibiot
therapi
patient
pharyng
pertseva
konopkina
li
kireeva
tv
dsma
intern
medicin
dniepropetrovsk
ukrain
purpos
studi
evalu
effectiv
streptococcu
expressdiagnost
adequ
antibiot
therapi
patient
pharyng
result
deal
clinic
microbiolog
comparison
patient
pharyng
use
streptococcu
antigen
express
diagnost
swab
backsid
pharynx
allow
get
posit
result
seven
case
follow
cultur
studi
confirm
result
posit
test
probabl
patient
pronounc
fever
headach
weak
case
associ
chronic
tonsil
isol
streptococcu
pyogen
suscept
ampicillin
claritromicin
erytromicin
azytromicin
clindamicin
ceftriaxon
levafloxacin
oxacillin
cefuroxim
roxytromicin
conclus
use
express
diagnost
streptococcu
antigen
allow
restrict
groundless
prescript
antibiot
therapi
patient
type
pharyng
ie
viral
candid
etc
alabaz
turgut
kocaba
e
tumgor
g
yaman
b
alhan
e
divis
pediatr
infecti
diseas
cukurova
univers
adana
turkey
b
depart
microbiolog
cukurova
univers
adana
turkey
chickenpox
common
viral
infect
usual
follow
benign
self
limit
cours
healthi
children
common
complic
children
varicella
superimpos
cutan
infect
pyogen
bacteria
streptococcu
pyogen
staphylococcu
aureu
varicella
gangrenosum
necrotis
soft
tissu
infect
complic
vesicular
erupt
chickenpox
rare
present
three
case
necrotis
soft
tissu
infect
follow
chicken
pox
children
admit
common
crust
lesion
necrotis
soft
tissu
infect
neck
back
inguin
area
contact
histori
ensu
vesiculopapular
rush
infect
caus
group
streptococci
two
case
aureu
one
case
institut
appropri
antibiot
therapi
patient
underw
surgic
explor
fasciotomi
debrid
widespread
use
varicella
vaccin
may
decreas
invas
infect
children
adolesc
adult
thu
decreas
burden
diseas
complic
impos
famili
societi
cefprozil
second
gener
cephalosporin
aim
open
multicentr
noncompar
studi
investig
efficaci
safeti
cefprozil
treatment
streptococc
tonsillopharyng
fiftyeight
patient
clinic
assess
sign
symptom
streptococc
infect
laboratori
confirm
sought
use
three
test
cultur
rapid
strepto
test
estim
antistreptolysin
aso
one
test
done
patient
treatment
day
mgkg
per
day
children
mg
per
day
adolesc
patient
clinic
assess
day
result
show
clinic
success
patient
laboratori
test
two
patient
treatment
withdrawn
nausea
abdomin
pain
patient
laboratori
test
least
one
test
osit
help
strepto
test
give
quickest
posit
result
test
cultur
posit
test
aso
test
limit
valu
conclus
cefprozil
show
high
clinic
efficaci
safeti
treatment
streptococc
tonsillopharyng
tsiara
militad
g
milioni
c
elisaf
intern
medicin
depart
univers
ioannina
ioannina
greec
streptococcu
group
b
agalactia
gb
rare
pathogen
healthi
male
adult
present
old
man
gb
isol
blood
cultur
case
report
man
admit
hospit
order
investig
osteolyt
lesion
lumbar
spine
two
week
experienc
sever
low
back
pain
radiat
right
leg
fever
aris
chill
rigor
gb
isol
blood
cultur
treatment
penicillin
initi
spine
ct
scan
reveal
osteolysi
vertebra
patient
transfer
us
previous
healthi
man
receiv
antihypertens
therapi
admiss
afebril
arthralgia
myalgia
clinic
examin
tender
right
pleurospondyl
angl
radiat
right
leg
laboratori
data
admiss
hb
gdl
wbc
l
esr
mmh
biochem
valu
serum
protein
electrophoresi
rectal
examin
prostat
specif
antigen
psa
normal
bone
marrow
aspir
biopsi
neg
transoesophag
ultrasound
reveal
veget
right
cusp
aortic
valv
low
grade
regurgit
mri
lumbar
spine
reveal
infecti
myositi
concomit
osteomyel
involv
vertebra
without
evid
osteolyt
lesion
thorough
investig
reveal
underli
immunosuppress
diseas
treatment
vancomycin
gentamycin
iv
initi
patient
discharg
hospit
excel
health
week
discuss
gb
infect
usual
occur
neonat
pregnant
adult
underli
diseas
diabet
mellitu
immunosuppress
common
site
infect
soft
tissu
present
case
gb
infect
rare
elderli
absenc
underli
diseas
common
site
involv
soft
tissu
bone
joint
heart
valv
account
involv
organ
although
patient
one
site
involv
respond
well
medic
treatment
without
surgic
debriment
heart
valv
replac
object
evalu
safeti
efficaci
rhugmcsf
combin
broadspectrum
antibiot
treatment
ccnf
method
result
retrospect
review
patient
pt
ccnf
treat
antibioticsrhugmcsf
hospit
januari
decemb
perform
five
patient
identifi
diagnosi
ccnf
age
rang
year
three
women
two
men
dental
infect
common
sourc
ccnf
one
patient
acut
tonsil
lead
ccnf
case
studi
experienc
infect
neck
spread
submandibular
subment
sublingu
retropharyng
parapharyng
space
infect
polymicrobi
diabet
mellitu
comorbid
one
case
pt
treat
dual
antibiot
coverag
vancomycinmeropenem
rhugmcsf
mcgkgdaili
given
sc
aggress
wound
care
rhugmcsf
given
day
spite
sever
infect
pt
recov
experienc
local
system
complic
discuss
ccnf
sever
bacteri
infect
cervic
fascia
result
extens
fascial
necrosi
widespread
undermin
surround
tissu
prompt
antibiot
therapi
combin
rhugmcsf
result
overal
surviv
experi
knowledg
first
report
describ
success
treatment
ccnf
use
broadspectrum
antibiot
combin
rhugmcsf
follow
case
add
clinic
manifest
cours
meningococc
diseas
previous
healthi
girl
present
acut
high
fever
purpur
rash
includ
conjuctiv
haemorrhag
hypotens
child
also
neck
stiff
presumpt
diagnosi
meningococc
septicaemia
made
treatment
penicillin
chloramphenicol
fluid
inotrop
initi
laboratori
investig
show
wbc
hb
gdl
hct
esr
mm
first
hour
pt
aptt
neisseria
meningitidi
group
b
isol
blood
cultur
csf
obtain
antibiot
start
grow
n
meningitidi
patient
advers
outcom
die
h
hospit
patient
develop
fulmin
meningococc
septicaemia
shock
clinic
diagnosi
aris
failur
compensatori
mechan
maintain
perfus
vital
organ
expens
non
vital
septic
shock
result
loss
circul
plasma
volum
due
increas
vascular
permeabl
maldistribut
intravascular
volum
young
children
preval
serogroup
b
meningococc
diseas
explain
immatur
immun
system
fact
group
b
capsul
synthesi
known
inhibit
altern
complement
pathway
activ
case
emphas
need
protect
n
meningitidi
group
b
result
fortyeight
patient
includ
studi
etiolog
agent
viral
n
mean
x
year
streptococcu
pneumonia
n
x
neisseria
meningitidi
x
viridan
x
p
multocida
age
peak
incid
bacteri
mening
winter
pneumococc
meningococc
viridan
cerebrospin
fluid
csf
find
viral
mening
x
white
cell
x
x
glucos
csf
serum
x
protein
mgdl
bacteri
mening
x
white
x
x
glucos
csf
x
mgdl
gram
stain
posit
cultur
posit
pneumococc
meningococc
strain
suscept
penicillin
case
fatal
rate
pneumococc
meningococc
mening
respect
conclus
case
bacteri
mening
accord
typic
epidemiolog
featur
age
season
case
fatal
rate
pneumococc
mening
appear
high
regardless
suscept
penicillin
none
receiv
pneumococc
vaccin
prior
becom
ill
diagnosi
therapi
meningococc
mening
trend
particular
romanian
model
lintmaer
moroti
r
popescu
popescu
c
institut
infecti
diseas
matei
bal
unit
bucharest
romania
background
newer
diagnosi
method
antimicrobi
expect
chang
manag
menigococc
mening
mm
improv
prognosi
object
determin
chang
diagnosi
method
therapi
mm
patient
infecti
diseas
hospit
compar
mm
manag
bucharest
literatur
data
method
retrospect
rewiew
mm
adult
patient
hospit
period
result
compar
studi
made
taken
medlin
result
episod
mm
studi
period
episod
episod
notic
defin
diagnosi
increas
increas
blood
cultur
specif
antimicrobi
monotherapi
maintain
penicilin
replac
ceftriaxon
hhc
replac
dexamethason
pathogen
therapi
notic
shorter
length
treatment
reduc
lethal
import
differ
result
studi
monotherapi
regimen
less
frequent
therapi
length
longer
howev
prognosi
similar
conclus
mm
manag
modifi
last
year
prognosi
improv
chang
bring
clear
cost
effect
benefit
tiouiri
th
kilani
b
amari
l
zouiten
f
kanoun
kf
ghbontini
ben
chaaben
rabta
hospit
infecti
diseas
tuni
tunisia
object
order
studi
epidemiolog
clinic
therapeut
characterist
infect
endocard
ie
method
review
case
ie
fulfil
duke
criteria
data
collect
period
unit
infecti
diseas
result
one
hundr
eight
case
identifi
mean
age
year
sex
ratio
eightyf
ie
occur
patient
nativ
valv
ie
prosthet
valv
fever
common
sign
congest
heart
failur
cutan
sign
common
primari
focu
ie
orthodont
blood
cultur
posit
case
one
case
serolog
test
identifi
rickettsia
conori
streptococci
staphylococci
isol
respect
echocardiographi
detect
abnorm
case
rheumat
heart
diseas
predispos
condit
empir
therapi
base
combin
b
lactam
aminoglycosid
recoveri
obtain
patient
cardiac
surgeri
perform
case
overal
mortal
rate
conclus
ie
affect
young
person
prevent
need
erad
acut
rheumat
arthriti
major
outbreak
legionnair
diseas
spain
diagnost
aspect
guerrero
c
toldo
cm
e
g
b
c
segovia
hospit
moral
mesegu
servicio
de
murcia
spain
b
departamento
de
facultad
de
medicina
universidad
de
murcia
murcia
spain
object
evalu
valu
differ
method
serolog
test
cultur
respiratori
secret
blood
cultur
urinari
antigen
test
diagnosi
legionella
pneumophila
pneumonia
outbreak
spain
result
studi
patient
recent
outbreak
legionellosi
murcia
spain
diagnosi
achiev
patient
urinari
antigen
posit
patient
patient
urinari
antigen
neg
serolog
respons
demonstr
indirect
immunofluoresc
ifa
patient
blood
cultur
process
neg
sputum
sampl
obtain
patient
l
pneumophila
isol
six
patient
direct
immunofluoresc
test
dfa
posit
conclus
although
serolog
diagnosi
sensit
method
urinari
antigen
test
great
valu
rapid
diagnosi
legionella
outbreak
murcia
isol
l
pneumophila
cultur
show
poor
sensit
probabl
low
sever
ill
purpos
evalu
chloramphenicol
initi
empir
antibiot
treatment
purul
mening
adult
studi
group
one
hundr
twenti
patient
hospit
diagnosi
purul
mening
depart
year
male
femal
age
rang
year
mean
age
year
children
year
includ
method
retrospect
analysi
studi
group
focus
antibiot
treatment
initi
chang
treatment
result
chloramphenicol
use
initi
antibiot
gener
cephalosporin
penicillin
ampicillin
five
antibiot
five
respect
treatment
chloramphenicol
switch
gen
cephalosporin
seven
patient
streptococcu
pneumonia
mening
five
patient
mening
unknown
etiolog
reason
chang
nonimprov
csf
formula
three
persist
csf
cultur
posit
two
persist
coma
seven
patient
conclus
repeat
necess
switch
chloramphenicol
gen
cephalosporin
treatment
purul
mening
pneumococc
unknown
etiolog
initi
treatment
strategi
chang
third
gen
cephalosporin
use
first
choic
antibiot
consent
intern
recommend
treatment
evalu
compar
group
treat
initi
chloramphenicol
gen
cephalosporin
need
sever
year
low
preval
multidrug
resist
mycobacterium
tuberculosi
jerez
de
la
fronteracadiz
spain
alado
jc
aller
ai
de
miguel
c
de
francisco
jl
calbo
l
hospit
del
sasjerez
microbiologia
jerez
de
la
frontera
cadiz
spain
introduct
aim
previou
report
indic
multidrug
resist
mycobacterium
tuberculosi
mtb
worldwid
problem
aim
studi
review
resist
mtb
firstlin
antimycobacteri
agent
area
materi
method
period
year
strain
mtb
isol
nontreat
patient
tuberculosi
strain
studi
isol
test
vitro
drug
suscept
isoniacidi
rifampicinr
streptomycin
ethambutol
use
bact
alert
method
organon
teknica
describ
manufactur
result
result
show
strain
resist
one
drug
singl
drug
resist
detect
nine
strain
one
r
two
one
e
three
mtb
strain
resist
one
drug
one
multidrug
resist
ir
incid
iresist
strain
period
fell
conclus
multidrug
resist
import
problem
area
isoniacid
resist
declin
admiss
level
investig
antituberculosi
drug
resist
pattern
pulmonari
tuberculosi
isol
southern
taiwan
area
higher
tuberculosi
incid
mortal
region
island
perform
hospitalbas
surveil
southern
taiwan
medic
center
combin
drug
resist
rate
least
one
five
firstlin
agent
isoniazid
rifampin
multidrug
resist
mdr
indic
high
resist
rate
compar
report
whoiuatld
global
project
northern
taiwan
resist
rate
two
secondlin
drug
cycloserin
kanamycin
respect
signific
decreas
trend
resist
rate
drug
except
streptomycin
observ
period
though
combin
drug
resist
rate
may
accur
tool
includ
previous
treat
case
inflat
resist
rate
observ
trend
suscept
pulmonari
tuberculosi
accompani
increas
percentag
tuberculosi
patient
receiv
complet
treatment
cours
decreas
percentag
case
lost
followup
kaohsiung
institut
new
government
regul
case
manag
suggest
use
intervent
program
lipid
profil
patient
multidrug
resist
pulmonari
tuberculosi
extrapulmonari
tuberculosi
may
sometim
present
confus
clinic
manifest
femal
patient
admit
histori
recurr
suprastern
abscess
year
mri
confirm
presenc
sternal
osteomyel
anterior
mediastin
mass
diagnosi
tuberculosi
prove
histolog
examin
acidfast
stain
patient
treat
firstlin
agent
isoniazid
rifampin
pyrazinamid
ethambutol
tobacco
smoke
factor
decreas
chemotherapi
effect
develop
drug
resist
patient
pulmonari
tuberculosi
shprykov
zhadnov
vz
shprykova
b
medic
academi
depart
tuberculosi
lung
diseas
nyzhni
novgorod
russian
feder
b
medic
clinic
infecti
laboratori
bacteriolog
nyzhni
novgorod
russian
feder
studi
effect
smoke
result
chemotherapi
patient
tuberculosi
lung
intens
tobacco
smoke
slow
clearanc
posit
sputum
lung
tissu
destruct
smoker
vs
nonsmok
p
drugresist
mtb
strain
found
isol
often
smoker
vs
nonsmok
p
b
resist
streptomycin
isoniazid
prevail
reach
heavi
smoker
respect
resist
rifampicin
increas
time
concentr
rifampicin
blood
serum
heavi
smoker
decreas
time
clinic
data
complet
correl
find
experi
experiment
cultur
develop
resist
streptomycin
isoniazid
less
rifampicin
studi
drug
sensit
effect
tobacco
smoke
condens
thu
find
show
develop
drug
resist
mtb
effect
compon
tobacco
smoke
also
show
less
effect
therapi
kilani
kb
ammari
la
tiouiri
ht
ben
tbc
rabta
hospit
infecti
diseas
tuni
tunisia
guerrero
c
actinomycosi
chronic
diseas
character
abcess
format
tissu
fibrosi
drain
sinus
caus
anaerob
bacteria
belong
genu
actinomyc
thorac
actinomycosi
may
involv
lung
pleura
mediastinum
chest
wall
author
present
case
pulmonari
actinomycosi
complic
cervicofaci
site
man
histori
cervicofaci
actinomycosi
treat
penicillin
g
year
ago
admit
rightsid
chest
pain
month
present
cough
fever
physic
examin
show
painless
indur
mass
neck
multipl
fistula
sternum
chest
radiograph
ct
scan
reveal
mass
upper
lobe
right
lung
infiltr
upper
lobe
left
one
magnet
reson
imag
confirm
previou
lesion
extend
process
sternum
right
collar
bone
bronchoscopi
perform
patient
antimicrobi
therapi
cultur
bronchoalveolar
lavag
fluid
neg
transbronchi
biopsi
conclus
fungal
serolog
neg
aspergillosi
histoplasmosi
blastomycosi
bacteri
examin
purul
drainag
sternal
wound
show
inclus
bodi
identifi
actinomyc
treat
penicillin
iv
month
switch
doxycyclin
month
treatment
asymptomat
radiolog
improv
kanellopoul
skarmouts
n
iglezo
b
mylona
e
martsouk
apostolopoul
f
b
papafranga
e
laboratori
clinic
microbiolog
sismanoglio
gener
district
hospit
attica
athen
greec
b
depart
pneumolog
sismanoglio
gener
district
hospit
attica
athen
greec
introduct
achromobact
xylosoxidan
rare
human
pathogen
import
caus
bacteremia
patient
cardiac
diseas
malign
immunosuppress
recent
recogn
emerg
microorgan
cystic
fibrosi
cf
whose
pathogen
role
unknown
aim
investig
sensit
eleven
differ
antibiot
xylosoxidan
strain
isol
adult
cf
method
suscept
test
kirbi
bauer
microdilut
method
wider
fransisco
soria
melguizo
sa
accord
nccl
recomend
result
resist
antibiot
follow
gentamicin
tobramycin
aztreonam
amikacin
ceftazidim
ticarcillin
carbapenem
cotrimoxazol
colistin
piperacillin
conclus
xylosoxidan
isol
cf
patient
appear
resist
usual
test
antibacteri
agent
colistin
use
aerol
antibiot
cf
patient
seem
effect
half
isol
strain
piperacillin
activ
antibiot
xylosoxidan
morri
ka
perri
jd
jain
gould
fk
microbiolog
depart
freeman
hospit
newcastl
upon
tyne
uk
alafosfalin
acid
antibacteri
peptid
mimet
inhibit
peptidoglycan
biosynthesi
report
invitro
activ
compound
combin
ceftazidim
cefsulodin
fosfomycin
piperacillintazobactam
aztreonam
ciprofloxacin
timentin
drug
combin
evalu
burkholderia
cepacia
strain
pseudomona
aeruginosa
strain
isol
patient
cystic
fibrosi
purpos
chequerboard
techniqu
adopt
use
doubl
dilut
antibiot
incorpor
highli
defin
agar
medium
free
antagonist
minimum
inhibitori
concentr
mic
fraction
inhibitori
concentr
fic
antibiot
combin
determin
reveal
antibiot
interact
occur
alafosfalin
combin
ceftazidim
meropenem
piperacillintazobactam
timentin
demonstr
highest
percentag
synergi
b
cepacia
p
aeruginosa
synergi
shown
occur
b
cepacia
strain
respect
p
aeruginosa
strain
four
combin
retest
isol
result
shown
reproduc
alafosfalin
show
potenti
treatment
cystic
fibrosi
patient
colonis
p
aeruginosa
andor
b
cepacia
appli
combin
agent
communityacquir
pneumonia
aetiolog
matter
lintmaer
popescu
popescu
c
institut
infecti
diseas
matei
bal
unit
bucharest
romania
aetiolog
pneumonia
one
criteria
use
determin
pneumonia
sever
howev
accept
identifi
base
therapi
less
expens
possibl
effect
object
studi
aim
evalu
role
aetiolog
identif
pneumonia
evalu
firstlin
therapi
pneumonia
method
conduct
retrospect
studi
infecti
diseas
hospit
patient
pneumonia
exclud
case
nosocomi
pneumonia
primari
endpoint
clinic
failur
death
icu
admiss
secondari
endpoint
averag
time
fever
length
stay
antimicrobi
regimen
chang
result
caus
agent
identif
rate
evolut
differ
patient
identifi
aetiolog
compar
patient
term
failur
lengthofstay
chang
antimicrobi
regimen
patient
inadequ
firstlin
therapi
sever
cours
ill
greater
rate
clinic
failur
longer
fever
lengthofstay
conclus
pneumonia
treatment
better
patient
identifi
caus
agent
includ
aetiolog
among
pneumonia
sever
criteria
especi
therapi
reevalu
result
pneumomococc
aom
detect
children
spn
pathogen
resist
rate
organ
antibiot
follow
penicillin
mgml
intermedi
resist
mic
mgml
mic
mgml
highli
resist
erythromycin
clindamycin
cotrimoxazol
chloramphenicol
isol
uniformli
suscept
rifambicin
vancomycin
larg
major
pneumococc
isol
mphenotyp
remain
strain
constitut
ml
phenotyp
variou
serogroup
detect
serogroup
predomin
one
follow
serogroup
nontyp
spn
strain
compromis
strain
conclus
high
preval
resist
penicillin
macrolid
cotrimoxazol
pneumococc
aom
childhood
recogn
strategi
prevent
aom
caus
drugresist
pneumococci
mandatori
start
materi
method
total
number
strain
examin
sensit
test
perform
kirbi
bauer
microdilut
method
pasco
difco
accord
nccl
guidelin
e
test
result
percentag
pneumonia
strain
reveal
high
level
resist
penicillin
mic
mgml
show
intermedi
resist
mic
mgml
resist
erythromycin
cotrimoxazol
mic
mgml
mic
mgml
respect
strain
sensit
cefotaxim
mic
mgml
vancomycin
mgml
meropenem
mic
mgml
levofloxacin
mgml
conclus
preval
high
resist
pneumonia
penicillin
seem
low
examin
strain
intermedi
resist
penicillin
pneumonia
isol
high
expect
strain
sensit
erythromycin
cotrimozaxol
pneumonia
isol
complet
sensit
levofloxacin
vancomycin
meropenem
beghi
g
aiolfi
maghini
l
patruno
v
aiolfi
e
marta
hospit
pulmonari
rehabilit
unit
ao
rivolta
dadda
itali
aim
studi
retrospect
evalu
effect
practic
antibiot
treatment
aecopd
patient
pt
admit
unit
method
introduc
antimocrobi
drug
sputum
specimen
collect
microbiolog
purpos
blood
analysi
monitor
advers
system
effect
perform
begin
end
treatment
antibiot
treatment
rang
day
accord
four
regimen
regimen
pt
therapi
amc
g
bid
cip
mg
bid
dox
mg
uid
lev
mg
uid
cla
mg
bid
miscellan
regimen
b
pt
therapi
ev
amc
g
bid
cla
mg
bid
regimen
c
pt
therapi
drug
regimen
pt
associ
two
antibiot
result
evalu
pt
requir
second
regimen
treatment
failur
previou
one
regimen
regimen
b
regimen
c
regimen
mild
advers
effect
detect
four
pt
result
confirm
oral
antibiot
treatment
practic
safe
effect
consid
first
line
regimen
also
hospit
patient
aecopd
becher
g
gillissen
roth
b
st
georg
medic
center
robertkochhospit
leipzig
germani
b
filt
lung
chest
diagnost
ltd
berlin
germani
patient
sever
form
chronic
obstruct
pulmonari
diseas
copd
prone
frequent
exacerb
bacteri
infect
judg
caus
least
half
exacerb
haemophilu
influenza
streptococcu
pneumonia
frequent
isol
gramneg
bacilli
account
sever
case
aggrav
inflammatori
process
airway
eventu
lead
respiratori
insuffici
aim
ongo
placebo
control
parallel
group
mono
center
studi
trial
evalu
benefici
effect
cefixim
reduc
bacteri
load
pulmonari
inflamm
patient
acut
bacteri
exacerb
sever
copd
thu
patient
receiv
random
fashion
either
cefixim
mgday
placebo
day
day
breath
condens
collect
use
ecoscreen
jaeger
germani
nitriteand
phanalysi
parallel
sputum
gather
detect
bacteri
strain
quantif
purpos
data
compar
clinic
outcom
paramet
lung
function
test
radiograph
find
serum
inflammatori
marker
length
hospit
stay
preliminari
data
obtain
confirm
success
antibiot
therapi
oral
cefixim
bacteri
relat
acut
exacerb
copd
use
approach
reduc
bacteri
load
concomitantli
lower
inflammatori
indic
central
peripher
airway
lead
clinic
improv
patient
soriano
garcia
f
fenol
b
fernandezrobla
r
coronel
p
c
gimeno
c
rodena
e
c
garcia
granizo
jj
fundacion
jimenez
diaz
microbiolog
madrid
spain
b
instituto
de
salud
carlo
iii
centro
nacion
microbiologia
majadahonda
spain
c
tedec
meiji
farma
scientif
alcala
de
henar
spain
fundacion
jimenez
diaz
epidemiolog
madrid
spain
purpos
describ
suscept
streptococcu
pneumonia
cefditoren
antimicrobi
serotyp
multicent
studi
south
europ
carri
total
strain
collect
septemb
march
adult
patient
yo
respiratori
tract
infect
respiratori
tract
sampl
blood
cultur
isol
sent
central
laboratori
n
madrid
spain
suscept
test
perform
broth
microdilut
sensititr
follow
nccl
recommend
serotyp
determin
quellung
reaction
dot
assay
carlo
iii
institut
strain
result
total
strain
typabl
preval
serotyp
two
hundr
sixtyfour
strain
group
differ
serotyp
proport
suscept
strain
serotyp
penicillin
erythromycin
levofloxacin
serotyp
mic
cefditoren
serotyp
serotyp
mgl
serotyp
conclus
preval
serotyp
suscept
higher
serotyp
serotyp
commun
acquir
pneumonia
studi
among
close
militari
commun
young
peopl
martynova
av
turkutyukov
vb
vostrikova
aa
andryukov
bg
vladivostok
state
medic
univers
epidemiolog
vladivostok
russian
feder
purpos
etiolog
pneumonia
still
partli
unknown
like
clear
etiolog
role
respiratori
pathogen
communityacquir
pneumonia
among
youth
chosen
model
close
commun
investig
etiolog
diseas
investig
mechan
transmiss
drugresist
mechan
method
studi
adult
age
close
militari
collect
present
two
public
hospit
one
urban
one
rural
acut
radiolog
confirm
pneumonia
winter
blood
lungaspir
cultur
mycobacteri
cultur
serotypespecif
pneumococc
antigen
detect
serolog
viral
atyp
agent
result
streptococcu
pneumonia
recogn
import
caus
communityacquir
pneumonia
probabl
account
case
communityacquir
pneumonia
among
youth
chlamydia
pneumonia
mycoplasma
pneumonia
respons
approxim
case
haemophilu
influenza
caus
sever
case
diseas
case
due
moraxella
catharrali
conclus
pneumococci
infect
account
case
diagnos
pneumonia
common
bacteri
infect
agent
low
incid
pneumonia
pneumonia
caus
pathogen
occur
within
group
individu
defici
immunolog
statu
berezin
en
cardenuto
md
nobuko
e
b
guerra
ml
c
brandileon
mc
santa
casa
pediatr
paulo
brazil
b
santa
casa
microbiolog
paulo
brazil
c
adolfo
lutz
microbiolog
paulo
brazil
adolfo
lutz
bacteriolog
paulo
brazil
determin
antimicrobi
suscept
sp
isol
upper
respiratori
tract
collect
np
swab
specimen
children
month
year
old
children
attend
outpati
clinic
paulo
citi
diagnosi
bacteri
infect
requir
antibiot
therapi
march
may
penicillin
suscept
isol
determin
screen
oxacillin
mcg
disk
perform
minim
inhibitori
concentr
e
test
perform
also
suscept
test
amoxicillin
cefaclor
result
sp
recov
np
children
carriag
sp
preval
children
attend
day
care
center
children
young
sibl
home
children
tobacco
user
home
preval
penicillin
nonsuscept
strain
intermedi
resist
strain
suscept
amoxicillin
resist
cefaclor
serotyp
common
find
suggest
nasopharyng
isol
streptococcu
pneumonia
children
upper
respiratori
infect
use
conduct
surveil
antimicrobi
resist
defin
geograph
area
abl
conclud
also
penicillin
intermedi
resist
strain
suscept
amoxicillin
hinojosa
rm
saenz
collazo
echaniz
g
b
universidad
autonoma
de
nuevo
leon
infectologia
monterrey
mexico
b
instituto
nacion
de
salud
publica
epidemiologia
cuernavaca
mexico
emerg
penicillinand
multidrugresist
pneumococc
strain
becom
global
concern
necessit
identif
epidemiolog
spread
strain
materi
nineti
streptococcu
pneumonia
clinic
isol
collect
march
march
type
done
capsular
reaction
pool
type
group
antisera
suscept
test
antimicrobi
done
e
test
disk
diffus
method
result
pneumonia
strain
classifi
serotyp
frequent
type
oxacillin
screen
test
detect
penicillinresist
pneumonia
strain
isol
children
adult
suscept
percentag
pneumonia
ceftriaxon
children
adult
pneumonia
isol
children
exhibit
suscept
azithromycin
adult
isol
suscept
rest
antimicrobi
agent
suscept
rang
pneumonia
lower
suscept
ceftazidim
ciprofloxacin
conclus
ceftriaxon
azithromycin
good
invitro
activ
pneumonia
strain
percentag
penicillinresist
pneumonia
detect
studi
alarm
therefor
conclud
continu
surveil
system
necessari
mexico
vertkin
al
prokhorovitch
ea
alexanyan
la
retrospect
analys
case
ambul
pneumonia
fatal
outcom
made
among
patient
die
ambul
pneumonia
prevail
age
prevail
sex
male
pneumonia
accompani
patholog
chronic
lung
diseas
alcohol
diabet
mellitu
patient
big
volum
lung
lesion
patient
suffer
bilobular
pneumonia
trilob
pneumonia
case
pneumonia
complic
abscess
format
andor
exud
pleurisi
studi
antibiot
therapi
use
patient
treatment
chang
antibiot
made
case
wherea
case
chang
prepar
made
though
sign
therapi
noneffect
obviou
thu
ration
antibiot
therapi
time
chang
noneffect
antibacteri
drug
significantli
import
choos
antibiot
patient
age
accompani
diseas
volum
lung
lesion
complic
defin
pneumonia
serious
taken
consider
perronn
c
rouveix
b
b
guillemot
c
zuck
p
reitz
c
e
tsatsari
e
raymond
servic
de
maladi
infectieus
garch
franc
b
cochin
pari
franc
c
institut
pasteur
pari
franc
de
metz
metz
franc
e
laboratoir
abbott
rungi
franc
object
describ
manag
lower
respiratori
tract
infect
lrti
healthi
adult
gener
practition
gp
method
questionnair
sent
repres
nation
sampl
gp
questionnair
assess
percept
manag
lrti
indic
antibiot
ab
case
lrti
healthi
adult
focal
sign
sign
sever
knowledg
microorgan
respons
acut
bronchiti
knowledg
afssap
french
agenc
safeti
health
product
recommend
result
three
thousand
seven
hundr
thirtyeight
gp
report
see
averag
patient
per
week
includ
patient
lrti
return
questionnair
main
result
present
follow
major
gp
main
object
visit
determin
indic
antibiot
accord
gp
alp
whoop
cough
rare
atyp
pneumonia
frequent
gp
also
declar
diagnosi
alp
often
easi
right
first
visit
contrast
atyp
pneumonia
complementari
investig
often
request
gp
consid
often
delay
prescript
antibiot
declar
tend
prescrib
macrolid
firstlin
treatment
final
gp
poor
knowledg
concern
microorgan
respons
acut
bronchiti
major
gp
declar
familiar
afssap
recommend
perronn
c
rouveix
b
b
guillemot
c
zuck
p
reitz
c
e
tsatsari
e
raymond
servic
de
maladi
infectieus
garch
franc
b
cochin
pari
franc
c
institut
pasteur
pari
franc
de
metz
metz
franc
e
laboratoir
abbott
rungi
franc
object
studi
manag
one
case
lower
respiratori
tract
infect
lrti
adult
gener
practition
gp
method
prospect
studi
conduct
repres
nation
sampl
gp
gp
includ
first
healthi
adult
patient
seen
data
collect
period
either
home
visit
offic
recent
cough
acut
fever
clinic
data
diagnost
percept
therapeut
approach
patient
collect
mean
standardis
questionnair
distribut
abbott
laboratori
result
three
thousand
seven
hundr
thirtyeight
gener
practition
includ
patient
conclus
lrti
adult
gp
observ
focal
sign
confirm
mark
predomin
bronchiti
compar
pneumonia
view
frequenc
sign
diagnosi
pneumonia
appear
overestim
onethird
clinic
situat
diagnos
bacteri
superinfect
acut
bronchiti
despit
recognis
diagnost
entiti
antibiot
prescript
immedi
case
delay
case
last
point
show
clinic
practic
differ
gp
percept
describ
prescrib
practic
shown
simultan
survey
gp
declar
prescrib
antibiot
immedi
delay
prescript
result
thirtythre
patient
men
mean
age
b
year
mean
apach
ii
score
bdqup
b
year
prospect
studi
thirteen
patient
identifi
risk
factor
sever
cap
etiolog
factor
reveal
patient
achiev
noninvas
method
psb
cultur
taken
eight
patient
posit
offend
organ
includ
streptococcu
pneumonia
six
case
gnb
sole
pathogen
six
case
haemophilu
influenza
pneumonia
klebsialla
pneumonia
two
case
aureu
two
legionella
pneumophila
one
patient
initi
antibiot
regimen
combin
marcodil
gen
success
patient
surviv
chang
empir
accord
cultur
result
patient
mortal
overal
mortal
rate
identif
caus
factor
seem
impact
surviv
conclus
sever
cap
icu
often
caus
pneumonia
gbn
high
mortal
entiti
seem
influenc
immedi
use
appropri
antibiot
combin
identif
caus
organ
underscor
need
knowledg
topic
microbiolog
help
design
effect
empir
initi
antibiot
regimen
mili
mn
golubev
sa
b
lugovoy
vy
voronov
gg
b
vitebsk
emerg
hospit
pharmacotherapi
unit
vitebsk
belaru
b
basic
clinic
pharmacolog
depart
vitebsk
state
medic
univers
vitebsk
belaru
purpos
studi
aim
assess
spectrum
predictor
antibiot
use
pneumonia
manag
region
emerg
hospit
belaru
patient
treatment
physician
characterist
case
collect
possibl
associ
examin
use
defin
daili
dose
methodolog
ddd
american
thorac
societi
at
guidelin
result
mean
treatment
durat
day
total
antibiot
bedday
bedday
use
antibiot
penicillin
aminoglycosid
macrolid
cephalosporin
tetracyclin
manova
certain
at
categori
associ
dddday
frequenc
definit
antibiot
use
dddday
higher
case
multilobar
infiltr
conclus
studi
indic
low
rate
macrolid
cephalosporin
use
high
one
aminoglycosid
antibiot
prescript
associ
diseas
sever
physician
person
rather
empir
choic
rule
recommend
acut
exacerb
copd
frequent
infect
agent
suspect
differ
type
penicillin
analysi
medic
document
pertseva
bogatska
ke
gashynova
ky
dsma
intern
medicin
dniepropetrovsk
ukrain
number
copd
case
increas
ukrain
treatment
acut
exacerb
ae
copd
alway
success
inadequ
antibiot
therapi
aim
studi
reveal
frequent
infect
agent
suscept
differ
type
penicillin
patient
ae
copd
medic
document
patient
ae
copd
type
studi
data
sputum
analysi
suscept
isol
agent
penicillin
ampicillin
oxacillin
amoxicillinclavulon
acid
evalu
patient
haemophilu
influencaeparainfluenca
klebsiella
pneumonia
staphylococcu
aureu
pseudomona
fluorescen
pseudomona
putida
serratia
marcescen
serratia
liquefacien
streptococcu
agalactia
acinetobact
baumanii
sampl
sputum
case
mixt
infect
bacteri
agent
agent
suscept
penicillin
ampicillin
oxacillin
howev
microorgan
suscept
amoxicillin
combin
clavulon
acid
studi
shown
frequent
infect
agent
caus
ae
copd
gramneg
microorgan
aureu
accord
antibiogram
prescript
amoxicillinclavulon
acid
expedi
case
pertseva
bogatska
ke
konopkina
li
kireeva
tv
gashynova
ky
dsma
intern
medicin
depart
dniepropetrovsk
ukrain
examin
patient
men
mean
age
year
acut
exacerb
cob
type
frequent
isol
agent
haemophilu
influenza
parainfluenza
eight
patient
gramneg
rod
staphylococcu
aureu
two
mix
six
one
patient
bacteri
agent
isol
sputum
high
suscept
azithromycin
found
case
gramposit
agent
h
influenza
parainfluenza
gramneg
agent
resist
drug
vitro
howev
treatment
mgday
day
clinic
effect
case
patient
acut
exacerb
cob
peculiar
infect
agent
caus
acut
exacerb
cob
studi
klebsiella
pneumonia
aureu
found
frequent
studi
high
efficaci
surnam
treatment
acut
exacerb
cob
establish
partial
posit
clinic
effect
therapi
patient
advers
event
efficaci
toler
amoxicillin
mgkg
bid
versu
amoxicillin
mgkg
tid
treatment
acut
otiti
media
aom
children
year
borek
guggenbichl
jp
b
biochemi
gmbh
intern
medic
depart
kundl
austria
b
depart
pediatr
univers
erlangen
erlangen
germani
five
hundr
sixteen
patient
mean
age
year
clinic
otoscop
diagnosi
aom
includ
random
doubl
blind
multicentr
studi
treat
day
either
amox
mgkg
bid
amox
mgkg
tid
assess
made
therapi
day
end
therapi
eot
day
follow
fu
day
primari
efficaci
endpoint
clinic
respons
eot
defin
success
cureimprov
failur
regimen
well
toler
one
drugrel
advers
event
ae
report
bid
patient
tid
patient
frequent
report
drugrel
ae
group
gastrointestin
symptom
bid
vs
tid
mainli
mild
moder
sever
regimen
clinic
equival
higher
cure
rate
bid
group
suggest
possibl
higher
benefit
bid
therapi
children
year
children
attend
famili
daycar
fdc
less
expos
upper
respiratori
tract
infect
group
daycar
gdc
therefor
antibiot
treatment
fewer
thu
carri
resist
bacteria
test
hypothesi
np
carriag
sp
hi
reduc
suscept
penicillin
pdsp
hi
bl
respect
investig
among
children
fdc
maximum
three
children
gdc
children
alp
maritim
franc
novemb
march
two
stage
cluster
sampl
children
attend
gdc
fdc
select
np
sampl
cultur
sp
hi
penicillin
suscept
test
disk
diffus
e
test
blactamas
product
apinh
test
biomerieux
lyon
two
hundr
thirtyf
children
fdc
gdc
age
month
sampl
age
sex
distribut
similar
group
sp
isol
children
fdc
children
gdc
p
proport
pdsp
respect
hi
present
children
gdc
vs
fdc
p
b
proport
hi
bl
vs
respect
antibiot
exposur
previou
month
concern
children
gdc
vs
fdc
p
correl
antibiot
use
carriag
pdsp
hi
b
strain
sp
hi
carriag
rate
significantli
lower
among
children
fdc
gdc
advis
altern
type
daycar
children
attend
gdc
reduc
exposur
thu
limit
spread
resist
bacteria
howev
proport
pdsp
hi
bl
similar
group
compar
pattern
antibiot
use
observ
continu
effort
must
concentr
parent
educ
enforc
recommend
manag
pediatr
upper
respiratori
tract
infect
period
januari
august
invas
haemophilu
influenza
hi
isol
collect
children
hospit
tuni
use
haemophilu
test
medium
test
antibiot
suscept
mic
betalactam
measur
e
test
betalactamas
product
determin
use
cefinas
test
biotyp
apinh
presenc
capsular
antigen
determin
use
hi
type
anti
sera
hi
strain
isol
meningitidi
bacteremia
arthriti
strain
serotyp
b
belong
biotyp
ii
amoxicillin
resist
betalactamas
produc
mechan
occur
betalactamas
produc
strain
vs
mgl
nonproduc
one
betalactamaseneg
amoxicillin
resist
among
invas
isol
antibiot
resist
concern
chloramphenicol
trimethoprimsulfamethoxazol
tetracyclin
kanamycin
invas
hi
infect
tunisian
children
alway
associ
type
b
strain
introduct
hib
vaccin
programm
tunisia
recommend
aim
studi
analys
clinic
pictur
treatment
neurolog
manifest
neuroborreliosi
children
studi
includ
children
year
neuroborreliosi
diagnos
basi
clinic
serolog
criteria
symptom
facial
palsi
occur
six
children
symptom
iii
cranial
nerv
palsi
three
children
mening
four
paresthesia
three
symptom
v
viii
nerv
palsi
mental
disturb
radiculoneur
cerebel
found
singular
case
children
receiv
ceftriaxon
intraven
week
total
recoveri
obtain
children
follow
first
cours
therapi
recoveri
follow
second
cours
therapi
amoxicillin
occur
one
child
mental
disord
one
vi
nerv
palsi
improv
achiev
second
cours
patient
radicul
howev
muscular
atrophi
persist
irrevers
unilater
deaf
found
child
viii
nerv
palsi
spite
three
cours
therapi
appli
infect
borrelia
burgdorferi
children
caus
wide
spectrum
neurolog
manifest
facial
palsi
common
sign
studi
appli
ceftriaxon
treatment
neuroborreliosi
characteris
good
effect
doubl
infect
c
pneumonia
pneumonia
caus
cystic
chang
lung
streharova
moravcikova
depart
infecti
diseas
univers
trnava
trnava
slovakia
chlamydia
pneumonia
mycoplasma
pneumonia
human
respiratori
pathogen
manifest
earli
childhood
immunolog
disbal
could
trigger
autoaggress
diseas
author
describ
case
girl
develop
multiorgan
failur
septic
state
follow
multipl
cystic
chang
lung
girl
diagnosi
cystic
fibrosi
author
consid
cystic
chang
consequ
doubl
infect
c
pneumonia
dzarlieva
momeva
l
temelkovska
g
balevska
p
pejkovska
medic
centr
neonatolog
bitola
former
yugoslav
republ
macedonia
unicef
skopj
support
nationwid
safe
motherhood
need
assess
repres
sampl
hospit
eighteen
matern
ward
facil
renov
certifi
babyfriendli
matur
newborn
success
adapt
extra
uterin
life
satisfactori
vital
paramet
h
day
mother
roomingin
system
aim
roomingin
system
reach
decreas
incid
neonat
infect
materi
method
histori
record
newborn
depart
period
month
neonat
born
suspect
infect
babi
newborn
born
meconium
stain
liquid
result
microbiolog
find
blood
cultur
staphylococcu
coagulaza
neg
swab
staphylococcu
aureu
escherichia
coli
staphylococcu
epidermidi
conclus
babi
risk
factor
infect
newborn
posit
find
year
roomingin
sistem
period
roomingin
newborn
roomingin
system
reach
decreas
incid
neonat
infect
break
chain
infect
mother
take
care
babi
help
staff
newborn
micro
environ
home
practic
also
reduct
nosocomi
infect
studi
antibiot
suscept
resist
factor
transmiss
among
antibiot
resist
salmonella
isol
children
affect
diarrhea
sharifzadeh
azad
univers
shahrekord
microbiolog
shahrekord
islam
republ
iran
spite
happen
drug
resist
antibacteri
therapi
still
best
rout
treatment
salmonellosi
man
anim
order
detect
domin
serotyp
salmonella
children
detect
antibiot
suscept
rfactor
transmiss
among
isol
salmonella
studi
conduct
diarrheic
stool
sampl
collect
children
affect
diarrhea
ayatollah
kashani
hospit
shahrekord
spring
autumn
isol
identif
salmonella
seven
serotyp
detect
one
typhi
anoth
six
serotyp
paratyphi
b
order
detect
antibiot
differ
antibiot
disk
use
disk
diffus
method
best
result
taken
ceftizoxim
cephtriaxon
cephazolin
chloramphenichol
rfactor
transfer
isol
salmonella
escherichia
coli
case
resist
penicillin
ampicillin
pharyng
colon
streptococcu
pneumonia
group
bh
evalu
randomli
select
school
children
age
year
riyadh
saudi
arabia
fiftysix
children
posit
cultur
either
organ
isol
school
children
pneumonia
penicillinsensit
three
penicillinresist
two
resist
two
antimicrobi
forti
isol
bh
group
bh
isol
penicillin
erythromycin
sensit
carrier
rate
among
school
children
penicillinresist
pneumonia
resist
two
antimicrobi
respect
carrier
rate
group
bh
riyadh
low
rate
antibioticresist
pneumonia
similar
rate
group
bh
carrier
among
school
children
seen
temper
area
boukadida
j
boukadida
n
b
hannechi
n
said
h
b
erraii
elmhabrech
h
chu
f
hach
laboratoir
de
microbiologi
souss
tunisia
b
c
base
souss
tunisia
acut
pharyng
frequent
patholog
group
streptococcu
incrimin
bacteria
howev
non
bhaemolyt
streptococcu
sbna
could
respons
aim
work
determin
part
non
b
hemolyt
streptococci
sbna
acut
pharyng
relat
antibiot
suscept
pattern
studi
realiz
soussetunisia
north
africa
month
may
origin
materi
isol
throat
swab
transystem
venturi
copan
bovezzo
mean
age
patient
year
extrem
year
sampl
cultur
blood
agar
plate
delay
h
maximum
identif
done
sampl
bhemolyt
coloni
groupag
pastorex
strep
sanofi
pasteur
franc
suscept
pattern
accord
nccl
norm
mic
determin
e
test
control
strain
pneumonia
atcc
twentyon
clinic
isol
sbna
distinguish
clinic
isol
bhemolyt
streptococci
recov
patient
acut
pharyng
without
symptom
virus
infect
tear
corysa
sneez
bhemolyt
streptococcu
repres
collect
sampl
sbna
isol
sbna
strain
group
g
streptococci
seven
strain
group
c
streptococci
three
strain
group
f
streptococci
suscept
pattern
sbna
antimicrobi
agent
follow
group
g
streptococci
peni
g
amoxicillin
pristinamycin
clindamycin
tetracyclin
telithromycin
group
c
streptococci
peni
amoxicillin
pristinamycin
group
f
streptococcipeni
tetracyclin
telithromycin
sbna
mic
penicillin
g
mgl
accord
avail
data
penicillin
g
amoxicillin
still
refer
treatment
acut
bacteri
pharyng
spite
new
antibiot
introduct
berezin
en
quevedo
sg
b
nicolla
l
b
viega
c
eizenberg
b
pedrosa
f
b
santo
ag
santa
casa
pediatr
paulo
brazil
b
elli
lilli
scientif
paulo
brazil
c
fac
abc
pediatr
santo
andr
brazil
univers
hospit
pediatr
paulo
brazil
multicent
open
label
prospect
random
trial
patient
year
age
proven
gabh
pharyng
random
receiv
either
cours
broad
spectrum
oral
cephalosporin
cefaclor
cours
amoxicillin
patient
includ
sign
symptom
streptococc
tonsillopharyng
rapid
streptococc
rapid
test
posit
patient
evalu
day
posttherapi
pharyng
cultur
conduct
baselin
followup
visit
day
consid
bacteriolog
erad
analysi
patient
posit
cultur
gabh
patient
rapid
streptococc
rapid
test
clinic
success
achiev
around
patient
evalu
erad
initi
pathogen
consid
patient
amoxil
arm
patient
cefaclor
arm
thirtyfour
patient
amoxil
arm
patient
cefaclor
arm
consid
bacteriolog
cure
second
cultur
perform
day
ten
day
penicillin
amoxicillin
therapi
may
best
therapeut
choic
pediatr
patient
develop
countri
rheumat
fever
still
import
problem
evalu
bacteri
erad
achiev
differ
antibiot
may
import
prophylact
affect
saccharomyc
boulardii
antibioticassoci
diarrhea
paediatr
age
group
erdev
tira
u
camurdan
mo
tanyer
g
dallar
ankara
educ
research
hospit
pediatr
ankara
turkey
process
result
antibiot
associ
diarrhea
alter
enter
flora
due
bacteria
saccharomyc
boulardii
yeast
isol
cover
kind
hazelnut
usag
becam
widespread
recent
enough
studi
boulardii
activ
pediatr
age
aim
defin
boulardii
activ
azithromycin
sulbactamampicilin
associ
diarrhea
pediatr
age
group
case
antibiot
usag
develop
diarrhea
wherea
rate
probiot
use
group
p
clostridium
difficil
toxin
defin
case
sulbactamampicilin
use
group
rate
diarrhea
sulbactamampicilin
use
group
group
use
boulardii
probiot
besid
sulbactamampicilin
p
b
observ
probiot
usag
decreas
diarrhea
rate
four
time
p
age
group
consid
rate
sulbactamampicilin
associ
diarrhea
increas
age
boulardii
effect
prevent
diarrhea
signific
age
p
antibiot
associ
diarrhea
common
clinic
problem
pediatr
age
group
boulardii
hope
give
probiot
especi
sulbactamampicilin
associ
diarrhea
grey
e
bilikova
e
hafe
bm
kovacicova
g
chovancova
b
huttova
b
krcmeri
v
school
health
trnava
univers
trnava
slovakia
b
postgradu
academi
medicin
neonat
clinic
bratislava
slovakia
purpos
studi
aim
studi
find
whether
artifici
abort
mother
impact
neonat
infect
futur
babi
result
obtain
therefor
compar
neonat
infect
born
mother
past
histori
abort
artifici
abort
within
year
babi
mother
experienc
abort
control
group
consist
neonat
hospit
clinic
time
period
accord
analysi
risk
factor
neonat
infect
found
prematur
week
gestat
vs
p
low
birth
g
vs
p
significantli
frequent
observ
babi
mother
past
histori
abort
drug
abus
heroin
vs
p
nicotin
use
vs
p
significantli
relat
neonat
infect
babi
mother
past
histori
abort
etiolog
analysi
show
candida
albican
vs
p
significantli
relat
neonat
infect
mother
past
histori
abort
conclus
reach
conclus
artifici
abort
direct
impact
health
mother
also
next
pregnanc
bacteraemia
patient
mortal
peadiatr
intens
care
unit
armenian
sh
singh
j
arrieta
ac
children
hospit
orang
counti
infecti
diseas
orang
usa
purpos
studi
identifi
factor
significantli
contribut
mortal
patient
bloodstream
infect
bsi
pediatr
intens
care
unit
picu
result
medic
record
patient
admit
picu
document
bsi
review
separ
episod
bsi
nine
patient
multipl
bsi
hospit
stay
casecontrol
model
use
case
bsi
eventu
mortal
control
surviv
bsi
patient
die
older
vs
year
pb
like
nosocomi
bsi
vs
pb
longer
hospit
prior
bsi
vs
day
pb
polymicrobi
bsi
vs
pb
infect
relat
mortal
irm
defin
death
within
day
bsi
significantli
higher
receiv
inadequ
antibiot
treatment
time
diagnosi
bsi
vs
p
b
well
gram
neg
bacteremia
andor
fungemia
vs
p
b
logist
regress
use
adjust
potenti
confound
variabl
conclus
found
older
multipl
organ
longer
hospit
prior
bsi
significantli
associ
overal
patient
mortal
irm
significantli
higher
inadequ
initi
antibiot
coverag
gram
neg
bacteremia
andor
fungemia
somer
r
diri
salman
n
ongen
b
b
rler
n
b
depart
pediatr
infecti
diseas
istanbul
univers
istanbul
medic
faculti
istanbul
turkey
b
depart
microbiolog
clinic
microbiolog
istanbul
univers
istanbul
medic
faculti
istanbul
turkey
teicoplanin
glycopeptid
antibiot
activ
broad
rang
gramposit
pathogen
includ
methicillinresist
staphylococci
offer
advantag
daili
administr
choic
administr
rout
lack
requir
routin
therapeut
drug
monitor
lower
propens
caus
nephrotoxitici
anaphylactoidlik
reaction
studi
efficaci
safeti
teicoplanin
evalu
retrospect
children
seriou
bacteri
infect
sixtythre
children
girl
boy
age
month
year
treat
teicoplanin
three
load
dosag
mgkg
h
interv
follow
mainten
dosag
mgkgday
infect
treat
pleural
empyema
joint
bone
infect
n
septicemia
skin
soft
tissu
infect
lung
abscess
pathogen
isol
staphylococcu
aureu
n
methicillin
resist
coagulaseneg
staphylococci
pneumonia
group
hemolyt
streptococci
n
durat
therapi
rang
day
median
day
clinic
success
cure
plu
improv
achiev
case
side
effect
attribut
teicoplanin
therapi
encount
teicoplanin
appear
effect
welltoler
treatment
seriou
gramposit
infect
children
risk
infect
present
children
acut
leukemia
two
hundr
sixti
episod
febril
neutropenia
analyz
children
age
year
aml
case
case
year
cytostat
therapi
protocol
mbfm
aml
mbfm
degre
fn
occur
case
aml
site
infect
blood
central
venou
cathet
respiratori
tract
pathogen
isol
blood
gramposit
cn
streptococcu
spp
gramneg
enterobacteria
pseudomona
aeruginosa
candida
spp
aspergillu
spp
treatment
fn
use
empir
antibiot
regimen
clinic
respons
notic
line
therapi
cephalosporin
gener
use
carbapenem
use
line
vancomycin
amphotericin
b
thirtytwo
percent
children
aml
children
die
sepsi
conclus
carbapenem
activ
line
antibiot
therapi
patient
aml
vancomycin
use
line
patient
amphotericin
b
vancomycin
use
combin
line
patient
aml
pavlenishvili
ivp
medic
academi
pediatr
tbilisi
georgia
drug
choic
case
complic
neonat
sepsi
pavlenishvili
g
iobashvili
tbilisi
medic
academi
georgian
societi
pediatr
chemotherapi
gspc
collabor
drug
therapeut
committe
dtc
childer
hospit
republ
finish
observ
studi
nosocomi
infect
neonat
icu
mention
hospit
studi
begin
novemb
period
observ
case
neonat
sepsi
due
gramneg
bacteria
thirtyfour
case
neonat
sepsi
caus
differ
stain
escherichia
coli
proteu
spp
acinetobact
notic
last
year
role
acinetobact
etiolog
neonat
sepsi
nosocomi
complic
neonat
sepsi
hospit
gradual
increas
observ
reveal
optim
case
complic
neonat
sepsi
accord
criteria
dt
use
ceftasidim
almost
case
use
ceftasidim
success
one
case
mortal
sinc
macrolid
resist
mr
streptococcu
pyogen
increas
europ
studi
incid
genet
basi
mr
pyogen
russia
pyogen
isol
baselin
followup
visit
children
acut
pharyng
receiv
penicillin
midecamycin
macrolid
studi
mr
evalu
agar
dilut
nccl
resist
mechan
pcr
total
pyogen
obtain
baselin
erythromycinresist
strain
erm
posit
one
mef
posit
one
neg
primer
use
erm
strain
induc
resist
clindamycin
repres
seven
pfge
profil
one
profil
found
strain
three
midecamycin
treat
patient
mr
select
therapi
one
strain
erm
one
mef
one
unknown
resist
determin
mef
strain
obtain
followup
visit
differ
pfge
pattern
mef
strain
isol
baselin
baselin
followup
strain
unknown
mechan
resist
uniqu
pfge
pattern
data
show
moder
incid
erythromycinresist
pyogen
smolensk
ribosom
methyl
erm
common
mechan
though
polyclon
natur
mr
establish
erm
strain
belong
clone
bacillu
cereu
infect
traumatologyorthopaedi
depart
retrospect
studi
reevalu
healthcar
practic
bacillu
cereu
cultur
patient
traumatolog
depart
develop
postop
wound
infect
august
march
patient
present
inferior
member
open
fractur
frequent
contamin
tellur
materi
requir
extern
fixat
genom
studi
clinic
isol
puls
field
gel
electrophoresi
random
analysi
polymorph
dna
allow
us
elimin
outbreak
furthermor
reduc
delay
patient
develop
infect
led
us
reevalu
procotol
use
institut
inde
patient
receiv
amoxycillin
clavulan
iv
antibioprophylaxi
anesthet
induct
relay
per
os
hour
product
potent
betalactamas
bacteria
associ
could
effici
furthermor
accordingli
afnor
en
norm
test
clinic
isol
sensit
princip
antisept
use
antisepsi
disinfect
iodophor
chlorid
deriv
biguanidin
observ
major
resist
strain
test
even
postop
wound
infect
consid
nosocomi
delay
appear
actual
think
bacillu
cereu
initi
present
tellur
materi
fact
led
us
propos
systemat
screen
bacillu
admiss
type
wound
administr
quinolon
ciprofloxacin
prophylaxi
intern
thiol
reactiv
oxygen
speci
candidacid
activ
exert
ntermin
peptid
human
lactoferrin
ps
purpos
studi
emerg
candida
albican
strain
resist
current
antifung
point
need
new
antifung
agent
e
g
antimicrobi
peptid
result
obtain
report
hlf
synthet
ntermin
peptid
human
lactoferrin
display
excel
kill
effect
fluconazoleresist
c
albican
suboptim
concentr
peptid
combin
fluconazol
act
synergist
previou
investig
reveal
hlf
requir
energ
mitochondrion
atp
releas
candida
ligat
atp
receptor
kill
effect
report
reactiv
oxygen
speci
ro
involv
kill
effect
hlf
sinc
intern
thiol
protect
cell
oxid
damag
observ
hlf
caus
reduct
intern
thiol
candida
interest
expect
nacetyllcystein
nac
precursor
glutathion
ro
scaveng
inhibit
kill
effect
hlf
diamid
oxid
intern
thiol
candidacid
hlf
diamid
act
synergist
kill
c
albican
ro
product
moreov
hlf
induc
activ
mitochondria
inhibit
nac
indic
intern
thiolsro
affect
mitochondri
activ
conclus
reach
candidacid
activ
hlf
involv
ro
product
reduct
intern
thiol
object
audit
conduct
explor
observ
increas
resist
ciprofloxacin
enterobacteriacea
isol
specimen
patient
hematolog
unit
result
enterobacteriacea
isol
specimen
patient
process
year
examin
number
specimen
per
year
respect
annual
percent
ciprofloxacin
resist
enterobacteriacea
conclus
conclus
drawn
audit
rapid
rise
ciprofloxacin
resist
may
possibl
attribut
use
fluoroquinolon
singl
agent
dose
mg
cut
patient
weight
kg
twice
day
neutropen
patient
till
neutrophil
exceed
subsequ
audit
prophylaxi
protocol
modifi
use
oral
colistin
unitstwic
day
combin
ciprofloxacin
mg
twice
day
prospect
audit
propos
test
benefit
combin
rhinocerebr
zygomycosi
diagnost
dilemma
emerg
physician
associ
morbid
mortal
rare
deadli
diseas
reduc
ps
samavedam
guleri
western
infirmari
clinic
microbiolog
glasgow
unit
kingdom
rhinocerebr
zygomycosi
rcz
rare
invas
rapidli
progress
opportunist
infect
caus
ubiquit
fungi
order
mucoral
usual
occur
diabet
immunocompromis
patient
emerg
physician
typic
see
patient
rcz
earliest
stage
masquerad
varieti
less
seriou
diseas
key
marker
like
necrot
patch
hard
palat
nasal
septum
turbin
mark
facial
pain
cellulit
mark
eye
neurolog
sign
may
present
late
diseas
report
case
rcz
caus
rhizopu
arrhizu
oryza
year
old
woman
poorli
control
diabet
present
rightsid
facial
droop
short
origin
gener
unwel
ct
scan
nonconclus
delay
present
key
marker
rcz
permit
diseas
rapidli
progress
despit
intens
antifung
therapi
ambisom
insulin
slide
scale
patient
rapidli
succumb
within
day
fine
needl
aspir
cytolog
less
invas
easier
equal
effect
altern
pre
op
biopsi
key
success
reduct
morbid
mortal
associ
rapidli
fatal
diseas
increas
awar
diseas
earli
diagnosi
correct
underli
metabol
derang
prompt
intens
antifung
therapi
amphotericin
b
radic
surgic
debrid
necrot
tissu
optim
dosag
ambisom
requir
discuss
clinic
audit
haematolog
ward
tertiari
care
hospit
studi
degre
correl
bacteraemia
oropharyng
screen
immunocompromis
patient
five
year
role
antibiot
prophylaxi
ps
guleri
butcher
western
infirmari
clinic
microbiolog
glasgow
unit
kingdom
introduct
clinic
audit
carri
immunocompromis
patient
includ
neutropen
patient
bone
marrow
autograft
transplant
recipi
hematolog
ward
gartnav
gener
hospit
glasgow
tertiari
care
center
object
aim
establish
degre
correl
bacteri
isol
oropharyng
screen
bacteraemia
episod
role
antibiot
prophylaxi
method
purpos
assess
whether
antiretrovir
therapi
art
intensif
gmcsf
use
remun
initi
stop
art
lead
viremia
contain
long
period
art
method
ten
adult
chronic
hiv
diseas
rna
level
vl
log
copiesml
median
cell
count
enrol
art
intensif
ddi
month
hydroxyurea
hu
mo
gmcsf
mo
remun
dose
art
stop
remun
continu
art
resum
rebound
vl
decreas
log
month
count
decreas
result
vl
rebound
patient
stop
art
develop
acut
retrovir
syndrom
ar
cell
decreas
increas
median
stoppag
week
art
resum
patient
vl
decreas
b
log
count
regain
level
rose
interrupt
patient
rebound
ar
peak
vl
loss
lower
p
week
art
patient
resum
therapi
breadth
magnitud
hivspecif
activ
increas
thymu
size
grew
patient
art
median
week
two
art
week
respect
log
conclus
approach
led
high
ar
incid
long
period
art
increas
hivspecif
respons
level
thymu
size
urinari
tract
infect
hospit
popul
signific
problem
studi
cather
patient
urinari
infect
corfu
hospit
urin
cultur
sent
bacteriolog
laboratori
collect
cathet
clinic
data
age
type
diseas
analys
sampl
cultur
mc
conkey
agarurotub
vitek
card
organ
identifi
vitek
automat
system
sensit
test
vitek
kirbybau
method
result
growth
organ
posit
cultur
bacteria
gram
rod
e
coli
pseudomona
spp
gram
cocci
enterococcu
spp
candida
spp
resist
e
coli
ampicillin
cotrimoxazol
quinolon
e
faecali
resist
vancomycin
conclus
possibl
interfer
acetaminophen
amoxicillin
clavulan
acid
ac
erythromycin
eri
efficaci
treatment
acut
otiti
media
aom
possibl
role
evolut
otiti
media
effus
ome
determin
gerbil
model
streptococcu
pneumonia
strain
exhibit
mic
ac
eri
mgl
respect
use
antibiot
test
mgkg
acetaminophen
mgkg
administ
min
antibiot
dose
antibiot
concentr
serum
middl
ear
exud
determin
antibiot
significantli
reduc
number
cultureposit
ear
coloni
count
serum
concentr
mic
microorgan
dose
interv
antibiot
concentr
middl
ear
exud
almost
ident
anim
receiv
receiv
acetaminophen
clinic
microbiolog
efficaci
correl
antibiot
concentr
middl
ear
exud
time
mic
microorgan
antibiot
antibiot
demonstr
efficaci
treatment
pneumococc
aom
rate
ome
acetaminophen
concomitantli
administ
interfer
efficaci
two
antibiot
test
prevent
evolut
aom
ome
parra
pont
c
cenjor
c
b
mj
c
aguilar
l
c
soriano
f
medic
microbiolog
madrid
spain
b
otorrinolaryngolog
madrid
spain
c
glaxosmithklin
medic
depart
madrid
spain
gerbil
model
otiti
media
effus
ome
induc
haemophilu
influenza
amoxicillinclavulanateacand
erythromycinerym
mgl
respect
use
evalu
efficaci
ac
mgkg
eri
mgkg
antibiot
administ
subcutan
h
postmiddl
ear
inocul
continu
tid
h
without
acetaminophen
ap
mgkg
administ
min
antibiot
dose
antibiot
concentr
serum
middl
ear
measur
bioassay
sampl
coloni
count
collect
day
ac
reduc
p
posit
sampl
coloni
count
versu
untreat
control
eri
posit
cultur
control
ac
ac
ac
eri
eri
eri
due
ac
eri
concentr
exceed
time
mic
despit
higher
percentag
antibiot
penetr
eri
versu
ac
versu
anim
receiv
ap
show
less
polymorphonuclear
cell
bacteria
receiv
antibiot
suggest
antiinflamatori
drug
diminish
phagocyt
therefor
effici
bacteri
clearanc
amoxycillin
treatment
acut
otiti
media
caus
penicillinresist
streptococcu
pneumonia
pharmacodynam
analysi
parra
pont
c
cenjor
c
b
g
mj
c
aguilar
l
c
soriano
method
serotyp
streptococcu
pneumonia
strain
exhibit
mic
amoxycillin
mgl
use
experiment
model
perform
gerbil
merion
unguiculatu
follow
previous
describ
procedur
amoxycillin
test
follow
dose
mgkg
amoxycillin
concentr
serum
middl
ear
exud
determin
drug
administr
result
dose
mgkg
significantli
reduc
number
cultureposit
ear
coloni
count
otorrhoea
p
compar
untreat
control
anim
treat
dose
lower
mgkg
dose
mgkg
achiev
antibiot
concentr
middl
ear
time
higher
mic
infect
strain
serum
concentr
mic
dose
interv
conclus
amoxycillin
dose
achiev
serum
concentr
similar
obtain
children
standard
dose
obtain
therapeut
microbiolog
efficaci
regardless
suscept
infect
strain
better
correl
found
antibiot
efficaci
antibiot
concentr
middl
ear
exud
efficaci
serum
concentr
suboptim
pharmacodynam
perspect
increas
preval
amoxycillin
among
e
coli
strain
hungarian
univers
hospit
e
e
nagi
e
depart
clinic
microbiolog
univers
szege
szege
hungari
background
amoxicillin
resist
acr
emerg
problem
escherichia
coli
report
differ
part
europ
aim
present
studi
evalu
statist
preval
acr
among
e
coli
isol
investig
genet
background
resist
method
e
coli
strain
isol
screen
acr
kirbi
disc
diffus
method
resist
betalactam
inhibitor
combin
differ
betalactam
antibiot
also
test
select
strain
underw
determin
betalactamas
activ
confirmatori
test
suspect
extend
spectrum
betalactamas
perform
pcr
test
tem
shv
gene
carri
plasmid
isol
select
strain
result
e
coli
strain
found
resist
amoxicillin
clavulan
amc
resist
strain
obtain
genitourinari
tract
acr
isol
found
blood
cultur
isol
prove
acr
isol
blood
cultur
genitourinari
tract
thirtyf
select
strain
analys
thirtytwo
also
resist
sam
six
resist
tzp
quantit
betalactamas
determin
show
increas
activ
strain
partial
suscept
amc
presenc
esbl
could
prove
three
acr
isol
open
parallelgroup
studi
compar
efficaci
toler
cef
cfix
mg
daili
treatment
commun
acquir
uncompl
uti
seventyeight
femal
patient
random
receiv
either
oral
cef
cfix
day
efficaci
treatment
evalu
clinic
respons
symptom
uti
dysuria
frequenc
urgenc
suprapubian
pain
clinic
sign
bacteriolog
respons
health
statu
measur
baselin
posttherapi
result
clinic
cure
complet
resolut
symptom
sign
rate
patient
receiv
cef
evalu
patient
patient
receiv
cfix
bacteriolog
respons
base
result
urin
cultur
obtain
posttherapi
pathogen
erad
cef
cfix
drug
relat
side
effect
report
cef
side
effect
experienc
patient
receiv
cfix
improv
health
statu
compar
visual
scale
score
baselin
poststudi
detect
higher
chang
averag
score
cef
cfix
wilcoxon
improv
valu
signific
day
therapi
case
cef
day
therapi
cfix
group
conclus
result
studi
indic
cef
cours
effect
cfix
produc
favour
clinic
outcom
achiev
higher
bacteriolog
erad
rate
furthermor
cef
better
toler
cefepim
fourth
gener
cephalosporin
broader
spectrum
antibacteri
activ
third
gener
cepfalosporin
activ
vitro
gramposit
aerob
bacteria
purpos
studi
measur
cefepim
concentr
plasma
bile
fluid
gall
bladder
tissu
patient
undergo
cholecystectomi
thirti
patient
male
femal
mean
age
year
data
accept
analysi
includ
studi
patient
receiv
iv
g
cefepim
sever
hour
administr
differ
time
interv
surgeri
sampl
obtain
plasma
bile
fluid
gall
bladder
tissu
concomitantli
antibiot
level
measur
agar
diffus
method
mean
delta
time
min
valu
plasma
bile
fluid
gall
bladder
tissu
mgml
respect
plasmabil
fluid
ratio
signific
correl
plasma
gall
bladder
tissu
concentr
correl
bile
fluid
plasma
cefepim
concentr
observ
minimum
inhibitori
concentr
mic
data
previou
vitro
studi
indic
cefepim
concentr
observ
plasma
bile
tissu
sampl
studi
would
adequ
typic
biliari
tract
pathogen
furthermor
cefepim
concentr
correl
well
favor
clinic
outcom
report
previou
clinic
studi
biliari
tract
infect
also
good
correl
delta
time
plasma
tissu
concentr
dose
given
closer
time
surgeri
cefepim
concentr
would
higher
reduc
possibl
infect
object
use
antibiot
may
lead
decreas
colon
resist
increas
format
resist
bacteria
present
concept
develop
overcom
untoward
effect
method
blactamas
bacillu
licheniformi
overproduc
bacillu
subtili
target
recombin
blactamas
enzym
trbl
releas
small
bowel
controlledreleas
formul
beagl
treat
bid
either
mgkg
ampicillin
iv
placebo
po
mgkg
ampicillin
iv
trbl
po
placebo
ivpo
stool
collect
day
sampl
cultur
total
main
group
aerob
anaerob
bacteria
yeast
temperatur
gradient
gel
electrophoresi
tgge
use
separ
ribosom
rna
gene
result
ampicillinplacebo
group
clearli
decreas
count
aerob
anaerob
bacteria
treatment
wherea
receiv
trbl
minor
overal
chang
occasion
chang
singl
speci
intraven
ampicillin
decreas
fecal
similar
percentag
similar
percentag
treatment
ampicillintrbl
differ
placebo
vs
conclus
accord
result
trbl
maintain
larg
intestin
microflora
almost
unchang
result
indic
trbl
promis
novel
approach
overcom
ecolog
advers
effect
gut
flora
caus
blactam
antibiot
agent
adami
sinc
broadspectrum
combin
amikacin
often
appli
nosocomi
infect
pharmacokinet
interact
might
interest
one
gram
aztreonam
g
amikacin
administ
intraven
singl
combin
six
healthi
volunt
blood
sampl
collect
regular
time
interv
concentr
antimicrobi
determin
microbiolog
assay
appli
strain
develop
resist
singl
agent
serial
passag
mean
concentr
amikacin
serum
administ
alon
combin
aztreonam
mgml
immedi
h
infus
antimicrobi
respect
concentr
aztreonam
mgml
auc
amikacin
administ
alon
combin
aztreonam
mg
hl
respect
respect
auc
aztreonam
mg
hl
conclud
coadministr
aztreonam
amikacin
result
earlier
clearanc
aztreonam
higher
level
amikacin
compar
administr
singl
antimicrobi
molecular
model
blactam
reveal
structur
basi
inhibit
penicillinbind
protein
suscept
blactamas
oral
bioavail
grail
bm
gupta
payn
jw
school
biolog
scienc
univers
wale
bangor
uk
blactam
antibiot
peptid
mimet
act
suicid
substrat
transpeptidas
enzym
cross
link
bacteri
cellwal
peptid
first
time
structur
electron
featur
need
recognit
transpeptidas
fulli
describ
use
innov
molecular
model
techniqu
compar
conform
form
adopt
cellwal
peptid
blactam
comparison
featur
backbon
ctermin
region
conform
activ
blactam
antibiot
model
cellwal
peptid
allow
definit
molecular
recognit
templat
requir
substrat
recognit
transpeptidas
share
structur
featur
allow
act
substrat
acyl
activesit
serin
howev
signific
differ
critic
backbon
torsion
two
substrat
provid
explan
inabl
enzym
complex
undergo
deacyl
step
caus
inhibit
transpeptidas
hand
blactamas
appear
evolv
molecular
mechan
facilit
deacyl
reaction
compens
alter
structur
orient
blactam
caus
differ
backbon
torsion
final
analysi
conform
repertoir
blactam
structur
featur
requir
substrat
uptak
peptid
transport
provid
insight
structur
tailor
optim
oral
absorpt
antimicrobi
suscept
proteu
mirabili
clinic
isol
produc
extend
spectrum
betalactamas
esbl
object
aim
present
studi
determin
vitro
suscept
antimicrobi
proteu
mirabili
isol
urinari
tract
infect
method
studi
suscept
profil
esbl
posit
p
mirabili
strain
three
adopt
children
india
age
rang
month
year
esbl
identifi
use
synerg
effect
clavulan
betalactam
ceftazidim
cefotaxim
vivo
efficaci
amoxicillin
amx
subtherapeut
dose
mgkg
tid
h
achiev
serum
level
mic
dose
interv
concomit
specif
serotherapi
singl
intraperiton
dose
dilut
hyperimmun
serum
hs
obtain
mice
immun
heatinactiv
strain
assess
pneumococc
sepsi
balbc
mous
model
mice
five
mice
treatment
group
intraperiton
infect
cfu
ml
serotyp
penicillinresist
strain
mic
mgl
penicillin
amx
respect
treatment
start
h
bacteri
inocul
studi
group
control
k
receiv
nonimmun
serum
nh
amxnh
hs
amxh
surviv
rate
time
purpos
studi
studi
perform
determin
consumpt
imipenem
resist
gramneg
pathogen
pseudomona
aeruginosa
acinetobact
sp
klebsiella
sp
escherichia
coli
proteu
mirabili
serratia
marcescen
enterobact
sp
imipenem
gramneg
pathogen
isol
sestr
milosrdnic
univers
hospit
zagreb
croatia
imipenem
sensit
test
perform
disk
diffus
e
test
method
consumpt
imipenem
express
hospit
day
period
result
obtain
imipenem
resist
acinetobact
sp
decreas
significantli
year
especi
first
month
p
lowest
consumpt
imipenem
record
imipenem
resist
gramneg
pathogen
decreas
significantli
conclus
reach
comsumpt
imipenem
might
lead
chang
resist
imipenem
among
acinetobact
strain
vachevadobrevski
rs
savov
ez
militari
medic
academi
clinic
microbiolog
sofia
bulgaria
purpos
acinetobact
baumanii
becom
increasingli
frequent
nosocomi
pathogen
hospit
betalactam
resist
strain
increas
especi
among
icu
isol
studi
suscept
baumanii
clinic
isol
betalactam
determin
esblproduc
strain
year
total
gramneg
nonferment
gnnf
isol
investig
semiautom
mini
api
system
bio
merieux
franc
eightyfour
baumanii
nonrep
isol
studi
esblproduc
doubledisk
synergi
test
ddt
atbbls
test
bio
merieux
franc
mic
betalactam
determin
e
test
ab
biodisk
sweden
result
baumanii
show
multidrug
resist
isol
resist
cefotaxim
cefoxitin
ceftazidim
amoxicillinclavulan
piperacillin
aztreonam
imipenem
investig
baumanii
express
esbl
activ
origin
frequent
icu
esbl
produc
strain
isol
endotrach
aspir
surgeri
wound
blood
cultur
conclus
gener
resist
level
higher
clinic
isol
baumanii
betalactam
ddt
seem
practic
method
esblscreen
atbbls
method
sensit
studi
display
first
report
esblproduc
baumanii
strain
countri
carbapenem
seem
activ
agent
baumanii
salmonella
infanti
strain
isol
newborn
babi
wassila
bourguiba
matern
tuni
exhibit
high
resist
penicillin
extendedspectrum
cephalosporin
cefotaxim
ceftriaxon
ceftazidim
cefpirom
aztreonam
remain
suscept
cefoxitin
imipenem
involv
character
enzymat
mechan
blactam
resist
investig
strain
isoelectricfocus
reveal
strain
produc
blactamas
pi
enzym
broadsubstr
profil
hydrolyz
amoxicillin
ampicillin
ticarcillin
cephaloridin
cefuroxim
cefotaxim
ceftriaxon
cefpirom
ceftazidim
highest
specif
activ
observ
ampicillin
cefotaxim
hydrolyz
effici
extendedspectum
cephalosporin
pi
extendedspectrum
blactamas
esbl
inhibit
clavulan
acid
sulbactam
inhibit
esbl
observ
mm
edta
thu
metal
ion
involv
hydrolysi
blactamas
resist
due
product
pi
esbl
transfer
dna
plasmid
escherichia
coli
basi
substrat
inhibit
profil
isoelectr
point
pi
esbl
previous
describ
infanti
tunisia
presenc
resist
plasmid
rais
concer
rapid
dissemin
among
bacteria
loss
effect
blactam
poizotmartin
enel
p
b
c
vionduri
f
c
dinh
c
drogoul
mp
c
gastaut
ja
c
assist
publiqu
de
marseil
cisih
sud
pr
ja
gastaut
marseil
franc
b
assist
publiqu
de
marseil
cellul
publiqu
marseil
franc
c
assist
publiqu
de
marseil
cisih
sud
marseil
franc
object
assess
liver
biopsi
lb
practic
cohort
coinfect
hcv
hiv
patient
follow
hiv
special
medic
unit
method
transvers
studi
questionnair
among
patient
pretherapeut
evalu
pcr
without
lb
month
result
among
patient
lost
follow
lb
lb
characterist
patient
median
age
year
sex
ratio
cdcstage
b
c
undetect
viral
median
antiretrovir
hcvgenotyp
caus
nonmad
lb
refus
patient
biopsi
contraind
hiv
clinic
contraind
antihcv
treatment
grade
iii
contraind
biopsi
nonadher
previou
hiv
follow
psychiatricdepress
decompens
drug
use
methadonebuprenorphin
treatment
consid
contraind
conclus
onethird
patient
afraid
lb
alcohol
psychiatricdepress
disord
princip
contraind
antihcv
treatment
seem
import
improv
inform
patient
lb
focu
alcohol
psychiatricdepress
disord
manag
popul
kashiwagi
kk
furusyo
nf
nakashima
hn
kashiwagi
sk
b
hayashi
jh
depart
environment
medicin
infecti
diseas
kyushu
univers
fukuoka
japan
b
nation
kyushu
medic
center
fukuoka
japan
purpos
studi
aim
prospect
studi
explor
effect
htlvi
coinfect
develop
hcc
among
patient
chronic
hcv
viremia
total
consecut
patient
chronic
hcv
viremia
studi
followedup
mean
period
year
infect
htlvi
infect
result
obtain
annual
hcc
develop
rate
patient
coinfect
hcv
htlvi
patient
infect
hcv
alon
hcc
significantli
higher
patient
coinfect
patient
patient
infect
hcv
alon
p
b
logrank
test
patient
age
year
hcc
develop
significantli
higher
seven
patient
coinfect
hcv
htlvi
eight
patient
hcv
alon
pb
logrank
test
wherea
signific
differ
hcc
develop
patient
age
without
htlvi
infect
respect
conclus
reach
htlvi
infect
acceler
develop
hcc
chronic
hcv
patient
especi
among
patient
age
year
analyz
hbv
genotyperel
clinic
differ
among
patient
chronic
hbv
infect
patient
serial
test
serum
alanin
aminotransferas
alt
hepat
b
e
antigen
hbeag
follow
mean
year
period
genotyp
b
c
found
patient
respect
hbeag
posit
alt
abnorm
rate
start
observ
period
significantli
higher
genotyp
c
patient
genotyp
b
patient
annual
rate
spontan
hbeag
disappear
genotyp
b
patient
much
higher
genotyp
c
patient
versu
respect
patient
genotyp
c
continu
hbeag
neg
entri
significantli
higher
alt
abnorm
genotyp
b
interestingli
patient
genotyp
c
becam
hbeag
neg
interferon
treatment
high
alt
abnorm
patient
alt
abnorm
serum
hbv
dna
posit
find
indic
hbv
genotyp
c
patient
sever
liver
deterior
delay
hbeag
disappear
continu
hbv
replic
hbeag
disappear
nossik
nn
nebolsin
b
zheltukhina
ga
c
yevstigneeva
rp
c
di
ivanovski
institut
virolog
viral
reproduct
moscow
russian
feder
b
pparminterprisi
co
chemistri
mocow
russian
feder
c
moscow
state
academi
fine
chemic
technolog
piptid
chemistri
moscow
russian
feder
object
studi
effect
gammalglutamylhistamin
gluha
deriv
nonspecif
immun
alfaifn
gammaifn
nk
cell
activ
antivir
activ
experiment
influenza
herp
viru
infect
mice
gluya
deriv
gluii
synthes
peptid
chemistri
techniqu
gluha
gluii
administ
ip
mgkg
influenza
viru
type
aaichi
show
protect
effect
even
high
infect
dose
rate
positivecontrol
group
effect
protect
herp
simplex
viru
enceph
mice
model
physicoemot
stress
mice
use
investig
ifn
system
nk
cell
activ
product
ifn
nk
cell
activ
splenocyt
decreas
h
stress
back
normal
level
day
shown
gluha
gluii
protect
substanti
prevent
decreas
nk
cell
activ
ifn
synthesi
poststress
period
normal
induc
ifn
synthesi
conclus
gluha
gluii
show
antivir
effect
influenza
viru
infect
mice
immunomodul
activ
abil
normal
ifn
synthesi
nk
cell
activ
depress
poststress
period
probabl
play
essenti
role
antivir
activ
dose
adjust
antiinfluenza
prodrug
oseltamivir
requir
patient
hepat
impair
oo
c
snell
pr
b
liu
b
martin
b
simkin
b
small
b
ward
p
b
hoffmannla
roch
inc
global
develop
nutley
usa
b
roch
product
ltd
global
develop
welwyn
garden
citi
uk
background
oseltamivir
ose
ro
tamiflu
oral
ethyl
ester
prodrug
activ
metabolit
oseltamivir
carboxyl
oc
ro
potent
select
neuraminidas
inhibitor
influenza
viru
purpos
studi
evalu
need
ose
dosag
adjust
hepat
impair
patient
hi
method
healthi
volunt
hv
versu
hi
childpugh
score
match
basi
age
year
gender
weight
compar
subject
receiv
mg
ose
result
base
c
max
ngml
auc
inf
ng
hml
analys
use
nomin
time
ls
mean
ratio
ci
hi
hv
similar
ose
valu
hi
margin
elev
suffici
requir
dose
adjust
aim
studi
investig
influenc
molecular
structur
macrocycl
pyridinophan
analog
antiinfluenza
antiherpet
activ
compound
use
approach
basi
simpl
represent
molecular
structur
represent
biolog
activ
substanc
allow
descript
spatial
structur
compound
complet
stereochem
inform
determin
spatial
structur
either
promot
interf
concret
biolog
activ
easi
realiz
molecular
design
compound
given
level
activ
help
combin
simplex
statist
characterist
qsar
partial
leastsquar
model
satisfactori
molecular
fragment
increas
antivir
activ
defin
demonstr
inform
use
design
direct
synthesi
sever
novel
antivir
agent
predict
high
antiinfluenza
antiherpet
activ
predict
activ
confirm
experiment
approach
use
develop
antivir
compound
work
partial
support
inta
foundat
grant
inta
lozitski
vp
ukrainian
mechnikov
research
antiplagu
institut
chemotherapi
odessa
ukrain
purpos
studi
research
antiinfluenza
activ
proteolyt
inhibitor
eaca
prevent
enhanc
proteolysi
interact
virion
cell
membran
decreas
penetr
virion
cell
eaca
bring
proteolyt
cleavag
haprecursor
hapolypeptid
reduc
infecti
viru
harvest
show
prophylact
therapeut
action
experiment
influenza
reduc
enhanc
alkalin
proteas
activ
lung
infect
eaca
promot
intensif
specif
antibodi
product
cell
immun
prevent
vessel
permeabl
hemorrhag
phenomena
decreas
destruct
bronchi
epithelium
reduc
durat
intox
catarrh
instanc
hyperthermia
sick
children
eaca
improv
index
immun
nonspecif
resist
decreas
rate
bacteri
complic
applic
eaca
treatment
influenza
arvi
children
recommend
ukrain
base
result
research
higher
effect
demonstr
result
combin
usag
eaca
specif
ig
deitiforin
unithyol
ribavirin
opinion
studi
effect
eaca
combin
applic
inhibitor
influenza
na
perspect
direct
antiinfluenza
research
develop
treat
immedi
varicella
patient
acyclovir
patient
older
year
past
year
institut
infecti
tropic
diseas
belgrad
immunocompet
varicella
patient
treat
cure
among
older
year
xray
perform
patient
diagnosi
pneumonia
made
patient
patient
older
year
varicella
benign
selflimit
diseas
strike
earli
ie
preschool
school
children
teenag
time
need
specif
therapi
neonat
immunocompet
adult
immunocompromis
patient
difficult
lifethreaten
diseas
immunocompet
adult
popul
pneumonia
seriou
sometim
fatal
complic
know
pathophysiolog
primari
varicella
infect
specif
therapi
acyclovir
start
immedi
make
diagnosi
patient
older
year
without
wait
xray
proof
pneumonia
brivudin
compar
acyclovir
treatment
herp
zoster
effect
acut
diseas
posttherapeut
pain
object
comparison
efficaci
safeti
brivudin
mg
acyclovir
mg
day
treatment
herp
zoster
method
randomis
doubleblind
studi
immunocompet
patient
year
brivudin
n
acyclovir
n
subgroup
patient
year
brivudin
acyclovir
examin
occurr
posttherapeut
pain
poststudi
survey
posttherapeut
pain
defin
zosterassoci
pain
regardless
intens
end
acut
zoster
result
brivudin
superior
acyclovir
reduc
time
last
occurr
new
vesicl
rr
itt
p
advantag
brivudin
pronounc
patient
year
rr
itt
incid
posttherapeut
pain
significantli
lower
brivudin
acyclovir
durat
pain
compar
treatment
group
rr
p
potenti
treatmentrel
advers
event
occur
brivudin
recipi
acyclovir
recipi
conclus
brivudin
mg
daili
day
superior
standard
acyclovir
stop
viral
replic
acut
herp
zoster
patient
year
brivudin
effect
acyclovir
reduc
risk
develop
posttherapeut
pain
brivudin
well
toler
acyclovir
varadinova
genova
p
garciaraso
b
terron
b
fiol
j
b
badena
f
b
laboratori
virolog
sofia
univers
sofia
bulgaria
b
chemistri
universitat
de
le
balear
palma
de
mallorca
spain
publish
cu
ii
complex
acyclovir
acv
activ
hsv
infect
mbd
present
data
activ
acv
complex
ni
ii
cd
ii
co
ii
ag
resist
acv
hsv
strain
comparison
effect
acv
sensit
strain
victoria
select
index
si
compar
acv
indic
activ
follow
data
obtain
time
less
select
inhibitor
strain
strain
victoria
ii
action
cd
acv
cl
ni
acv
h
cl
ni
acv
higher
control
ii
time
less
select
inhibitor
acv
iv
si
two
time
higher
strain
five
time
lower
strain
victoria
acv
data
show
select
acv
resist
hsv
strain
increas
acv
bond
proper
metal
ion
method
antivir
activ
herp
simplex
viru
type
variant
resist
acyclovir
determin
use
commonli
accept
method
virus
grown
continu
cultur
maxim
toxic
dose
determin
administr
compound
oral
mgkg
intraabdomin
mgkg
white
mice
mass
g
condit
anim
control
h
mice
pneumonia
model
use
test
activ
vivo
result
deriv
test
activ
resist
acyclovir
maximum
protect
cell
reach
concentr
compound
mgkg
test
compound
low
toxic
anim
die
intraabdomin
per
oral
administr
substanc
use
compound
led
essenti
relief
diseas
anim
number
squar
viru
specif
area
inflamm
lung
decreas
compar
control
untreat
group
test
compound
protect
anim
similar
acyclovir
use
control
conclus
deriv
carboalkoxysulfanil
acid
activ
hsv
vitro
vivo
act
acyclovir
resist
variant
virus
markiewicz
r
szepietowski
jc
b
jelfa
sa
medic
depart
jelenia
gora
poland
b
depart
dermatolog
univers
medicin
wroclaw
poland
background
denotivir
antiinflammatori
agent
antivir
immunomodulatori
activ
possess
also
mild
antibacteri
antifung
action
purpos
studi
aim
present
give
overview
recent
studi
demonstr
denotivir
efficaci
herpet
infect
result
obtain
vitro
studi
reveal
denotivir
dose
cytotox
um
significantli
inhibit
herp
simplex
viru
hsv
replic
fibroblast
kidney
cell
cultur
moreov
show
denotivir
dose
mgml
markedli
inactiv
min
incub
giunea
pig
research
denotivir
dmso
appear
superior
dmso
alon
untreat
group
therapi
anim
skin
infect
huge
differ
eythema
oedema
score
studi
group
howev
group
treat
denotivir
contrast
other
vesicl
develop
sever
clinic
studi
show
use
denotivir
control
herpet
infect
dermatolog
ophthalmolog
otolaryngolog
major
studi
within
hour
drug
applic
itch
pain
relief
note
within
day
vesicular
lesion
dri
conclus
reach
conclus
denotivir
effect
antiherpet
agent
studi
conduct
cow
affect
teat
papillomatosi
first
step
cow
locat
one
three
group
first
group
contain
four
cow
year
treat
fig
tree
ficu
carica
latex
second
group
contain
four
cow
year
treat
solut
salicyl
acid
third
group
contain
four
cow
control
group
one
two
follow
treatment
fig
tree
latex
salicyl
acid
superfici
necrosi
begun
day
wart
disappear
day
control
group
day
chang
number
lesion
larger
first
observ
day
one
mark
wart
disappear
day
anoth
wart
disappear
six
present
day
comparison
effect
salicyl
acid
fig
latex
show
similar
effect
treatment
udder
papillomatosi
cow
laboratori
marker
skelet
muscl
toxic
hivinfect
patient
crosssect
casecontrol
survey
frequenc
potenti
correl
antiretrovir
therapi
clinic
signific
outcom
manfredi
r
motta
r
patrono
calza
l
chiodo
f
boni
p
assess
skelet
muscl
toxic
among
hivinfect
outpati
p
p
alter
cpk
assay
ul
may
novemb
compar
p
randomli
select
among
laboratori
exam
interv
casecontrol
studi
among
p
alter
cpk
level
six
femal
receiv
antiretrovir
overal
frequenc
alter
cpk
among
p
underw
laboratori
workout
month
cpk
alter
transient
p
valu
rang
mean
ul
recogn
time
month
p
show
concomit
high
aldolas
level
ul
myopathi
rhabdomyolisi
recogn
four
p
myositi
confirm
one
p
histopatholog
multivari
logist
regress
analysi
exclud
unexpect
preval
male
gender
p
signific
differ
emerg
p
control
age
risk
hiv
infect
iv
drug
use
durat
hiv
infect
prior
antihiv
therapi
length
select
drug
combin
administ
nucleosid
analogu
hiv
diseas
stage
mean
count
hiv
viremia
sign
durat
lipodystrophi
increas
glucos
triglycerid
cholesterol
level
therapi
muscl
abnorm
though
frequent
asymptomat
underestim
hiv
diseas
complic
role
metabol
ie
mitochondri
alter
deserv
investig
poor
efficaci
nonnucleosid
revers
transcriptas
inhibitor
nnrti
base
salvag
haart
hivinfect
patient
heavili
pretreat
class
antiretrovir
compound
manfredi
r
calza
l
chiodo
f
infecti
diseas
univers
bologna
bologna
itali
poorli
compar
literatur
seri
show
conflict
result
nnrtibas
rescu
haart
rate
virolog
success
assess
respons
rescu
haart
includ
nnrti
patient
p
treat
nucleosid
analogu
na
proteas
inhibitor
pi
month
respect
nnrti
viremia
copiesml
prospect
follow
year
provid
ensur
adher
efavirenz
use
p
nevirapin
delavirdin
two
p
earli
laboratori
improv
mean
peak
viral
load
decreas
log
signific
reduct
vs
baselin
p
last
month
mean
increas
zenith
count
obtain
p
p
remain
cellsml
year
switch
nnrti
multivari
analysi
concurr
introduct
novel
pi
p
andor
differ
na
p
act
favor
month
followup
p
genotyp
mutat
confer
nnrti
crossresist
usual
associ
broad
resist
profil
predict
failur
p
p
respons
vari
accord
durat
type
prior
therapi
select
nnrti
deep
salvag
nnrtibas
haart
poor
transient
virolog
outcom
also
p
evid
sustain
immunolog
respons
expect
p
introduc
novel
pina
mutat
impair
nnrti
activ
entitl
better
outcom
fatal
lactic
acidosi
without
elev
liverenzym
treatment
stavudin
didanosin
efavirenz
case
report
winzer
r
langmann
p
zilli
klinker
h
medizinisch
poliklinik
der
schwerpunkt
hepatologieinfektiologi
germani
nucleosid
revers
transcriptas
inhibitor
nrti
caus
variou
side
effect
mani
thought
due
effect
mitochondria
hiv
posit
hiv
rna
copiesml
cell
count
obes
bodymassindex
femal
patient
month
well
toler
effect
antiretrovir
therapi
stavudin
didanosin
efavirenz
slight
gastrointestin
discomfort
suddenli
develop
lactic
acidosi
arterialph
die
day
later
despit
intens
care
continu
venoven
haemodiafiltr
sodiumbicarbon
infus
high
dose
vitamin
respir
patholog
examin
show
enlarg
liver
g
yellowish
appear
pasti
consist
microscop
appear
massiv
macroand
microvesicular
fatti
degener
slight
sign
termin
pancreat
report
case
give
evid
massiv
lactat
acidosi
may
develop
without
previous
disarrang
laboratori
paramet
liver
pancreat
function
fatal
outcom
may
evolv
without
accompanyingil
efficaci
toler
atorvastatin
treatment
hypercholesterolemia
hivinfect
patient
receiv
haart
calza
l
manfredi
r
chiodo
f
divis
infecti
diseas
univers
bologna
bologna
itali
introduct
signific
increas
plasma
triglycerid
cholesterol
level
report
patient
treat
haart
prolong
metabol
imbal
could
significantli
act
longterm
prognosi
outcom
hivinfect
person
patient
method
fourteen
hivinfect
patient
pibas
haart
sinc
least
month
present
hypercholesterolemia
mgdl
least
durat
unrespons
hypolipidem
diet
physic
exercis
treat
singl
daili
dose
atorvastatin
mg
month
result
one
patient
eclud
evalu
due
earli
dropout
ongo
antiretrovir
treatment
includ
ritonavir
four
case
indinavir
four
nelfinavir
three
saquinavir
hardgel
two
close
followup
atorvastatin
therapi
decreas
total
cholesterol
level
versu
respect
baselin
valu
observ
eight
patient
reach
normal
valu
cholesterol
mild
gastroenter
symptom
found
one
treat
patient
skelet
muscl
liver
toxic
observ
discuss
studi
pharmacolog
treatment
atorvastatin
prove
certainli
effect
manag
dietresist
hypercholesterolemia
associ
favour
toler
adher
profil
effect
combin
antiretrovir
therapi
regimen
provir
dna
level
peripher
blood
mononuclear
cell
pbmc
examin
patient
use
endpoint
dilut
pcr
serial
clone
sequenc
gag
region
major
clone
defin
numer
analyz
clone
observ
period
rang
month
mean
month
five
patient
one
primarystag
infect
receiv
three
antiretrovir
drug
rna
level
reduc
undetect
ie
copiesml
provir
dna
level
number
major
clone
reduc
four
patient
rna
level
reduc
remain
detect
five
patient
two
remain
patient
receiv
two
rather
three
antiretrovir
drug
rna
level
increas
result
suggest
popul
major
clone
may
affect
rna
level
reduc
follow
combin
regimen
antiretrovir
therapi
saquinavir
hard
gel
shg
part
spontan
deintensif
antihiv
regimen
follow
success
highli
activ
antiretrovir
therapi
haart
manfredi
r
calza
l
chiodo
f
infecti
diseas
univers
bologna
bologna
itali
inductionmainten
concept
poorli
studi
hiv
patient
p
shg
never
assess
prolong
respons
potent
proteas
inhibitor
pi
base
haart
p
refus
indinavir
ritonavir
nelfinavirbas
haart
achiev
longterm
viral
suppress
resort
nucleosid
analogu
na
follow
prospect
p
assess
month
na
chang
prior
haart
interrupt
month
due
advers
event
p
p
request
p
viremia
copiesml
present
sinc
month
viremia
hivrna
copiesml
maintain
p
higher
viral
load
occur
p
month
relat
prehaart
viremia
ml
frequent
recoveri
count
mutat
codon
failur
chang
na
p
drop
cellsml
found
month
eight
p
also
virolog
failur
immunolog
deterior
earlier
deeper
na
chang
p
p
introduc
shgnovel
na
success
induct
potent
pibas
haart
stabl
outcom
suboptim
haart
includ
less
effect
better
toler
shg
may
effect
year
especi
novel
na
introduc
specif
mutat
absent
despit
lower
potenc
drug
good
safeti
complianc
profil
may
recov
simplifi
regimen
object
evalu
efficaci
antiretrovir
therapi
art
two
three
drug
nervou
reservoir
patient
thirteen
acut
neurolog
art
naiv
aid
patient
underw
pair
simultan
sampl
plasma
cerebrospin
fluid
csf
quantit
detect
rna
amplicor
roch
art
patient
underw
ct
andor
mr
brain
perform
diagnosi
hiv
relat
neurolog
acut
inflammatori
diseas
diagnosi
patient
receiv
art
receiv
two
nrti
receiv
haart
includ
two
nrti
one
proteas
inhibitor
patient
underw
pair
simultan
followup
plasma
csf
month
treatment
result
patient
baselin
level
hivrna
higher
p
b
plasma
log
csf
log
patient
receiv
dual
therapi
undetect
level
cutoff
copiesml
viral
rna
followup
csf
plasma
three
seven
patient
detect
plasma
rna
patient
haart
undetect
rna
plasma
csf
follow
conclus
dual
nrti
therapi
rapidli
effect
csf
high
penetr
drug
permeabl
blood
barrier
lower
hiv
rna
baselin
level
plasma
haart
rapidli
equal
effect
csf
plasma
report
fulmin
fatal
hepat
failur
start
highli
activ
antiretrovir
therapi
haart
hiv
subject
without
chronic
viral
hepat
case
report
naiv
aid
woman
clinic
symptom
due
pcp
observ
baselin
alt
increas
mnv
mild
hepatosteatosi
silent
cholelithiasi
serolog
hbv
hdv
hcv
neg
igg
antihav
antiebv
anticmv
antihsv
present
rna
log
count
pcp
treatment
cotrimoxazol
alt
valu
increas
mnv
nevertheless
complet
treatment
liver
enzym
return
pretreat
valu
sever
day
start
haart
stavudin
lamivudin
efavirenz
day
patient
show
efavirenzrel
skin
rush
resolv
within
day
without
treatment
discontinu
fourteen
day
start
haart
jaundic
appear
laboratori
reveal
sever
alt
increas
mnv
hyperbilirubinemia
mgdl
die
acut
liver
failur
syndrom
within
day
haart
efavirenzbas
regimen
result
highli
hepatotox
given
presenc
hepatosteatosi
recent
hepatotox
caus
nonantiretrovir
treatment
previou
idiosyncrat
reaction
efavirenz
experi
bulgarian
herbal
extract
improv
gener
condit
hivposit
patient
method
use
combin
bulgarian
herbal
extract
treat
six
patient
divid
two
group
three
symptomat
three
asymptomat
hivinfect
three
patient
asymptomat
hivinfect
treat
herbal
extract
anoth
three
patient
symptomat
hivinfect
treat
combin
herbal
extract
antiretrovir
therapi
gener
statu
patient
evalu
subject
object
surveil
immunolog
monitor
perform
absolut
count
lymphocyt
result
patient
shown
obviou
improv
gener
condit
high
spirit
work
capac
good
appetit
sleep
restor
bodi
weight
number
lymphocyt
lightli
increas
constant
conclus
combin
bulgarian
herbal
extract
shown
signific
posit
effect
gener
condit
improv
qualiti
life
antifung
activ
vitro
vivo
combin
voriconazol
amphotericin
b
candida
cryptococcu
spp
hitchcock
ca
andrew
rj
lewi
bgh
pye
gw
oliv
gp
troke
pf
pfizer
global
research
develop
depart
discoveri
biolog
sandwich
uk
purpos
present
studi
design
determin
whether
activ
voriconazol
vor
novel
triazol
reduc
candid
cryptococc
infect
addit
standard
antifung
agent
amphotericin
b
amb
vor
test
combin
standard
antifung
agent
vitro
use
checkerboard
mic
determin
test
vivo
immun
normal
guinea
pig
model
fungal
infect
result
indic
efficaci
vor
candida
albican
c
neoforman
antagonis
amb
vitro
furthermor
guinea
pig
model
system
candidiasi
intracrani
cryptococcosi
antagon
observ
lower
dose
vor
either
amb
basi
reduct
tissu
fungal
load
highest
dose
vor
amb
show
antagon
combin
still
effect
significantli
reduc
fungal
tissu
load
compar
vehicletr
control
anim
conclus
result
suggest
vor
may
use
combin
standard
antifung
agent
futur
studi
elucid
clinic
potenti
vor
combin
therapi
manag
candida
cryptococcu
infect
warrant
itraconazol
treatment
pityriasi
versicolor
tiodorov
j
jovanov
binic
nikol
lj
faculti
medicin
clinic
dermatovenerolog
ni
serbia
yugoslavia
comparison
two
shortterm
dose
schedul
itraconazol
carri
patient
pityriasi
versicolor
patient
divid
two
group
group
consist
patient
complet
therapi
control
clinic
diagnosi
confirm
mycolog
direct
microscop
examin
first
group
receiv
mg
itraconazol
daili
day
second
group
receiv
mg
daili
day
patient
control
clinic
mycolog
day
initi
treatment
erythema
scale
pruritu
evalu
clinic
clinic
mycolog
cure
patient
accept
cure
cure
rate
first
group
second
group
day
effect
two
group
similar
none
patient
report
sideeffect
fungal
urinari
infect
emerg
speci
antifung
suscept
trend
antibodi
respons
badawi
kamel
ai
b
fam
ns
elsay
elian
sae
c
theodor
bilharz
medic
research
institut
tbmri
microbiolog
giza
egypt
b
theodor
bilharz
medic
research
institut
tbmri
urosurgeri
giza
egypt
c
faculti
medicin
medic
microbiolog
immunolog
cairo
univers
cairo
egypt
object
assess
role
candida
speci
patient
urinari
tract
infect
uti
without
schistosomiasi
andor
cancer
bladder
compar
chromogen
chromagar
cma
biggi
agar
morpholog
corn
meal
rice
agartween
media
biochem
candifast
test
identif
candida
speci
suscept
antifung
agent
use
e
test
candifast
perform
elisa
test
detect
anticandida
antibodi
igm
igg
serum
evalu
result
c
albican
frequent
speci
respons
fungal
uti
howev
nonalbican
speci
c
glabrata
c
tropicali
c
krusei
also
isol
rice
agartween
found
cheap
avail
suffici
make
final
identif
cma
could
identifi
c
glabrata
biggi
agar
could
adequ
differenti
candida
speci
candifast
biochem
identif
show
low
sensit
e
test
sabouraud
dextros
agar
sda
simpl
method
mic
determin
could
detect
sdd
strain
case
azol
conclus
emerg
nonalbican
speci
c
glabrata
c
tropicali
c
krusei
contribut
complic
uti
necessit
accur
isol
identif
candida
speci
level
morpholog
rice
agartween
antifung
suscept
use
e
test
sda
siml
rapid
scheme
routin
identif
clinic
import
yeast
purpos
classif
allerg
fungal
rhinosinus
afr
base
immunolog
relationship
host
fungu
afr
must
differenti
fungal
rhinosinus
infect
includ
acut
invas
chronic
invas
fungal
ball
saprophyt
colon
although
mani
case
fungal
rhinosinus
caus
speci
aspergilli
dermatiac
mould
becom
emerg
pathogen
immunocompet
individu
result
case
studi
involv
year
male
suffer
facial
pain
headach
postnas
drip
loss
smell
hiv
neg
nonsmok
follow
laboratori
test
perform
iuml
gl
gl
allergen
specif
ige
alternaria
kul
fbcnormal
except
eosinophil
slightli
rais
l
ct
scan
indic
fungu
prolifer
bone
eros
extens
diseas
adjac
anatom
area
sinu
tissu
follow
debrid
sent
microscopi
cultur
hypha
microscop
observ
cultur
yield
two
dermatiac
fungi
bipolari
spp
alternaria
spp
conclus
import
differenti
two
speci
curvularia
helminthosporum
drechelria
exserohilum
knowledg
dermatiac
fungi
import
direct
appropri
antifung
therapi
select
correct
antigen
postsurg
immunotherapi
initi
debrid
irrig
antifung
activ
vitro
vivo
combin
voriconazol
amphotericin
b
aspergillu
fumigatu
hitchcock
ca
andrew
rj
lewi
bgh
pye
gw
oliv
gp
troke
pf
pfizer
global
research
develop
depart
discoveri
biolog
sandwich
uk
purpos
key
requisit
new
antifung
drug
demonstr
devoid
signific
antagon
combin
agent
combin
new
triazol
voriconazol
vor
standard
antifung
agent
amphotericin
b
amb
test
aspergillu
fumigatu
vitro
guinea
pig
model
infect
confirm
antifung
activ
antagonis
use
combin
therapi
vor
studi
combin
amb
vitro
use
checkerboard
mic
determin
test
vivo
use
immun
normal
immunocompromis
guinea
pig
model
system
aspergillosi
result
result
indic
potenc
vor
antagonis
amb
vivo
inde
lower
concentr
vor
signific
improv
reduc
fungal
burden
vivo
model
achiev
addit
amb
vitro
antagon
found
vor
amb
although
signific
antagonist
effect
vor
activ
conclus
result
vitro
vivo
model
aspergillosi
suggest
vor
may
use
combin
standard
antifung
agent
therefor
justifi
examin
vor
combin
therapi
clinic
set
vitro
activ
caspofungin
compar
amphotericin
b
fluconazol
itraconazol
candida
speci
arikan
sancak
b
hascelik
g
depart
microbiolog
clinic
microbiolog
hacettep
univers
medic
school
ankara
turkey
purpos
evalu
vitro
activ
caspofungin
variou
candida
spp
particularli
isol
decreas
amphotericin
b
fluconazol
itraconazol
suscept
method
suscept
test
done
nccl
microdilut
guidelin
clinic
candida
strain
mic
mgml
read
h
result
caspofungin
mic
h
shown
tabl
mic
h
similar
h
read
expectedli
evid
crossresist
detect
caspofungin
drug
test
caspofungin
similarli
activ
fluconazoleor
itraconazolesuscept
resist
isol
conclus
caspofungin
activ
vitro
candida
spp
test
caspofungin
mic
slightli
higher
c
parapsilosi
compar
speci
activ
fluconazoleand
itraconazoleresist
isol
noteworthi
valid
data
requir
clinic
investig
oropharyng
microbiolog
sampl
bmt
patient
evalu
weekli
cultur
day
reveal
presenc
fungi
patient
four
patient
bmt
bmt
bmt
one
patient
candida
norvegensi
isol
throat
buccal
palat
surfac
three
c
albican
two
c
krusei
three
c
norvegensi
four
patient
chosen
comper
antifung
sensit
extracellular
virul
factor
use
fungitest
method
determin
sensit
isol
flucytosin
amphotericin
b
miconazol
ketoconazol
fluconazol
fluconazol
sensit
also
determin
e
test
basi
fungitest
data
three
c
norvegensi
isol
sensit
flucytosin
amphotericin
b
also
ketoconazol
case
fluconazol
miconazol
prove
suscept
depend
upon
dose
mic
fluconazol
valu
determin
e
test
three
c
norvegensi
isol
mgml
respect
oropharyng
isol
c
norvegensi
produc
high
amount
extracellular
aspart
proteas
phospholipas
similarli
c
albican
strain
enzym
may
contribut
pathogenesi
new
emerg
candida
speci
vitro
activ
antifung
antisept
agent
rhodotorula
sp
preney
l
guiguen
c
gangneux
jp
laboratori
parasitologiemycologi
chu
de
renn
franc
purpos
studi
rhodotorula
speci
common
saprophyt
yeast
widespread
natur
sinc
last
year
implic
sever
sever
infect
especi
immunocompromis
patient
variou
antifung
therapi
use
howev
limit
data
avail
suscept
rhodotorula
sp
antifung
antisept
agent
materi
method
work
evalu
vitro
activ
eight
antifung
agent
strain
rhodotorula
strain
r
rubra
nine
strain
r
glutini
use
atb
fungu
system
biomerieux
etest
strip
abbiodisk
besid
effect
eight
antisept
agent
assess
suspens
r
rubra
quantif
yeast
exposur
antisept
agent
perform
subcultur
use
microtitr
method
plate
result
discuss
strain
test
suscept
amphotericin
b
nystatin
twentynin
strain
suscept
ketoconazol
intermedi
econazol
strain
resist
fluconazol
cmi
mgml
itraconazol
cmi
mgml
resist
miconazol
suggest
antifung
therapi
must
adapt
rhodotorula
yeast
implic
invas
infect
besid
min
exposur
sodium
hypochlorit
chlorhexidin
ecodiol
isopropyl
alcoholalkylamin
show
fungicid
activ
suscept
test
aspergillu
fumigatu
emerg
aspergillu
pathogen
modif
nccl
method
logotheti
kapsanakigotsi
e
b
velegraki
zagoura
b
depart
microbiolog
mycolog
refer
laboratori
medic
school
univers
athen
athen
greec
b
biolog
depart
section
ecolog
systemat
univers
athen
athen
greec
aspergillosi
high
risk
group
patient
still
associ
high
mortal
rate
aspergillu
fumigatu
primari
pathogen
opportunist
aspergillu
speci
emerg
amphotericin
b
ab
itraconazol
voriconazol
vo
terbinafin
te
minimum
inhibitori
concentr
mic
determin
modifi
nccl
microdilut
method
stock
drug
solut
prepar
rpmi
dimethyl
sulfoxid
dmso
polyethylen
glycol
peg
inocula
fumigatu
group
flavu
group
qualiti
control
strain
prepar
accord
modifi
nccl
guidelin
plate
incub
read
h
peg
effect
dissolv
vo
either
dmso
peg
dissolv
te
low
h
ab
vo
te
mic
mgl
record
terreu
parasiticu
resist
ab
certain
clinic
isol
demonstr
clinic
vitro
resist
standard
suscept
test
would
offer
reliabl
assist
select
monitor
antifung
therapi
otag
f
aslan
g
ozturk
c
microbiolog
depart
faculti
medicin
mersin
univers
mersin
turkey
rate
opportunist
fungal
infect
risen
markedli
speci
potenti
resist
antifung
agent
rapid
presumpt
speci
level
identif
crucial
allow
direct
antifung
therapi
studi
isol
yeast
clinic
specimen
identifi
atb
id
c
biomerieux
franc
number
identifi
yeast
respect
candida
albican
six
c
glabrata
five
c
tropicali
three
c
parapsilosi
two
c
krusei
two
c
kefyr
one
c
guillermondii
one
c
dubliniensi
twentyon
strain
investig
antifung
sensit
atb
fungu
kit
biomerieux
franc
result
follow
sensit
detect
myconasol
flusitozin
nystatin
econasol
amphtericin
b
ketokonazol
import
achiev
empirik
treatment
opportunist
candida
infect
follow
resist
antifung
shakhmatov
da
strelchenco
ov
novosibirsk
state
medic
academi
dermatovenerolog
novosibirsk
russian
feder
present
stage
russia
background
high
case
rate
syphili
becom
necessari
exclud
biolog
fals
posit
serolog
test
serodiagnosi
syphili
signific
limit
direct
detect
pallidum
suspect
blood
may
serv
altern
diagnost
strategi
polymeras
chain
reaction
pcr
wide
use
amplif
method
studi
patient
receiv
examin
relat
treatment
syphili
std
clinic
person
direct
hospit
routin
serolog
examin
reveal
doubt
result
pcr
reaction
carri
nest
primer
pair
base
dna
sequenc
kda
gene
pallidum
pcr
util
whole
blood
complex
serolog
test
ftaab
tit
use
rdqup
gold
standard
result
sensit
pcr
specif
select
comparison
pcr
result
vdrl
ftaab
treponem
immobilis
test
tit
shown
concurr
conclus
preliminari
result
pcr
whole
blood
syphili
detect
reveal
high
sensit
specif
possibl
obtain
rapid
result
unclear
case
chlamydia
pneumonia
cp
atyp
pathogen
whit
intracellular
locat
whose
erad
difficult
past
year
object
mani
studi
lead
demonstr
relationship
presenc
develop
widespread
multifactori
patholog
atherosclerosi
asthma
lack
erad
becom
import
clinic
social
problem
studi
object
comprehens
pathogen
interact
mechan
character
therapeut
protocol
cold
lead
complet
erad
cp
organ
research
princip
made
studi
molecular
mechan
root
pathogen
perman
insid
host
cell
use
prolifer
apoptosi
test
underlin
differ
behaviour
infect
cell
toward
control
cell
presenc
mgml
ie
peptid
inhibit
prolifer
induc
apoptosi
vitro
inhibit
nfkb
uninfect
cell
prolifer
decreas
comparison
whit
control
one
infect
decreas
moreov
use
variou
apoptosisinduc
infect
cell
show
apoptosi
uninfect
caspac
iii
activ
increas
significantli
uninfect
cell
conclus
cp
could
delay
elimin
host
inhibit
apoptosi
via
nfkb
activ
hryniewiecki
gzyl
b
rawczynskaenglert
depart
acquir
valvular
heart
diseas
nation
institut
cardiolog
warsaw
poland
b
depart
sera
vaccin
nation
institut
hygien
warsaw
poland
infect
endocard
ie
frequent
caus
problem
diagnosi
especi
blood
cultur
neg
fungal
etiolog
also
fungal
superinfect
bacteri
ie
purpos
studi
purpos
studi
evalu
use
broadrang
fungal
pcr
diagnosi
fungal
superinfect
bacteri
ie
twentyf
blood
sampl
taken
analysi
patient
infect
endocard
ie
diagnos
accord
duke
criteria
includ
posit
blood
cultur
suspicion
fungal
superinfect
establish
serolog
investig
five
patient
confirm
blood
cultur
two
patient
control
group
consist
patient
without
infect
dna
isol
use
commerci
avail
snap
kit
amplif
product
analyz
gel
electrophoresi
stain
ethidium
bromid
result
obtain
fungal
dna
found
two
patient
fungal
superinfect
bacteri
ie
confirm
cultur
remain
patient
ie
control
fungal
dna
found
conclus
reach
broadrang
fungal
pcr
fast
inexpens
tool
detect
fungal
dna
prone
contamin
speciesspecif
pcr
method
may
valuabl
identif
fungal
superinfect
bacteri
ie
diagnosi
fungal
ie
rivanera
lilli
lozzi
piunno
mancini
c
microbiolog
scienc
public
health
rome
itali
aim
aim
studi
evalu
eia
method
detect
antibodi
ttv
viru
ttv
investig
antitt
viru
preval
patient
hepat
b
hbv
viru
hepat
c
hcv
viru
group
high
risksubject
hepat
healthi
subject
elisa
method
nuclear
laser
vienna
lab
use
ttv
ns
antigen
aa
aa
appli
detect
antittv
serolog
screen
perform
sampl
italian
subject
result
posit
rate
antittv
antibodi
patient
hepat
b
high
risk
hepat
patient
antittv
also
found
healthi
peopl
conclus
antittv
detect
group
studi
howev
posit
rate
similar
patient
hepat
b
high
risk
hepat
respect
heathli
peopl
result
shown
tt
viru
frequent
itali
patient
infect
other
transmit
virus
gener
popul
posit
found
healthi
adult
includ
studi
suggest
viru
might
transmit
nonparenter
studi
pattern
antibodi
ttv
may
infecti
marker
ttv
similar
antihcv
stress
test
miniatur
identif
system
design
neisseria
haemophilu
rich
bannatyn
rm
memish
za
b
king
fahad
nation
guard
hospit
divis
microbiolog
riyadh
saudi
arabia
b
king
fahad
nation
guard
hospit
infect
prevent
control
riyadh
saudi
arabia
report
incid
occur
laboratori
bbl
crystal
identif
system
neisseria
haemophilu
use
identifi
haemophiluslikeorgan
numer
profil
gener
system
databas
convent
biochem
test
subsequ
reveal
identif
brucella
melitensi
common
isol
area
result
revel
subject
system
mini
stresstest
collect
isol
b
melitensi
two
numer
profil
obtain
neither
list
system
databas
brucella
speci
misidentifi
moraxella
speci
moraxella
phenylpyruvica
haemophilu
influenza
biotyp
iv
variou
identif
system
two
case
laboratoryacquir
brucellosi
attribut
misidentif
credit
bbl
crystal
identif
system
neisseria
haemophilu
neither
gener
profil
number
misidentifi
organ
assign
confid
level
instead
properli
direct
user
resort
convent
method
secur
identif
studi
addit
brucella
isol
strain
differ
geograph
sourc
confirm
uniqu
biochem
profil
identifi
may
worthwhil
incorpor
databas
would
consider
assist
area
brucellosi
widespread
clone
character
aspergillu
flavu
chong
tk
woo
pci
leung
asp
yuen
ky
univers
hong
kong
microbiolog
hong
kong
hong
kong
purpos
studi
clone
character
antigen
protein
serodiagnosi
infect
caus
aspergillu
flavu
commonest
aspergillu
speci
caus
aspergilloma
ao
invas
aspergillosi
ia
asia
result
obtain
clone
gene
encod
first
antigen
cell
wall
protein
flavu
code
protein
amino
acid
residu
sequenc
featur
present
antigen
cell
wall
mannoprotein
penicillium
marneffei
aspergillu
fumigatu
describ
previous
contain
serineand
threoninerich
region
glycosyl
signal
peptid
put
glycosylphosphatidylinositol
attach
signal
sequenc
specif
antibodi
gener
recombin
protein
purifi
escherichia
coli
allow
character
indirect
immunofluoresc
stain
indic
present
cell
wall
hypha
conidia
flavu
furthermor
observ
patient
ao
ia
due
flavu
develop
specif
antibodi
respons
conclus
reach
suggest
recombin
protein
antibodi
may
use
serodiagnosi
patient
ao
ia
protein
may
repres
good
cell
surfac
target
host
humor
immunitiy
grape
purpos
investig
basi
increas
resist
trimethoprim
sulphamethoxazol
method
pcr
screen
integron
clinic
urinari
tract
isol
perform
isol
test
resist
antibiot
integron
isol
sequenc
result
integron
class
found
isol
class
integron
found
eight
isol
studi
resist
five
antibiot
shown
carri
integron
nineteen
isol
resist
trimethoprim
carri
integron
one
isol
shown
carri
thu
probabl
also
carri
integron
none
isol
shown
carri
one
five
trimethoprim
resist
gene
known
exist
outsid
integron
three
isol
resist
sulphonamid
shown
carri
neither
dfr
aad
gene
cassett
found
sequenc
integron
conclus
resist
trimethoprim
trimethoprim
resist
isol
mediat
gene
detect
case
three
sulphonamid
resist
isol
sequenc
integron
contain
dfr
gene
carri
gene
cassett
mediat
resist
modern
antibiot
unusu
diagnosi
tool
unusu
present
alveolar
echinococcosi
report
two
case
local
progress
anim
bite
bardonnet
k
bart
jm
loiseau
j
estavoy
jm
heyd
b
badet
jm
dubiez
piarroux
r
bressonhadni
collabor
centr
prevent
treatment
human
echinococcosi
univers
franc
introduct
classic
human
contamin
rout
alveolar
echinococcosi
ae
ingest
egg
two
except
human
case
report
extens
local
evolut
ae
bite
case
patient
underw
surgeri
seven
time
muscl
grow
tumour
develop
bite
diagnosi
muscl
ae
assess
histopatholog
examin
serolog
test
accord
echinococcu
sp
infect
case
man
present
catscratch
fever
right
supraclavicular
tumefact
follow
cat
bite
five
recurr
occur
differ
surgic
explor
indic
multipl
abscess
cervic
muscl
serolog
test
favour
echinococcu
sp
infect
pathologist
describ
parasit
wall
suggest
hydatidosi
specif
pcr
histolog
sampl
prompt
diagnosi
ae
conclus
except
observ
liver
usual
locat
ae
lesionfre
chronic
inflammatori
ae
lesion
develop
local
lymphat
chain
area
bite
site
perform
diagnosi
unusu
form
ae
necessari
add
unusu
test
specif
pcr
classic
test
antibiot
resist
foodborn
salmonella
emerg
public
health
concern
integron
recogn
main
genet
vehicl
antibiot
resist
gramneg
bacteria
includ
salmonella
purpos
present
studi
investig
presenc
class
integron
resist
isol
sever
serotyp
salmonella
isol
poultri
product
determin
associ
multidrugresist
phenotyp
total
isol
salmonella
belong
seven
differ
serotyp
test
frequent
multiresist
phenotyp
found
alon
togeth
resist
streptomycin
tetracyclin
seven
resist
three
antimicrobi
agent
includ
quinolon
amoxicillin
pcr
analysi
cs
cs
primer
detect
presenc
class
integron
kb
one
isol
multiresist
phenotyp
amoxicillin
chloramphenicol
streptomycin
trimethoprimsulphametoxazol
tetracyclin
find
suggest
uncontrol
use
antimicrobi
agent
food
anim
may
contribut
develop
pattern
resist
observ
salmonella
isol
also
presenc
integron
low
preval
human
salmonella
serotyp
associ
food
anim
underscor
public
health
problem
antibiot
resist
acquisit
spread
preval
antimicrobi
resist
campylobact
jejuni
c
coli
isol
broiler
pig
franc
avrain
l
humbert
f
b
sander
p
c
kempf
afssa
umb
ploufragan
franc
b
afssa
hqpap
ploufragan
franc
c
afssa
lermvd
franc
caeca
standard
export
freerang
broiler
fecal
sampl
pig
collect
french
slaughterhous
preval
campylobact
jejuni
c
coli
strain
standard
export
freerang
broiler
standard
export
product
often
isol
speci
c
jejuni
wherea
c
coli
predomin
freerang
product
sampl
collect
pig
contain
c
coli
sensit
strain
ampicillin
nalidix
acid
enrofloxacin
broiler
ciprofloxacin
pig
tetracyclin
erythromycin
gentamicin
test
agar
dilut
method
broiler
percentag
resist
strain
respect
c
jejuni
c
coli
pig
percentag
resist
c
coli
respect
broiler
product
signific
differ
distribut
speci
percentag
resist
strain
observ
accord
type
product
administr
antimicrobi
enzym
dhp
dihydroptero
synthas
particip
folat
synthesi
pathway
well
recogn
target
sulphonamid
enzym
preced
dhp
pathway
pppk
dihydropterin
pyrophosphokinas
anoth
interest
candid
drug
target
metabol
role
pppk
provid
one
substrat
dhp
earlier
studi
suggest
pppk
dhp
enzym
need
physic
contact
full
enzym
activ
studi
potenti
interact
enzym
initi
far
indic
weak
interact
detect
gelfiltr
experi
twohybrid
system
confirm
result
current
develop
method
studi
substrat
channel
interf
interact
could
lead
impair
growth
thu
use
inhibitori
drug
also
clone
sequenc
operon
code
enzym
folat
biosynthesi
differ
clinic
isol
streptococcu
pyogen
comparison
reveal
isol
mosaic
structur
operon
suggest
horizont
transfer
genet
materi
occur
multiresist
gene
cluster
plasmid
clinic
isol
e
faecium
werner
g
hildebrandt
b
klare
witt
w
depart
nosocomi
infect
robert
koch
institut
wernigerod
branch
germani
purpos
strain
isol
urin
sampl
patient
perman
cathet
purpos
studi
identifi
local
resist
determin
isol
result
isol
resist
follow
antibiot
penicillin
ampicillin
gentamicin
highlevel
streptomycin
highlevel
erythromycin
clindamycin
vancomycin
teicoplanin
ciprofloxacin
moxifloxacin
nourseothricin
rifampicin
fusid
acid
lowlevel
mgl
show
suscept
oxytetracyclin
phosphomycin
chloramphenicol
trimethoprimsulfamethoxazol
linezolid
quinupristindalfopristin
hybrid
pcr
sequenc
experi
local
cluster
consist
sever
resist
gene
composit
element
plasmid
cluster
includ
gene
transposon
vana
ermb
aad
plasmid
transfer
filterm
fusid
acid
highlevel
resist
enterococcu
faecium
recipi
select
either
erythromycin
vancomycin
resist
howev
transpos
determin
determin
becam
mobiliz
help
conjug
transposon
transconjug
besid
other
highlevel
resist
fusid
acid
suscept
penicillin
ampicillin
pfge
transconjug
demonstr
pattern
almost
ident
recipi
clearli
differ
donor
conclus
resist
gene
e
faecium
could
arrang
cluster
mobil
via
mobilizabletransfer
plasmid
lilli
rivanera
barbacini
ig
lozzi
mancini
c
depart
scienc
public
health
univers
la
sapienza
microbiolog
rome
itali
aim
hepat
g
viru
hgv
new
rna
viru
parenter
trasmit
frequentley
found
patient
chronic
hepat
c
infect
role
chronic
liver
deseas
unknown
aim
studi
determin
preval
hgv
infect
patient
infect
hcv
ninetyeight
patient
infect
hcv
evalu
presenc
hgv
rna
hcv
genotyp
distribut
genotyp
genotyp
genotyp
four
genotyp
hcv
rna
hgv
rna
detect
rtnest
pcr
result
infect
hepat
g
viru
detect
patient
hgv
rna
neg
none
patient
genotyp
result
hgv
rna
posit
preval
hgv
infect
patient
infect
hcv
genotyp
genotyp
conclus
infect
hgv
occur
frequent
sampl
patient
chronic
hepat
c
observ
height
preval
hcvhgv
coinfect
patient
infect
hcv
genotyp
associ
hcv
genotyp
indipend
sourc
infect
infact
patient
histori
intraven
drug
use
character
extendedspectrum
betalactamas
esbl
mediat
resist
salmonella
spp
durban
south
africa
moodley
p
essack
b
gaje
k
sturm
w
depart
medic
microbiolog
nelson
r
mandela
school
medicin
school
infect
univers
natal
durban
south
africa
b
school
pharmaci
pharmacolog
univers
durban
westvil
durban
south
africa
background
gastroenter
common
condit
among
paediatr
popul
present
king
edward
viii
hospit
durban
south
africa
juli
notic
suscept
salmonella
spp
isol
stool
sampl
among
children
resist
multipl
antibiot
aim
character
phenotyp
resist
mechan
involv
method
minimum
inhibitori
concentr
mic
ampicillin
azithromycin
ciprofloxacin
cefepim
cefuroxim
cefotaxim
ceftazidim
ceftriaxon
cefoxitin
chloramphenicol
cotrimoxazol
gentamicin
determin
mean
agar
dilut
method
isol
subject
e
test
extendedspectrum
betalactamas
esbl
product
isoelectr
focus
perform
preliminari
step
enzym
character
result
conclus
thirti
isol
multiresist
salmonella
spp
obtain
antibiogram
type
reveal
six
differ
resist
phenotyp
isol
depict
ceftazidimeceftazidim
ratio
consid
put
esblproduc
isol
express
betalactamas
pi
valu
rang
indic
tem
shvandor
ctxmrelat
esbl
nine
isol
express
two
betalactamas
two
isol
express
three
betalactamas
evid
simultan
express
temand
shvderiv
esbl
well
simultan
express
multipl
temor
shvderiv
esbl
singl
isol
phenomenon
report
esblposit
klebsiella
pneumonia
isol
hospit
neutrophil
exhibit
reduc
chemiluminesc
respons
serum
opson
klebsiella
pneumonia
produc
extend
spectrum
blactamas
esbl
object
investig
abil
esbl
nonesblproduc
klebsiella
pneumonia
isol
treat
human
serum
induc
chemiluminesc
respons
neutrophil
method
oxid
burst
induc
interact
esbl
nonesblproduc
klebsiella
pneumonia
isol
neutrophil
healthi
individu
monitor
measur
chemiluminesc
respons
cl
pool
sera
healthi
individu
serv
sourc
complement
pretreat
bacteria
cl
respons
trigger
serum
treat
zymosan
serv
posit
control
serum
opson
klebsiella
strain
arbitrarili
grade
high
h
low
l
induc
cl
cl
respons
induc
bacteria
cl
respect
induc
opson
zymosan
result
nonesblproduc
klebsiella
isol
induc
high
cl
respons
neutrophil
wherea
esblproduc
klebsiella
isol
pb
conclus
strain
harbor
esbl
plasmid
virul
nonesblproduc
strain
virtu
higher
tendenc
escap
serumdepend
recognit
neutrophil
osiri
autom
system
suscept
test
agar
diffus
techniqu
chegrani
f
kolbert
shah
pm
frankfurt
zentrum
der
inneren
medizin
med
iii
schwerpunkt
infektiologi
frankfurt
main
germani
object
osiri
measur
zone
size
compar
manual
measur
inhibit
zone
use
round
rp
mm
mueller
hinton
squar
agarpl
sqp
variat
mm
zone
size
measur
defin
toler
major
error
vme
defin
classif
resist
organ
sensit
osiri
thirti
thousand
two
hundr
ninetyeight
singl
measur
test
antibiot
staphylococci
enterobacteriacea
done
accord
din
recommend
result
vancomycin
rifampicin
gentamicin
gave
best
result
rp
concord
vancomycin
rifampicin
teicoplanin
perform
best
sqp
test
staphylococci
worst
result
rp
gave
cefuroxim
fosfomycin
sqp
fosfomycin
ofloxacin
enterobacteriacea
amikacin
gentamicin
ciprofloxacin
perform
best
rp
worst
nalidixinacid
piperacillin
concord
sqp
amikacin
cefotaxim
gentamicin
nitrofurantoin
cotrimoxazol
major
error
seen
test
perform
interpret
osiri
rapid
reliabl
system
suscept
test
round
squar
agarpl
excel
expert
system
altindi
aktep
oc
kocagoz
b
kocatep
univers
school
medicin
microbiolog
afyon
turkey
b
diom
inc
tr
istanbul
turkey
diobacit
two
section
plate
contain
sheep
blood
agar
one
side
sheep
blood
agar
bacitracin
mgml
compar
effici
identif
group
beta
hemolyt
streptococcu
gab
two
differ
growth
plate
one
contain
sheep
blood
agar
bacitracin
b
contain
bsxt
use
latexagglutin
comparis
throat
specimen
obtain
case
inocul
diobacit
plate
first
one
side
sheep
blood
agar
side
b
overnight
inocul
coloni
beta
hemolysi
sheep
blood
agar
growth
b
inocul
sheep
blood
agar
antibiogram
identif
disc
contain
u
b
mg
sxt
oxoid
uk
place
onto
plate
incub
overnight
coloni
beta
hemolysi
defin
bsensit
coloni
resist
sxt
defin
gab
coloni
serolog
classifi
latexagglutin
oxoid
uk
seventyon
inocul
reveal
growth
gab
diobacit
plate
inocul
coloni
sheep
blood
agar
found
sensit
b
found
sensit
b
resist
sxt
defin
gab
latex
test
compar
latexagglutin
test
found
diobacit
method
sensit
spesif
respect
method
agar
diffus
techniqu
recommend
din
use
determin
iz
read
use
aura
manual
staphylococci
enterobacteriacea
variat
autom
measur
zone
size
mm
manual
read
consid
within
accept
rang
result
six
thousand
fiftytwo
zone
size
determin
staphylococci
enterobacteriacea
mha
display
tendenc
smaller
zone
size
autom
read
isa
well
staphylococci
enterobacteriacea
side
autom
read
present
isa
precis
result
mha
overal
less
major
discrep
mm
found
isa
iz
gener
smaller
mha
tabl
show
differ
manual
autom
measur
zone
size
differ
media
speci
discov
seven
case
resist
case
metronidazol
experi
clarithromycin
conclus
result
show
e
test
compar
ad
clarithromycin
metronidazol
find
confirm
nccl
recommendant
classic
ad
time
consum
everi
day
use
laboratori
use
screen
agar
plate
mgml
metronidazol
detect
possibl
resist
could
solut
rokosz
sawickagrzelak
meszaro
j
b
luczak
depart
medic
microbiolog
univers
medic
school
warsaw
poland
b
depart
bacteriolog
state
institut
hygien
warsaw
poland
purpos
identifi
esblposit
strain
compar
two
method
appli
detect
extendedspectrum
betalactamas
esbl
method
two
hundr
sixti
strain
gramneg
rod
cultur
clinic
specimen
hospit
patient
identif
strain
perform
automat
atb
system
biomerieux
franc
strain
identifi
esblposit
basi
doubledisc
synergi
test
ddst
accord
jarlier
et
al
result
strain
also
determin
use
novel
method
esbl
detect
dd
diagnost
disc
accord
appleton
two
disc
appli
test
cpd
cefpodoxim
cd
cefpodoximeclavulan
acid
oxoid
england
result
consist
result
two
method
ddst
dd
obtain
case
among
examin
strain
consist
result
concern
strain
enter
rod
five
among
strain
mostli
nonfer
rod
conclus
novel
method
esblproduc
detect
dd
object
easier
interpret
doubledisc
synergi
test
ddst
diagnost
disc
test
use
basic
one
confirm
result
ddst
difficult
case
assess
e
test
determin
penicillin
resist
pneumococci
sener
b
g
erci
g
depart
clinic
microbiolog
hacettep
univers
medic
faculti
ankara
turkey
greater
need
suscept
test
method
distinguish
suscept
resist
pneumococci
altern
method
could
e
test
compar
refer
agar
dilut
method
studi
penicillin
suscept
total
pneumococci
determin
e
test
agar
dilut
method
streptococcu
pneumonia
atcc
enterococcu
faecali
atcc
use
control
result
given
effect
anox
condit
minimum
inhibitori
concentr
metronidazol
helicobact
pylori
de
la
obra
sanz
p
loma
e
roman
jl
alarcon
lopezbrea
object
studi
determin
effect
incub
anox
condit
metronidazol
resist
helicobact
pylori
method
total
clinic
isol
use
studi
mic
determin
agar
dilut
method
use
muellerhinton
agar
plu
lyse
hors
blood
three
plate
seri
contain
twofold
dilut
metronidazol
mgl
prepar
first
one
incub
microaerophil
condit
oxoid
day
second
third
seri
incub
anaerob
anaerob
system
oxoid
h
respect
transfer
microaerophil
enviro
complet
day
incub
result
microaerophil
incub
strain
resist
respect
h
anaerob
preincub
four
strain
resist
respect
h
anaerob
preincub
strain
resist
respect
conclus
anaerob
preincub
caus
increas
sensit
metronidazol
extent
depend
length
anaerob
period
method
suscept
antibiot
perform
microdilut
method
accord
nccl
guidelin
product
blactamas
test
nitrocefin
stick
oxoid
result
mgml
appear
respect
ampicillin
amoxicillinclavulan
cefaclor
ceftriazon
erythromycin
azithromycin
clarithromycin
ciprofloxacin
imipenem
tetracyclin
trimethoprimsulfamethoxazol
blactamas
detect
strain
conclus
catarrhali
isol
uniformli
suscept
test
antimicrobi
except
ampicillin
product
blactamas
respons
ampicillin
resist
catarrhali
strain
almost
behavior
vitro
test
microlid
erythromycin
azithromycin
clarythromycin
rokosz
sawickagrzelak
luczak
depart
medic
microbiolog
univers
medic
school
warsaw
poland
purpos
isol
identifi
determin
drugsuscept
fungal
strain
cultur
fecal
sampl
routin
submit
detect
clostridium
difficil
toxin
case
antibioticassoci
diarrhea
aad
method
one
hundr
fecal
sampl
hospit
patient
examin
may
c
difficil
toxin
ab
detect
directli
stool
c
difficil
tox
ab
ii
test
techlab
usa
fecal
specimen
inocul
ccca
candida
id
biomerieux
franc
media
c
difficil
fungi
identifi
standard
microbiolog
procedur
suscept
fungal
strain
antifung
agent
determin
atb
fungu
biomerieux
franc
result
c
difficil
toxin
detect
c
difficil
strain
isol
examin
specimen
sixtytwo
fungal
strain
genera
cultur
stool
sampl
c
albican
isol
massiv
fungal
growth
observ
primari
plate
case
fiftyf
fungal
strain
suscept
nystatin
amphotericin
b
ketoconazol
miconazol
econazol
conclus
case
antibioticassoci
diarrhea
fungal
strain
respons
symptom
diseas
certain
person
aad
treat
antifung
agent
result
total
isol
penicillin
nonsuscept
intermedi
resist
erythromycin
nonsuscept
nonsuscept
antibiot
found
conclus
penicillin
administr
elimin
penicillin
suscept
strain
preval
penicillin
nonsuscept
strain
increas
well
erythromycin
nonsuscept
one
mean
proport
erythromycin
nonsuscept
strain
increas
time
erythromycin
elimin
suscept
strain
antibiot
preval
penicillin
nonsuscept
strain
would
increas
initi
data
explain
coselect
result
observ
differ
surveil
studi
antimicrobi
suscept
capsular
typesgroup
streptococcu
pneumonia
isol
caus
pneumococc
diseas
bulgaria
setchanova
l
gergova
r
ioneva
b
sredkova
v
c
depart
microbiolog
medic
univers
sofia
bulgaria
b
depart
microbiolog
ii
citi
hospitalsofia
sofia
bulgaria
c
depart
microbiolog
faculti
medicin
pleven
bulgaria
prospect
studi
pneumococc
infect
perform
cooper
five
clinic
microbiolog
laboratori
bulgaria
mic
valu
antimicrobi
serotypeserogroup
distribut
determin
strain
streptococcu
pneumonia
pneumococci
isol
patient
system
respiratori
infect
incid
penicillin
gintermedi
penicillin
gresist
isol
respect
rate
resist
antimicrobi
cefotaximeceftriaxon
erythromycin
clindamycin
tetracyclin
chloramphenicol
trimethoprimsulfamothoxazol
ciprofloxacin
rifampin
pneumonia
isol
belong
capsular
typesgroup
common
serotypesserogroup
bulgaria
aim
determin
pneumococc
antibiot
resist
rate
serotyp
resist
isol
hospit
mic
valu
isol
year
determin
agar
dilut
method
serotyp
perform
use
pool
antisera
pneumotest
result
follow
n
object
ass
antimicrobi
suscept
clinic
isol
pseudomona
aeruginosa
obtain
monitor
trend
antimicrobi
resist
method
mic
determin
microdilut
test
accord
nccl
antibiot
test
ceftazidim
caz
aztreonam
atm
imipenem
imp
gentamicin
cn
tobramycin
tb
amikacin
ak
ciprofloxacin
cip
result
total
isol
includ
urin
common
site
isol
outpati
isol
hospit
patient
respiratori
sampl
frequent
suscept
antibiot
caz
atm
imp
cn
tb
ak
cip
comparison
suscept
data
show
increas
resist
rate
signif
caz
vs
atm
vs
cn
vs
tb
vs
ak
vs
cip
vs
signific
differ
found
follow
circumst
isol
intens
care
unit
inpati
signif
resist
caz
atm
imp
isol
respiratori
sampl
resist
caz
atm
isol
urin
sampl
resist
cip
conclus
although
antimicrobi
suscept
level
decreas
p
aeruginosa
isol
still
show
good
suscept
percentag
antibiot
test
antimicrobi
suscept
test
clinic
isol
bordetella
pertussi
report
isol
rouen
franc
leme
l
nouvellon
caron
f
b
lemeland
jf
chu
rouen
bacteriologi
rouen
franc
b
chu
rouen
maladi
infectieus
et
tropical
rouen
franc
report
increas
clinic
incid
pertussi
develop
resist
bordetella
pertussi
erythromycin
prompt
collect
antimicrobi
suscept
test
recent
clinic
isol
patient
hospit
rouen
mic
nine
antimicrobi
agent
erythromycin
josamycin
spiramycin
roxithromycin
ketolid
hmr
cotrimoxazol
ciprofloxacin
rifampicin
amoxicillin
measur
agar
dilut
method
muellerhinton
agar
contain
hors
blood
mbc
erythromycin
rifampicin
also
determin
four
isol
b
pertussi
isol
fulli
suscept
nine
antimicrobi
agent
test
mic
mcgml
erythromycin
ketolid
hmr
ciprofloxacin
josamycin
spiramycin
roxithromycin
rifampicin
cotrimoxazol
amoxicillin
mbc
mcgml
eyrthromycin
rifampicin
conclus
isol
b
pertussi
remain
extrem
suscept
antimicrobi
agent
test
especi
macrolid
resist
detect
final
erythromycin
remain
molecul
choic
macrolid
also
confirm
good
invitro
activ
addit
good
invitro
potenc
rifampicin
togeth
great
diffus
within
respiratori
tract
suggest
rifampicin
potenti
clinic
efficaci
pertussi
emerg
streptococcu
pneumonia
sp
diminish
suscept
penicillin
g
psdp
suggest
use
antibiot
newer
fluoroquinolon
fq
resist
phenotyp
consecut
pneumococc
strain
isol
patient
four
hospit
observatoir
de
pneumocoqu
du
nordpa
de
calai
studi
strain
suscept
penicillin
g
psdp
refer
strain
provid
centr
nation
de
renc
de
pneumocoqu
ad
studi
activ
pefloxacin
ciprofloxacin
norfloxacin
sparfloxacin
levofloxacin
moxifloxacin
studi
reserpin
use
detect
efflux
phenotyp
method
use
perform
accord
recommend
de
lantibiogramm
de
la
de
microbiologi
strain
resist
phenotyp
fq
deduc
comparison
mic
diamet
obtain
obtain
refer
strain
known
phenotyp
fq
resist
phenotyp
correl
blactam
agent
suscept
wild
type
phenotyp
observ
among
suscept
psdp
strain
respect
wild
efflux
mechan
deduc
addit
reserpin
norfloxacin
repres
predomin
phenotyp
detect
among
sp
suscept
penicillin
g
well
among
psdp
aim
studi
determin
macrolid
resist
phenotyp
sp
isol
three
french
depart
alp
maritim
doub
nord
nasopharyng
aspir
children
age
month
year
attend
dcc
random
sampl
children
attend
randomli
select
dcc
obtain
three
period
spring
autumn
winter
depart
children
attend
dcc
children
sampl
analysi
macrolid
suscept
sp
strain
perform
use
casfm
method
strain
decreas
suscept
penicillin
spdp
resist
erythromycin
tripl
disk
diffus
method
erythromycin
e
clindamycin
cl
spiramycin
use
determin
resist
phenotyp
macrolid
resist
well
known
phenomenon
franc
confirm
studi
result
show
constitut
phenotyp
predomin
part
europ
frequenc
efflux
mechan
lower
observ
usa
canada
develop
antibiot
resist
surveil
helicobact
pylori
england
wale
elviss
nc
owen
rj
central
public
health
laboratori
laboratori
enter
pathogen
london
uk
purpos
helicobact
pylori
antibiot
resist
key
contribut
factor
infect
patient
fail
drug
treatment
aim
survey
rate
primari
invitro
resist
differ
locat
link
diseas
sever
antral
gastric
biopsiescultur
receiv
phl
chelmsford
midessex
isol
london
isol
bangor
north
wale
suscept
metronidazol
mtz
clarithromycin
cla
tetracyclin
tet
amoxicillin
amx
test
disc
diffus
also
e
test
cla
mtz
result
overal
resist
rate
isol
mtz
cla
suscept
amx
tet
dual
resist
rate
breakdown
locat
show
mark
differ
mtz
resist
highest
london
compar
chelmsford
bangor
contrast
cla
rate
london
bangor
chelmsford
london
major
mtz
resist
isol
nonuk
born
individu
nonuk
vs
uk
comparison
duoden
ulcerassoci
isol
nonulc
patient
indic
similar
rate
mtz
resist
conclus
resist
rate
may
vari
significantli
locat
depend
local
popul
nonuk
birth
key
risk
factor
primari
resist
mtz
resist
strain
local
resist
rate
taken
account
test
treat
strategi
potryku
j
benetkiewicz
wegrzyn
g
depart
molecular
biolog
univers
gdansk
gdansk
poland
purpos
studi
abil
extrud
wide
rang
compound
multidrug
efflux
pump
recent
becom
import
issu
combat
bacteri
infect
acrabtolc
major
efflux
system
escherichia
coli
investig
effect
acra
plasmidborn
intrins
chloramphenicol
tetracyclin
ampicillin
resist
result
conclus
recent
report
chloramphenicol
sensit
e
coli
mutant
express
cat
chloramphenicol
resist
gene
strain
shown
bear
nonsens
mutat
acra
gene
studi
indic
mutat
least
part
respons
observ
chloramphenicol
sensit
phenotyp
mutat
seem
also
influenc
strain
suscept
ampicillin
teta
c
mediat
plasmidborn
tetracyclin
resist
although
teta
c
protein
retain
biolog
function
consider
growth
impair
mutant
strain
cultur
tetracyclin
contain
medium
delet
acrab
locu
prevent
growth
presenc
tetracyclin
upon
addit
ampicillin
mutant
underw
lysi
rapidli
control
strain
also
observ
acrab
delet
deriv
e
coli
strain
tri
elucid
role
acra
gene
product
phenomena
describ
exist
efflux
pump
wild
type
isol
drugresist
bacteria
raja
ray
rr
medic
microbiolog
parasitolog
calcutta
univers
kolkata
india
efflux
pump
possess
bacteri
cell
differ
kind
bacteria
present
newer
mode
drug
resist
mani
organ
capac
bacteri
cell
caus
outward
flow
noxiou
agent
known
howev
consider
time
respect
tetracyclin
recent
interest
efflux
pump
system
brought
light
previous
illunderstood
mechan
drug
resist
involv
noxiou
agent
toxin
poison
found
high
level
resist
pseudomonad
toward
cetrimid
germicid
definit
chromosomalplasmidmedi
genesmechan
could
identifi
likewis
occurr
nonantibiot
sensit
vibrio
staphylococci
pseudomonad
background
high
level
resist
common
antibiot
suggest
mechan
interfer
efflux
pump
account
sensit
case
involv
multipl
resist
marin
isol
v
parahaemolyticu
numer
clinic
use
antibiot
never
expos
also
suggest
possibl
role
efflux
pump
determin
resist
simultan
develop
multipl
marin
toxinspoison
noxiou
agent
interact
oxacillin
glycopeptid
teicoplaninresist
mutant
staphylococcu
epidermidi
reduc
suscept
vancomycin
greco
aa
ben
hassen
laboratori
servic
nation
bonemarrow
transplant
center
tuni
tunisia
select
laboratorygener
mutant
staphylococcu
epidermidi
capabl
grow
presenc
mgl
teicoplanin
methicillinresist
mic
mgl
teicoplaninsensit
mic
mgl
vancomycinsensit
mic
mgl
clinic
isol
epidermidi
previou
work
studi
differ
phenotyp
characterist
acquir
teicoplaninresist
mutant
interdisciplinari
meet
antiinfecti
chemotherapi
decemb
poster
session
work
examin
interact
oxacillin
glycopeptid
teicoplaninresist
mutant
epidermidi
reduc
suscept
vancomycin
studi
combin
antibiot
activ
oxacillin
glycopeptid
use
differ
method
modifi
disk
diffus
test
e
test
timekil
assay
popul
analysi
profil
synergist
activ
glycopeptid
combin
oxacillin
teicoplaninresist
mutant
demonstr
bactericid
effect
synergi
seen
parent
strain
moreov
synergi
glycopeptid
oxacillin
occur
suppress
subpopul
highest
level
glycopeptid
resist
conclud
combin
glycopeptid
oxacillin
may
possibl
altern
treatment
infect
caus
methicillinresist
teicoplaninresist
epidermidi
composit
chang
microcosm
biofilm
induc
applic
minocyclin
preliminari
studi
aim
studi
observ
effect
applic
minocyclin
upon
microcosm
dental
plaqu
plaqu
cultiv
constant
departmenth
film
fermentor
cdff
produc
biofilm
condit
mimick
present
vivo
composit
biofilm
determin
viabl
count
select
nonselect
media
proport
antibiot
resist
genera
within
biofilm
determin
viabl
count
utilis
media
contain
minocyclin
mgml
commenc
antibiot
puls
biofilm
total
viabl
anaerob
count
cfu
per
biofilm
neglig
cfubiofilm
minocyclineresist
bacteria
howev
h
introduct
antibiot
total
count
reduc
cfubiofilm
whilst
number
minocyclineresist
bacteria
risen
cfubiofilm
final
sampl
time
point
h
total
viabl
anaerob
count
cfubiofilm
whilst
number
minocyclineresist
bacteria
cfubiofilm
henc
low
basal
level
inher
resist
minocyclin
within
microcosm
dental
plaqu
increas
consider
biofilm
expos
minocyclin
mechan
resist
aminoglycosid
amg
e
coli
isol
children
communityacquir
urinari
tract
infect
cauti
method
year
nine
center
took
part
studi
mic
antimicrobi
determin
agar
dilut
method
describ
nccl
guidelin
result
total
consecut
urin
isol
children
age
month
year
cauti
collect
frequent
isol
speci
children
cauti
e
coli
follow
klebsiella
spp
proteu
spp
result
vitro
suscept
test
e
coli
amg
shown
tabl
resist
strain
condit
product
amgmodifi
enzym
found
follow
phenotyp
among
resist
strain
gentamicin
tobramycin
aac
v
aac
iv
enzym
gentamicin
due
ant
enzym
conclus
amikacin
activ
amg
e
coli
resist
gentamicin
netilmicin
mainli
determin
product
aac
v
enzym
effect
blactamas
inhibitor
bli
evolut
resist
r
blactam
bl
gram
blactam
antimicrobi
still
frequent
use
among
bacteria
respons
high
resist
blactam
gramneg
rod
frequent
mechan
product
blactamas
use
bli
revers
partial
mechan
resist
expect
chang
frequenc
r
use
year
sinc
venezuelan
group
bacteri
resist
health
institut
countri
analys
publish
data
bacteri
resist
isol
patient
bacteri
infect
come
hospit
use
diffus
disk
accord
nccl
softwar
program
whonet
world
health
organ
net
use
follow
trend
r
gramneg
rod
bl
alon
bli
decad
statist
analys
made
evalu
differ
among
percentag
resist
two
seri
p
result
discuss
differ
r
bl
blbli
piperacillin
piperacillintazobactam
r
isol
except
escherichia
coli
serratia
spp
ampicilin
ampicilinsulbactam
cefoperazon
cefoperazonesulbactam
expect
gramneg
rod
resist
blactam
bli
lower
blactam
alon
furthermor
differ
seri
grow
higher
time
result
relev
expect
sinc
bli
shown
blactamas
inductor
trend
resist
r
blactam
other
antimicrobi
p
aeruginosa
venezuelan
medic
centr
nosocomi
no
communitarian
resist
order
approach
infect
produc
resist
bacteria
conveni
consid
hospit
commun
two
separ
ecosystem
hospit
ecosystem
special
relev
infect
r
gramneg
aerob
bacilli
today
main
respons
no
infect
special
refer
pseudomona
aeruginosa
infect
resist
bacteria
world
wide
problem
special
relat
no
sinc
venezuelan
group
bacteri
resist
health
institut
countri
identifi
analys
publish
data
bacteri
r
antimicrobi
blactam
quinolon
aminoglicosid
isol
patient
bacteri
infect
come
hospit
commun
use
diffus
disk
accord
nccl
softwar
program
whonet
world
health
organ
net
use
statist
signific
p
determin
applic
x
techniqu
show
signific
differ
r
p
aeruginosa
no
communitarian
highest
differ
piperacilina
tobra
also
establish
signific
differ
r
aris
public
hospit
privat
hospit
highest
differ
ceftazidim
amika
show
tendenc
decreas
frequenc
r
sinc
evid
privat
hospit
blactam
aminoglicosid
new
antimicrobi
new
mechan
action
futur
new
technolog
solv
today
problem
howev
import
tool
today
prevent
antimicrobi
must
make
suitabl
suscept
antibiot
enterobact
cloaca
citrobact
freundii
drink
water
quintera
sm
sousa
jc
peix
l
depart
microbiolog
faculti
pharmaci
univers
oporto
oporto
portug
increas
use
antimicrobi
farm
togeth
practic
raw
sewag
discharg
receiv
water
result
signific
increas
number
antibiot
resist
bacteria
present
aquat
environ
object
determin
antimicrobi
suscept
focu
blactam
resist
among
enterobacteriacea
strain
isol
raw
drink
water
sampl
sever
isol
enterobact
cloaca
citrobact
freundii
obtain
drink
water
screen
antibiot
suscept
pattern
use
agar
diffus
techniqu
accord
nccl
procedur
e
cloaca
strain
well
c
freundii
strain
show
resist
amoxicillin
amoxicillin
clavulan
acid
reduc
incid
resist
sever
other
antibiot
also
observ
obtain
result
suggest
strain
isol
raw
drink
water
greater
suscept
antimicrobi
agent
pathogen
strain
hospit
outpati
infect
natur
antimicrobi
resist
phenotyp
usual
describ
c
freundii
e
cloaca
seem
appli
strain
isol
human
infect
notwithstand
high
suscept
test
isol
blactam
role
environment
bacteria
reservoir
resist
gene
justifi
period
monitor
valid
index
resist
spread
snapshot
soil
use
bacteri
commun
trace
evolut
metalresist
quintera
sm
sousa
jc
peix
l
monteiro
nm
b
depart
microbiolog
faculti
pharmaci
univers
oporto
oporto
portug
b
depart
zoolog
anthropolog
faculti
scienc
univers
oporto
oporto
portug
well
known
pathogen
bacteria
special
resist
antimicrobi
agent
heavi
metal
pose
public
health
risk
great
concern
detect
name
soil
gener
relat
pollut
studi
heavi
metal
resist
pattern
microflora
isol
pollut
dump
area
unpollut
soil
environ
examin
plate
growth
cover
percentag
soil
sampl
determin
use
muellerhinton
plate
supplement
differ
heavi
metal
concentr
parallelli
use
icpa
possibl
ascertain
real
heavi
metal
concentr
soil
sampl
found
percentag
plate
growth
cover
use
sampl
close
link
level
chemic
pollut
measur
locat
moreov
use
anova
found
signific
differ
locat
dump
site
show
highest
toler
test
metal
newman
test
pattern
result
consist
use
data
icpa
furthermor
possibl
observ
pseudomona
spp
rel
high
mic
studi
metal
might
becom
relev
model
public
health
issu
ecotoxicolog
studi
biochem
characterist
environment
isol
listeria
monocytogen
moshtaghi
h
garg
sr
b
mandokhot
uv
b
shahrekord
univers
food
hygien
shahrekord
islam
republ
iran
b
haryana
agricultur
univers
food
hygien
hisar
india
purpos
investig
carri
studi
biochem
reaction
listeria
monocytogen
isol
differ
sourc
environ
result
total
isol
l
monocytogen
obtain
sampl
agricultur
soil
faecal
matter
anim
sewag
isol
gramposit
small
rod
catalas
posit
oxidas
neg
motil
tumbl
motil
hang
drop
aerob
facult
anaerob
ferment
produc
acid
glucos
isol
l
monocytogen
beta
haemolyt
posit
camp
reaction
staphylococcu
aureu
isol
neg
phenyl
alanin
deaminas
ornithin
decarboxylas
lysin
decarboxylas
malon
util
beta
galactosidas
test
also
neg
acid
product
arabinos
dxylos
mannitol
solubl
starch
sucros
acid
produc
rhamnos
salicin
trehalos
hydrogen
sulfid
product
record
tripticas
soy
broth
lead
acet
paper
strip
neg
tripl
sugar
iron
agar
isol
found
hydrolys
aesculin
isol
l
monocytogen
two
produc
acid
lactos
serotyp
isol
serotyp
conclus
conclud
l
monocytogen
serotyp
least
ferment
lactos
show
differ
reaction
method
sampl
preenrich
bhi
broth
without
vancomycin
mgl
plate
onto
menterococcu
agar
without
antibiot
vancomycin
mgl
gentamicin
mgl
kanamycin
mgl
streptomycin
mgl
repres
coloni
morpholog
isol
identifi
enterococcu
sp
previou
describ
pcr
use
identifi
e
faecium
e
faecali
characteris
vancomycin
resist
genotyp
also
use
identif
suscept
test
antibiot
perform
agar
dilut
method
nccl
result
three
hundr
fiftythre
enterococci
isol
total
faecal
sampl
n
major
enterococci
identifi
e
faecium
e
faecali
enterococcu
sp
resist
almost
antibiot
studi
observ
vancomycin
teicoplanin
ampicillin
tetracyclin
erythromycin
ciprofloxacin
chloramphenicol
gentamicin
streptomycin
kanamycin
linezolid
vancomycin
resist
enterococci
present
vana
genotyp
conclus
resist
sever
common
antibiot
use
therapi
observ
among
enterococci
isol
healthi
human
commun
mani
isol
present
multiresist
concern
presenc
vana
genotyp
among
popul
may
constitut
reservoir
vancomycin
resist
gene
antimicrobi
resist
tetracyclineresist
oral
bacteria
mercuri
releas
dental
amalgam
may
select
mercuryresist
oral
bacteria
mercuri
resist
often
associ
multipl
antibiot
resist
aim
studi
determin
whether
tetracyclineresist
oral
bacteria
children
without
amalgam
fill
also
resist
mercuri
b
multipl
antibiot
tetracyclineresist
organ
isol
isosensitestblood
agar
contain
tetracyclin
mgml
mic
hgcl
sever
antibiot
determin
use
agar
dilut
bsac
one
hundr
three
organ
isol
patient
without
amalgam
ninetyon
streptococcu
speci
seven
neisseria
speci
three
veillonella
dispar
two
rothia
speci
fiftyseven
percent
exhibit
resist
least
one
antibiot
mercuryresist
penicillinresist
ampicillinresist
erythromycinresist
fiftytwo
organ
isol
patient
amalgam
fortyf
streptococcu
speci
five
neisseria
speci
one
v
dispar
one
staphylococcu
aureu
sixtythre
percent
exhibit
resist
least
one
antibiot
mercuryresist
penicillinresist
ampicillinresist
show
erythromycinresist
statist
result
show
tetracyclineresist
organ
presenc
dental
amalgam
affect
level
resist
mercuri
antibiot
test
conwaywallac
hl
mullani
p
bedi
r
b
wilson
eastman
dental
institut
univers
colleg
london
microbiolog
london
uk
b
eastman
dental
institut
univers
colleg
london
transcultur
oral
health
london
uk
purpos
studi
determin
preval
antibioticresist
oral
bacteria
children
receiv
antibiot
month
prior
sampl
plaqu
sampl
obtain
children
age
year
plate
onto
media
contain
penicillin
ampicillin
tetracyclin
erythromycin
vancomycin
resist
isol
enumer
subcultur
frozen
subsequ
identif
process
repeat
month
later
result
obtain
bacteria
resist
antibiot
present
children
sampl
time
except
case
ampicillin
penicillin
month
proport
antibioticresist
bacteria
oral
microflora
rang
erythromycin
ampicillin
proport
bacteria
resist
particular
antibiot
remain
reason
constant
sampl
period
two
case
penicillin
ampicillin
statist
signific
chang
proport
resist
bacteria
differ
time
period
conclus
reach
result
studi
reveal
bacteria
resist
wide
rang
antibiot
may
isol
children
administ
agent
month
prior
sampl
furthermor
mani
case
proport
bacteria
resist
particular
antibiot
remain
constant
period
antimicrobi
use
intens
care
unit
result
pharmacoepidemiolog
studi
itali
periti
p
eift
srl
firenz
itali
retrospect
survey
antimicrobi
chemotherapi
use
intens
care
unit
itali
carri
use
computer
questionnair
auspic
journal
chemotherapi
icu
contact
repli
mainli
gener
postsurg
pediatr
unit
mean
bed
nine
doctor
nurs
antimicrobi
agent
use
ward
almost
alway
polychemotherapi
preval
use
betalactam
aminoglycosid
glycopeptid
empir
treatment
first
h
hospit
admiss
continu
use
mediumhigh
dose
combin
antimicrobi
chemotherapi
justifi
microbiolog
test
reveal
onethird
bacteri
pathogen
resist
approxim
gramposit
bacteria
methicillinresist
wherea
gramneg
strain
resist
least
one
test
antibiot
forti
percent
respond
icu
furnish
microbiolog
test
data
three
quarter
indic
incid
chemoresist
isol
strain
fungal
infect
less
frequent
bacteri
commonli
isol
agent
candida
spp
conclus
sampl
icu
examin
show
adequ
reason
use
antimicrobi
agent
heavi
relianc
mediumhigh
dose
combin
therapi
due
elev
incid
resist
isol
found
plasma
concentr
p
urinari
excret
u
bactericid
activ
gatifloxacin
gat
mg
versu
ciprofloxacin
cip
mg
healthi
volunt
singl
oral
dose
boy
kinzigschipp
b
rgel
f
b
well
naber
kg
hospit
st
elisabeth
urolog
clinic
straub
germani
b
institut
biomed
pharmaceut
research
ibmp
germani
twelv
volunt
receiv
singl
oral
dose
mg
gat
versu
mg
cip
assess
p
h
u
hplc
urinari
bactericid
titer
ubt
eight
interv
h
mean
pmax
gatcip
mg
ucum
mean
gatcip
ubt
ie
highest
twofold
dilut
urin
still
bactericid
determin
nine
uropathogen
one
refer
strain
mic
mgml
microdilut
gatcip
escherichia
coli
atcc
e
coli
klebsiella
pneumonia
proteu
mirabili
pseudomona
aeruginosa
saprophyticu
two
strain
aureu
two
strain
e
faecali
median
ubt
measur
within
first
h
gatifloxacin
five
gramneg
strain
incl
p
aeruginosa
five
gramposit
strain
median
ubt
ciprofloxacin
gramneg
strain
incl
p
aeruginosa
five
gramposit
strain
ubt
h
gat
significantli
superior
ciprofloxacin
gramposit
strain
differ
two
e
coli
strain
inferior
klebsiella
proteu
pseudomona
strain
ubt
h
gat
gener
superior
cip
show
differ
proteu
pseudomona
strain
gat
show
overal
compar
urinari
bactericid
activ
cip
agreement
clinic
studi
perform
previous
malaria
one
preval
endem
infecti
diseas
affect
human
bichat
hospit
case
malaria
acut
ill
report
among
patient
hospitalis
intraven
treat
quinin
retrospect
studi
consist
compar
therapeut
drug
monitor
tdm
quinin
distinguish
respect
patient
cure
infecti
medic
depart
imd
intens
care
unit
icu
standardis
quinin
regimen
establish
malaria
attack
respect
icu
treatment
consist
infus
load
dose
h
quinin
dilut
glucos
follow
mgkgday
plasma
quinin
maxim
concentr
assess
select
liquid
extract
spectrofluorometri
detect
statist
analysi
perform
use
test
result
show
patient
compar
weight
kg
quinin
dose
plasma
concentr
significantli
differ
icu
imd
respect
versu
mgkgday
pb
versu
mgl
p
b
icu
imd
respect
therapeut
rang
mgl
request
therapeut
concentr
mgl
limit
toxic
mgl
convey
import
tdm
intraven
quinin
treatment
avoid
infratherapeut
toxic
concentr
simultan
central
nervou
system
distribut
use
microdialysi
pharmacokinet
model
electroencephalogram
effect
norfloxacin
rat
chenel
marchand
dupui
bouquet
couet
w
univers
pharmaci
pharmacolog
poitier
franc
purpos
investig
epileptogen
activ
norfloxacin
pharmacokinet
pk
model
approach
assess
contribut
distribut
process
across
blood
barrier
bbb
delay
effect
method
rat
receiv
iv
bolu
dose
norfloxacin
mgkg
convuls
effect
quantifi
electroencephalogram
eeg
record
h
postdos
arteri
blood
sampl
collect
drug
assay
plasma
unbound
norfloxacin
concentr
monitor
brain
extracellular
fluid
ecf
use
microdialysi
vivo
calibr
probe
retrodialysi
ciprofloxacin
result
eeg
effect
reach
maximum
min
postdos
pkpd
effect
compart
model
success
fit
data
relationship
effect
concentr
effect
site
best
describ
spline
function
norfloxacin
concentr
brain
ecf
rel
low
compar
plasma
level
ecfplasma
area
curv
auc
ratio
equal
central
distribut
rapid
therefor
effect
versu
brain
ecf
concentr
curv
still
exhibit
mark
hysterisi
conclus
delay
observ
plasma
concentr
norfloxacin
convuls
effect
explain
slow
distribut
norfloxacin
across
bbb
pagoulat
kanellakopoul
k
b
vafiad
kostakopoulo
th
c
kastrioti
b
giamarel
h
c
depart
anesthesia
sismanoglio
gener
hospit
greec
b
depart
intern
medicin
athen
medic
school
athen
greec
c
depart
urolog
athen
medic
school
athen
greec
csf
kinet
van
fu
studi
patient
underw
short
urolog
surgeri
spinal
anesthesia
patient
exclud
alreadi
receiv
antibiot
suffer
renal
hepat
dysfunct
van
administ
g
h
infus
serum
csf
sampl
collect
postdos
mean
serum
level
follow
min
h
mgml
five
patient
h
mgml
five
patient
h
mgml
six
patient
h
mgml
six
patient
h
mgml
seven
patient
fu
administ
mg
dose
h
infus
serum
csf
sampl
taken
postdos
mean
serum
concentr
found
follow
min
mgml
six
patient
min
h
mgml
six
patient
h
mgml
five
patient
h
mgml
six
patient
h
mgml
five
patient
csf
van
fu
undetect
conclud
absenc
mening
inflamm
van
fu
penetr
appli
microbiolog
assay
csf
barrier
comparison
pharmacolog
intraven
oral
given
moxifloxacin
invitro
model
wiegand
pfeil
e
wiedemann
b
univers
bonn
pharmaceut
microbiolog
bonn
germani
purpos
intraven
form
iv
mg
moxifloxacin
mox
one
newer
fluoroquinolon
recent
approv
fda
iv
treatment
higher
peak
serum
concentr
achiev
comparison
oral
administr
po
dose
antibacteri
activ
fluoroquinolon
concentr
depend
therefor
simul
human
pharmacokinet
singl
po
iv
dosag
mg
mox
invitro
model
use
six
differ
gramneg
posit
pathogen
elucid
differ
effect
two
dose
schedul
result
comparison
pharmacolog
paramet
auc
mic
show
increas
tabl
could
predict
enhanc
antibacteri
effect
howev
analysi
kill
curv
follow
paramet
kamax
maxim
kill
activ
aac
area
kill
curv
h
reveal
major
differ
po
iv
dosag
conclus
serum
concentr
oral
administr
alreadi
suffici
high
show
optim
bactericid
effect
mox
slightli
increas
higher
peak
concentr
higher
aucmic
ratio
thu
concentr
depend
linear
end
alreadi
concentr
achiev
oral
dose
document
aucmic
calcul
easili
translat
dose
schedul
background
bacteria
grow
vivo
multipli
much
slowli
vitro
whether
bactericid
activ
quinolon
may
affect
increas
gener
time
g
studi
batch
cultur
method
limit
nutrient
suppli
gener
time
lengthen
approxim
h
h
altern
quinolon
ad
bacteri
cultur
lag
exponentialand
stationari
phase
recent
clinic
isol
escherichia
coli
expos
multipl
mic
ciprofloxacin
norfloxacin
kill
rate
calcul
analog
growth
rate
result
bactericid
activ
quinolon
test
e
coli
minim
influenc
reduc
gener
time
ciprofloxacin
concentr
mic
elimin
test
strain
within
h
test
system
ad
lag
exponenti
growth
phase
four
time
higher
concentr
need
reduc
cfu
within
h
ad
stationari
phase
norfloxacin
significantli
less
activ
conclus
contrast
norfloxacin
bactericid
activ
ciprofloxacin
minim
affect
gener
time
growth
phase
bacteria
wiegand
pfeil
e
wiedemann
b
univers
bonn
pharmaceut
microbiolog
bonn
germani
purpos
moxifloxacin
mox
one
newer
fluoroquinolon
avail
parenter
applic
pharmacolog
intraven
oncedaili
dose
od
mg
mox
determin
five
gramneg
posit
pathogen
streptococcu
pyogen
streptococcu
pneumonia
moraxella
catarrhali
escherichia
coli
klebsiella
pneumonia
twicedaili
dose
bid
mg
mox
simul
gramposit
speci
order
increas
bactericid
effect
result
determin
efficaci
kill
curv
analyz
follow
paramet
calcul
kamax
maxim
kill
activ
log
cfu
ka
conclus
intraven
oncedaili
dose
mox
activ
test
pathogen
gramneg
speci
rapidli
kill
h
similar
kamax
pronounc
initi
effect
two
gramposit
speci
gener
slow
reduct
viabl
cell
count
kamax
reach
h
efficaci
mox
measur
aac
kamax
pyogen
pneumonia
extent
increas
second
dose
howev
analysi
kill
curv
reveal
major
differ
od
bid
even
od
nearli
give
maxim
bacter
activ
mox
gramposit
pathogen
object
evalu
dose
proportion
amoxicillin
compar
respect
pkpd
paramet
two
dosag
regimen
method
dose
proportion
amoxicillin
evalu
use
linear
regress
mean
auc
c
max
data
differ
bioequival
studi
volunt
perform
formul
contain
variou
amount
amoxicillin
alon
combin
clavulan
acid
volunt
receiv
singl
oral
dose
rang
mg
amoxicillin
plasma
concentr
determin
hplcuv
lcmsm
method
time
mic
tmic
express
dose
interv
calcul
three
target
mic
valu
mgl
mg
g
dosag
regimen
result
absorpt
amoxicillin
auc
show
linear
depend
correl
coeffici
correl
coeffici
linear
regress
cmax
depend
actual
dose
respect
tmic
dosag
regimen
similar
larg
overlap
confid
interv
support
pd
breakpoint
mgl
g
regimen
tmic
mgl
ci
conclus
analysi
show
dose
proportion
amoxicillin
dosag
rang
mg
support
pharmacodynam
rational
g
bid
dosag
regimen
piperacillintazobactam
concentr
profil
high
dose
administr
pattern
nosocomi
pneumonia
due
mecan
ventil
pedeboscq
gruson
b
bassoua
v
hilbert
g
b
pometan
jp
st
hospit
pharmaci
bordeaux
franc
b
pellegrin
hospit
reanim
bordeaux
franc
piperacillin
p
tazobactam
antibacteri
spectrum
cover
largest
part
bacteria
respons
pneumonia
due
mechan
ventil
due
import
bacteri
inoculum
pharmacokinet
paramet
modif
intens
care
patient
high
dose
betalactamin
seem
necessari
obtain
antibiot
concentr
suspect
bacteria
mic
minim
inhibitori
concentr
led
us
compar
patient
pneumonia
due
mechan
ventil
two
intermitt
administr
pattern
g
three
time
day
usual
pattern
versu
g
four
time
day
high
dose
pattern
studi
carri
collabor
intens
care
unit
bacteriolog
depart
pharmaci
antibiot
concentr
determin
twentythre
take
blood
execut
within
h
period
addit
two
bronchial
secret
sampl
concern
p
seric
concentr
high
dose
pattern
seem
adapt
rel
high
residu
concentr
mgml
three
hour
inject
seric
concentr
lower
mgml
activ
threshold
first
second
day
residu
bronchial
concentr
p
seem
suffici
although
concentr
activ
threshold
result
correl
mic
determin
bacteriolog
depart
correl
make
us
abl
conclud
better
efficaci
high
dose
pattern
intens
care
patient
antiinflammatori
drug
interfer
absorpt
tissu
penetr
amoxycillin
del
fiol
fs
menon
sz
b
caramez
th
b
celotto
tf
b
lope
ra
b
univers
sorocaba
pharmacolog
sorocaba
brazil
b
school
pharmaci
univers
sorocaba
sorocaba
brazil
antibiot
antiinflammatori
frequent
associ
clinic
practic
concern
quantiti
antibiot
reach
infect
site
may
reduc
presenc
antiinflammatori
drug
purpos
present
studi
analys
steroid
dexamethason
dexa
ain
celecoxib
cele
influenc
penetr
amoxicillin
inflam
tissu
thirti
femal
rat
rattu
norvegicu
use
surgic
implant
pvc
spong
back
form
granulomat
tissu
one
week
later
anim
divid
three
group
one
group
receiv
amox
mgkg
anoth
receiv
amox
mgkg
plu
cele
mgkg
last
receiv
amox
mgkg
plu
dexa
mgkg
one
hour
later
anim
sacrif
concentr
amoxicillin
serum
tissu
investig
differ
among
group
quantiti
absorb
mgml
mgml
mgml
reduct
tissu
concentr
amoxicillin
p
b
tukeykram
group
receiv
drug
dexamethason
group
differ
tissu
concentr
amoxicillin
result
indic
inflam
tissu
signific
reduct
antibiot
penetr
induc
sinultan
dexamethason
therapi
predict
optim
amoxicillin
dose
regimen
base
coupl
pharmacokinet
data
bactericid
activ
background
given
short
halflif
amoxicillin
amx
administ
least
three
time
day
patient
acut
exacerb
chronic
bronchiti
order
achiev
serum
concentr
well
mic
respons
pathogen
howev
sever
author
recommend
twicedaili
administr
higher
dose
shorter
period
assess
relationship
amx
sputum
concentr
antibacteri
activ
follow
two
treatment
schedul
healthi
volunt
subject
method
twelv
healthi
volunt
random
receiv
amx
day
dose
either
g
bd
mg
bd
serum
sputum
collect
everi
day
h
morn
administr
day
last
dose
amx
concentr
determin
hplc
fluorometr
detect
sputum
kill
activ
determin
haemophilu
influenza
streptococcu
pneumonia
moraxella
catarrhali
result
mean
serum
concentr
measur
h
morn
administr
mg
bd
mgl
g
bd
mic
three
microrgan
contrast
sputum
concentr
alway
mgl
term
sputum
kill
activ
g
bd
effect
mg
bd
pneumonia
catarrhali
wherea
sputum
sampl
activ
h
influenza
conclus
optim
amoxicillin
treatment
schedul
establish
basi
serum
pharmacokinet
galmich
h
louchahi
k
tod
drugeon
h
giroud
jp
rouveix
b
servic
de
pharmacologi
cliniqu
hopit
cochin
pari
crepit
hopit
avicenn
bobigni
servic
de
microbiologi
hopit
laennec
nant
franc
background
cysteinebas
mucolyt
commonli
use
combin
antibiot
treat
patient
acut
exacerb
chronic
bronchiti
aecb
also
use
allow
vitro
mic
determin
sputum
specimen
conduct
vitro
exvivo
compat
studi
design
detect
possibl
interact
mucolyt
antibiot
method
serial
sampl
bronchial
secret
collect
aecb
patient
healthi
volunt
receiv
g
amoxicillin
twice
day
day
two
mucolyt
use
fluidifi
sputum
specimen
digesteur
acetylcystein
solut
amoxicillin
assay
use
chromatograph
system
fluorometr
detect
sampl
also
test
microbiolog
assay
result
amoxicillin
could
detect
presenc
mucolyt
agent
conclus
mucolyt
interact
may
explain
amoxicillin
fixat
fluidifi
mucoprotein
taken
account
assess
antibiot
efficaci
vivo
del
fiol
fs
ferro
c
b
albuquerqu
et
b
univers
sorocaba
pharmacolog
sorocaba
brazil
b
uniso
school
pharmacolog
sorocaba
brazil
physician
frequent
recommend
macrolid
administ
milk
decreas
discomfort
caus
thu
object
studi
verifi
interfer
milk
absorpt
distribut
erythromycin
eryt
clarithromycin
clar
roxithromycin
roxi
azithromycin
azit
forti
femal
rat
rattu
norvegicu
use
surgic
implant
pvc
spong
back
granulomat
tissu
format
one
week
later
anim
divid
group
receiv
drug
eryt
clar
roxi
azit
without
milk
mlkg
ca
mgml
anim
sacrif
serum
tissu
concentr
drug
investig
reduct
pb
tukeykram
serum
tissu
concentr
presenc
milk
azit
clar
reduct
roxi
serum
concentr
presenc
milk
mgml
alter
tissu
concentr
reduct
eryt
p
b
serum
concentr
presenc
milk
mgml
reduct
tissu
concentr
milk
decreas
effect
treatment
erythromycin
roxithromycin
bioavail
macrolid
affect
coadministr
milk
del
fiol
fs
souza
gp
b
duzzi
mr
b
univers
sorocaba
pharmacolog
sorocaba
brazil
b
uniso
school
pharmacolog
sorocaba
brazil
degre
tetracyclin
absorb
differ
greatli
absorpt
impair
concurr
ingest
dival
trival
cation
thu
object
studi
investig
interfer
milk
absorpt
distribut
tetracyclin
tetr
oxytetracyclin
oxyt
minocyclin
mino
doxycyclin
doxi
forti
femal
rat
rattu
norvegicu
use
surgic
implant
pvc
spong
back
granulomat
tissu
format
one
week
later
anim
divid
group
receiv
drug
tetr
oxyt
mino
doxi
without
milk
mlkg
ca
mgml
anim
sacrif
drug
concentr
serum
tissu
determin
reduct
pb
tukeykram
serum
tissu
concentr
presenc
milk
mino
reduct
p
b
doxi
serum
concentr
presenc
milk
mgml
tissu
concentr
oxyt
reduct
pb
serum
concentr
presenc
milk
mgml
tissu
concentr
tetr
result
show
reduct
p
b
serum
concentr
presenc
milk
mgml
tissu
concentr
milk
decreas
tetracyclin
bioavail
effect
isotop
studi
oxin
label
platelet
platelet
kinet
thrombocytopen
malaria
patient
introduct
thrombocytopenia
common
featur
human
malaria
excess
splenic
platelet
pool
suggest
play
role
uncompl
case
malaria
moder
shorten
platelet
life
span
period
decreas
parasitaemia
seem
plausibl
caus
frequent
observ
thrombocytopenia
consumpt
coagulopathi
eventu
manifest
dissemin
intravascular
coagul
describ
malaria
uncompl
malaria
howev
dissemin
intravascular
coagul
rare
found
result
malaria
patient
sequestr
differ
normal
platelet
halflif
reduc
patient
p
falciparum
malaria
h
normal
day
one
patient
p
vivax
malaria
platelet
half
live
h
conclus
signific
differ
sequestr
platelet
compar
healthi
individu
could
detect
inlabel
platelet
scintigraphi
especi
enhanc
splenic
sequestr
previous
expect
caus
thrombocytopenia
therefor
mechan
sequestr
respons
dramat
reduc
life
span
platelet
acut
malaria
zaharanka
ag
rozhdestvenski
da
vitebsk
state
medic
univers
vitebsk
belaru
aim
studi
chromatingeterogen
test
ct
result
sperm
subject
take
doxycyclin
macrolid
erythromycin
e
jozamycin
j
azytromycin
moder
therapeut
dose
method
forti
healthi
volunt
year
studi
daili
dose
e
administ
dose
four
time
per
day
day
j
meal
twice
daili
day
meal
daili
day
ct
evalu
dna
condit
human
spermatozoid
perform
treatment
twice
day
treatment
well
month
treatment
cours
complet
result
ct
data
analysi
reveal
mean
amount
defect
spermatozoid
treatment
day
treatment
index
denatur
dna
pb
day
pb
one
month
treatment
cours
amount
gener
cell
denatur
dna
respect
p
b
case
e
treatment
amount
defect
spermatozoid
chang
day
day
month
month
pb
case
use
ct
result
control
point
pb
case
j
treatment
respect
p
case
conclus
data
obtain
permit
conclud
demonstr
high
level
toxic
male
gener
cell
effect
preserv
month
cours
treatment
object
studi
effect
aggress
isol
decontamin
measur
control
outbreak
multiresist
acinetobact
baumanii
mrab
icu
outbreak
index
case
transfer
mediterranean
hospit
directli
openplan
icu
sever
injuri
head
thorax
die
shortli
admiss
sputum
bronchoalveolar
lavag
fluid
blood
cultur
chest
drain
swab
grew
mrab
resist
ampicillin
coamoxiclav
aztreonam
amikacin
ceftazidim
cefotaxim
cefuroxim
ciprofloxacin
gentamicin
meropenem
piptazobactam
tobramycin
sensit
colistin
within
day
mrab
isol
two
icu
patient
isol
demonstr
ident
antimicrobi
suscept
profil
icu
close
admiss
thoroughli
clean
patient
isol
contact
screen
icu
reopen
howev
mrab
isol
fourth
patient
patient
isol
icu
close
second
time
thoroughli
clean
contact
isol
discharg
subsequ
patient
screen
neg
mrab
conclus
illustr
import
aggress
isol
measur
thorough
supervis
clean
control
outbreak
need
screen
patient
resist
bacteria
admiss
intens
care
unit
gener
hospit
extend
spectrum
betalactamaseposit
bacteria
isol
neonat
intens
care
unit
sandorcinova
z
siegfri
l
kmetova
viragova
b
institut
medic
microbiolog
faculti
medicin
univers
pj
safarik
kosic
slovakia
b
hospit
kosicesaca
neonat
intens
care
unit
kosic
slovakia
extendedspectrum
betalactamas
hydrolys
penicilin
cephalosporin
includ
thirdgener
cephalosporin
aztreonam
esbl
predominantli
produc
klebsiella
spp
may
present
enterobacteriacea
aim
present
studi
investig
occurr
esblproduc
bacteria
isol
patient
hospit
neonat
intens
care
unit
icu
fifti
escherichia
coli
klebsiella
spp
isol
rectum
patient
hospit
neonat
icu
mic
antimicrobi
agent
determin
standard
agar
plate
dilut
method
accord
nccl
guidelin
screen
esbl
product
investig
strain
show
reduc
suscept
mic
equal
andor
mll
least
one
third
gener
cephalosporin
esbl
product
detect
doubl
disk
synergi
test
ddst
e
test
esbl
pcr
employ
specif
primer
presenc
blashv
blatem
gene
use
ddst
e
test
among
e
coli
isol
express
esbl
detect
three
former
method
among
klebsiella
spp
isol
product
esbl
found
two
latter
method
esblposit
e
coli
strain
presenc
blatem
gene
fragment
detect
esblposit
klebsiella
spp
gene
encod
shvtype
betalactamas
found
isol
staphylococci
wound
swab
suscept
antibiot
markov
mij
shopovski
e
despotovski
v
angelevski
nikolovski
b
militari
hospit
microbiolog
skopj
former
yugoslav
republ
macedonia
purpos
determin
percent
staphylococci
wound
swab
establish
suscept
antibiot
materi
method
wound
swab
evalu
standard
microbiolog
techniqu
bacteria
identifi
strip
atb
express
system
suscept
test
perform
strip
dilut
techniqu
read
system
result
last
year
total
wound
swab
evalu
militari
hospit
skopj
posit
bacteri
find
determin
swab
isol
bacteri
speci
staphylococci
staphylococcu
aureu
isol
methycillin
resist
aureu
epidermidi
haemolyticu
homini
chromogen
lugdunensi
nine
intermediu
lentu
sciuri
warneri
seven
isol
suscept
aureu
penicillin
ampicillin
amoksicillinclavulon
acid
ceftazidim
gentamicin
tetracyclin
erythromycin
lincomycin
ciprofloksacin
cotrimoxazol
vancomycin
fusid
acid
cefixim
azitromicin
conclus
studi
frequent
isol
bacteria
wound
swab
staphylococci
especi
aureu
suscept
except
penicillin
high
antibiot
studi
went
januari
decemb
maribor
teach
hospit
staphylococcu
aureu
isol
collect
mrsa
mrsa
recov
routin
clinic
materi
surveil
swab
nose
throat
skin
isol
convent
cultur
media
use
surveil
swab
mrsascreen
plate
manitol
salt
agar
oxacillin
trypticas
soy
broth
nacl
ad
aureu
identifi
catalas
dnase
tubecoagulas
test
antibiot
suscept
determin
diskdiffus
method
accord
ncci
guidelin
mrsa
isol
test
sensit
follow
antimicrobi
gentamicin
netilmicin
ciprofloxacin
erythromycin
chloramphenicol
tetracyclin
cotrimoxazol
vancomycin
clindamycin
found
mrsa
isol
sensit
vancomycin
partial
total
resist
rest
import
differ
year
mrsa
isol
complet
suscept
vancomycin
resist
antimicrobi
use
extent
although
monitor
mrsa
suscept
antimicrobi
year
show
import
chang
antimicrobi
resist
period
monitor
mrsa
suscept
antimicrobi
revalu
current
treatment
regimen
mrsa
infect
necessari
staphylococcu
aureu
strain
reduc
suscept
vancomycin
among
clinic
isol
univers
hospit
warsaw
visa
especi
hvisa
difficult
found
routin
laboratori
investig
examin
aureu
strain
isol
store
laboratori
sever
last
year
strain
isol
staphylococc
strain
mrsa
well
mssa
mic
vancomycin
perform
standard
dilut
method
among
strain
isol
last
year
three
strain
recogn
visa
mic
valu
mgl
frequenc
visa
aim
found
hvisa
strain
popul
analysi
use
analysi
strain
grow
concentr
mgl
vancomycin
inoculum
chosen
strain
recogn
hvisa
frequenc
hvisa
among
investig
strain
hvisa
visa
strain
methicillin
resist
vitro
activ
vancomycin
teicoplanin
oxacillin
staphylococci
isol
patient
surgic
intens
care
unit
kucuk
e
karayel
n
kansiz
e
institut
cardiolog
univers
istanbul
istanbul
turkey
object
oxacillinresist
staphylococci
emerg
major
infect
control
problem
hospit
aim
studi
evalu
vitro
activ
vancomycin
teicoplanin
oxacillin
staphylococci
materi
method
studi
perform
januari
decemb
univers
istanbul
institut
cardiolog
antimicrobi
suscept
staphylococci
isol
vancomycin
teicoplanin
oxacillin
investig
e
test
accord
nccl
guidelin
result
fiftyf
clinic
isol
staphylococcu
aureu
one
hundr
twentyfour
clinic
isol
coagulas
neg
staphylococci
cn
none
staphylococci
isol
resist
vancomycin
three
cn
isol
intermedi
six
cn
isol
resist
teicoplanin
twentyeight
aureu
resist
oxacillin
nineti
cn
isol
also
resist
methicillin
conclus
nosocomi
staphylococc
infect
especi
intens
care
unit
increas
day
day
staphylococc
infect
major
problem
mani
hospit
accord
experi
rate
oxacillin
resist
staphylococci
isol
hospit
also
increas
methicillinresist
staphylococcu
aureu
mrsa
clinic
signific
pathogen
mrsa
resist
mani
kind
antibiot
caus
nosocomi
infect
around
world
antisept
use
prevent
infect
mrsa
antisepticresist
mrsa
strain
isol
clinic
specimen
antisept
resist
gene
confer
resist
mani
kind
drug
structur
resist
mechan
energydepend
drug
efflux
system
addit
fluoroquinolon
fq
resist
gene
nora
confer
also
resist
mani
kind
antisept
studi
relat
suscept
antisept
fq
mrsa
strain
isol
japan
total
strain
mrsa
isol
hospit
japan
acriflavin
af
acrinol
benzethonium
chlorid
benzalkonium
chlorid
chlorhexidin
diglucon
use
antisept
norfloxacin
sparfloxacin
also
use
experi
mic
determin
agar
doubledilut
method
recommend
nccl
mrsa
show
resist
af
mic
ugml
strain
resist
specif
antisept
fqsuscept
strain
suscept
antisept
studi
show
antisepticresist
mrsa
wide
spread
hospit
japan
drug
choic
treatment
seriou
infect
caus
mrsa
still
vancomycin
howev
sometim
failur
observ
especi
monotherapi
conflict
present
literatur
effect
combin
action
vancomycin
betalactam
present
work
common
effect
vancomycin
methicillin
chosen
staphylococcu
aureu
strain
examin
investig
strain
character
visa
hvisa
clone
obtain
hvisa
popul
analysi
two
method
perform
e
test
methicillin
vancomycin
place
media
supplement
second
antibiot
chessboard
microanalysi
increas
concentr
antibiot
fic
index
calcul
differ
combin
concentr
basi
fic
index
shown
simultan
action
vancomycin
methicillin
synergist
examin
strain
visa
hvisa
appropri
concentr
differ
combin
observ
effect
addit
indiffer
antagon
never
observ
synergist
effect
observ
case
standard
aureu
strain
sensit
methicillin
supplement
media
nacl
substanti
decreas
observ
effect
incid
antibiot
resist
staphylococcu
aureu
strain
hungari
special
refer
mrsa
di
c
z
kamotsay
k
e
rozgonyi
f
institut
medic
microbiolog
semmelwei
univers
budapest
hungari
januari
decemb
total
staphylococcu
aureu
strain
isol
patient
admit
clinic
semmelwei
univers
examin
antibiot
sensit
disc
diffus
test
resist
individu
antimicrobi
follow
penicillin
oxacillin
erythromycin
ciprofloxacin
amikacin
netilmicin
tobramycin
gentamicin
clindamycin
mupirocin
tetracyclin
chloramphenicol
teicoplanin
vancomycin
mrsa
blactamas
produc
show
coresist
erythromycin
ciproflxacin
amikacin
netilmicin
mupirocin
multipl
resist
mrsa
strain
mupirocintetracyclineschloramphenicol
amount
tripl
resist
oxacillinciprofloxacinnetilmicin
detect
meca
gene
pcr
randomli
chosen
mrsa
qualifi
mg
oxacillin
disc
result
meca
posit
indic
tradit
disc
diffus
test
overestim
frequenc
mrsa
strain
particularli
environ
usag
penicillin
cephalosporin
liber
hungari
consequ
select
pressur
blactamresist
blactamas
induct
exist
everywher
conclus
coher
rel
low
frequenc
multipl
resist
mrsa
strain
urg
need
routin
avail
genet
method
appli
mrsa
detect
object
main
object
studi
monitor
antibiot
resist
identifi
newemerg
resist
mechan
earli
stage
prevent
dissemin
earli
detect
prevent
outbreak
method
laboratori
use
antibiot
disc
sensit
test
methodolog
nccl
zone
size
measur
object
use
biomic
autom
radiu
zone
reader
result
throughout
year
januari
till
decemb
survey
organ
collect
outpati
depart
radiooncolog
depart
medic
depart
obg
depart
surgicaloncolog
non
icu
depart
icu
depart
strain
enterobacteriacea
resist
gener
fluoroquinolon
strain
esbl
posit
strain
staphylococcu
aureu
five
strain
resist
methicilin
mrsa
collect
strain
enterococci
whereabout
two
resist
glycopeptid
vre
strain
pesudomona
aeruginosa
resist
aminoglycosid
conclus
nation
restrict
antibiot
polici
hand
hand
local
hospit
antibiot
polici
regular
rotat
antibiot
use
prevent
treatment
depart
lead
case
posit
situat
antibiot
resist
compar
slovakian
european
center
antimicrobi
resist
nosocomi
strain
staphylococcu
aureu
dekhnich
av
stratchounski
ls
edelstain
ia
narezkina
ad
institut
antimicrobi
chemotherapi
smolensk
russian
feder
purpos
determin
antimicrobi
resist
staphylococcu
aureu
caus
nosocomi
infect
smolensk
region
hospit
result
total
aureu
strain
isol
studi
antimicrobi
test
includ
oxacillin
oxa
erythromycin
eri
clindamycin
cli
gentamicin
gen
vancomycin
van
linezolid
lnz
tetracyclin
tet
chloramphenicol
chl
rifampicin
rif
fusid
acid
fu
trimethoprimsulfamethoxazol
ts
ciprofloxacin
cip
mupirocin
mup
quinupristindalfopristin
qd
suscept
test
interpret
perform
agar
dilut
accord
nccl
guidelin
applic
result
present
conclus
activ
antimicrobi
vancomycin
linezolid
quinupristindalfopristin
fusid
acid
mupirocin
follow
cotrimoxazol
rifampicin
betalactam
macrolid
lincosamyd
tetracyclin
chloramphenicol
use
treatment
nosocomi
aureu
infect
investig
staphylococc
infect
within
year
among
neonat
hospit
infect
neonat
icu
tertiari
neonat
referr
center
univari
analysi
assess
risk
factor
neonat
infect
staphylococcu
aureu
vs
without
aureu
perform
total
number
case
case
aureu
isol
variou
sampl
case
blood
cultur
case
urin
case
eye
swab
case
gastric
content
signific
differ
comparison
control
group
colon
aureu
predictor
infect
nasal
swab
throat
swab
ear
swab
skin
swab
umbil
swab
significantli
commonli
observ
neonat
infect
aureu
infect
etiolog
analysi
show
copathogen
escherichia
coli
viridan
streptococci
significantli
frequent
associ
neonat
infect
caus
aureu
comparison
organ
accord
local
infect
site
conjunct
thrush
stomat
commonest
aureu
neonat
infect
outcom
similar
infect
without
signific
differ
group
mortal
similar
infect
probabl
initi
therapi
centr
contain
antistaphylococcali
activ
agent
cefuroxim
cefotaxim
plu
aminoglycosid
morozova
ot
semina
na
laboratori
hospit
infect
central
research
institut
epidemiolog
moscow
russian
feder
purpos
studi
role
enterococcu
spp
aetiolog
nosocomi
infect
among
patient
children
clinic
hospit
suscept
strain
antibiot
method
strain
enterococci
isol
patient
hospit
infect
result
aetiolog
structur
enterococcu
infect
show
predomin
skin
soft
tissu
infect
urinari
tract
infect
bloodstream
infect
pneumonia
infect
central
nervou
system
gastrointestin
tract
eye
surgic
wound
infect
rare
incid
variou
nosolog
form
infect
caus
often
e
faecali
e
faecium
antibiot
resist
ampicillin
betalactam
occur
e
faecium
isol
strain
e
faecali
suscept
drug
highlevel
gentamicin
resist
demonstr
e
faecali
isol
e
faecium
highlevel
streptomycin
resist
show
e
faecali
e
faecium
e
faecali
activ
fluoroquinolon
e
faecium
resist
vancomycin
resist
enterococci
conclus
e
faecali
predomin
aetiolog
structur
nosocomi
infect
due
enterococcu
spp
antibiot
resist
pattern
two
speci
enterococci
differ
stran
suscept
vancomycin
evalu
antimicrobi
resist
enterococcu
spp
experi
year
lopezbarba
j
jesu
de
la
call
perezramo
microbiolog
laboratori
puerto
real
univers
hospit
spain
object
determin
quantit
chang
antimicrobi
resist
enterococcu
isol
clinic
signific
urinari
sampl
patient
remit
laboratori
microbiolog
year
period
materi
period
studi
compris
sampl
process
isol
enterococcu
follow
convent
method
isol
enterococci
strain
identif
suscept
antibiot
perform
autom
system
microscan
c
dadebehr
c
panel
combo
cgp
data
process
statist
system
statgraph
plu
result
enterococcu
identifi
e
faecali
e
faecium
resist
shown
tabl
conclus
resist
va
tei
e
faecali
remain
last
year
high
resist
erythromycin
tetracilin
resist
quinolon
antibiot
use
communityacquir
infect
justifi
suscept
test
clinic
strain
isol
group
microorgan
e
faecium
antimicrobi
resist
high
increasingli
imipenem
meropenem
erythromycin
quinolon
characterist
strain
e
faecium
colon
neutropen
patient
abbassi
ms
achour
w
ben
hassen
laboratori
bone
marrow
transplant
center
tuni
tunisia
digest
colon
enterococcu
faecium
neutropen
patient
gut
decontamin
import
seventeen
multiresist
strain
e
faecium
isol
stool
seven
neutropen
patient
target
epidemiolog
analysi
determin
mic
amoxicillin
gentamicin
vancomycin
transfer
gentamicin
resist
recipi
strain
e
faecali
filterm
assay
analysi
plasmid
profil
e
faecium
strain
transconjug
amplif
pcr
gene
aac
aph
code
bifunct
enzym
use
primer
give
fragment
kb
among
seventeen
strain
eleven
antibiotyp
gentamicin
mic
mgl
amoxicillin
mgl
strain
sensit
vancomycin
ten
strain
harbor
plasmid
kb
transfer
frequenc
also
found
gentamicinresist
transconjug
howev
strain
belong
nine
distinguish
plasmid
profil
highlevel
gentamicin
resistantstrain
posit
pcr
amplif
aac
aph
gene
featur
studi
strain
establish
endogen
origin
specif
everi
patient
share
highlevel
resist
gentamicin
gut
decontamin
treatment
gentamicin
enhanc
either
spread
preserv
easytransfer
plasmid
carri
genet
transpos
element
frequenc
antibiot
resist
bacteria
isol
patient
suffer
infecti
complic
follow
implant
prosthet
devic
f
k
rozgonyi
f
institut
medic
microbiolog
semmelwei
univers
budapest
hungari
patient
indwel
joint
prosthesi
earli
recognit
prompt
therapi
infect
locat
may
critic
reduc
risk
seed
joint
implant
heamatogen
year
period
total
swab
aspir
patient
infecti
complic
follow
implant
prosthet
devic
cultur
cultiv
identif
strain
perform
convent
method
vitek
system
suscept
test
disc
diffus
potent
pathogen
recov
case
gram
posit
cocci
particular
staphylococcu
spp
prove
commonli
isol
bacteria
coagulaseneg
staphylococcu
cn
isol
frequent
follow
aureu
enterococcu
faecali
e
faecium
gramneg
anaerob
isol
resist
individu
antimicrobi
aureu
cn
follow
methicillin
clindamycin
fluoroquinolon
mupirocin
resist
strain
aureu
found
among
cn
strain
result
could
essenti
ration
select
treatment
orthoped
ward
result
analys
period
percentag
isol
enterococcu
sp
strain
among
nonrepetit
clinic
isol
respect
cultur
strain
identifi
e
faecali
e
faecium
e
gallinarum
e
avium
preval
e
faecium
strain
isol
frequenc
respect
vancomycinresist
strain
identifi
e
faecium
compris
isol
speci
conclus
frequenc
isol
enterococcu
sp
blood
cultur
haematolog
patient
remain
rel
stabl
predomin
enterococc
speci
isol
patient
e
faecium
record
first
time
emerg
vancomycinresist
e
faecium
compris
isol
speci
kalai
ben
hassen
achour
w
greco
laboratori
microbiolog
nation
bone
marrow
transplant
center
tuni
tunisia
april
june
nonrep
strain
pseudomona
aeruginosa
isol
immunocompromis
patient
thirtysix
percent
strain
isol
abscess
blood
cultur
urin
suscept
antibiot
studi
routin
disk
diffus
method
casfm
mic
determin
use
agar
dilut
antibiot
four
aminosid
two
fluoroquinolon
serotyp
differ
train
perform
use
antisera
intern
antigen
type
system
serotyp
studi
show
resist
c
cochin
port
royal
hospit
servic
de
gynecologieobstetriqu
site
st
vincentdepaul
pari
franc
cochin
port
royal
hospit
cclin
pari
franc
aim
determin
risk
marker
outbreak
postpartum
endometr
due
group
streptococcu
design
casecontrol
studi
use
data
collect
structur
form
set
case
postpartum
endometr
diagnos
depart
obstetr
pari
hospit
network
day
decemb
group
control
consist
women
deliv
depart
period
particip
case
control
find
case
smoke
often
pregnanc
vs
p
receiv
often
immunosuppress
treatment
control
vs
p
instrument
deliveri
need
often
case
control
vs
p
case
hospit
deliveri
ward
z
depart
often
control
vs
p
examin
deliveri
often
midwif
x
vs
nurs
provid
care
case
control
vs
p
conclus
smoke
receiv
immunosuppress
treatment
pregnanc
instrument
deliveri
significantli
associ
postpartum
endometr
pb
midwif
nurs
might
involv
transmiss
infect
petoukhova
sokolova
e
dmitrieva
n
nummaev
b
b
laboratori
microbiolog
cancer
research
center
russia
moscow
russian
feder
b
depart
oncogynecolog
cancer
research
centr
moscow
russian
feder
aim
studi
assess
efficaci
periop
ap
total
pt
includ
two
hundr
one
pt
cervic
cancer
cc
undergon
extens
hysterectomi
pt
cancer
vulva
cv
extens
vulvoectomi
pt
ovarian
cancer
oc
extensivecombin
oper
fiftyon
pt
group
receiv
ap
amoxicillinclavulan
amcl
g
iv
min
prior
oper
g
iv
thrice
per
day
day
fifti
pt
group
receiv
cefotaxim
ctx
g
iv
min
prior
oper
g
four
time
per
day
daysmetronidazol
mtz
mg
two
time
per
day
period
one
hundr
forti
pt
retrospect
control
receiv
ii
gener
cephalosporin
linkosamid
oper
rate
swi
pt
cc
cv
oc
respect
dwi
respect
uti
respect
ap
amcl
effect
compar
ctxmtz
swi
vs
respect
pb
dwi
vs
respect
p
b
rate
postop
uti
equival
two
group
vs
p
thu
ap
amcl
preferr
option
extens
oper
og
pt
fiftyeight
patient
random
two
group
group
treatment
consist
patient
group
consist
patient
control
patient
age
differ
surgic
intervent
gener
anaesthesia
h
accompani
copd
artifici
pulmonari
ventil
use
case
earli
postsurgeri
period
patient
group
administ
inhal
therapi
includ
ipratopium
bromid
combin
fenoterol
atrov
berodu
ambrocsol
lazolvan
nebul
inhal
therapi
administ
patient
group
influenc
inhal
therapi
pulmonari
ventil
respiratori
metabol
restor
faster
resuscit
patient
group
end
first
h
group
day
percent
rate
respect
artifici
pulmonari
ventil
end
h
respect
time
patient
stay
resuscit
depart
day
group
day
group
end
week
pneumonia
develop
one
patient
group
eight
patient
group
aerosol
therapi
applic
acceler
medic
deliveri
respiratori
tract
increas
local
activ
effect
good
prophylaxi
surgic
hospit
pneumonia
variat
ethiolog
earli
late
onset
ventil
associ
pneumonia
nikolopoulo
j
dagan
michailid
karabela
e
kavada
k
retsou
antoniad
rasidaki
depart
respiratori
abstract
failur
icu
sotiria
gener
chest
diseas
hospit
athen
greec
purpos
compar
distribut
caus
microorgan
suscept
antibiot
outcom
earli
late
vap
greek
icu
method
result
retrospect
studi
mechan
ventil
mv
patient
pt
earli
late
vap
period
diagnosi
vap
made
clinic
radiograph
criteria
quantit
cultur
bronchial
secret
vap
diagnos
pt
consecut
admiss
icu
pt
develop
vap
receiv
antibiot
three
episod
vap
develop
day
mv
earli
vap
caus
multiresist
acinetobact
antibioticsuscept
pseudomona
aeroginosa
group
one
pt
die
septic
shock
relat
vap
two
pt
surviv
fourteen
pt
develop
vap
day
mv
late
vap
five
case
caus
multiresist
p
aeroginosa
two
case
mrsa
two
case
multiresist
acinetobact
two
case
suscept
antibiot
klebsiella
pneumonia
three
polymicrobi
caus
multiresist
microorgan
mrsa
gnb
four
pt
die
septic
shock
relat
vap
five
pt
die
anoth
caus
five
pt
surviv
conclus
earli
late
onset
episod
vap
caus
potenti
drugresist
bacteria
p
aeroginosa
caus
earli
vap
suscept
mortal
attribut
earli
late
vap
similar
antibiot
prophylaxi
oncolog
major
reconstruct
orthopaed
surgeri
de
bias
p
ciampalini
l
aston
capanna
r
azienda
ospedaliera
careggi
oncolog
reconstruct
centr
aoc
florenc
itali
last
year
patient
schedul
oncolog
surgeri
major
reconstruct
procedur
randomis
either
vancomycin
teicoplanin
prophylaxi
prophylaxi
perform
either
vancomycin
g
iv
twice
daili
teicoplanin
daili
iv
two
hundr
patient
includ
four
patient
agre
studi
protocol
exclud
treat
patient
teicoplanin
patient
vancomycin
patient
oper
oncolog
diseas
remain
underw
major
orthopaed
procedur
experienc
case
red
man
syndrom
five
case
moder
hypotens
five
patient
postop
complic
two
deep
venou
thrombosi
one
pulmonari
embol
two
postop
haematoma
five
patient
observ
wound
dehisc
two
patient
show
clinic
sign
ssi
microbiolog
examin
posit
mrsa
one
patient
recov
infect
medic
therapi
patient
show
local
tumour
recurr
amput
thigh
last
surgeri
infect
still
present
clinic
microbiolog
examin
conclus
infect
rate
compar
infect
rate
clean
surgeri
patient
normal
risk
infect
teicoplanin
show
lower
toxic
longer
halflif
simpler
way
infus
current
choic
high
risk
surgeri
injuri
contamin
sharp
articl
health
care
worker
gener
hospit
celj
slovenia
lesnicar
g
sibanc
b
depart
infecti
diseas
medic
center
celj
celj
slovenia
prospect
studi
carri
januari
till
june
regist
subcutan
injuri
sharp
object
mostli
nurs
clean
servic
worker
case
incid
occur
outsid
hospit
person
medic
worker
case
injuri
caus
object
needl
use
known
patient
hepat
b
posit
fiftyf
injur
health
worker
previous
vaccin
hepat
b
protect
antibodi
hepat
b
blood
found
health
worker
test
antibodi
hepat
c
hiv
neg
case
follow
incid
major
injur
person
ie
vaccin
hepat
b
person
also
receiv
passiv
prophylaxi
human
immunoglobulin
hepat
b
none
injur
person
develop
diseas
show
evid
seroconvers
year
gener
well
specif
prevent
measur
practis
hospit
becam
rigor
thu
approxim
health
worker
risk
alreadi
vaccin
hepat
b
improv
measur
prevent
dissemin
multidrugresist
bacteria
mrb
crosssect
survey
conduct
analys
healthcar
worker
hcw
isol
precaut
knowledg
mrb
infect
investig
outpati
depart
exclud
four
declar
involv
care
mrb
patient
emerg
obstetr
nuclear
medicin
bacteriolog
two
hundr
eight
hcw
answer
paramed
staff
physician
thirtythre
percent
report
know
frequent
alway
patient
mrb
statu
wish
mrb
statu
mention
test
form
advic
request
letter
mrb
patient
visit
test
appropri
time
answer
gown
mask
use
systemat
report
hcw
report
better
isol
precaut
knowledg
physician
nurs
investig
assist
physician
declar
lower
complianc
use
gown
glove
drawsheet
hcw
also
lower
educ
isol
precaut
less
interest
educ
program
studi
suggest
necess
improv
mbr
infect
inform
physician
investig
assist
seem
insuffici
awar
hospit
infect
control
therefor
educ
strategi
target
physician
investig
assist
work
outpati
investig
depart
develop
outbreak
clostridium
difficil
associ
diarrhoea
infecti
diseas
depart
risk
factor
hygien
measur
assess
henoun
loukili
n
martin
remi
v
hansmann
christmann
universitair
de
strasbourg
maladi
infectieus
et
tropical
strasbourg
franc
shock
bedridden
statu
age
year
previou
antibiot
treatment
point
women
shock
bedridden
statu
age
year
immunosuppress
vast
major
patient
male
femal
respect
could
classifi
subgroup
lower
score
six
point
less
limit
risk
death
men
women
respect
wherea
patient
highest
score
subgroup
point
risk
men
women
conclus
risk
stratif
patient
ap
possibl
simpl
clinic
variabl
avail
admiss
procalcitonin
pct
creactiv
protein
crp
differenti
system
inflammatori
respons
syndrom
sir
sepsi
sever
sepsi
lups
ursu
l
b
slavcovici
carstina
clinic
depart
teach
hospit
infecti
diseas
clujnapoca
romania
b
laboratori
depart
teach
hospit
infecti
diseas
clujnapoca
romania
object
evalu
valu
pct
differenti
patient
sir
sepsi
sever
sepsi
bacteremia
comparison
crp
design
prospect
studi
includ
patient
meet
criteria
sir
sepsi
sever
sepsi
consensu
confer
accp
sccm
admit
period
patient
method
total
patient
includ
eight
sir
sepsi
sever
sepsi
sixteen
patient
bacteremia
pct
crp
evalu
first
h
admiss
pct
brahm
pctq
test
crp
turbidimetr
assay
sensit
specif
predict
valu
differ
cutoff
point
crp
pct
determin
result
cut
point
ngml
pct
mgdl
crp
sensit
specif
sepsi
respect
ppv
npv
respect
ppv
npv
cutoff
point
ngml
pct
accur
predict
sever
sepsi
sensit
specif
ppv
pct
level
least
ngml
good
predictor
bacteremia
sensit
specif
ppv
npv
conclus
pct
good
discrimin
marker
character
level
inflamm
caus
infect
predict
bacteremia
giamarel
h
aoun
b
klasterski
j
b
anagnostopoulo
n
c
galani
l
c
grecka
p
c
panaret
e
c
papageorgi
e
c
repoussi
p
c
syrseloudi
pct
consid
use
diagnost
marker
neutropen
patient
bacteremia
andor
sever
sepsi
giamarellosbourbouli
ej
et
al
clin
infect
di
attempt
defin
valu
diagnosi
local
infect
neutropen
host
daili
determin
pct
creactiv
protein
crp
perform
onset
fever
subject
male
femal
age
year
variou
haematolog
malign
aml
nhl
md
develop
neutropenia
pmnsmm
chemotherapi
thirtythre
patient
present
fever
unknown
origin
fuo
local
bacteri
infect
lbi
pneumonia
acut
pyelonephr
soft
tissu
infect
acut
pharyng
pct
determin
immunoluminometr
assay
crp
nephelometri
conclud
febril
neutropenia
follow
local
bacteri
infect
accompani
significantli
higher
level
pct
case
fuo
vs
ngml
similar
differ
observ
crp
lack
appropri
specif
studi
includ
patient
categor
proven
probabl
possibl
system
fungosi
accord
eortc
criteria
show
sign
infect
use
control
blood
sampl
receiv
day
onset
sign
fungal
infect
twice
week
pct
level
determin
immunochemiolumin
assay
candida
aspergillu
antigen
level
elisa
five
patient
pct
indic
earli
sign
infect
albeit
bare
detect
limit
six
patient
howev
show
significantli
increas
titr
preced
time
death
posit
antigen
titr
observ
patient
proven
probabl
system
fungosi
half
control
group
neg
antigen
titr
high
rate
fals
neg
also
observ
pct
antigen
titr
increas
parallel
patient
unfavor
outcom
pct
antigen
titr
reliabl
indic
earli
diagnosi
system
fungal
infect
although
may
use
prognost
tool
sever
lactulos
factor
decreas
endotoxaemia
obstruct
jaundic
koutelidaki
im
papazioga
v
makri
giamarellosbourbouli
ej
b
giamarel
h
b
papazioga
thessaloniki
med
school
surgic
clinic
thessaloniki
greec
b
depart
intern
medicin
athen
medic
school
athen
greec
bacteri
transloc
process
implic
pathogenesi
spontan
periton
order
evalu
impact
lactulos
administr
system
endotoxaemia
obstruct
jaundic
induc
rabbit
common
bile
duct
ligat
anim
divid
two
group
group
five
rabbit
receiv
lactulos
group
b
six
rabbit
receiv
mlkg
lactulos
oral
oral
cathet
blood
collect
daili
oper
total
durat
four
day
sampl
appli
cultur
determin
endotoxin
lp
lal
assay
concentr
lp
group
euml
day
respect
respect
concentr
lp
group
b
blood
cultur
steril
group
differ
